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Abstract  
The glycocalyx of eukaryotic cells plays a crucial role in many biochemical communication processes. The molecular 
mechanisms underlying these processes are difficult to investigate and are still not fully understood. For example, 
non-covalent interactions between carbohydrate ligands and their lectin receptors are accompanied by 
conformational changes between the interacting partners. Such changes might reflect a principal conformational 
control of carbohydrate-protein interactions, which has received only little attention until to date. Hence, the central 
focus of this thesis is to synthesize photoswitchable glycomimetics and investigate the role of light-induced 
conformational changes in carbohydrate recognition. Photoinduced changes in glycoconjugtaes have been 
accomplished already earlier by introduction of a photoswitchable unit, namely azobenzene. E→Z isomerization of 
azobenzenes have been utilised in photocontrolling biomolecules like nucleic acids and peptides. Thus azobenzene 
glycoconjugates are principal target molecules of our research. Photoirradiation of azobenzene glycosides at ~ 365 
nm induces E→Z isomerization leading to a certain E/Z ratio in the photostationary state (PSS). The special features 
of azobenzene glycoconjugates featuring an E→Z→E isomerization option in solution will eventually allow us to 
utilise this type of molecules with -D-mannose-specific lectins, such as the bacterial lectin FimH. In addition, 
azobenzene glycosides can be attached to different scaffolds or immobilised on surfaces to test as well as switch 
bacterial adhesion (Fig. 1). 
 
Figure 1: Vision of photoswitchable bacterial adhesion employing E→Z isomerization of azobenzene glycosides. 
In this context, a new class of azobenzene glycosides were synthesized and their photochromic properties were 
studied in solution by 
1
H NMR and UV-Vis spectroscopy and they were tested as inhibitors for type 1 fimbriae-
mediated bacterial adhesion. To mimic the cell surface glycocalyx, azobenzene glycosides were immobilised on gold 
surfaces to form photoswitchable glyco-SAMs. Photoisomerization was performed on the gold surface and monitored 
by IRRAS and UV-Vis spectroscopy. To get insight in the conformational control of carbohydrate recognition in a 
multivalence context, photosensitive glyconanopartices were also prepared and binding efficiency of different isomers 
was tested with the lectin ConA. 
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Zusammenfassung 
Die Glykokalyx von eukaryontischen Zellen spielt eine entscheidende Rolle in vielen biologischen 
Kommunikationsprozessen. Die molekularen Mechanismen, die diesen Prozessen unterliegen, sind schwer zu 
untersuchen und bisher immer noch nicht vollständig verstanden. Beispielsweise gehen nicht-kovalente 
Wechselwirkungen zwischen Kohlenhydratliganden und deren Lektinrezeptoren immer mit Konformationsänderungen 
der beteiligten Interaktionspartner einher. Solche Änderungen weisen auf eine prinzipielle Konformationskontrolle von 
Kohlenhydrat-Protein-Wechselwirkungen hin, der bislang nur wenig Aufmerksamkeit geschenkt wurde. Daher liegt 
der Schwerpunkt der hier vorliegenden Arbeit in der Synthese von photoschaltbaren Glykomimetika und der 
Untersuchung lichtinduzierter Konformationsänderungen in Kohlenhydraterkennungsprozessen. Die Untersuchung 
photoinduzierter Änderungen in Glycokonjugaten wurde durch die Einführung einer photoschaltbaren Einheit möglich, 
dem Azobenzol. Die E→Z-Isomerisierung von Azobenzolen wurde bereits zur Photokontrolle von Biomolekülen wie 
Nukleinsäuren und Peptiden genutzt. Daher sind Azobenzolglykokonjugate von großem Interesse für die Forschung. 
Die Bestrahlung von Azobenzolglykosiden mit einer Wellenlänge von ~365 nm induziert eine E→Z Isomerisierung, 
was zu einem bestimmten E→Z-Verhältnis im photostationären Zustand (PSS) führt. Diese speziellen Eigenschaften 
von Azobenzolglykokonjugaten, besonders die Möglichkeit von einer E→Z→E-Isomerisierung in Lösung, könnte es 
ermöglichen, diese Moleküle als Testsysteme zur Untersuchung -D-Mannose-spezifischer Lektine (wie zum Beispiel 
dem bakteriellen Lektin FimH) zu nutzen. Des Weiteren können die erhaltenen Azobenzolglykoside zu verschiedenen 
Derivaten funktionalisiert oder auf Oberflächen wie Gold immobilisiert werden, um bakterielle Adhäsion FimH zu 
testen und zu schalten (Abb. 1). 
 
Abbildung 1: Die Vision schaltbarer bakterieller Adhäsion durch E→Z-Isomerisierung von Azobenzolglykosiden. 
In diesem Zusammenhang wurde eine neue Klasse von Azobenzolglykosiden synthetisiert. Deren photochrome 
Eigenschaften wurden in Lösung mittels 
1
H-NMR- und UV-Vis-Spektroskopie untersucht. Sie wurden außerdem als 
Inhibitoren für die Typ-1-Fimbrien- vermittelte bakterielle Adhäsion getestet. Um die glycosylierte Zelloberfläche zu 
mimikrieren wurden photoschaltbare Glyko-SAMs durch Immobilisierung von Azobenzolglykosiden auf einer 
Goldoberfläche hergestellt. Die Photoisomerisierung wurde auf den Goldoberflächen durchgeführt und mittels IRRAS 
sowie UV-Vis-Spektroskopie verfolgt. Um einen Einblick in die konformative Kontrolle von Kohlenhydrat-
Erkennungsprozessen in einem multivalenten Kontext zu bekommen, wurden auch lichtsensitive Glykonanopartikel 
synthetisiert. Dabei wurden die Bindungseffizienzen der zwei verschiedenen Isomere mit dem Lektin ConA getestet. 
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Abbreviations 
Ac   Acetyl 
atm.   Atmosphere 
ATR    Attenuated total reflection 
CCA    α-cyano-4-hydroxycinnamic acid 
CRD   Carbohydrate Recognition Domain 
Cy   Cyclohexane 
DBU   1,8-Diazobicyclo[5.4.0.]undec-7-en 
DEAD   Diethylazodicarboxylate 
DIAD   Diisopropylazodicarboxylate 
DIC   N,N′-Diisopropylcarbodiimide 
DLS   Dynamic light scattering 
DMF   Dimethylformamide 
DMSO  Dimethylsulfoxide 
ESI   Electrospray ionization 
Et   Ethyl 
Glc   Glucose 
GFP   Green fluorescent protein 
HATU (O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium-
hexafluorophosphate) 
mg Milligram 
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MALDI Matrix-Assisted Laser Desorption Ionisation 
Man Mannose 
Me Methyl 
MeMan Methyl--D-mannoside 
min Minutes 
NMR Nuclear Magnetic Resonance 
PEG Polyethyleneglycol 
pNPMan p-Nitrophenylmannoside 
PSS Photostationary states 
PTSA p-Toluenesulfonic acid 
RT Room Temperature 
Rf Retention factor 
SAM Self-assembled Monolayer 
TBDMS tert-Butyldimethylsilyl 
THF Tetrahydrofuran 
UV-Vis Ultraviolet and Visible 
  
 
 
1. Introduction 
 
Carbohydrates are one of the most important fundamental classes of biomolecules next 
to proteins and nucleic acids. These are body's ideal fuel for many biological functions 
by providing the energy required for muscles and the molecular diversity for information 
exchange. Carbohydrates are composed of one or more sugar units, the simplest form 
is the monosaccharide. In monosaccharides, the hydroxyl group at the anomeric 
position can undergo a glycosylation reaction, a process in which carbohydrates as 
glycosyl donors are attached to other carbohydrates or non-carbohydrate molecules as 
the glycosyl acceptors. The resulting glycosidic bond be α- or β- configurated. On the 
cell surface, carbohydrates are covalently linked to other biomolecules like proteins 
(glycoproteins, proteoglycans) or lipids (glycolipids, gangliosides) and thus exist in the 
form of glycoconjugates.[1] Specific interactions of these glycoconjugates with proteins 
are of high crucial importance for biological recognition events like cell adhesion, cell 
communication and receptor binding. Glycoconjugate interactions occurring on the cell 
surfaces are not fully understood until today. Thus, studying the complexity of structure, 
function and biological relevance of carbohydrates on the cell surface is the central 
focus of glycobiological research. 
 
Each eukaryotic cell surface is covered by complex carbohydrates, forming a layer that 
is called “glycocalyx”. Glycocalyx constituents are arranged on cell surfaces in a diverse 
and heterogeneous manner (Fig. 1.1).[2]  
 
 
Figure 1.1: Schematic representation of different carbohydrates on the cell surface.  
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Each cell has its own glycocalyx characteristics and specific glycosylation pattern.[3]  
The quality of the glycocalyx distinguishes disease cells and healthy cells and plays a 
crucial role in many biological processes. 
 
An especially interesting example for the specific type of glycosylation of cells is the   
blood group antigens. A small structural variation in the terminal saccharide unit of a 
blood group glycoconjugate results in four different types of blood groups namely A, B, 
AB and O (Fig. 1.2).[4] In blood group A, B or AB the galactose moiety is glycosylated 
with N-acetylgalactosamine or a galactose moiety, respectively whereas in blood group 
O, the terminal end of galactose is not further glycosylated. 
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Figure 1.2: Presentation of different carbohydrate antigens in various blood groups. 
 
 
1.1 Carbohydrate-protein interactions 
 
Proteins that bind certain carbohydrates specifically are called “lectins”. The first lectin 
was discovered in plants and later found in other organisms like bacteria, viruses, and 
animals as well as humans. Lectins contain one or more binding sites for specific non-
covalent complexation of carbohydrate ligands. Lectins are non-immunogenic in origin 
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and have no enzymatic function.[5-6] Some of the most common monosaccharides that 
are recognized by lectins are D-glucose, D-galactose, D-mannose, N-acetylglucosamine, 
N-Acetylgalactosamine, L-fucose and N-Acetylneuraminic acid (Fig. 1.3).[7]   
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Figure 1.3: Examples of some monosaccharide structures that are recognized by lectins. 
 
Carbohydrate-protein interactions are strongly governed by hydrogen bonds, which are 
often mediated via water molecules, tight metal coordination with Ca2+ or Mn2+ ions, 
respectively, van der Waals and hydrophobic interactions.[8]  Based on the amino acid 
sequence and 3D structure of lectins, the most important classes of lectins have been 
defined as C-type, S-type, and P-type. C-type lectins binds to carbohydrates in a Ca2+-
dependent manner. S-type lectins selectively bind to galactose and N-
acetylgalactosamine, P-type lectins binds to mannose-6-phosphate receptors.[9] 
 
 
3
 
 
1.2 Multivalency 
Multivalent interactions play a decisive role in biological processes like cell adhesion, 
cell-cell signaling, attachment of viruses to host cells, etc.[16-17] Monovalent carbohydrate 
ligands bind weakly to their binding partners with a binding constant in millimolar to 
micromolar range. By multivalency, stronger binding is achieved by multiple interactions 
between carbohydrates and proteins, resulting in an overall high avidity.[10-12] “Affinity” 
refers to the strength of monovalent receptor-ligand interactions, whereas “avidity” 
refers to the strength of association resulting from many weak interactions.[2] To explain 
the concept of multivalency effects in carbohydrate-protein interactions the first 
synthetic multivalent oligosaccharide mimetic was reported in 1978 by Y. C. Lee and co-
workers.[13-14] They found that, a linear increase in number of carbohydrate ligands 
leads to a logarithmically increased avidity to the receptor protein, an effect that was 
called “cluster glycoside effect”. 
For example, multivalent interactions of a virus to its receptor on the host cell surface 
leads to stable adhesion (Fig. 1.4a). Since the virus has multiple binding sites, its affinity 
to the host cell ligands can be effectively increased (Fig. 1.4b). In analogy, multivalent 
ligands have enormous potential in inhibiting and fighting viruses effectively compared 
to the respective monovalent ligand (Fig. 1.4c).[15] 
 
Figure 1.4: a) Multivalent binding of virus to cell surface; b) inhibition by monovalent ligands; c) inhibition 
by multivalent ligands, more effective than by the monovalent ligands. Adapted with permission from ref. 
15. Copyright John Wiley and Sons.  
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Understanding multivalency effects occurring in natural systems is yet another 
challenge. There are different possible mechanisms which explain the multivalency 
effect and some of the relevant mechanisms are mentioned below (Fig. 1.5). In one 
approach, the strength of multivalent receptor-ligand interactions is stronger than the 
analogous monodentate receptor-ligand interaction (Fig 1.5a). In another approach, 
multivalency is enhanced by the secondary binding site along with the primary binding 
site on the target protein (Fig 1.5b). In the last approach, the strength of multivalent 
interactions is largely increased due to their ability to cluster their receptors (Fig 1.5c).[18] 
Thus, multivalent ligands can exhibit a variety of different activities based on different 
binding modes.[19]  
 
Figure 1.5: Examples for different binding modes in multivalency (organe – carbohydrate; blue – 
receptor). (a) chelate effect; (b) interaction with primary and secondary binding site of receptor; (c) 
receptor clustering.
[19] 
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1.3 Bacterial adhesion  
Bacterial infections are usually initiated by adhesion and colonization of bacteria to the 
host cell surface. For example, adhesion of uropathogenic Escherichia coli (UPEC) 
bacteria to the carbohydrate receptors on the bladder epithelium can cause urinary tract 
infection and inflammation.[20] To accomplish adhesion, bacteria utilize adhesive 
organells called fimbriae. Fimbriae are hair-like structures with a length between 0.1-2 
µm and a width of ~7nm and are expressed on the surface of bacteria (Fig. 1.6a).[21-22] 
Mannose-specific bacterial adhesion is mediated by a lectin called FimH that is located 
at the tips of type 1 fimbriae. The protein FimH consists of two domains, a lectin domain 
called carbohydrate recognition domain (CRD) and a pilin domain which is required for 
fimbriae assembly (Fig. 1.6b).[23-24]  
 
Figure 1.6: (a) Transmission electron micrograph (TEM) image of type 1 fimbriated E. coli bacteria. 
Adapted with permission from ref. 22. Copyright John Wiley and Sons; (b) cartoon of lectin subunit with 
FimH at the fimbrial tip. Adapted with permission from ref. 23. Copyright Elsevier. 
 
 In order to inhibit and to understand type 1 fimbriae-mediated bacterial adhesion, 
several mannosidic glycomimetics were synthesized and investigated as ligands of 
FimH.[22, 25-28] It is known from X-ray studies that the bacterial lectin FimH binds to α-D- 
mannosyl units (glycone part) with the aglycone part sticking out of the carbohydrate 
binding site.[21, 29-31] The entrance of the FimH carbohydrate binding site is flanked by 
two aromatic tyrosine residues, Tyr48 and Tyr137 forming the so called “tyrosine 
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gate”.[24] This hydrophobic gate at the entrance of the FimH carbohydrate recognition 
domain facilitates π-π interactions with the synthetic mannosidic ligands holding a 
aromatic aglycon, which in turn increases its affinity for FimH.[32-33] For example p-
nitrophenyl α- D-mannoside shows greater inhibitory potency than methyl α-D-
mannoside. Inhibition of bacterial adhesion by designed antagonists can be employed in 
the context of a specific antiadhesive therapy.[34] Eventually antiadhesives could 
become therapeutics against infections like urinary tract infections.[32, 34-35]  
 
1.4 Glycomimetics  
In order to understand the molecular details of carbohydrate-protein interactions 
occuring on the cell surface and its biological functions, an ultimate requirement is the 
isolation of the involved carbohydrate ligands from natural sources. However, to get 
them in required quantity in high purity for study their functions in detail is highly 
demanding.  For this, one has to rely on the synthetic approach where a synthetic 
chemist also plays an important role in making interesting glycomimetics to unravel the 
involved biochemical processes. Designing glycomimetics is an approach of making 
carbohydrate molecules according to the naturally occurring carbohydrate ligands with 
various alterations.[36-38] These glycomimetics are useful tools with structural features 
which facilitate the understanding of binding specificity and other fundamental 
properties of carbohydrate-protein interactions, paving the way to important biochemical 
answers.[19] 
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Glycocluster                Glycodendrimer                    Glycopolymer 
                                  
                                    Glyconanoparticle           Glyco-SAMs  
 
 
Figure 1.7: Different types of multivalent glycomimetics. 
 
 A considerable amount of monovalent and multivalent glycomimetics have been 
synthesized and reviewed.[11, 28, 39-45] For example, some of the multivalent glycomimeti-
cs are glycocluster, glycodendrimers, glycopolymers, glyconanoparticels and glyco-
SAMs (Fig. 1.7).[46-48] To mimic the glycosylated cell surface, various carbohydrates can 
be immobilized on artificial surface leading to so called “glycoarrays” that are used in 
glycobiology. For example, carbohydrate derivatives with an alkyl unit with terminal thiol 
group will form a self-assembled monolayer (SAMs) on a gold surface to obtain “glyco-
SAMs”.[27, 49]  
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2. Photoswitches 
2.1 Photoswitchable molecules  
Nature, possesses perfectly designed biomolecules in all living organisms.  Scientists 
try to understand the profound principles by making those biomolecules in a synthetic 
way. An elegant example found in nature is a photoswitchable biomolecule that is 
involved in the vision process, rhodopsin system (Fig. 2.1).[50] When retinal is linked with 
the protein opsin, a light-induced isomerization (cis to trans isomerization) process 
leads to a conformational change in the opsin structure. This triggers a cascade of 
events leading to signal transduction along the optical nerve to the brain, and we 
receive them as visual signals. 
 
 
Figure 2.1: Cis-trans isomerization in rhodopsin triggers a cascade of events leading to signal 
transduction along the optical nerve to the brain, and we receive them as visual signals.
[51]
 
 
The term “photochromism” derives from the Greek words “phos” and “chroma”, which 
means light and color, indicating a photoinduced change in colour. The word 
photochromism was introduced in the early 1950s to indicate the photoinduced   change 
in color of certain compounds. Undoubtedly, synthetic photoswitchable molecules have 
been inspired by those photo-responsive systems found in nature. Eventually, organic 
chemists have demonstrated some profound effects of photoswitchability by 
synthesizing photoswitchable molecules as inhibitors, which provided an indirect 
approach to gain understanding on changes of spatial and temporal control of 
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biomolecular structure and their functional differences between two isomeric states as a 
function of light.[52-54] 
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Figure 2.2: The photoinduced and thermal transformations of representative photochromic compounds.  
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Photochromic transformations are unimolecular reactions with a unique property of 
interconvertion of two isomers, which involves either ring closing and opening reaction  
(coloration and decoloration) or trans → cis and cis → trans isomerization (Fig. 2.2). 
In many cases, upon absorption of ultraviolet (UV) light the colourless closed isomer 
changes to a coloured open isomer, irradiation with visible light can reverse the 
molecule to its original colorless form. For example, spiropyran 1a ring-opens to the 
merocyanine 1b upon ultraviolet irradiation. The photogenerated coloured isomer 1b 
eventually reverts to the initial state 1a after thermal ring closing or by visible 
irradiation.[55-56] Similarly, diarylethene generates two isomers 2a and 2b, using ring 
closing and ring opening photoreactions. The ring closing reaction of 2a gives isomer 2b 
by a cyclization reaction when irradiated with UV light, however unlike spiropyran the 
photogenerated isomer 2b is thermally stable and the reverse reaction to the original 
state is only possible by exposing the compound to visible light irradiation.[54, 57-58] As 
similar kind of ring opening and closing photochromic properties can also be seen in 
fulgides (e.g. 3a and 3b).[59-60]  
Alternative to ring opening and closing reactions, photoinduced cis-trans isomerization 
of stilbene and azobenzene can also be used to implement photochromic 
transformations. The transformation from the trans to the cis form can be effected by 
irradiation with UV light of appropriate wavelength, the reverse cis → trans 
isomerization process is achieved by visible light. Stilbene (1,2-diphenylethylene) was 
derived from the Greek word stilbos, which means shining. Stilbenes have two isomeric 
forms the stable trans-stilbene (4a) which is not sterically hindered and the less stable 
cis-stilbene (4b) which is sterically hindered. Resveratrol (3,4′,5-trihydroxy-trans-
stilbene) is a promising natural product found in grapes and in red wine. The anticancer 
activity of resveratrol was first studied by Jang et al.[61] Oxidative stress is a preliminary 
step in the appearance and development of cardiovascular diseases, which decrease 
the bioavailability of nitric oxide (NO) in endothelium vessels, leading to endothelial 
dysfunction. One of the mechanisms involved by resveratrol and some stilbene 
derivatives in curing endothelical dysfunction by maintaining sufficient nitric oxide 
bioavailability in vascular endothelium during oxidative stress.[62-63]  
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Another interesting example for a cis → trans isomerization process is azobenzene. 
Azobenzene was first described by Krollpfeiffer et.al in 1934.[64] Photoinduced reversible 
isomerization to turn the trans into the cis isomer of azobenzene results in different 
chemical and physical properties, change in dipole moment (trans ~ 0 D; cis ~3 D) and 
change of distance between end to end carbon in the 4- and 4′ position of azobenzene 
(Fig 2.3).[65] Irradiation of trans-azobenzene 5a with UV light of appropriate wavelength 
results in the formation of the cis-isomer 5b. The photo-generated cis isomer 
reisomerizes to its original trans-isomer either thermally or by irradiation with visible 
light. Further details of azobenzene and its potential application in biological context are 
described in chapter 2.2. 
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Figure 2.3: cis-trans isomerization of azobenzene  
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2.2 Azobenzene isomerization  
Azobenzene, unarguably represents one of the most important organic compounds with 
a wide range of applications. Although azobenzenes are known since the 18th century 
and have been widely used in dye industry,[66] over the past decades considerable 
attention has been spent on its light-triggered switching properties in the area of 
polymers,[67-69] molecular switches,[70] protein modification,[71-72] drug delivery,[73] 
magnetic resonance imaging,[74] etc. Making synthetic analogues of this molecule is a 
challenge to synthetic chemists. 
 Azobenzene can be regarded as a derivative of diazene (HN=NH) group, where both 
hydrogen atoms are replaced by phenyl groups. The classical methods involved in the 
synthesis of azobenzenes are “azo coupling reaction”, coupling of diazonium salts with 
activated aromatic compounds, “Mills reaction”, reaction between aromatic nitroso 
derivatives with anilines and several other methods for the preparation of azobenzene 
derivatives have been reported.[75-76] 
  
 
Figure 2.4:  UV-Vis spectra of trans- (E-) and cis- (Z-) azobenzene in ethanol. Adapted with permission 
from ref. 75. Copyright Elsevier. 
 
 The trans- or E- isomer, respectively is thermodynamically more stable than the cis- or 
Z- isomer. A typical UV-visible absorption spectrum for trans- and cis- isomers of 
azobenzene are shown in Fig 2.4. For the trans- isomer, the absorption band around 
~350 nm arises due to the π-π* transition. After irradiation with visible light of 
13
 
 
appropriate wavelength, formation of the cis- isomer can be observed by increase in 
absorption at ~440 nm due to the n-π* transition. Depending on the substitution pattern 
of a azobenzene derivatives,  absorption maxima and kinetic of back isomerization will 
differ greatly.[77] The mechanism underlying in the isomerization of azobenzene from 
trans → cis has always been subject of interest and four different mechanistic pathways 
are proposed in the literature (Fig. 2.5).[78-80] 
N N
N N
N N
N N
N N
N N
N N N N
N N
N N
Rotation
Inversion
Concerted
Inversion
Inversion-assisted
rotation
trans-Azobenzene cis-Azobenzene
 
 
Figure 2.5: Different possible pathways for azobenzene photoisomerization.
[80]  
 
Among the photochromic molecules, azobenzenes have been extensively 
studied for their unique photoisomerization and their role in controlling the functions of 
biomolecules like protein and nucleic acids.[43, 74, 81-85]   
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2.3 Azobenzene derivatives in biological chemistry 
2.3.1 Azobenzene in nucleic acid  
Nucleic acids are large biomolecules found in all living organisms. Hybridization 
between two complementary DNAstrands is an unique property of nucleic acids 
underlying biological functions such as transcription or posttranscriptional gene 
silencing (siRNA). Reversible photocontrol of nucleic acid activity has been achieved 
using photoswitchable molecular glue, which are known in literature.[51],[86] For example,  
naphthyridine carbamate dimer (NCD) was integrated into photoswitchable molecular 
glue (NCDA) by incorporating azobenzene between two base-recognizing naphthyridine 
derivatives (Fig 2.6). NCDA in the cis-configuration induces the formation of dsDNA 
from two single stranded DNA structure (ssDNA), whereas in the trans-configuration 
dissociation of double stranded DNA structure (dsDNA) was observed, favouring ssDNA 
(Fig 2.6).[87] Thus, introduction of azobenzene enables the control of hybridization and 
dehybridization of DNA by an external light stimulus. 
 
Figure 2.6: Photocontrol of DNA hybridization and dehybridization by photoswitchable molecular glue 
(NCDA). The trans-isomer favours single stranded-DNA structure (ssDNA), whereas cis-isomer favours 
hybridization resulting in double-stranded DNA (dsDNA). Adapted with permission from ref. 87. Copyright 
American Chemical Society. 
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2.3.2 Azobenzene in Proteins/Peptides 
 
Reversible photocontrol of protein structure and its functions have also been studied 
using photoswitchable azobenzene derivatives.[72, 88] For example, Wooley et al. have 
shown that incorporation of a azobenzene functional group into a peptide chain allows 
control of helicity.[89-92] A key principle in their approach was to utilize the thiol active 
iodoacetamide functionalized azobenzene derivative with a very short linker between 
the azobenzene and the peptide (Fig. 2.7). Incorporation of a iodoacetamide- 
azobenzene derivative to the thiol moiety of a cystine residue of the peptide favours 
effective switching of the peptide backbone. More importantly, distance between two 
cystine residues and length of the crosslinkers determines the proteins structure and its 
activity. For example, trans-configuration of the azobenzene cross-linker attached at i, i 
+ 11, spaced Cys residues stabilized the helical structure and in the cis-configuration 
leads to distorted helical structure, due to shorter end to end distance of the corsslinker 
(Fig. 2.8) 
HN N
N NH
OI
O I
Vis
UV
N N
N
H O
I
HN
O
I
 
 
Figure 2.7: Azobenzene derivative with short linker (ethylene spacer) for effective cis →trans  
isomerization on the peptide backbone. 
 
 
 
Figure 2.8: Photoisomerization of the corsslinker from trans→cis isomer leads to destabilization of the 
helix. Adapted with permission from ref. 91. Copyright American Chemical Society. 
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2.3.3 Azobenzene in neurobiology 
 
Also the function of ion channels can be changed by photoisomerization of azobenzene 
derivatives. Ion channels play an important role in neural activities and their functions 
are influenced by ligand, voltage and temperature. Azobenzene-based photoswitchable 
ion channels are used since 1970s as a means to control neural activity artificially.[93] 
 
 
 
Figure 2.9: Light induced switching of ion channels and its receptors using photoswitchable ligands.  
(A) optical control of the nicotinic acetylcholine receptor (nAChR) of the neuromuscular junction is 
achieved by attaching a choline agonist group via a photoisomerizable tether (red) near the two allosteric 
sites of the receptor; The receptor is activated with azobenzene derivative (compound B) in trans-
conformation and deactivated in cis-conformation; C)  in SPARK, the active site (pore) of the voltage-
dependent K+ channel Shaker is reversibly blocked with azobenzene derivative (compound D) in trans-
conformation and unblocked in cis-conformation; (E)  in LiGluR, the photoisomerizable tethered glutamate 
agonist MAG (compound F) is attached to each of the four allosteric sites in the receptor. The receptor is 
deactivated with azobenzene in trans-conformation and activated in cis-conformation. (Figure adapted 
from the journal “physiology”).
[94]
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3-(α-Bromomethyl)-3'-[α-(trimethylammonium) methyllazobenzene bromide (QBr) (Fig 
2.9A, 2.9B) was the first photochromic compound to be nanoengineered with the 
nicotinic acetylcholine receptor of the neuromuscular junction which was pioneered by 
Erlanger et al.[95] The receptor was activated by the trans conformation of the 
azobenzene whereas deactivated in cis conformation of azobenzene. 
Later several groups reported the structure-based design of the ion channel 
gramicidin.[96-97] Trauner and colleagues further extended photocontrol of ion channels 
using azobenzene modification. Maleimide-linked azobenzene quaternary ammonium 
salts (Fig 2.9C, 2.9D) was used as synthetic photoisomerizable azobenzene derivatives 
that regulated the K+ ion channel (SPARK), in which the channel is blocked in trans- 
configuration of the azobenzene moiety and retaining the blocker in cis-configuration.[98] 
The same group extended their work in ionotropic glutamate receptor (iGluR) by 
attaching a photoisomerizable maleimide-linked azobenzene glutamate derivative, in 
which the receptor is deactivated in the trans-configuration and activated in the cis- 
configuration (Fig 2.9E, 2.9F).[99] Lately, they also studied the photocontrol of neural 
activity in vivo with in  zebrafish.[100] 
 
2.4  Azobenzene derivatives in glycobiology 
Although, azobenzene photoswitches are greatly utilized in protein and nucleic acid 
chemistry, azobenzene has rarely been utilized in carbohydrate chemistry particularly in 
a biological context.[75],[85] It has become evident that spatial distribution of 
glycoconjugates and the conformational characteristics of the glycocalyx plays a crucial 
role in biological processes involving carbohydrates. However, a systematic 
investigation of conformational changes and the impact of ligand orientation in 
carbohydrate-protein interactions has been less explored until today.[43, 85] In order to 
investigate the importance of spatial distribution and orientation of carbohydrates as 
ligands of their receptors, azobenzene glycosides became principal targets for our 
research. E/Z isomerization of azobenzene glycosides results in substantial 
18
 
 
conformational changes of the attached carbohydrate moieties and thus this 
isomerization process can be used to alter the orientation of carbohydrate ligands. 
This thesis describes the synthesis of various azobenzene glycosides, their photocromic 
properties in solution and their interaction with live E. coli bacteria and human cells 
(chapter 3). Also, functionalization of azobenzene glycosides on gold surfaces and their 
interaction with lectins will be explained (chapter 4). In addition, modification of type I 
antifreeze proteins (AFP) by photoswitchable azobenzene glycosides is described 
briefly in this thesis (chapter 5). 
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3.  Synthesis and properties of azobenzene glycoconjugates in 
solution. 
For any relevant application of azobenzene glycoconjugates, their photochemical 
properties have to meet the requirements for biological testing. Only few examples of 
azobenzene glycoconjugates are known in literature and no systematic investigation of 
their photochromic properties has been published so far.[72, 75] In view of this, we have 
designed and synthesized various photoswitchable azobenzene glycosides and studied 
their photophysical properties in solutions (chapter 3.2 and 3.3). In addition to this, E 
and Z isomers of azobenzene glycoside were tested as inhibitors of type 1 fimbriae-
mediated bacterial adhesion of E. coli (chapter 3.1). 
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3.1 Synthesis and testing of the first azobenzene mannobioside as                    
photoswitchable ligand for the bacterial lectin FimH. 
Vijayanand Chandrasekaran, Katharina Kolbe, Femke Beiroth, Thisbe K. Lindhorst*  
 
Beilstein J. Org. Chem. 2013, 9, 223-233. 
 
In this full research paper, azobenzene mannobiosides and mannobiosides were 
synthesized, their photochromoic properties were studied in solution and E- and Z- 
isomers were tested as inhibitors of type 1-fimbriated bacterial adhesion of E. coli (Fig 
3.1). High yielding E→Z isomerization process and a long life time (1/2 =178.5 h) of the 
Z-isomer for the azobenzene mannobioside was observed. Biological testing results 
showed that both isomers have nearly the same inhibitory potency, which is in well 
agreement with computer-aided docking studies. This finding suggests that the same 
molecule can be immobilized and test the adhesion of E. coli on photoswichable 
glycoarrays. 
 
Figure 3.1: The depicted azobenzene mannobioside was tested as inhibitor of the bacterial lectin FimH. 
In this project, F. Beiroth performed the molecular docking studies, K. Kolbe did the 
biological testing and I did the synthesis and studied the photochromic properties of 
azobenzene glycosides. All authors contributed in writing this article and supplementary 
material. 
21
223
Synthesis and testing of the first azobenzene
mannobioside as photoswitchable ligand
for the bacterial lectin FimH
Vijayanand Chandrasekaran, Katharina Kolbe, Femke Beiroth
and Thisbe K. Lindhorst*
Full Research Paper Open Access
Address:
Christiana Albertina University of Kiel, Otto Diels Institute of Organic
Chemistry, Otto-Hahn-Platz 3/4, D-24098 Kiel, Germany, Fax: +49
431 8807410
Email:
Thisbe K. Lindhorst* - tklind@oc.uni-kiel.de
* Corresponding author
Keywords:
azobenzene glycosides; bacterial adhesion; E/Z photoisomerisation;
FimH antagonists; mannobiosides; molecular switches; sweet
switches
Beilstein J. Org. Chem. 2013, 9, 223–233.
doi:10.3762/bjoc.9.26
Received: 08 November 2012
Accepted: 18 January 2013
Published: 01 February 2013
This article is part of the Thematic Series "Molecular switches and cages".
Guest Editor: D. Trauner
© 2013 Chandrasekaran et al; licensee Beilstein-Institut.
License and terms: see end of document.
Abstract
In order to allow spatial and temporal control of carbohydrate-specific bacterial adhesion, it has become our goal to synthesise
azobenzene mannosides as photoswitchable inhibitors of type 1 fimbriae-mediated adhesion of E. coli. An azobenzene mannobio-
side 2 was prepared and its photochromic properties were investigated. The E→Z isomerisation was found to be highly effective,
yielding a long-lived (Z)-isomer. Both isomers, E and Z, show excellent water solubility and were tested as inhibitors of mannoside-
specific bacterial adhesion in solution. Their inhibitory potency was found to be equal and almost two orders of magnitude higher
than that of the standard inhibitor methyl mannoside. These findings could be rationalised on the basis of computer-aided docking
studies. The properties of the new azobenzene mannobioside have qualified this glycoside to be eventually employed on solid
support, in order to fabricate photoswitchable adhesive surfaces.
Introduction
Adhesion of bacteria to surfaces can be a severe problem both
in vivo and in vitro. Hence, inhibition of bacterial adhesion by
powerful antagonists is highly desirable, however, ideally on
demand, that is, in a specific and spatially as well as temporally
resolved way. Often bacterial adhesion depends on the inter-
action of adhesive organelles called fimbriae. They project from
the surface of bacteria and contain lectin domains to attach to
certain carbohydrate ligands of a glycosylated surface such as
the glycocalyx of eukaryotic target cells (Figure 1A) [1-4]. This
offers the possibility to inhibit bacterial adhesion by designed
22
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Figure 1: The α-(1→3)-linked mannobioside α-D-Man-(1→3)-D-Man 1 (B) is a potent disaccharide ligand for the bacterial lectin FimH and can thus
inhibit type 1 fimbriae-mediated bacterial adhesion to glycosylated surfaces (A). Introduction of an azobenzene aglycone moiety turns glycoside 1 into
a putative photoswitchable antagonist 2 of mannose-specific bacterial adhesion, displaying an (E)-, as well as a (Z)-form (C). In a future perspective
azobenzene glycosides such as 2 can be further functionalised to be attached to oligofunctional core molecules or immobilised on surfaces (D).
antagonists of the respective carbohydrate-specific bacterial
lectins [5]. In order to expand the scope of carbohydrate-based
antiadhesives, it has become our goal to make photoswitchable
ligands of bacterial lectins to allow blocking of bacterial adhe-
sion in a photocontrolled manner.
One of the best-known fimbriae are the type 1 fimbriae of
uropathogenic E. coli (UPEC), which comprise the α-D-
mannosyl-specific lectin FimH at the tip of the fimbrial shaft.
FimH antagonists are currently considered as new therapeutics
for the treatment of urinary tract infections [6]. The carbo-
hydrate specificity of FimH has been investigated in great detail
[7] and its structure is well-known from several X-ray studies
[8-11]. It has turned out that the 1,3-linked mannobioside α-D-
Man-(1→3)-D-Man (1, Figure 1B) is an ideal disaccharide
ligand for FimH [3,12]. All other isomeric mannobiosides do
not bind favourably to FimH. Therefore, we have designed the
respective azobenzene mannobioside 2 (Figure 1C) in order to
make a photoswitchable FimH antagonist available. Photoirra-
diation of azobenzene glycosides at ~365 nm effects E→Z
isomerisation of the N=N double bond, and thermal relaxation
or irradiation at ~450 nm leads to Z→E back isomerisation
[13,14]. In the case that the E→Z isomerisation process is high-
yielding and the lifetime of the (Z)-form of the azobenzene
glycoside is long enough, it can be employed in bacterial adhe-
sion assays independently from the more stable (E)-isomer.
Eventually, this type of azobenzene mannobioside can be
further functionalised to be attached to various supports such as
oligofunctional core molecules [15] or surfaces, to achieve
switchable adhesive surfaces in continuation of our work on
glycoarrays [16-18] (Figure 1D).
In this account, we describe the synthesis of the azobenzene
mannobioside 2 as well as of mannoside 6, investigation of their
photochromic properties, and testing of mannobioside 2 as an
inhibitor of type 1 fimbriae-mediated bacterial adhesion. Inter-
pretation of the test results was supported by computer-aided
docking studies.
Results
Synthesis of azobenzene mannobioside 2
For the preparation of azobenzene mannobioside 2, the azoben-
zene mannoside 6 was prepared first. Thus, mannosylation of
the hydroxy-functionalised azobenzene 4 by using the mannosyl
23
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Scheme 1: Synthesis of azobenzene mannoside 6 and azobenzene mannobioside 2 by glycosylation.
trichlororacetimidate 3 [19] led to the respective azobenzene
α-mannosides 5 in 81% yield (Scheme 1). Treatment of 5 under
Zemplén conditions [20] furnished the deprotected mannoside 6
in a basically quantitative reaction. Then, a standard protecting-
group strategy was employed to allow the synthesis of the 3-OH
unprotected mannoside 10, which is a key intermediate serving
as the glycosyl acceptor in the following disaccharide synthesis.
First, regioselective protection of the primary 6-hydroxy group
in 6 was accomplished by using TBDMS chloride in pyridine to
yield 7. Then, triethylorthoacetate was employed to make the
orthoester 8, which, without intermediate purification steps,
could be carried on in a sequence of silyl ether-deprotection
leading to the intermediate 9, acetylation of the 4- and
6-hydroxy groups, and then acid-mediated regioselective ring
opening of the 2,3-orthoester in the same pot to yield the free
3-OH azobenzene mannoside 10 in an overall yield of 43%.
Thus, the required protecting group pattern was obtained in a
highly efficient way, based on the regioselective opening of
orthoacetates to yield a vicinal arrangement of equatorial OH
and axial O-acetyl groups [21,22]. The acetylation pattern was
24
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Table 1: Characterisation of the (E)- and (Z)-isomers of azobenzene glycosides 6 and 2.
azobenzene
glycoside
E/Za
(GS)
E/Za
(PSS)
H-1 (ppm)
(E)-isomer
H-1 (ppm)
(Z)-isomer
UV–vis
absorption
maxima (nm)
λmax(E), λmax(Z)
half-life, τ1/2 (h)
6 99:1 3:97 5.54b 5.34b 347, 440c 89
2 95:5 4:96 5.65d 5.52d 339, 429e 178.5
aaccording to the integration ratio of H-1(E) and H-1(Z) in the 1H NMR spectrum;
b10 mM concentration in DMSO-d6;
c50 µM concentration in DMSO;
d8 mM concentration in D2O;
e65 µM concentration in H2O.
clearly confirmed by 1H NMR spectroscopy showing the
expected downfield shift for the H-3 signal resonating at
4.32 ppm (H-2: 5.30 ppm, H-4: 5.17 ppm).
Next, glycosylation of the key intermediate 10 by using the
mannosyl donor 3 gave the desired mannobioside 11 in 76%
yield. Finally, removal of the O-acetyl groups according to
Zemplén led to the unprotected 1,3-linked target mannobioside
α-D-Man-(1→3)-D-Man (2).
With the two azobenzene glycosides 6 and 2 at hand, their solu-
bility and photochromic properties were then investigated and
compared. Mannoside 6 showed only poor solubility in most
organic solvents, except for DMSO. Unfortunately, it was also
not soluble in water, or in water/DMSO mixtures, which would
allow biological testing. Mannobioside 2, on the other hand,
showed good solubility in polar organic solvents as well as in
pure water. Thus, it was amenable to biological testing in
aqueous buffer.
E→Z photoisomerisation of azobenzene mannoside 6 was
studied in DMSO, while isomerisation of azobenzene manno-
bioside 2 was performed in water. Photoirradiation was carried
out in the dark at room temperature by employing a 365 nm
LED. Photostationary states (PSS) were reached after
10 minutes of irradiation for both compounds. E→Z isomerisa-
tion was observed by both 1H NMR and UV–vis spectroscopy.
The E/Z ratios of the ground state (GS) as well as of the
photostationary state were determined on the basis of the
integration of the anomeric H-1 protons in the 1H NMR spec-
trum. Half-life were determined by UV–vis spectroscopic
observation of the thermal Z→E relaxation process (Supporting
Information File 1). The respective data are collected in
Table 1.
Fortunately, the mannobioside 2 is ideally suited for biological
testing as it is soluble in water and aqueous buffer, respectively.
Photoirradiation of the (E)-isomer leads to almost quantitative
isomerisation, and the life time of the resulting (Z)-isomer is
long enough to test this isomer independently from the more
stable (E)-form.
Biological testing of azobenzene mannobio-
side 2
As a test system for mannose-specific bacterial adhesion, fluo-
rescent GFP-transfected E. coli bacteria (pPKL1162) [23] were
employed and tested on a mannan-coated polystyrene microtiter
plate surface. In this setup the amount of bacterial adhesion
correlates with fluorescence intensity and can be quantified by
using a standard microtiter plate reader. For inhibition of
bacterial adhesion, two sets of serially diluted solutions of 2
were prepared to inhibit adhesion of fluorescing E. coli to the
mannan surface. In one case, a stock solution of (E)-2 was seri-
ally diluted, in the second case, this stock solution of (E)-2 was
irradiated for 15 minutes to obtain the pure (Z)-2 isomer for
subsequent serial dilution. The effect of both isomers as inhibi-
tors of mannose-specific bacterial adhesion was then measured
in a concentration-dependent way. From the testing results
sigmoidal inhibition curves were obtained (Supporting Informa-
tion File 1) from which IC50 values for every individual inhib-
itor were deduced. The IC50 value reflects the concentration at
which a compound inhibits 50% of bacterial adhesion to a
mannan-coated surface. The determined IC50 values were refer-
enced to the inhibitory potency of methyl α-D-mannoside
(MeMan) and p-nitrophenyl α-D-mannoside (pNPMan), res-
pectively, each tested on the same plate. Thus, relative inhib-
itory potencies (RIP values) were obtained, which allow com-
parison of inhibitory potencies of different inhibitors, even
when they were not tested in the same experiment. The testing
results collected in Table 2 show that the inhibitory power of
mannobioside 2 is roughly the same, regardless of whether its
(E)- or (Z)-form was employed. Inspection of their relative
inhibitory potencies reveals that both isomers of 2 are equally
potent inhibitors of type 1 fimbriae-mediated bacterial
adhesion, similar to the power of the well-known mannoside
pNPMan.
25
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Table 2: Inhibition of adhesion of E. coli to a mannan-coated surface. The inhibitory potencies of (E)- and (Z)-2 are compared to the standard inhibi-
tors MeMan and pNPMan. a
MeMan pNPMan (E)-2 (Z)-2
IC50 ± SD (mM)
5.205 ± 0.416 0.064 ± 0.018 0.073 ± 0.001
0.073 ± 0.003 0.078 ± 0.006 0.084 ± 0.002
RIP (MeMan) ± SD IP ≡ 1 81 ± 25 71 ± 1
RIP (pNPMan) ± SD IP ≡ 1 0.94 ± 0.07 0.87 ± 0.02
aAverage values from duplicate results; SD: standard deviation (from one assay); RIP: relative inhibitory potency referenced to either MeMan or
pNPMan, each tested on the same microtiter plate.
In order to support the interpretation of the obtained test results,
binding of (E)-2 and (Z)-2 to the bacterial lectin FimH was
investigated by computer-aided docking studies to get an idea
of their interactions with the carbohydrate-recognition domain
(CRD) of the lectin.
Docking of azobenzene mannobioside 2 into
the carbohydrate binding site of FimH
To visualise complexation of the (E)- and (Z)-isomers of
azobenzene mannobioside 2 within the CRD of FimH FlexX
[24-26], flexible docking and consensus scoring [27,28], as
implemented in Sybyl 6.9 [29], was employed. Docking was
based on two different X-ray structures of FimH. They differ in
the conformation of the so-called tyrosine gate at the entrance
of the CRD, formed by the side chains of Y48 and Y137. One
structure is crystallised in an “open-gate” conformation [9],
another in the “closed-gate” conformation [10]. Affinity of any
FimH ligand is improved when it exerts favourable interactions
with the tyrosine gate of FimH. Thus, this substructure is an
important feature of the rim of the carbohydrate binding site of
this lectin.
Before minimisation of the ligands, the bond angle of the N=N
double bond of the azobenzene moiety was manually set as
180° for (E)-2 and as 90° for (Z)-2 [30]. Then docking was
performed holding the FimH CRD fixed whereas the ligands
were allowed to change their conformations under the influ-
ence of the force field. A FlexX scoring value has been attri-
buted to each of the 30 obtained conformations (Table 3). This
value correlates with the binding affinity of the ligand for the
FimH CRD, more negative values suggesting higher binding
affinity than less negative ones.
Docking gave very similar results for both isomers of manno-
bioside 2, (E)-2 and (Z)-2. Scoring values based on the open-
Table 3: FlexX scoring values for the (E)- and the (Z)-isomer of 2
based on two different crystal structures in comparison to MeMan and
pNPMan.
Ligand “open-gate” structure
[9]
“closed-gate” structure
[10]
MeMan −22.5 −23.3
pNPMan −24.9 −27.4
(E)-2 −28.8 −20.4
(Z)-2 −28.7 −21.6
gate structure of FimH are almost equal (−28.8 and −28.7), and
also the scoring values obtained with the closed-gate structure
do not differ significantly (−20.4 and −21.6). Interestingly, the
predictions for pNPMan and also MeMan are the opposite,
suggesting better binding to the closed-gate conformation of
FimH, as described earlier [31]. Representative snapshots as
depicted in Figure 2 show that both isomers have the terminal
mannoside complexed within the CRD of the lectin, as
expected, and furthermore, that in both cases the azobenzene
moiety exerts effective interactions with the tyrosine gate
involving both benzene rings.
Regardless of whether the (E)- or the (Z)-form of 2 is
complexed with FimH, favourable π–π interactions can be
formed between the azobenzene moiety and the tyrosine gate at
the entrance of the CRD, though in different ways. The only
difference that is seen is that, apparently, the interactions of
mannobioside 2 with the open-gate conformation of FimH are
advantageous over those with the closed-gate form. From the
bioassay in solution phase it can certainly not be decided, which
conformation the bacterial lectin adopts to interact with com-
pound 2; however, our test results confirm that both isomers of
the azobenzene mannobioside 2 have the same power as inhibi-
tors of FimH-mediated bacterial adhesion.
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Figure 2: Connolly [32,33] descriptions of the FimH CRD with the docked azobenzene mannobioside 2. Top: (E)-isomer (A, closed-gate; B, open-gate
conformation). Bottom: (Z)-isomer (C, closed-gate; D, open-gate conformation).
Discussion
The azobenzene mannobioside 2 was selected as a photoswitch-
able inhibitor of the bacterial lectin FimH based on earlier find-
ings about the inhibitory potency of several mannobiosides
[34,35]. Its synthesis was straightforward and high-yielding. It
has very convenient photochromic properties as the E→Z
isomerisation is almost quantitative and the resulting (Z)-isomer
is especially long-lived. Both isomers are very well water-
soluble and could be independently tested as inhibitors of
mannose-specific bacterial adhesion and showed an equal and
high inhibitory potency in the range of the well-known high-
affinity inhibitor p-nitrophenyl α-D-mannoside (pNPMan). This
result can be rationalised by computer docking, showing that
regardless of the configuration of the N=N double bond of the
azobenzene moiety in 2, favourable interactions can be formed
with the tyrosine gate of the FimH CRD. While the terminal
mannoside portion is complexed in the carbohydrate binding
site, the first mannoside does not add significantly to the
affinity and this is in accordance with other studies on the com-
plexation of oligosaccharides by FimH [11]. However, this
mannose ring acts as a spacer moiety, sticking out straight from
the CRD and placing the azobenzene portion in an orientation
that allows flexible interactions with the tyrosine gate at the
entrance of the carbohydrate binding site of the lectin.
Apparently, the affinity of 2 to the open-gate form of FimH is
higher than to the closed-gate conformation, a finding that
differs from many other docked FimH ligands. Here, the higher
affinity for the open-gate FimH can be explained by strong π–π
stacking of the first aromatic ring of the azobenzene unit with
the tyrosine gate.
As both isomers of 2 interact equally well with FimH, they
can’t be used to switch type 1 fimbriae-mediated bacterial adhe-
sion in solution. On the other hand, the obtained results support
the idea to immobilise the azobenzene mannobioside on a solid
support to photocontrol the adhesive properties of the resulting
surface. In this approach the azobenzene N=N double bond can
be used as a hinge region to bend down the terminal mannose
moiety of the compound, which is critical for specific bacterial
27
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adhesion. Thus, upon E→Z isomerisation, the ligand will no
longer be available for the interaction with the FimH-termi-
nated type 1 fimbriae that mediate adhesion. In this approach,
the second mannose moiety of the mannobioside is important
both to mediate hydrophilicity and to intensify the steric effect
that photoswitching has on the exposition of the terminal
mannoside.
Conclusion
The azobenzene mannosides presented herein resemble a struc-
ture quite similar to biaryl mannosides, which have been intro-
duced lately and shown to be of medical relevance as FimH
antagonists [6]. Thus, our novel “sweet switches” [15] appear to
be highly promising FimH ligands, with the additional feature
of a photoswitchable moiety. The biomedicinal potential of
azobenzene glycosides seems even higher when their favour-
able physiological properties are considered, such as low
toxicity [36] and receptor specificity of the azobenzene aglycon
[37]. It will be our next goal to employ derivatives of azoben-
zene mannobioside 2  for immobilisation to test the
photoswitching of adhesion on surfaces.
Experimental
Materials and general methods
p-Hydroxyazobenzene was purchased from Sigma Aldrich and
used without further purification. Moisture-sensitive reactions
were carried out under nitrogen in dry glassware. Thin-layer
chromatography was performed on silica-gel plates (GF 254,
Merck). Detection was effected by UV and/or charring with
10% sulfuric acid in EtOH followed by heat treatment at
~180 °C. Flash chromatography was performed on silica gel 60
(Merck, 230–400 mesh, particle size 0.040–0.063 mm) by using
distilled solvents. Optical rotations were measured with a
Perkin-Elmer 241 polarimeter (sodium D-line: 589 nm, length
of cell: 1 dm) in the solvents indicated. 1H and 13C NMR
spectra were recorded on Bruker DRX-500 and AV-600 spec-
trometers at 300 K. Chemical shifts are reported relative to
internal tetramethylsilane (δ = 0.00 ppm) or D2O (δ =
4.76 ppm). Full assignment of the peaks was achieved with the
aid of 2D NMR techniques (1H/1H COSY and 1H/13C HSQC).
IR spectra were measured with a Perkin Elmer FT-IR Paragon
1000 (ATR) spectrometer. ESI mass spectra were recorded on
an Esquire-LC instrument from Bruker Daltonics. MALDI-TOF
mass spectra were recorded on a Bruker Biflex III instrument
with 19 kV acceleration voltage, and 2,5-dihydroxybenzoic acid
(DHB) was used as the matrix. UV–vis absorption spectra were
performed on Perkin-Elmer Lambda-241 or Varian Cary-5000
at a temperature of 18 ± 1 °C. Photoirradiaton was carried out
by using a LED (emitting 365 nm light) from the Nichia
Corporation (NC4U133A) with a FWHM of 9 nm and an
optical power output (Po) ~ 1 W.
For NMR assignments the following numbering was used:
(E)-p-(Phenylazo)phenyl 2,3,4,6-tetra-O-acetyl-α-D-
mannopyranoside (5). To a solution of the mannosyl donor 3
(5.00 g, 10.2 mmol) and p-hydroxyazobenzene (4, 2.01 g,
10.2 mmol) in dry CH2Cl2 (100 mL) BF3·etherate (1.88 mL,
15.2 mmol) was added at 0 °C under N2 atmosphere, and the
reaction mixture was stirred at this temperature for 15 min.
Then, stirring was continued at rt for about 6 h, and then the
reaction was quenched by the addition of satd. aq. NaHCO3
solution (50 mL). The phases were separated, the aqueous phase
was extracted with CH2Cl2 (2 × 150 mL), and the combined
organic phases were dried over MgSO4. This was filtered, and
the filtrate was concentrated under reduced pressure. Purifica-
tion of the crude product by column chromatography (cyclo-
hexane/ethyl acetate, 3:1) gave the title glycoside 5 as an orange
crystalline solid (4.33 g, 8.19 mmol, 81%). Mp 53–55 °C; Rf
0.35 (cyclohexane/ethyl acetate 2:1); [α]20D +0.86 (c 0.9,
DMSO); 1H NMR (500 MHz, CDCl3) δ 7.92 (d, J = 9.0 Hz,
2H, H-9, H-11), 7.89 (d, J = 8.5 Hz, 2H, H-14, H-18),
7.53–7.45 (m, 3H, H-15, H-16, H-17), 7.23 (d, J = 9.0 Hz, 2H,
H-8, H-12), 5.62 (d, J1,2 = 1.8 Hz, 1H, H-1), 5.58 (dd, J2,3 =
3.6 Hz, J3,4 = 10.1, 1H, H-3), 5.49 (dd, J1,2 = 1.8 Hz, J2,3 =
3.6 Hz, 1H, H-2), 5.39 (dd~t, J3,4 = J4,5 = 10.0 Hz, 1H, H-4),
4.30 (dd, J5,6a = 5.4 Hz, J6a,6b = 12.0 Hz, 1H, H-6a), 4.14–4.07
(m, 2H, H-5, H-6b), 2.21, 2.06, 2.05, 2.03 (each s, each 3H, 4
OAc); 13C NMR (125 MHz, CDCl3) δ 170.5, 169.9, 169.9,
169.7 (4 C=O), 157.6 (C-7), 152.6 (C-13), 148.4 (C-10), 130.8
(C-16), 128.9 (C-15, C-17), 124.6 (C-9, C-11), 123.1 (C-14,
18), 116.8 (C-8, C-12), 95.7 (C-1), 69.4 (C-5), 69.3 (C-2), 68.8
(C-3), 65.9 (C-4), 62.1 (C-6), 20.9, 20.7, 20.7, 20.6 (4 COCH3);
IR (ATR) : 2929, 1743, 1598, 1496, 1366, 1209, 1029 cm−1;
ESIMS (m/z): [M + Na]+ calcd for C26H28N2O10, 551.5; found,
551.1.
(E)-p-(Phenylazo)phenyl α-D-mannopyranoside (6). To a
solution of the acetyl-protected glycoside 5 (600 mg,
1.14 mmol) in dry MeOH (6 mL), a catalytic amount of solid
NaOMe was added under N2 atmosphere, and the reaction mix-
ture was stirred for 5 h at rt. Then it was neutralized with
Amberlite IR 120 ion-exchange resin and filtered. The filtrate
was evaporated under reduced pressure to yield the deprotected
28
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mannoside 6 as a pale yellow solid (393 mg, 1.09 mmol, 96%).
Mp 183–185 °C; Rf 0.34 (ethyl acetate/MeOH 4:1); [α]20D
+1.40 (c 1.0, DMSO); 1H NMR (500 MHz, DMSO-d6) δ 7.86
(d, J = 8.7 Hz, 2H, H-9, H-11), 7.82 (d, J = 7.7 Hz, 2H, H-14,
H-18), 7.53–7.45 (m, 3H, H-15, H-16, H-17), 7.26 (d, J =
8.7 Hz, 2H, H-8, H-12), 5.53 (bs, 1H, H-1), 3.89 (dd~bs, 1H,
H-2), 3.73 (dd, J3,4 = 9.2 Hz, J3,2 = 3.0 Hz, 1H, H-3), 3.58–3.47
(m, 3H, H-6a, H-4, H-6b), 3.38 (mc, 1H, H-5); 13C NMR
(125 MHz, DMSO-d6) δ 158.9 (C-7), 155.5 (C-13), 151.9
(C-10), 130.9 (C-16), 129.4 (C-15, C-17), 124.3 (C-9, C-11),
122.3 (C-14, C-18), 117.1 (C-8, C-12), 98.7 (C-1), 75.2 (C-5),
70.6 (C-3), 69.9 (C-2), 66.6 (C-4), 60.9 (C-6); UV, λmax:
347 nm; ε = 25907 ± 529 L × mol−1 × cm−1; IR (ATR) : 3337,
2920, 1599, 1584, 1496, 1227 cm−1; MALDI-TOFMS (m/z):
[M + H]+ calcd for 361.36; found, 361.21; anal. calcd for
C18H20N2O6: C, 59.99; H, 5.59; N, 7.77; found: C, 61.07; H,
5.80; N, 8.07.
NMR spectroscopic data for (Z)-6. 1H NMR (500 MHz,
DMSO-d6) δ 7.32 (t, J = 7.8 Hz, 2H, H-15, H-17), 7.18 (t, J =
7.4 Hz, 1H, H-16), 6.97 (d, J = 8.9 Hz, 2H, H-9, H-11), 6.82
(dd, J = 8.2 Hz, J = 6.7 Hz, 4H, H-8, H-12, H-14, H-18), 5.32
(d, J1,2 = 1.6 Hz, 1H, H-1), 3.77 (dd, J2,3 = 3.1 Hz, J1,2 =
1.9 Hz, 1H, H-2), 3.62 (dd, J3,4 = 9.3 Hz, J3,2 = 3.3 Hz, 1H,
H-3), 3.52 (dd, J5,6a = 2.1 Hz, J6a,6b= 11.8 Hz, 1H, H-6a),
3.48–3.36 (m, 2H, H-4, H-6b), 3.31 (ddd, J4,5 = 9.4 Hz, J5,6a =
5.8 Hz, J5,6b = 2.1 Hz, 1H, H-5); 13C NMR (125 MHz, DMSO-
d6) δ 155.4 (C-7), 153.8 (C-13), 147.3 (C-10), 129.1 (C-15,
C-17), 127.0 (C-16), 122.5 (C-8, C-12), 119.4 (C-14, C-18),
116.7 (C-9, C-11), 98.7 (C-1), 74.8 (C-5), 70.3 (C-3), 69.7
(C-2), 66.3 (C-4), 60.7 (C-6); UV, λmax: 440 nm, ε = 2635 ± 76
L × mol−1 × cm−1.
(E)-p-(Phenylazo)phenyl 6-O-tert-butyldimethylsilyl-α-D-
mannopyranoside (7). To a solution of the azobenzene
mannoside 6 (3.00 g, 8.33 mmol) in pyridine (30.0 mL) tert-
butyldimethylchlorosilane (1.38 g, 9.17 mmol) was added and
the reaction mixture was stirred at rt for 18 h, after which TLC
showed complete consumption of the starting material. The
reaction was quenched with MeOH (2.0 mL) and further diluted
with ethyl acetate (150 mL). Then it was washed with satd. aq.
NaHCO3 solution (30 mL) and the aqueous phase extracted
with ethyl acetate (2 × 50 mL). The combined organic phases
were dried over MgSO4 and filtered, and the filtrate concen-
trated under reduced pressure to obtain the crude product. Puri-
fication by flash column chromatography (CH2Cl2/MeOH 3:7)
gave the title compound as a dark orange solid (3.16 g,
6.66 mmol, 80%). Mp 74 °C; Rf 0.59 (CH2Cl2/MeOH 7:1);
[α]20D +73 (c 0.97, MeOH); 1H NMR (500 MHz, MeOH-d4) δ
7.94–7.88 (m, 4H, H-9, H-11, H-14, H-18), 7.57–7.49 (m, 3H,
H-15, H-16, H-17), 7.30 (d, J = 9.0 Hz, 2H, H-8, H-12), 5.62 (d,
J1,2 = 1.7 Hz, 1H, H-1), 4.08 (dd, J1,2 = 1.8 Hz, J2,3 = 3.4 Hz,
1H, H-2), 3.98 (dd, J5,6a = 1.8 Hz, J6a,6b = 11.2 Hz, 1H, H-6a),
3.94 (dd, J2,3 = 3.5 Hz, J3,4 = 9.1 Hz, 1H, H-3), 3.82 (dd, J5,6b
= 6.5 Hz, J6a,6b = 11.3 Hz, 1H, H-6b), 3.71 (t, J = 9.4 Hz, 1H,
H-4), 3.65 (mc, 1H, H-5), 0.83 (s, 9H, tert-butyl), 0.04, 0.05
(each s, each 3H, 2 Si-CH3) ppm; 13C NMR (125 MHz, MeOH-
d4) δ 160.4 (C-7), 154.1 (C-13), 149.18 (C-10), 131.8 (C-16),
130.2 (C-15), 125.5 (C-17), 123.6 (C-9), 118.2 (C-11), 100.0
(C-1), 76.2 (C-5), 72.3 (C-2), 71.7 (C-3), 68.6 (C-4), 64.4 (C-6),
26.4 (C(CH3)3), 19.1 (C(CH3)3), −5.13 (2 Si-CH3) ppm; IR
(ATR) : 3337, 2928, 1599, 1498, 1229, 1006, 685 cm−1;
ESIMS (m/z): [M + Na]+ calcd for C24H34N2O6Si, 497.1;
found, 497.2;.
(E)-p-(Phenylazo)phenyl 6-O-tert-butyldimethylsilyl-2,3-O-
(ethylorthoacetyl)-α-D-mannopyranoside (8). To a solution
of mannoside 7 (500 mg, 1.05 mmol) in toluene (8.0 mL),
triethylorthoacetate (773 µL, 4.22 mmol) and a catalytic amount
of p-toluenesulfonic acid were added at rt, and the reaction mix-
ture was stirred for 3.5 h, after which TLC showed complete
consumption of the starting material. Then, it was neutralised
with triethylamine (100 µL), and the solution was diluted with
water (10 mL). It was extracted with toluene (2 × 20 mL), and
the extract was concentrated under reduced pressure to get
crude 8 (600 mg) as a red viscous syrup, which was used in the
next reaction step without further purification.
(E)-p-(Phenylazo)phenyl 2,3-O-(ethylorthoacetyl)-α-D-
mannopyranoside (9). The crude intermediate 8 (600 mg) was
dissolved in CH2Cl2 (6.0 mL), tetrabutylammonium fluoride
(1 M solution in THF, 1.68 mL) was added, and the reaction
mixture was stirred at rt for 4 h, after which TLC showed
complete consumption of the starting material. Then, it was
concentrated under reduced pressure to obtain crude 9 as a dark
red viscous syrup (594 mg), which was used in the next reac-
tion step without further purification.
(E ) -p - (Phenylazo)phenyl  2 ,4 ,6 - tr i -O -acety l -α -D-
mannopyranoside (10). The crude orthoester-protected
mannoside 9 (594 mg) was dissolved in pyridine (2.5 mL), and
acetic anhydride (1.26 mL) was added for O-acetylation. The
reaction mixture was stirred at rt for 3 h. Then, pyridine was
removed under reduced pressure, and the residue was dissolved
in ethyl acetate (20 mL) and washed with satd. aq. NaHCO3
solution (10 mL). The aqueous phase was extracted with ethyl
acetate (2 × 25 mL), the combined organic phases were dried
over Na2SO4 and filtered, and the filtrate concentrated was
under reduced pressure to obtain a syrupy intermediate. It was
dissolved in 80% acetic acid (2.5 mL), and the mixture was
stirred at rt for 1.5 h to effect regioselective cleavage of the
orthoester. Then, ethyl acetate (50 mL) was added and the
29
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organic layer was washed with water (5 mL) and dried over
MgSO4. It was filtered, and the filtrate was evaporated to obtain
the crude product, which purified by column chromatography
(cyclohexane/ethyl acetate 2:1) to yield the free 3-OH title
mannoside 10 as a bright orange solid (220 mg, 0.453 mmol,
43% over three steps). Mp 144–146 °C; Rf 0.21 (cyclohexane/
ethyl acetate); [α]20D +70 (c 0.96, CH2Cl2); 1H NMR
(500 MHz, CDCl3) δ 7.92 (d, J = 8.9 Hz, 2H, H-9, H-11), 7.89
(d, J = 7.9 Hz, 2H, H-14, H-18), 7.53–7.44 (m, 3H, H-15, H-16,
H-17), 7.19 (d, J = 8.9 Hz, 2H, H-8, H-12), 5.69 (d, J1,2 =
1.4 Hz, 1H, H-1), 5.30 (dd, J1,2 = 1.7 Hz, J2,3 = 3.8 Hz, 1H,
H-2), 5.17 (t, J = 10.0 Hz, 1H, H-4), 4.32 (m, 2H, H-3, H-6a),
4.11 (dd, J5,6b = 2.2 Hz, J6a,6b = 12.4 Hz, 1H, H-6b), 4.05 (mc,
1H, H-5), 2.23, 2.15, 2.03 (each s, each 3H, 3 OAc), 1.62 (bs,
OH) ppm; 13C NMR (150 MHz, CDCl3) δ 171.3, 170.6, 170.4
(3 COCH3), 157.7 (C-7), 152.6 (C-13), 148.3 (C-10), 130.8
(C-16), 129.1 (C-15, C-17), 124.6 (C-9, C-11), 122.7 (C-14,
C-18), 116.7 (C-8, C-12), 95.42 (C-1), 71.99 (C-2), 69.14 (C-5),
69.04 (C-4), 68.47 (C-3), 62.15 (C-6), 20.97, 20.91, 20.69 (3
COCH3) ppm; IR (ATR) : 3453, 2961, 1737, 1228, 1023,
798 cm−1; ESIMS (m/z): [M + H]+ calcd for C24H26N2O9,
509.1; found, 509.2.
(E)-p-(Phenylazo)phenyl 3-O-(2,3,4,6-tetra-O-acetyl-α-D-
mannopyranosyl)-2,4,6-tri-O-acetyl-α-D-mannopyranoside
(11). The 3-OH unprotected mannoside 10 (50 mg, 103 µmol)
and the mannosyl donor 3 (101 mg, 206 µmol) were dissolved
in dry CH2Cl2 (10 mL), and the mixture was cooled to −10 °C
under N2 atmosphere. To this ice-cooled solution BF3·etherate
(13 µL, 108 µmol) was added and the mixture was stirred at
0 °C for about 30 min. Then, the reaction mixture was allowed
to warm to rt and stirred for another 4 h. The reaction mixture
was then quenched by the addition of a catalytic amount of
solid NaHCO3 and concentrated under reduced pressure to
obtain the crude product as a dark reddish-brown syrup. Purific-
ation by column chromatography (CH2Cl2/ethyl acetate 8:2)
gave the acetyl-protected mannobioside 11 as a pale yellow
solid (64 mg, 78 µmol, 76%). Mp 84–85 °C; Rf 0.57 (CH2Cl2/
ethyl acetate 8:2); [α]20D +103 (c 0.86, CH2Cl2); 1H NMR
(500 MHz, CDCl3) δ 7.92 (d, J = 9.0 Hz, 2H, H-9, H-11), 7.89
(d, J = 7.1 Hz, 2H, H-14, H-18), 7.46–7.38 (m, 3H, H-15, H-16,
H-17), 7.18 (d, J = 9.0 Hz, 2H, H-8, H-12), 5.65 (d, J1,2 =
1.7 Hz, 1H, H-1), 5.46 (dd, J1,2 = 1.8 Hz, J2,3 = 3.5 Hz, 1H,
H-2), 5.40 (t, J = 10.1 Hz, 1H, H-4′), 5.30 (mc, 1H, H-3′), 5.26
(mc, 1H, H-4), 5.09 (d, J1,2 = 1.7 Hz 1H, H-1′), 5.06 (dd, J1,2 =
1.9 Hz, J2,3 = 2.9 Hz, 1H, H-2′), 4.41 (dd, J2,3 = 3.5 Hz, J3,4 =
9.9 Hz, 1H, H-3), 4.30 (dd, J5,6b = 6.3 Hz, J6a,6b = 12.7 Hz, 1H,
H-6a), 4.24 (dd, J5′,6b′ = 5.8 Hz, J6a′,6b′ = 12.3 Hz, 1H, H-6a′),
4.14–4.10 (m, H-5′, H-6b), 4.08 (dd, J5,6a = 2.4 Hz, J6a,6b =
12.3 Hz, 1H, H-6b), 3.99 (ddd, J4,5 = 10.2 Hz, J5,6a = 2.3 Hz,
J6a,6b = 5.8 Hz, 1H, H-5), 2.20, 2.09, 2.08, 2.03, 2.00, 1.97,
1.94 (each s, each 3H, 7 OAc) ppm; 13C NMR (125 MHz,
CDCl3) δ 170.6, 170.5, 170.4, 170.0, 169.9, 169.8, 169.6 (7
COCH3), 157.4 (C-7), 152.6 (C-13), 148.4 (C-10), 130.8
(C-16), 129.1 (C-15, C-17), 124.6 (C-9, C-11), 122.71 (C-14,
C-18) 116.7 (C-8, C-12), 99.1 (C-1′), 95.6 (C-1), 74.8 (C-3),
70.8 (C-2), 69.9 (C-2′), 69.9, 69.6 (C-5, C-5′), 68.3 (C-4), 67.4
(C-4′), 65.9 (C-3′), 62.5, 62.7 (C-6, C-6′), 20.9, 20.8, 20.7, 20.7,
20.7, 20.6, 20.6 (7 COCH3) ppm; IR (ATR) : 1743, 1213,
1032, 838 cm−1; ESIMS (m/z): [M + Na]+ calcd for
C38H44N2O18, 839.3; found, 839.2.
(E)-p-(Phenylazo)phenyl 3-O-(α-D-mannopyranosyl)-α-D-
mannopyranoside (2). The acetyl-protected disaccharide 11
(50 mg, 61.2 µmol) was dissolved in dry MeOH (2 mL) and a
catalytic amount of solid NaOMe was added under N2 atmos-
phere. The reaction mixture was stirred for 5 h at rt, and then it
was neutralized with Amberlite IR 120 ion-exchange resin. It
was then filtered and thoroughly washed with MeOH (2 ×
20 mL), and the filtrate was evaporated to obtain the crude pro-
duct, which after purification by flash column chromatography
(CH2Cl2/methanol 9:1) gave the final mannobioside 2 as a pale
yellow solid (29.3 mg, 56.1 µmol, 92%). Mp 107–109 °C; Rf
0.08 (CH2Cl2/MeOH 9:1); [α]20D +18.4 (c 0.48, MeOH);
1H NMR (500 MHz, D2O) δ 7.81 (d, J = 8.2 Hz, 2H, H-9,
H-11), 7.75 (d, J = 7.4 Hz, 2H, H-14, H-18), 7.53–7.49 (m, 3H,
H-15, H-16, H-17), 7.24 (d, J = 8.3 Hz, 2H, H-8, H-12), 5.65 (s,
1H, H-1), 5.16 (s, 1H, H-1′), 4.29 (mc, 1H, H-2), 4.14 (dd, J2,3
= 3.1 Hz, J3,4 = 10.3 Hz, 1H, H-3′), 4.06 (mc, 1H, H-2′),
3.89–3.81 (m, 3H, H-3, H-4, H-4′), 3.79–3.62 (m, 6H, H-6a,
H-6b, H-5, H-5′, H-6a′, H-6b′) ppm; 13C NMR (125 MHz,
D2O) δ 158.2 (C-7), 151.3 (C-13), 148.2 (C-10), 131.4 (C-16),
129.6 (C-15, C-17), 124.4 (C-9, C-11), 122.2 (C-14, C-18),
117.3 (C-8, C-12), 102.4 (C-1′), 97.8 (C-1), 77.9 (C-3′), 73.8
(C-5), 73.5 (C-3), 70.5 (C-4′), 70.1 (C-2′), 69.5 (C-2), 66.9
(C-5′), 65.9 (C-4), 61.1 (C-6), 60.6 (C-6′) ppm; IR (ATR) :
3318, 2927, 1599, 1231, 1007, 685 cm−1; MALDI-TOFMS
(m/z): [M + Na]+ calcd for C24H30N2O11, 545.18; found,
545.17; UV, λmax: 339 nm, ε = 14776 ± 729 L × mol−1 × cm−1;
anal. calcd for C24H30N2O11 × 1.1 H2O: C, 52.11; H, 6.09; N,
5.07; found: C, 52.04; H, 5.79; N, 5.06.
NMR-spectroscopic data for (Z)-2. 1H NMR (500 MHz, D2O)
δ 7.32 (t, J = 7.1 Hz, 2H, H-15, H-17), 7.24 (t, 1H, H-16), 7.00
(dd, J = 1.9 Hz, J = 8.9 Hz, 2H, H-9, H-11), 6.95 (dd, J =
1.9 Hz, J = 8.9 Hz, 2H, H-8, H-12), 6.91 (dd, J = 1.3 Hz, J =
7.8 Hz, 2H, H-14, H-18), 5.52 (s, 1H, H-1), 5.12 (s, 1H, H-1′),
4.22 (mc, 1H, H-2), 4.07 (mc, 1H, H-3′), 4.03 (dd, J1,2 = 1.7 Hz,
J2,3 = 3.2 Hz, 1H, H-2′), 3.85–3.82 (m, 2H, H-3, H-4),
3.79–3.59 (m, 7H, H-4′, H-6a, H-6b, H-5, H-5′, H-6a′, H-6b′)
ppm; 13C NMR (125 MHz, D2O) δ 155.3 (C-7), 153.5 (C-13),
146.9 (C-10), 129.2 (C-15, C-17), 128.2 (C-16), 123.4 (C-8,
30
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C-12), 120.3 (C-14, C-18), 116.9 (C-9, C-11), 102.4 (C-1′),
97.8 (C-1), 77.8 (C-3′), 73.7 (C-5), 73.4 (C-3), 70.4 (C-4′), 70.1
(C-2′), 69.4 (C-2), 66.8 (C-5′), 65.9 (C-4), 61.0 (C-6), 60.6
(C-6′) ppm; UV, λmax: 429 nm, ε = 1699 ± 68 L × mol−1 ×
cm−1.
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1. Data of photoisomerization  
Photoirradiation experiments were carried out at room temperature by using 365 nm LED lights 
(Product Number: NC4U133A) from Nichia Corporation (NJSE107) with power dissipation 
1.4 W and luminous flux 44 [lm]. Photoisomerization experiments with compound 6 were 
performed in DMSO and with compound 2 in water. Upon irradiaton, the photostationary state 
(PSS) was within 10 min for both compounds, as observed by UV–vis spectroscopy, The EZ 
isomerisation process is reflected by a decrease of the π–π* transition and an increase in the n–π* 
transition band. 
The kinetics of the Z→E relaxation process was determined by UV–vis spectroscopy in the dark. 
For determination of the rate constants, a graph of ln(A∞−At) was plotted as a function of time; 
where A∞ is the absorbance of the π–π* transition at infinitive time and At is the absorbance at 
time t after the relaxation process was started. The negative slope k of the linear plot is the rate 
constant of the Z→E relaxation process. The half life 1/2 as 1/2 = ln 2/k. 
 
 
 
Figure S1: UV–vis spectra of thermal ZE relaxation of mannoside 6 in DMSO (50 µM) at 
18 ± 1 °C. 
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Figure S2: UV–vis spectra of thermal ZE relaxation of the mannobioside 2 in water (65 µM) 
at 18 ± 1 °C. 
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Figure S3: 
1
H NMR spectra of (E)-6 and (Z)-6 in DMSO-d6 (500 MHz). 
 
 
Figure S4: 
13
C NMR spectra of (E)-6 and (Z)-6 in DMSO-d6 (125 MHz). 
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Figure S5: 
1
H NMR spectra of (E)-2 and (Z)-2 in D2O (500 MHz). 
 
 
Figure S6: 
13
C NMR spectra of (E)-2 and (Z)-2 in D2O (125 MHz). 
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2. Bioassays 
Media and buffer solutions: Carbonate buffer solution (pH 9.6): sodium carbonate (1.59 g) and 
sodium hydrogen carbonate (2.52 g) were dissolved in double-distilled water (1.00 L). PBS 
buffer solution (pH 7.2): sodium chloride (8.00 g), potassium chloride (200 mg), sodium 
hydrogen phosphate dihydrate (1.44 g) and potassium dihydrogenphosphate (200 mg) were 
dissolved in double-distilled water (1.00 L). PBST buffer solution (pH 7.2): PBS buffer + 0.05% 
v/v Tween® 20. LB medium: tryptone (10.0 g), sodium chloride (10.0 g) and yeast extract 
(5.00 g) were dissolved in distilled, deionised water (1.00 L); after autoclaving, ampicillin 
(100 mg) and chloramphenicol (50.0 mg) were added. pH values were adjusted by using 0.1 M 
HCl or 0.1 M NaOH.  
Cultivation of bacteria: E. coli bacteria (strain pPKL1162) [1] were grown on LB medium 
overnight at 37 °C in a sterilized tube. After centrifugation and washing with PBS buffer 
(2 × 2.00 mL) the bacteria pellet was suspended to a concentration of 2.00 mg/mL in PBS buffer. 
GFP assay: The published assay [2] was adapted and modified as follows: Black (nunc 
Maxisorp) plates were treated with a solution of mannan from Saccharomyces cerevisiae 
(1.2 mg/mL in carbonate buffer, pH 9.5; 100 μL/well) and allowed to dry at 37 °C overnight. 
The plates were washed with PBST (3 × 150 μL/well). Before use the wells were blocked with 
BSA (5% in PBS, 120 μL/well) for 2 h at 37 °C and then washed with PBST (3 × 150 μL/well). 
Serial dilutions of the examined inhibitor mannobioside 2 ((E)- or (Z)-configured, respectively) 
were prepared in the plates (50 µL/well). The bacteria suspension (2 mg bacteria/mL, 
50 μL/well) was added and the plates were agitated (80 rpm) and incubated for 1 h at 37 °C. 
After washing with PBS (2 × 150 μL) the wells were filled with PBS (100 μL/well) and the 
fluorescence intensity (485 nm/535 nm) was determined. 
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Figure S7: Inhibition curves obtained in inhibition of adhesion of E. coli to a mannan-coated 
surface. The isomers (E)- and (Z)-2 were tested on one microtiter plate together with pNPMan. 
The sigmoidal concentration–response curves were fitted by nonlinear regression. 
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Figure S8: Inhibition curves obtained in inhibition of adhesion of E. coli to a mannan-coated 
surface. The isomers (E)- and (Z)-2 were tested on one microtiter plate together with MeMan. 
The sigmoidal concentration–response curves were fitted by nonlinear regression. 
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3. Docking studies 
Computer-aided docking was performed by using FlexX flexible docking and consensus scoring, 
as implemented in Sybyl 6.9 [3] as described previously [4]. Docking was based on two 
published X-ray structures of the bacterial lectin FimH [5] (1KLF (open-gate) and 1UWF 
(closed-gate structure)). The torsion angle of the azobenzene moiety was manually set up to 180° 
for the (E)- and to 90° for the (Z)-isomer and then the structures were minimized by using the 
Tripos force field and Gasteiger–Hückel charges. Thirty conformations and FlexX scoring values 
were obtained for each ligand and listed in Tables S1–S4. 
Table S1: Scoring values for docking of E-configured azobenzene mannobioside 2 into the 
closed-gate structure of FimH. 
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Table S2: Scoring values for docking of E-configured azobenzene mannobioside 2 into the 
open-gate structure of FimH. 
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Table S3: Scoring values for docking of Z-configured azobenzene mannobioside 2 into the 
closed-gate structure of FimH. 
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Table S4: Scoring values for docking of Z-configured azobenzene mannobioside 2 into the 
open-gate structure of FimH. 
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3.2  Sweet switches: Synthesis and photochemical properties of 
azobenzene glycosides. 
Vijayanand Chandrasekaran, Eugen Johannes, Hauke Kobarg, Frank D. Sönnichsen, 
Thisbe K. Lindhorst* 
Chem. Eur. J, to be submitted. 
 
Before exploring azobenzene glycoconjugates in biochemical applications it is essential 
to have knowledge about their photochromic properties in solution. Although few 
examples of carbohydrates conjugated to azobenzene are known, the systematic 
investigations of their photochemical properties has not been published yet. 
In this manuscript, a series of azobenzene glycosides was synthesized. All the 
compounds were varied with regard to the anomeric configuration ( or , mannose or 
glucose, respectively), then configuration of the carbohydrates at C-2 and different 
substituents on the azobenzene moiety (Fig 4.1.2). Photochromic properties for the 
photoswitchable glycoconjugates were studied, compared and discussed. 
 
Figure 3.2: Retrosynthetic cuts for the preparation of different azobenzene glycosides. All  are varied with 
regard to anomeric configuration ( or , mannose or glucose, respectively) and substituent at the 
azobenzene moiety. 
In this project, E. Johannes synthesized the azobenzene -D-glucosides (4-6), H. 
Kobarg synthesized compound 29 and I synthesized all azobenzene -D-mannosides 
(1-3) and -D-glucosides (7-9, 26 and 27). I and T. K. Lindhorst wrote the manuscript 
and supporting information. 
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Introduction 
“Sweet switches” are carbohydrate derivatives that can be reversibly 
shifted between two structurally different states in order to control 
their function. Such functional saccharides are envisioned to serve 
as molecular tools to study the details of carbohydrate recognition in 
a biochemical context. For example, switching the orientation of 
carbohydrate epitopes within an array of glycans allows to study the 
consequences of carbohydrate orientation on surfaces in essential 
biological processes such as carbohydrate-protein interactions [1, 
2]and cell adhesion.  
Our minimalistic “sweet switch” design for structure-function 
studies comprises a selected saccharide covalently linked to a 
photoactive compound. For the latter, we select the azobenzene 
moiety, as it is well known to serve as a reliable photoresponsive 
unit, permitting to switch (an attached glycoside) between two 
independently addressable states.[3] Irradiation of the planar and 
more stable E-azobenzene form with UV light ( 365 nm) effects 
transition to the bent Z-isomer. Thus, E/Z isomerization of the 
azobenzene unit effects a considerable change in the spatial 
orientation of the conjugated sugar moiety. By exposure to visible 
light ( > 440 nm) or by thermal equilibration, the azobenzene Z-
isomer relaxes back to the E-form according to a half life 1/2 which  
 
is an individual parameter of a specific azobenzene derivative 
(Figure 1). 
 
 
Figure 1. E/Z Isomerization of azobenzene glycosides leads to a significant change in 
orientation of the ligated carbohydrate moiety and can thus effect essential biological 
processes connected to carbohydrate recognition: (i) lectin binding; (ii) no lectin 
binding. 
Whereas in nucleic acid and protein chemistry the azobenzene 
unit has been frequently used as photoswitchable unit,[4]  only few 
examples of carbohydrate-azobenzene conjugates are known and no 
systematic investigation of their photochromic properties has been 
published so far.[5-7] In addition, carbohydrates have mostly been 
conjugated to the azobenzene sub-structure by peptide coupling, and 
only rarely glycosidically linked azobenzene dervatives have been 
prepared.[8-10] In azobenzene glycosides, the azobenzene unit is O-
glycosidically attached to the relevant carbohydrate. Here, in order 
[a] V. Chandrasekaran, E. Johannes, H. Kobarg, Prof. Dr. F. D. Sönnichsen, 
Prof. Dr. Th. K. Lindhorst 
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Christiana Albertina University of Kiel 
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 2 
to validate this class of sweet switches for biochemical applications, 
a series of different azobenzene glycosides was synthesized and 
their photochromic properties compared. Azobenzene glycosides 
were varied with regard to configuration at C-2 of the carbohydrate 
ring (mannose or glucose, respectively), the anomeric configuration 
( or , respectively), and a substituent at the azobenzene moiety. 
Accordingly, nine azobenzene glycosides (Figure 2) were selected 
as target molecules for this study and their E/Z isomerization 
investigated.  
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Figure 2. Target azobenzene glycosides: Structural characteristics were systematically 
varied to study their effect on the photochromic properties of the respective glycoside. 
Preparation of azobenzene glycosides can be rather straight-
forward. Just one or two retrosynthetic cuts, respectively, are 
required for their synthesis (Figure 3). Either glycosylation of the 
hydroxylated azobenzene aglycon furnishes the target glycoside in 
one step; or first an appropriate glycosidic aniline is prepared and 
then condensation with a nitrosoarene completes the synthetic route 
(Mills reaction).[11] 
 
Figure 3. One or two retrosynthetic cuts, respectively, are required to approach 
azobenzene glycosides: (i) glycosylation and/or (ii) condensation of anilines and 
nitrosoarenes. 
Results and Discussion 
Synthesis of azobenzene glycosides: owing to our long 
standing  interest in -mannoside-specific proteins such as the 
bacterial lectin FimH, we started with the preparation -D-
mannosides (1-3, Figure 2). Glycosides of the 1,2-trans-type such as 
the -D-mannosides can be obtained from the appropriate 
azobenzene alcohol employing an O-acylated glycosyl donor in a 
stereospecific glycosylation reaction. The neighbouring group 
participation of the 2-O-acyl group of the sugar ring ensures the 
stereospecific course of the glycosylation reaction. Thus, for the 
synthesis of azobenzene -D-mannosides, O-acetylated mannosyl 
trichloroacetimidate 10[12, 13] was used as a starting material 
(Scheme 1). According to Schmidt’s procedure,[14, 15] Lewis acid 
catalyzed reaction of 10 with the commercially available 4-
hydroxyazobenzene 12 gave the -configured mannoside 15 and its 
deprotection under Zemplén conditions[16] gave the target 
mannoside 1. It turned out that this mannoside has a rather limited 
solubility in water and is therefore not suitable for biological tests. 
Thus, we aimed at introducing a carboxy group as substituent on the 
azobenzene aglycone in order to improve water solubility. The 
carboxy-substituted azobenzene derivative 13, o-(p-
hydroxyphenylazo)benzoic acid (HABA), is commercially available. 
For glycosylation, it was converted into its methyl ester 14 and then 
Lewis acid-promoted reaction with the glycosyl donor 10, as before, 
led to the -mannoside 16 in high yield. Zemplén deacetylation,[16] 
converted 16 into the methyl ester 3 and treatment with LiOH in a 
subsequent step delivered the unprotected o’-carboxy-substituted 
azobenzene glycoside 2. Interestingly, the water solubility of the 
methyl ester 3 was better than that of the carboxylic acid 2. Thus, 
azobenzene mannoside 3 is the best candidate for testing 
photoswitching in aqueous solution in this series of azobenzene 
mannosides, e.g. to investigate binding to mannose-specific lectins. 
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Scheme 1. Synthesis of azobenzene glycosides 1-3 and 7-9. (a) BF3-Et2O, CH2Cl2, RT, 
overnight, 15 (with 12: 81%), 16 (with 14: 84%), 17 (with 12: 73%), 18 (with 14: 79%); 
(b) MeOH/HCl, reflux, 5 h, 85%; (c) NaOMe, MeOH, RT, overnight, 1 (92%), 3 (89%), 
7 (90%), 9 (83%); (d) LiOH, THF-H2O (2:1), RT, overnight, 2 (93%), 8 (91%). 
In full analogy to the synthesis of the -mannosides 1-3, the 1,2-
trans-type -glucosides 7-9 were obtained employing the glucosyl 
donor 11 (Scheme 1).[14, 17] Overall, the synthesis of the first two 
sets of azobenzene glycosides, 1-3 and 7-9 required only a handful 
of high-yielding steps furnishing the final products as coloured 
crystalline compounds. 
In order to compare the influence of the anomeric configuration on 
E/Z isomerization of an azobenzene glycoside, the series of -D-
glucosides was then supplemented by the -D-glucosides 4-6. These 
glucosides are representatives of the 1,2-cis-glycoside type, and 
therefore more difficult to synthesize stereoselectively. A number of 
methods providing a stereospecific access to -glucosides have been 
introduced, however, require a more or less high number of 
synthetic steps. We therefore refrained from a glycosylation 
approach for the synthesis of 4-6. Instead the synthesis was started 
with p-aminophenyl -D-glucoside 19 which can be obtained by 
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catalytic reduction of commercially available p-nitrophenyl -D-
glucoside in a quantitative reaction.[18, 19] In a second step, the amine 
19 was submitted to condensation with the respective nitrosoarenes 
(Scheme 2). Acid-catalyzed condensation with nitrosobenzene 
delivered the unprotected target glucoside 4 in high yield. Likewise, 
target glucoside 5 was derived from condensation of 19 with the 
nitrosobenzene derivative 21, which was obtained from its 
carboxylic acid ester 20[20] and employed in situ. In order to 
facilitate purification of the condensation product, it was submitted 
to O-acetylation with acetic anhydride in pyridine to yield glucoside 
22, which could be easily purified. De-O-acetylation of pure 22 
according to Zemplén[19] furnished the methoxycarbonyl-substituted 
glucoside 6 and saponification of 6 with LiOH gave the carboxylic 
acid derivative 5. 
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Scheme 2. Synthesis of azobenzene glycosides 4, 5 and 6. (a) Acetic acid, RT, overnight, 
96%; b) oxone, CH2Cl2-H2O (16:20), RT, 20 h; (c) pyridine, acetic anhydride, RT, 
overnight, 89%; (d) NaOMe, MeOH, RT, overnight, 96%; (e) LiOH, THF-H2O (2:1), 
RT, 18 h, 95%. 
In addition to the nine target azobenzene glycosides 1-9, we 
were interested in mannosides 26 and 27 (Scheme 3) as these two 
compounds are promising antagonists of the mannose-specific 
bacterial lectin FimH.[21, 22] The glycosyl acceptor diol 23 was 
obtained according to the literature,[23] and a subsequent 
glycosylation using the mannosyl donor 10 gave a mixture of the 
mono- and bis-glycosylated azobenzene mannosides 24 and 25 in 
37% and 31% yield, respectively, after separation by column 
chromatography. De-O-acetylation led to the OH-free target 
glycosides 26 and 27 in high yield. The bis-glycosylated glycoside 
27 is a symmetrical molecule, which displays one signal set for both 
mannosyl moieties in its NMR spectra. For comparison of the 
photochromic properties of the mono-glycosylated azobenzene 
alcohol 26 (vide infra), the respective glucoside 29 was also 
prepared in analogy to the synthesis of 26 (Scheme 3).  
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Scheme 3. Synthesis of azobenzene glycoside 26 and 27. (a) BF3-Et2O, CH2Cl2, RT, 
overnight, 24 (37%), 25 (31%); (b) NaOMe, MeOH, RT, overnight, 26 (88%), 27 (93%), 
29 (89%); (c) and 28 (31%). 
Photoisomerization studies: With this collection of new 
azobenzene glycosides in hand, EZ photoisomerization was 
studied by 1H NMR spectroscopy, and kinetics of the relaxation 
process (ZE) were determined by UV-Vis spectroscopy. To allow 
for a comparison of the photochromic properties of the investigated 
azobenzene glycosides, all photoisomerization experiments were 
performed in DMSO. Photostationary states (PSS) were reached 
after irradiation at 365 nm for ~30 min. In the 1H NMR spectra, E 
and Z isomers were easily distinguished and quantified by 
integration, as they display well separated chemical shift for the 
aromatic protons or the anomeric H-1 of the sugar ring (Table 1). 
Half lifes 1/2 of thermal ZE isomerisation were determined by 
UV-Vis spectroscopy employing 50 M solutions in DMSO (shown 
for azobenzene mannoside 1 in Figure 4; for other glycosides see 
Supporting Information). 
 
While in the ground state (GS) all investigated azobenzene 
glycosides are nearly 100% E-configured. E/Z ratios in the PSS 
obtained after irradiation of a sample at 365 nm vary significantly 
among the 12 investigated glycosides. Unsubstituted azobenzene 
glycosides 1, 4, and 7, as well as the bivalent mannoside 27 could be 
isomerized almost quantitatively (Table 2) with long-lived Z-
isomers having half lifes 1/2 of up to over 90 h. A comparison of the 
unsubstituted azobenzene glycosides 1, 4, 7 shows that in this row, 
neither the anomeric linkage nor the configuration of the 2-
substituent of the sugar ring significantly influences the PSS. On the 
other hand, irradiation of the azobenzene glycosides bearing a 
substituent at the azobenzene aglycon resulted in larger E/Z ratios. 
In the extreme cases of the carboxy-substituted glycosides 2 and 5 
irradiation led to E/Z ratios of 85/15 and 76/24, respectively. 
However, the carboxy-substituted analogue of the -glucoside series, 
8, shows a E/Z ratio of ~ 40/60 after irradiation, thus differed 
significantly from 2 and 5. Here, the -glycosidic linkage makes a 
difference! Comparison of the methoxycarbonyl-substituted 
azobenzene glycosides leads to the conclusion, the configuration of 
the 2-hydroxyl group is significant. While glucosides 6 and 9 have 
E/Z ratios of ~40/60 in the PPS, the analogous mannoside 3 showed 
10/90. Half lifes of the ortho’-substituted azobenzene glycosides 
vary between 2 and 5 h. Thus in these cases the Z-isomers are much 
shorter lived than in case of the non substituted azobenzene 
glycosides 1, 4, and 7. 
 
The bis-glycosylated azobenzene 27 showed photochromic 
properties similar to the unsubstituted azobenzene glycosides. 
However, for the para’-OH-substituted azobenzene mannoside 26 
EZ photoisomerization could not be observed in the NMR.  
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Table 1. Chemical shifts (DMSO-D6 at 500 MHz) of anomeric protons (H-1) in ppm of E- and Z-configured azobenzene glycosides. Integration of H-1 signals was used to determine 
E/Z ratios in the PSS. 
H-1 1  2 3 4 5 6 7 8 9 27 
E 5.53 5.53 5.53 5.55 5.57 5.57 5.04 4.99 5.00 5.51 
Z 5.32 5.30 5.31 5.35 5.34 5.35 4.80 4.78 4.80 5.34 
 
 
Figure 4. Series of UV-Vis spectra monitoring the thermal ZE relaxation of Z-
azobenzene glycoside 1 in DMSO: Absorption peaks due to nπ* transition are 
decreasing and absorption due to ππ* transition simultaneously increases. 
Table 2. Photochromic properties of synthesized azobenzene glycosides. 
Azobenzene 
glycoside 
Substituent GS 
E/Z ratios[a] 
(ɛ)[b]  
PSS 
E/Z ratios[a] 
(ɛ)[b] 
UV-Vis 
absorption 
maxima [nm] 
λmax(E), λmax(Z) 
half 
life 
(1/2) 
[h][c] 
1 (α-man) H 99:1 
(25907) 
3:97 (2635) 347, 440 89  
2 (α-man) ortho’-CO2H 99:1 
(29362) 
85:15 (3106) 341, 423 2  
3 (α-man) ortho’-
CO2Me 
98:2 
(21694) 
10:90 (3452) 345, 426 5  
4 (α-glc) H 99:1 
(15804)  
2:98 (1712) 356, 439 36  
5 (α-glc) ortho’-CO2H 98:2 
(13715) 
76:24 (1407) 341, 424 2.5  
6 (α-glc) ortho’-
CO2Me 
99:1 
(16943) 
45:55 (1734) 345, 426 2 
7 (β-glc) H 98:2 
(23274) 
4:96 (1704) 347, 439 94  
8 (β-glc) ortho’-CO2H 99:1 
(28335) 
41:59 (2521) 337, 425 4  
9 (β-glc) ortho’-
CO2Me 
98:2 
(18722) 
39:61 (2071) 346, 425 5  
26 -Man 
para’-OH 
99:1 
(19804) 
Fast kinetics 363, 480 _ 
27 -Man 
para--Man 
98:2 
(18810) 
5:95 (1395)  358, 446  24 
29 -Glu  
para’-OH 
 
99:1 
(17871) 
Fast kinetics 362, 476 _ 
[a] E/Z ratios are based on the integrals of the respective anomeric protons H-1 in the 1H 
NMR spectrum (10 mg samples in ~550 µL DMSO-D6, 500 MHz); [b] ɛ: extinction 
coefficient [mol x L-1 x cm-1]; [c] 1/2: half lifes were determined by UV-Vis 
spectroscopy (50 µM samples in DMSO).  
 
Discussion of photochromic properties: The fact that 
isomerisation of the para’-OH-substituted azobenzene mannoside 
26 was not observed is in line with reports from the literature, 
showing that p-hydroxy-substituted azobenzene derivatives are 
charactzerized by extremely fast kinetics of thermal relaxation of the 
Z isomer.[24] The electron-donating effect of the OH-substituent 
lowers the barrier for thermal back isomerisation leading to 
relaxation times in the ms range. This feature is also emphasized by 
our observation that the p-OH-substituted azobenzene glucoside 29 
behaves exactly the same as the anlogous mannoside 26 (Table 2), 
regardless whether isomerisation is carried out in DMSO, EtOH, or 
water. Interestingly, fast isomerization dynamics can facilitate the 
use of sweet switches in applications, where fast information 
processing is required. Such hydroxy-substituted sweet switches are 
of great interest for all applications, where short-lived excited states 
and rapid relaxation are required, e.g. the study of biological 
regulatory processes.   
 
Finally, carboxy- and methoxycarbonyl substitutions had significant 
effects on the isomerization behaviour of the investigated 
azobenzene glycosides in accordance with earlier observations made 
for differently substituted azobenzenes.[25-27] It was suggested that 
substituents on the azobenzene sub-structure can alter the 
isomerization mechanism and as a consequence EZ 
photoisomerization becomes less effective. In addition, it has been 
stated that formation of intramolecular hydrogen bonds can lead to 
fast ZE thermal recovery.[28] For the investigated azobenzene 
glycosides substitution, the PSS correlates with the half life 1/2 of 
the Z isomer. Larger E/Z ratios parallel with shorter life times of the 
less stable Z isomer, suggesting that the barrier for thermal 
relaxtaion is lowered. While substitution effects could hardly be 
predicted, it is apparent, that the anomeric linkage of a glycoside can 
influence photoisomerisation behaviour (cf. 5 and 8) as well as the 
configuration of the 2-OH group can be crucial (cf. 3 vs. 6 and 9). 
Preliminary structural models suggest that the substituents installed 
in the ortho'-position of the azobenzene moiety can interact with the 
azo group, whereas interaction with the glycosidic aglycon is less 
likely. Future theoretical studies might help to reveal, which effects 
are caused by effects or protonation by a carboxy substituent. 
Conclusion 
The employed carboxy- and methoxycarbonyl-substituted 
azobenzene derivatives provide an option for immobilization of the 
respective glycosides, derived thereof, on surfaces or for other 
further modification and conjugation. This is of interest to 
eventually study the influence of E/Z isomerization within an array 
of azobeneze glycosides on carbohydrate-specific cell adhesion. 
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Experimental Section 
General methods: p-Hydroxyazobenzene and o-(p-hydroxyphenylazo)benzoic acid 
were purchased from Sigma Aldrich and used without further purification. Air/moisture 
sensitive reactions were carried out under nitrogen in dry glassware. Thin layer 
chromatography was performed on silica gel plates (GF 254, Merck). Detection was 
effected by UV and subsequent charring with 10% sulfuric acid in EtOH followed by 
heat treatment at ~180 °C. Flash chromatography was performed on silica gel 60 
(Merck, 230-400 mesh, particle size 0.040-0.063 mm) using distilled solvents. Melting 
points were determined on a Büchi 510 apparatus. Optical rotations were measured with 
a Perkin-Elmer 241 polarimeter (sodium D-line: 589 nm, length of cell: 1 dm) in the 
solvents indicated. 1H and 13C NMR spectra were recorded on Bruker DRX-500 and 
AV-600 spectrometers at 300 K. Chemical shifts are relative to internal 
tetramethylsilane (δ = 0.00 ppm) or D2O (δ = 4.76 ppm) and are reported in ppm. Full 
assignment of the peaks was achieved with the aid of 2D NMR techniques (1H-1H 
COSY and 1H-13C HSQC). For PSS determination all 1H NMR spectra were recorded in 
DMSO-D6 (cf. Table 2), in the Experimental Section in each individual case the best 
resolved NMR spectra are reported in the respective deuterated solvents. UV-Vis 
absorption spectra were performed on Perkin-Elmer Lambda-14 and Varian Cary-5000 
at a temperature of 18 + 1 °C. Photoirradiaton (EZ isomerization) was carried out 
with a high pressure mercury lamp UV-P 250C from Panacol-Elosol using bandpass 
filters with 365 nm wavelenth were obtain from Laser components. IR spectra were 
measured with a Perkin Elmer FT-IR Paragon 1000 (ATR) spectrometer. ESI mass 
spectra were recorded on a Esquire-LC instrument from Bruker Daltonics. MALDI-
TOF mass spectra were recorded on a Bruker Biflex III instrument with 19 kV 
acceleration voltage. 2,5-Dihydroxybenzoic acid (DHB) was used as a matrix. High 
resolution mass spectra (HRMS) were measured in LTQ Velos Orbitrap (Thermo 
Scientific) mass spectrometer equipped with nano electrospray source in positive ion 
mode. Elemental analyses were performed using a Euro Vector CHNS-O-element 
analyzer (Euro EA 3000) at the Institute of Inorganic Chemistry, Christiana Albertina 
University of Kiel.  
Nomenclature and NMR assignements are in accordance with the compound numbering 
indicated in Figure 5. The glycoside glycon moiety is numbered from 1 to 6, aglycon 
numbering is ascending from 6, starting with the atom adjacent to the glycosidic bond 
being number 7. 
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Figure 5. Numbering of hydrogen and carbon atoms for assignment of NMR data 
exemplified with mannoside 3.  
Half life determination: Rate constants (Supporting Information) and half lifes 1/2 of 
thermal ZE relaxation of azobenzene glycosides were determined in the dark by UV-
Vis spectroscopy: Plotting of ln(A∞ - At) as a function of time gave a straight line with a 
negative slope k. (A∞ and At are the absorbance of π-π* transition at infinitive time (A∞) 
and at time (At) respectively.) In the case of glycosides 2, 5, and 6 some deviation in 
linearity of the plot occurred because of the very fast relaxation process.  
E-p-(Phenylazo)phenyl -D-mannopyranoside (1): To a solution of the protected 
glycoside 15 (600 mg, 1.14 mmol) in dry MeOH (6 mL) NaOMe (15 mg) was added 
under N2 atmosphere and the reaction mixture was stirred at RT overnight. The reaction 
mixture was neutralized with Amberlite IR 120 ion exchange resin, it was filtered, the 
filtrate was evaporated under reduced pressure and the crude product was 
recrystallization from MeOH which gave title compound 1 as pale yellow solid (376 mg, 
1.04 mmol, 92%). M.p. 183-185 °C; Rf = 0.33 (CH2Cl2/MeOH, 4:1); []
20
D = + 1.40 (c 
= 1.0, DMSO); 1H NMR (500 MHz, DMSO-D6): δ = 7.86 (d, J = 8.7 Hz, 2H, H-9, H-
11), 7.82 (d, J = 7.7 Hz, 2H, H-14, H-18), 7.56 (t, J = 7.6 Hz, 2H, H-15, H-17), 7.52 (d, 
J = 7.3 Hz, 1H, H-16), 7.26 (d, J = 8.7 Hz, 2H, H-8, H-12), 5.53 (bs, 1H, H-1), 3.89 
(dd~bs, 1H, H-2), 3.73 (dd, J3,4 = 9.2 Hz, J3,2 = 3.0 Hz, 1H, H-3), 3.58-3.47 (m, 3H, H-
6a, H-4, H-6b), 3.38 (mc, 1H, H-5); 
13C NMR (125 MHz, DMSO-D6): δ = 158.9 (C-7), 
155.5 (C-13), 151.9 (C-10), 130.9 (C-16), 129.4 (C-15, C-17), 124.3 (C-9, C-11), 122.3 
(C-14, C-18), 117.1 (C-8, C-12), 98.7 (C-1), 75.2 (C-5), 70.6 (C-3), 69.9 (C-2), 66.6 (C-
4), 60.9 (C-6); IR (ATR): ṽ = 3337, 2920, 1599, 1584, 1496, 1227 cm-1; ɛ = 25907 + 
529  L x mol-1 x cm-1; MALDI-TOF MS calcd for C18H20N2O6 [M+H]
+: 361.36; found: 
361.21; HRMS calcd for C18H20N2O6 [M+H]
+: 361.1394; found 361.1388; elemental 
analysis calcd (%) for C18H20N2O6 (360.36): C 59.99, H 5.59, N 7.77; found: C 61.07, H 
5.80, N 8.07. 
E-p-(o-Carboxyphenylazo)phenyl -D-mannopyranoside (2): To a solution of the 
methyl ester 3 (200 mg, 0.478 mmol) in THF-H2O (2:1, 3 mL) LiOH (14.8 mg, 0.622 
mmol) was added and the reaction mixture stirred overnight at RT. It was neutralized 
with Amberlite IR 120 ion exchange resin, diluted with MeOH (25 mL), it was filtered 
and the filtrate was evaporated under reduced pressure to get the pure title glycoside 
(180 mg, 0.45 mmol, 93 %) as a pale yellow solid. M.p. 116-117 °C; Rf = 0.21 (ethyl 
acetate/MeOH, 8:2); []20D = + 1.21 (c = 0.9, DMSO); 
1H NMR (500 MHz, CD3OD): δ 
= 7.94 (d, J = 9.0 Hz, 2H, H-9, H-11), 7.92 (dd, J = 7.7 Hz, J = 1.3 Hz, 1H, H-15), 7.73 
(dd, J = 8.1 Hz, J = 1.1 Hz, H-18), 7.68 (dt, J = 7.7 Hz, J = 1.5, J = 7.3 Hz, 1H, H-17), 
7.59 (dt, J = 7.5 Hz, J = 7.4, J = 1.3 Hz, 1H, H-16), 7.34 (d, J = 9.0 Hz, 2H, H-8, H-12), 
5.65 (d, J = 1.8 Hz, 1H, H-1), 4.08 (dd, J2,3 = 3.4, J2,1 = 1.9 Hz, 1H, H-2), 3.96 (dd, J3,4 
= 9.5, J3,2 = 3.4 Hz, 1H, H-3), 3.83-3.74 (m, 3H, H-4, H-6a, H-6b), 3.61 (ddd, J5,4 = 9.8, 
J5,6a = 5.4 Hz, J5,6b = 2.5, 1H, H-5); 
13C NMR (125 MHz, CD3OD): δ = 170.9 (C-19), 
161.0 (C-7), 152.5 (C-13), 149.1 (C-10), 133.1 (C-17), 131.2 (C-16), 130.9 (C-15), 
126.8 (C-14), 126.2 (C-9, C-11), 118.6 (C-18), 118.1 (C-8, C-12), 100.1 (C-1), 75.8 (C-
5), 72.4 (C-3), 71.8 (C-2), 68.3 (C-4), 62.7 (C-6); IR (ATR): ṽ = 3394, 2936, 1719, 
1595, 1498, 1243 cm-1; ɛ = 29362 + 1037 L x mol-1 x cm-1; MALDI-TOF MS calcd for 
C19H20N2O8 [M+Na]
+: 427.37; found: 427.10; HRMS calcd for C19H20N2O8 [M+H]
+: 
405.1292; found 405.1282.  
E-p-(o-Methoxycarbonylphenylazo)phenyl -D-mannopyranoside (3): To a solution 
of the acetylated glycoside 16 (2.00 g, 3.41 mmol) in dry MeOH (20 mL) a catalytic 
amount of NaOMe was added under N2 atmosphere. The reaction mixture was stirred at 
RT overnight and then it was neutralized with Amberlite IR 120 ion exchange resin, 
filtered and the filtrate was concentrated. Purification by flash column chromatography 
(ethyl acetate/MeOH, 9:1) gave the title compound as an orange solid (1.20 g, 2.87 
mmol, 89 %). M.p. 108-110 °C; Rf = 0.29 (ethyl acetate/MeOH, 9:1); []
20
D = + 1.34 (c 
= 1.0, MeOH); 1H NMR (500 MHz, D2O): δ = 7.85 (d, J = 8.4 Hz, H-15), 7.84(d, J = 
9.0 Hz, 2H, H-9, H-11), 7.65 (t, J = 7.6 Hz, 1H, H-17), 7.53 (t, J = 7.9 Hz, H-16), 7.47 
(d, J = 7.7 Hz, 1H, H-18), 7.24 (d, J = 8.8 Hz, 2H, H-8, H-12), 5.67 (d, 1H, J1,2 = 1.2 Hz 
H-1), 4.14 (dd, J1,2 = 1.6, J1,3 = 3.2 Hz,1H, H-2), 4.02 (dd, J3,4 = 9.6, J2,3 = 3.3 Hz, 1H, 
H-3), 3.83 (s, 3H, CO2CH3), 3.75-3.66 (m, 3H, H-4, H-6a,H-6b), 3.64-3.30 (m, 1H, H-
5); 13C NMR (125 MHz, D2O): δ = 170.1 (C-19), 169.8 (C-7), 158.7 (C-13), 147.2 (C-
10), 133.1 (C-17), 130.1 (C-15), 129.9 (C-16), 126.0 (C-14), 124.8 (C-9/C-11), 119.8 
(C-18), 117.3 (C-8/C-12), 97.8 (C-1), 73.5 (C-5), 70.3 (C-3), 69.7 (C-2), 66.5 (C-4), 
60.6 (C-6), 53.0 (C-20); IR (ATR): ṽ = 3344, 2930, 1715, 1596, 1497, 1231 cm-1; ɛ = 
21694 + 696 L x mol-1 x cm-1; MALDI-TOF MS calcd for C20H22N2O8 [M+Na]
+: 
427.40; found: 427.08; HRMS calcd for C19H20N2O8 [M+H]
+: 405.1292; found 
405.1282; elemental analysis calcd for C20H22N2O8 (418.13): C 57.41, H 5.30, N 6.70; 
found: C 57.27, H 5.48, N 6.68. 
E-p-(Phenylazo)phenyl -D-glucopyranoside (4): The glucoside 19 (238 mg, 0.89 
mmol) and nitrosobenzene (103 mg, 0.97 mmol, 1.1 eq.) were dissolved in glacial acid 
(20 mL) and the reaction mixture was stirred at RT for 18 h. Then, it was concentrated 
and the residual purified by flash column chromatography (ethyl acetate/MeOH, 
9:1pure MeOH) to obtain the title glucoside (305 mg, 0.85 mmol, 96%), as an orange 
solid. M.p. 206-207 °C; Rf = 0.62 (ethyl acetate/MeOH, 1:1); []
22
D = + 2.21 (c = 0.2, 
DMSO); 1H NMR (500 MHz, DMSO-D6): δ = 7.88 (d, J = 8.9 Hz, 2H, H-9, H-11), 7.84 
(d, J = 7.2 Hz, 2H, H-14, H-18), 7.58 (t, J = 7.4 Hz, 2H, H-15, H-17), 7.52 (d, J = 7.2 
Hz, 1H, H-16), 7.28 (d, J = 8.9 Hz, 2H, H-8, H-12), 5.55 (d, J1,2 = 3.6 Hz, 1H, H-1), 
3.66 (dd~t, J = 9.2 Hz, 1H, H-3), 3.56 (mc, 1H, H-6a), 3.47 (mc, 1H, H-6b), 3.44 (mc, 
1H, H-5), 3.42 (dd, J2,3 =9.7, J2,1 = 3.6 Hz, 1H, H-2), 3.21 (dd~t, J = 9.1 Hz, 1H, H-4); 
13C NMR (125 MHz, DMSO-D6): δ = 158.9 (C-7), 155.5 (C-13), 151.9 (C-10), 130.9 
(C-16), 129.4 (C-15, C-17), 124.3 (C-9, C-11), 122.3 (C-14, C-18), 117.2 (C-8, C-12), 
97.6 (C-1), 73.9 (C-5), 72.8 (C-3), 71.3 (C-2), 69.6 (C-4), 60.5 (C-6); IR (ATR): ṽ = 
3382, 3288, 2918, 1597, 1496, 1234; cm-1; ɛ = 15804 + 256 L x mol-1 x cm-1; ESI MS 
calcd for C18H20N2O6 [M+Na]
+: 383.121; found: 383.138; HRMS calcd for C18H20N2O6 
[M+H]+: 361.1394; found: 361.1379. 
E-p-(o-Carboxyphenylazo)phenyl -D-glucopyranoside (5): The methyl ester 6 (430 
mg, 1.03 mmol) was dissolved in THF-H2O (1:1, 10 mL), LiOH (49 mg, 2.06 mmol, 2 
eq.) was added and the reaction mixture stirred overnight at RT. After neutralization 
with Amberlite IR 120 ion exchange resin, it was filtered and the filtrate concentrated 
under reduced pressure to obtain the pure title glycoside as a yellow solid (395 mg, 0.78 
mmol, 95 %). M.p. 173-174 °C; Rf = 0.36 (ethyl acetate/MeOH, 1:1); []
22
D = + 1.93 (c 
= 0.18, DMSO); 1H NMR (500 MHz, DMSO-D6): δ = 7.84 (d, J = 9.0 Hz, 2H, H-9, H-
11), 7.77 (mc, 1H, H-15), 7.66 (mc, 1H, H-17), 7.56 (mc, 2H, H-16, H-18), 7.29 (d, J = 
9.0 Hz, 2H, H-8, H-12), 5.57 (d, J1,2 = 3.6 Hz, 1H, H-1), 3.66 (dd~t, J3,4 = 9.2 Hz, 1H, 
H-3), 3.57 (mc, 1H, H-6a), 3.48 (mc, 1H, H-6b), 3.45 (mc, 1H, H-5), 3.43 (dd, J2,3 = 9.7, 
J1,2 = 3.6 Hz, 1H, H-2), 3.21 (dd~t, J4,3 = 9.2 Hz, 1H, H-4); 
13C NMR (125 MHz, 
DMSO-D6): δ = 168.3 (C-19), 159.9 (C-7), 150.7 (C-13), 146.9 (C-10), 131.6 (C-17), 
130.0 (C-14), 129.9 (C-16), 129.1 (C-15), 124.6 (C-9, C-11), 118.1 (C-18), 117.2 (C-8, 
C-12), 97.6 (C-1), 74.0 (C-5), 72.8 (C-3), 71.3 (C-2), 69.7 (C-4), 60.6 (C-6); IR (ATR): 
ṽ = 3366, 2921, 1728, 1597, 1479, 1240 cm-1; ɛ = 13715 + 2132 L x mol-1 x cm-1; 
MALDI-TOF MS calcd for C19H20N2O8 [M+Na]
+: 427.11; found: 427.10; HRMS calcd 
for C19H20N2O8 [M+H]
+: 405.1292; found: 405.1276. 
E-p-(o-Methoxycarbonylphenylazo)phenyl -D-glucopyranoside (6): To a solution 
of the glycoside 22 (630 mg, 1.07 mmol) in dry MeOH (12 mL) NaOMe (18 mg) was 
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added under N2 atmosphere and the reaction mixture was stirred at RT for 18 h. Then it 
was neutralized with Amberlite IR 120 ion exchange resin, filtered and the filtrate 
evaporated. The residual was purified by GPC on Sephadex LH-20 (MeOH) to yield the 
title compound (431 mg, 1.03 mmol, 96 %) as an orange solid. M.p. 144-145 °C; Rf = 
0.72 (ethyl acetate/MeOH, 1:1); []22D = + 1.81 (c = 0.2, DMSO); 
1H NMR (500 MHz, 
DMSO-D6): δ = 7.84 (d, J = 8.9 Hz, 2H, H-9, H-11), 7.76 (dd, J = 7.6, J = 1.4 Hz, 1H, 
H-15), 7.70 (mc, 1H, H-17), 7.63 (dd, J = 8.0, J = 1.2 Hz, 1H, H-18), 7.58 (dt, J =7.4, J 
= 1.3 Hz, 1H, H-16) 7.29 (d, J = 9.0 Hz, 2H, H-8, H-12), 5.55 (d, J1,2 = 3.6 Hz, 1H, H-
1), 3.81 (s, 3H, CO2CH3), 3.66 (dd~t, J3,4 = 9.2 Hz, 1H, H-3), 3.57 (dd, J5,6a = 11.4, J6a,6b 
= 1.6 Hz, 1H, H-6a), 3.48 (mc, 1H, H-6b), 3.46 (mc, 1H, H-5), 3.43 (dd, J2,3 = 9.7, J2,1 = 
3.5 Hz, 1H, H-2), 3.21 (dd~t, J4,3 = 9.2 Hz, 1H, H-4); 
13C NMR (150 MHz, DMSO-D6): 
δ = 167.6 (C-19), 160.22 (C-7), 150.8 (C-13), 146.9 (C-10), 132.2 (C-17), 130.1 (C-16), 
129.3 (C-15), 128.4 (C-14), 124.7 (C-9, C-11), 119.5 (C-18), 117.4 (C-8, C-12), 97.7 
(C-1), 74.1 (C-5), 72.9 (C-3), 71.4 (C-2), 69.8 (C-4), 60.6 (C-6), 52.4 (C-20); IR (ATR): 
ṽ = 3327, 2921, 2853, 1715, 1596, 1497, 1230 cm-1; ɛ = 16943 + 383 L x mol-1 x cm-1; 
ESI MS calcd for C20H22N2O8 [M+Na]
+: 457.101; found: 457.112; HRMS calcd for 
C20H22N2O8 [M+H]
+: 419.1449; found: 419.1439. 
E-p-(Phenylazo)phenyl β-D-glucopyranoside (7): The protected glycoside 17 (300 mg, 
0.568 mmol) was dissolved in dry MeOH (3 mL) and treated with NaOMe (6 mg), 
under N2 atmosphere. The reaction mixture was stirred at RT overnight, then it was 
neutralized with Amberlite IR 120 ion exchange resin, filtered and the filtrate 
evaporated. The crude product was purified by flash column chromatography (10% 
MeOH in CH2Cl2) to yield the unprotected title glycoside (185 mg, 0.514 mmol, 90%) 
as yellow solid. M.p. 180-181 °C; Rf = 0.29 (cyclohexane/MeOH, 4:1); [α]
20
D = - 0.37 (c 
=0.85, DMSO); 1H NMR (500 MHz, DMSO-D6): δ = 7.90 (d, J = 8.8 Hz, 2H, H-9, H-
11), 7.87 (d, J = 7.4 Hz, 2H, H-14, H-18), 7.61-7.58 (m, 2H, H-15, H-17), 7.54 (mc, 1H, 
H-16), 7.23 (d, J = 8.9 Hz, 2H, H-8, H-12), 5.04 (d, J = 7.3 Hz, 1H, H-1), 3.73 (dd, J6a,6b 
= 11.6, J5,6a = 5.2 Hz, 1H, H-6a), 3.51 dd~t, J5,6a = 5.9 Hz, J6a,6b = 11.8, 1H, H-6b), 3.42 
(ddd, J5,6a = 5.7, J5,6b = 2.8 Hz, J4,5 = 9.2 Hz 1H, H-5), 3.32-3.28 (m, 2H, H-3, H-2), 
3.23-3.19 (m, 1H, H-4); 13C NMR (125 MHz, DMSO-D6): δ = 159.9 (C-7), 151.9 (C-
13), 146.9 (C-10), 130.9 (C-16), 129.4 (C-15, C-17), 124.3 (C-9, C-11), 122.3 (C-14, 
18), 116.7 (C-8, C-12), 100.0 (C-1), 77.1 (C-5), 76.5 (C-3), 73.2 (C-2), 69.6 (C-4), 60.6 
(C-6); IR (ATR): ṽ = 3242, 1600, 1589, 1495, 1232 cm-1 ; ɛ = 23274 + 1121 L x mol-1 x 
cm-1; MALDI-TOF MS calcd for C18H20N2O6 [M+H]
+: 361.36; found: 361.17; HRMS 
calcd for C18H20N2O6 [M+H]
+: 361.1394; found 361.1385; elemental analysis calcd (%) 
for C18H20N2O6 (360.13): C 59.99, H 5.59, N 7.77 ; found: C 59.55, H 5.59, N 7.13. 
E-4-(2′-Carboxyphenylazo)phenyl β-D-glucopyranoside (8): The methyl ester 9 (100 
mg, 0.24 mmol) was dissolved in THF-H2O (2:1, 3 mL), LiOH (7.5 mg, 0.31 mmol) 
was added and the reaction mixture stirred at RT overnight. Then it was neutralized 
with Amberlite IR 120 ion exchange resin, diluted with methanol (20 mL), filtered and 
the filtrate was evaporated to yield the title glycoside (88 mg, 0.22 mmol, 91%) as a 
pale yellow solid. M.p. 194-195 °C; Rf = 0.22 (ethyl acetate/MeOH, 8:2); []
20
D = - 
0.39 (c = 0.78, DMSO); 1H NMR (500 MHz, CD3OD): δ = 7.94 (d, J = 9.0 Hz, 2H, H-9, 
H-11), 7.82 (dd, J = 7.6 Hz, J = 1.3 Hz, 1H, H-15), 7.71 (dd, J = 7.8 Hz, J = 0.9 Hz, 1H, 
H-18), 7.60 (dt, J = 8.0 Hz, J = 7.7 Hz, J = 1.5 Hz, 1H, H-17), 7.54 (dt, J = 7.4 Hz, J = 
7.4 Hz, J = 1.3 Hz, 1H, H-16), 7.28 (d, J = 9.0 Hz, 2H, H-8, H-12), 5.07 (d, J = 7.6 Hz, 
1H, H-1), 3.95 (dd, J6a,6b = 12.1, J5,6a = 2.2 Hz, 1H, H-6a), 3.75 (dd, J6a,6b = 12.1, J5,6b = 
5.7 Hz, 1H, H-6b), 3.56-3.52 (m, 3H, H-2, H-3, H-5), 3.45 (mc, 1H, H-4); 
13C NMR 
(125 MHz, CD3OD, 125 MHz): δ = 173.3 (C-19), 161.9 (C-7), 151.8 (C-13), 149.3 (C-
10), 134.2 (C-14), 132.0 (C-17), 131.2 (C-16), 130.2 (C-15), 126.0 (C-9, C-11), 118.4 
(C-18), 117.9 (C-8, C-12), 101.9 (C-1), 78.3 (C-5), 77.9 (C-3), 74.7 (C-2), 71.3 (C-4), 
62.5 (C-6); IR (ATR): ṽ = 3329, 2498, 1699, 1592, 1499, 1246 cm-1; ɛ = 28335 + 345 L 
x mol-1 x cm-1; MALDI-TOF MS calcd for C19H20N2O8 [M+Na]
+: 427.37; found: 
427.14; HRMS calcd for C19H20N2O8 [M+H]
+: 405.1292; found 405.1283. 
E-p-(o-Methoxycarbonylphenylazo)phenyl β-D-glucopyranoside (9): The protected 
glucoside 18 (152 mg, 0.259 mmol) was dissolved in dry MeOH (2 mL) and a catalytic 
amount of NaOMe was added under N2 atmosphere. The reaction mixture was stirred at 
RT overnight, it was neutralized with Amberlite IR 120 ion exhange resin and filtered. 
The filtrate was evaporated and the crude product was purified by flash chromatography 
(ethyl acetate/MeOH, 9:1) to yield the title compound (90 mg, 0.215 mmol, 83 %) as a 
pale yellow solid. M.p. 142-143 °C; Rf = 0.29 (ethyl acetate/MeOH, 4:1); []
20
D = - 
0.66 (c = 1.0, MeOH); 1H NMR (500 MHz, CD3OD): δ = 7.88 (d, J = 9.0 Hz, 2H, H-9, 
H-11), 7.76 (d, J = 7.4 Hz, 1H, H-15), 7.67-7.64 (m, 2H, H-17, H-18), 7.53 (mc, 1H, H-
16), 7.26 (d, J = 9.0 Hz, 2H, H-8, H-12), 5.05 (d, J = 7.6 Hz, 1H, H-1), 3.93 (dd, J6a,6b = 
12.1, J5,6a = 2.3 Hz, 1H, H-6a), 3.87 (s, 3H, CO2CH3), 3.72 (dd, J6a,6b = 12.1, J5,6b = 5.7 
Hz, 1H, H-6b), 3.54-3.48 (m, 3H, H-2, H-3, H-5), 3.42 (mc, 1H, H-4); 
13C NMR (125 
MHz, CD3OD): δ = 169.9 (C-19), 161.9 (C-7), 152.9 (C-13), 149.2 (C-10), 133.0 (C-
17), 130.8 (C-16), 130.5 (C-15), 130.0 (C-14), 125.9 (C-9, C-11), 120.3 (C-18), 118.0 
(C-8, C-12), 101.9 (C-1), 78.3 (C-5), 77.9 (C-3), 74.8 (C-2), 71.3 (C-4), 62.5 (C-6), 52.9 
(C-20); IR (ATR): ṽ = 3323, 2942, 1723, 1598, 1498, 1235 cm-1; ɛ = 18722 + 400 L x 
mol-1 x cm-1; MALDI-TOF MS calcd for C20H22N2O8 [M+Na]
+: 441.40; found: 441.12; 
HRMS calcd for C19H20N2O8 [M+H]
+: 405.1292; found 405.1283; elemental analysis 
calcd for C20H22N2O8 (418.13): C 57.41, H 5.30, N 6.70 ; found: C 56.06, H 5.52, N 
6.34.  
E-p-(Phenylazo)phenyl 2,3,4,6-tetra-O-acetyl--D-mannopyranoside (15): To a 
solution of the mannosyl donor 10 (900 mg, 1.83 mmol) and p-hydroxyazobenzene (12, 
398 mg, 2.01 mmol) in dry CH2Cl2 (18 mL) BF3-Et2O (347 μL, 2.74 mmol, 1.2 eq.) was 
added at 0 °C under N2 atmosphere. The reaction mixture was stirred at RT overnight, 
then the reaction was quenched by addition of satd. aq. NaHCO3 (18 mL). The phases 
were separated, the aqueous phase was extracted with CH2Cl2 (3 x 30 mL), the 
combined organic phases were washed with water (2 × 20 mL) and dried over Na2SO4. 
It was filtered and the filtrate was concentrated under reduced pressure. Purification of 
the crude product by column chromatography (cyclohexane/ethyl acetate, 3:7) gave the 
title glycoside (780 mg, 1.47 mmol, 81%) as an orange crystalline solid. M.p. 53-55°C; 
Rf = 0.25 (cyclohexane/ethyl acetate, 7:3); []
20
D = + 0.86 (c = 0.9, DMSO); 
1H NMR 
(500 MHz, CDCl3): δ = 7.92 (d, J = 9.1 Hz, 2H, H-9, H-11), 7.90-7.87 (m, 2H, H-14, H-
18), 7.52-7.49 (m, 2H, H-15, H-17), 7.46 (dt, J = 4.9 Hz, J = 1.9 Hz, 1H, H-16), 7.23 (d, 
J = 9.1 Hz, 2H, H-8, H-12), 5.62 (d, J1,2 = 1.8 Hz, 1H, H-1), 5.39 (dd, J3,4 = 10.0, J2,3 = 
3.6 Hz, 1H, H-3), 5.49 (dd, J2,3=3.5 Hz, J1,2 = 1.8 Hz, 1H, H-2), 5.39 (dd~t, J4,3 = J4,5 = 
10.1 Hz, 1H, H-4), 4.28 (mc, 1H, H-6a), 4.12-4.07 (m, 2H, H-5, H-6b), 2.21, 2.06, 2.05, 
2.03 (each s, each 3H, 4 OAc); 13C NMR (125 MHz, CDCl3): δ = 170.5, 169.9, 169.9, 
169.7 (4 C=O), 157.6 (C-7), 152.6 (C-13), 148.4 (C-10), 130.8 (C-16), 128.9 (C-15, C-
17), 124.6 (C-9, C-11), 123.1 (C-14, 18), 116.8 (C-8, C-12), 95.7 (C-1), 69.4 (C-5), 69.3 
(C-2), 68.8 (C-3), 65.9 (C-4), 62.1 (C-6), 20.9, 20.7, 20.7, 20.6 (4 CO2CH3); IR (ATR): 
ṽ = 2929, 1743, 1598, 1496, 1366, 1209, 1029 cm-1; ESI MS calcd for C26H28N2O10 
[M+Na]+: 551.57; found: 551.17.  
E-p-(o-Methoxycarbonylphenylazo)phenyl 2,3,4,6-tetra-O-acetyl--D-mannopyranoside 
(16): To a solution of the mannosyl donor 10 (3.00 g, 6.09 mmol) and p-(o-
methoxycarbonylphenylazo)phenol (14, 1.72 g, 6.72 mmol) in dry CH2Cl2 (45 mL)  
BF3-Et2O (927 μL, 7.32 mmol, 1.2 eq.) was added at 0°C under N2 atmosphere. The 
reaction mixture was stirred at RT overnight, then the reaction was quenched by 
addition of aq. NaHCO3 (30 mL). The phases were separated, the aqueous phase was 
extracted with CH2Cl2 (3 x 100 mL), the combined organic layers were washed with 
water (2×50 mL) and dried over Na2SO4. It was filtered and the filtrate was 
concentrated under reduced pressure. Purification of the residue by flash column 
chromatography (cyclohexane/ethyl acetate, 1:4) gave the title glycoside (3.00 g, 5.12 
mmol, 84%) as a yellow crystalline solid. M.p. 120-121 °C; Rf = 0.21 
(cyclohexane/ethyl acetate, 1:4), [α]20D = + 0.806 (c =1.0, MeOH); 
1H NMR (500 MHz, 
CDCl3): δ = 7.91 (d, J = 8.9 Hz, 2H, H-9, H-11), 7.82 (d, J = 7.5 Hz, 1H, H-15), 7.61-
7.56 (m, 2H, H-17, H-18), 7.49-7.46 (m, 1H, H-16), 7.23 (d, J = 8.9 Hz, 2H, H-8, H-12), 
5.63 (d, J1,2 = 1.7 Hz, 1H, H-1), 5.58 (dd, J3,4 = 10.0, J3,2 = 3.5 Hz, 1H, H-3), 5.48 (dd, 
J2,3=3.5 Hz, J1,2 = 1.8 Hz, 1H, H-2), 5.39 (t, J4,3 = J4,5 = 9.9 Hz, 1H, H-4), 4.30 (dd, J6a,6b 
= 12.7, J5,6a = 5.9 Hz, 1H, H-6a), 4.08-4.11 (m, 2H, H-5, H-6b), 3.91 (s, 3H, CO2CH3), 
2.22, 2.06, 2.05, 2.03 (each s, each 3H, 4 OAc); 13C NMR (125 MHz, CDCl3): δ = 170.4, 
169.9, 169.9, 169.7 (4 C=O), 167.9 (C-19), 157.9 (C-7), 151.9 (C-13), 148.4 (C-10), 
131.9 (C-17), 129.7 (C-15), 129.6 (C-16), 128.5 (C-14), 125.0 (C-9, C-11), 118.8 (C-
18), 116.8 (C-8, C-12), 95.6 (C-1), 69.5 (C-5), 69.2 (C-3), 68.7 (C-2), 65.8 (C-4), 62.0 
(C-6), 52.3 (C-20), 20.9, 20.7, 20.7, 20.6 (4 CO2CH3); IR (ATR): ṽ = 2954, 1744, 1715, 
1597, 1498, 1366, 1210 cm-1; ESI MS calcd for C28H30N2O12 [M+Na]
+: 609.58; found: 
609.16.  
E-p-(Phenylazo)phenyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside (17): The 
glucosyl donor 11 (500 mg, 1.02 mmol) and p-hydroxyazobenzene (12, 221 mg, 1.12  
mmol) were dissolved in dry CH2Cl2 (10 mL) and BF3-Et2O (128 μL, 1.02 mmol) was 
added at 0 °C. The reaction mixture was stirred at RT overnight and then the reaction 
was quenched by addition of aq. NaHCO3 (1 mL). The phases were separated and the 
aqueous phase was extracted with CH2Cl2 (25 mL). The combined organic phases were 
washed with water (2 × 10 mL) and dried over Na2SO4. It was filtered, the filtrate 
concentrated under reduced pressure and the residual purified by flash chromatography 
(cyclohexane/ethyl acetate, 3:7) to yield the title glucoside (390 mg, 0.74 mmol, 73%) 
as an orange solid. M.p. 166-167 °C; Rf = 0.27 (cyclohexane/ethyl acetate, 7:3); 
1H 
NMR (500 MHz, CDCl3): δ = 7.91 (d, J = 9.0 Hz, 2H, H-9, H-11), 7.89 (d, J = 7.2 Hz, 
2H, H-14, H-18), 7.53-7.49 (m, 2H, H-15, H-17), 7.46 (mc, 1H, H-16), 7.11 (d, J = 8.9 
Hz, 2H, H-8, H-12), 5.33-5.31 (m, 2H, H-2, H-3), 5.21-5.27 (m, 2H, H-1, H-4), 4.31 (dd, 
J6a,6b = 12.3, J5,6a = 5.5 Hz, 1H, H-6a), 4.20 (dd, J6a,6b = 12.3, J5,6b = 2.4 Hz, 1H, H-6a), 
3.92 (ddd, J5,6a = 5.5, J5,6b = 2.4 Hz, J4,5 = 9.9 Hz 1H, H-5), 2.09, 2.08, 2.06, 2.05 (each s, 
each 3H, 4 OAc); 13C NMR (125 MHz, CDCl3): δ = 170.6, 170.2, 169.4, 169.3 (4 C=O), 
158.8 (C-7), 152.6 (C-13), 148.6 (C-10), 130.8 (C-16), 129.1 (C-15, C-17), 124.5 (C-9, 
C-11), 122.7 (C-14, C-18), 117.1 (C-8, C-12), 98.7 (C-1), 72.6 (C-5), 72.3 (C-2), 71.2 
(C-3), 68.3 (C-4), 61.9 (C-6), 20.7, 20.7, 20.6, 20.6 (4 CO2CH3); IR (ATR): ṽ = 1740, 
1598, 1497, 1366, 1220 cm-1; ESI MS calcd for C26H28N2O10 [M+Na]
+: 551.51; found: 
551.17.  
E-p-(o-Methoxycarbonylphenylazo)phenyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyrano-
side (18): The glucosyl donor 11 (170 mg, 0.345 mmol) and o-(p-
hydroxyphenylazo)methyl benzoate (14, 97.3 mg, 0.38 mmol) were dissolved in dry 
CH2Cl2 (5 mL) and BF3-Et2O (53 μL, 0.42 mmol, 1.2 eq.) was added at 0°C. The 
reaction mixture was stirred at RT overnight and then the reaction was quenched with 
aq. NaHCO3 (10 mL). The phases were separated and the aqueous phase was extracted 
with CH2Cl2 (20 mL). The combined organic phases were washed with water (10 mL) 
and dried over Na2SO4. It was filtered and the filtrate concentrated under reduced 
pressure. Purification of the residual by column chromatography (cyclohexane/ethyl 
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acetate, 7:3) gave the title glucoside (160 mg, 0.273 mmol, 79%) as an orange solid. 
M.p. 118-119 °°C; Rf = 0.24 (cyclohexane/ethyl acetate, 7:3); [α]
20
D = - 0.20 (c = 1.0, 
MeOH); 1H NMR (500 MHz, CD3OD): δ = 7.89 (d, J = 9.0 Hz, 2H, H-9, H-11), 7.77 
(td, J = 7.6 Hz, J = 1.0 Hz, 1H, H-15), 7.65-7.64 (m, 2H, H-17, H-18), 7.54 (mc, 1H, H-
16), 7.19 (d, J = 9.1 Hz, 2H, H-8, H-12), 5.49 (d, J1,2 = 7.9 Hz, 1H, H-1), 5.42 (dd~t, J3,4 
= J2,3 = 9.5 Hz, 1H, H-3), 5.22 (dd, J2,3=9.6 Hz, J1,2 = 7.9 Hz, 1H, H-2), 5.14 (dd~t, J4,3 
= J4,5 = 9.7 Hz, 1H, H-4), 4.33 (dd, J6a,6b = 12.3, J5,6a = 5.1 Hz, 1H, H-6a), 4.19 (dd, J6a,6b 
= 12.3 Hz, J5,6b5 = 2.4 Hz, 1H, H-6b), 3.87 (s, 3H, CO2CH3), 2.06, 2.06, 2.04, 2.01 (each 
s, each 3H, 4 OAc); 13C NMR (125 MHz, CD3OD): δ = 172.2, 171.5, 171.2, 171.1 (4 
C=O), 169.8 (C-19), 160.8 (C-7), 152.9 (C-13), 149.7 (C-10), 133.1 (C-17), 130.9 (C-
16), 130.5 (C-15), 130.1 (C-14), 125.9 (C-9, C-11), 120.2 (C-18), 118.1 (C-9, C-12), 
99.1 (C-1), 74.3 (C-3), 73.2 (C-5), 72.6 (C-2), 69.7 (C-4), 63.1 (C-6), 52.9 (C-20), 20.6, 
20.5, 20.5, 20.5 (4 CO2CH3); IR (ATR): ṽ = 1739, 1598, 1501, 1367, 1211 cm
-1; ESI 
MS calcd for  C28H30N2O12  [M+Na]
+: 609.58; found: 609.17.  
E-p-(o-Methoxycarbonylphenylazo)phenyl 2,3,4,6-tetra-O-acetyl--D-gluco-pyranoside 
(22): To a solution of oxone (7.86 g, 12.8 mmol) in H2O (20 mL) the aniline 20 (966 mg,  
6.39 mmol) and CH2Cl2 (20 mL) was added and the reaction mixture was stirred at RT 
for 20 h under N2 atmosphere. Then, the phases were separated and the aq. phase was 
extracted with CH2Cl2 (50 mL). The combined organic phases were successively 
washed with aq. HCl (1 M, 50 mL), aq. NaHCO3 (50 mL) and brine (50 mL). It was 
dried over MgSO4, filtered and the filtrate was concentrated to yield the crude nitroso 
intermediate 21 (1.05 g, 6.36 mmol) which was proceeded without further purification. 
It was combined with the aniline 19 (648 mg, 2.39 mmol) and the reaction partners were 
dissolved in glacial acid (20 mL) and stirred for 18 h at RT. Then, the solution was 
concentrated and the crude product dissolved in pyridine (5 mL) and treated with acetic 
anhydride (1.13 mL, 11.9 mmol, 5 eq.) at RT for 52 h under N2 atmosphere. Then, the 
solution was concentrated and co-evaporated with toluene. The residual was purified by 
flash column chromatography (ethyl acetate/cyclohexane, pure ethyl acetate 1:1) to 
yield the protected title glycoside (1.25 g, 2.13 mmol, 89%) as an orange solid. M.p. 
55 °C; Rf = 0.5 (methanol/ethyl acetate, 1:2); [α]
22
D = + 1.83 (c = 0.26, DMSO); ); 
1H 
NMR (500 MHz, CDCl3): δ = 7.91 (d, J = 8.9 Hz, 2H, H-9, H-11), 7.81 (mc, 1H, H-15), 
7.58 (mc, 2H, H-17, H-18), 7.47 (ddd, J = 7.7, J = 6.4, J = 2.2 Hz, 1H, H-16), 7.22 (d, J 
= 8.9 Hz, 2H, H-8, H-12), 5.83 (d, J1,2 = 3.6 Hz, 1H, H-1), 5.72 (dd, J2,3 = 10.0, J3,4 = 
9.6 Hz, 1H, H-3), 5.18 (dd, J3,4 = 9.5 Hz, J4,5=10.1 Hz, 1H, H-4), 5.08 (dd, J1,2 = 3.6 Hz, 
J2,3 =10.2 1H, H-2), 4.26 (dd, J5,6a = 12.3, J6a,6b = 4.52 Hz, 1H, H-6a), 4.11 (mc, 1H, H-
5), 4.07 (dd, J5,6b = 12.2, J6a,6b = 2.3 Hz, 1H, H-6b), 3.91 (s, 3H, CO2CH3), 2.08, 2.06, 
2.05, 2.04 (each s, each 3H, 4 OAc); 13C NMR (125 MHz, CDCl3): δ = 170.5, 170.2, 
169.5, 167.9 (4 C=O), 158.9 (C-7), 151.9 (C-13), 148.5 (C-10), 131.9 (C-17), 129.7 (C-
15). 129.6 (C-16), 125.1 (C-9, C-11), 118.8 (C-18), 116.8 (C-8, C-12), 94.7 (C-1), 70.3 
(C-2), 69.9 (C-3), 68.3 (C-5), 68.2 (C-4), 61.5 (C-6), 52.3 (C-20), 20.7, 20.66, 20.63, 
20.59 (4 CO2CH3); IR (ATR): ṽ = 1741, 1596, 1498, 1367, 1214 cm
-1; ESI MS calcd for 
C26H28N2O10 [M+Na]
+: 609.169; found: 609.167. 
E-p-(o-Hydroxyphenylazo)phenyl 2,3,4,6-tetra-O-acetyl--D-mannopyranoside 
(24) and E-p-[p-(2,3,4,6-tetra-O-acetyl--D-mannopyranosyloxy)]phenylazophenyl 
2,3,4,6-tetra-O-acetyl--D-mannopyranoside (25): To a solution of the mannosyl  
donor 10 (1.00 g, 2.03 mmol) and p,p'-dihydroxyazobenzene 23 (200 mg, 0.93 mmol) in 
dry CH3CN (15 mL) BF3-Et2O (260 μL, 2.01 mmol) was added at 0 °C under N2 
atmosphere. The reaction mixture was stirred at RT overnight and then aq. NaHCO3 (5 
mL) was added to quench the reaction. It was diluted with ethyl acetate (100 mL), the 
phases were separated and the organic phase was washed with water (2 × 15 mL). It was 
dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure. 
Purification by flash column chromatography (cyclohexane/ethyl acetate, 6:4) gave the 
mono-glycosylated product 24 (190 mg, 0.349 mmol, 37%) as the first fraction, 
followed by the divalent glycoside 25 (268 mg, 0.307 mmol, 31%) as pale yellow solids. 
24: M.p. 109-110 °C; Rf = 0.26 (cyclohexane/ethyl acetate, 1:1); []
20
D = + 0.75 (c = 
1.0, CH2Cl2); 
1H NMR (600 MHz, CDCl3): δ = 7.85 (d, J = 9.0 Hz, 2H, H-14, H-18), 
7.83 (d, J = 8.9 Hz, 2H, H-9, H-11), 7.19 (d, J = 9.0 Hz, 2H, H-15, H-17), 6.94 (d, J = 
8.8 Hz, 2H, H-8, H-12), 5.61 (d, J1,2 = 1.6 Hz, 1H, H-1), 5.59 (dd, J3,4 = 10.0, J3,2 = 3.4 
Hz, 1H, H-3), 5.48 (dd, J2,3=3.5 Hz, J1,2 = 1.8 Hz, 1H, H-2), 5.39 (dd~t, J3,4 = J4,5 = 10.1 
Hz, 1H, H-4), 4.30 (dd, J5,6a = 12.1, J6a,6b = 5.3 Hz, 1H, H-6a), 4.12-4.08 (m, 2H, H-5, 
H-6b), 2.22, 2.07, 2.06, 2.04 (each s, each 3H, 4 OAc); 13C NMR (150 MHz, CD3OD): 
δ = 170.7, 170.3, 170.1, 169.8 (4 C=O), 158.3 (C-7), 157.2 (C-16), 148.5 (C-13), 147.1 
(C-10), 124.8 (C-14, C-18), 124.3 (C-9, C-11), 116.8 (C-15, C-17), 115.8 (C-8, C-12), 
95.7 (C-1), 69.4 (C-5), 69.3 (C-2), 68.9 (C-3), 65.9 (C-4), 62.1 (C-6), 20.9, 20.7, 20.7, 
20.7 (CO2CH3); IR (ATR): ṽ = 3407, 1744, 1587, 1498, 1368; 1211 cm
-1; ESI MS calcd 
for C26H28N2O11 [M+Na]
+: 567.51; found: 567.16. 
25: M.p. 167-169 °C; Rf = 0.15 (cyclohexane/ethyl acetate, 1:1); []
20
D = + 0.89 (c=1.0, 
CH2Cl2); 
1H NMR (500 MHz, CDCl3): δ = 7.89 (dd, J = 9.0 Hz, 4H, H-9, H-11, H-14, 
H-18), 7.22 (d, J = 9.0 Hz, 4H, H-8, H-12, H-15, H-17), 5.61 (d, J1,2 = 1.7 Hz, 2H, 2 H-
1), 5.58 (dd, J3,4 = 10.0, J2,3 = 3.5 Hz, 2H, 2 H-3), 5.48 (dd, J2,3=3.5 Hz, J1,2 = 1.8 Hz, 
2H, 2 H-2), 5.38 (dd~t, J3,4 = J4,5 = 10.1 Hz, 2H, 2 H-4), 4.31-4.26 (m, 2H, 2 H-6a), 
4.11-4.07 (m, 4H, 2 H-5, 2 H-6b), 2.21, 2.06, 2.05, 2.03 (each s, each 6H, 8 OAc); 13C 
NMR (150 MHz, CDCl3): δ = 170.5, 169.9, 169.9, 169.7 (8 C=O), 157.5 (C-7, C-16), 
148.4 (C-13, C-10), 124.5 (C-9, C-11, C-14, C-18), 116.8 (C-8, C-12, C-15, C-17), 95.7 
(C-1), 69.5 (C-5), 69.3 (C-2), 68.8 (C-3), 65.9 (C-4), 62.1 (C-6), 20.9, 20.7, 20.7, 20.7 
(8 CO2CH3C);IR (ATR): ṽ = 2992, 1748, 1599, 1582, 1496, 1368, 1213 cm
-1; ESI MS 
calcd for C40H46N2O20 [M+Na]
+ : 897.26; found: 897.23. 
E-p-(p-Hydroxyphenylazo)phenyl -D-mannopyranoside (26): The protected mannoside 
24 (100 mg, 0.184 mmol) was dissolved in dry MeOH (2 mL) and a catalytic amount of 
NaOMe was added. The reaction mixture stirred at RT overnight and was then 
neutralized with Amberlite IR 120 ion exchange resin. It was filtered and the filtrate 
evaporated to yield the pure title compound (61 mg, 0.162 mmol, 88%) as light orange 
solid. M.p. 206-207 °C; Rf = 0.18 (CH2Cl2/MeOH, 9:1); []
20
D = + 1.02 (c = 1.0, 
MeOH); 1H NMR (500 MHz, CD3OD): δ = 7.82 (d, J = 9.0 Hz, 2H, H-9, H-11), 7.78 (d, 
J = 8.9 Hz, 2H, H-14, H-18), 7.25 (d, J = 9.0 Hz, 2H, H-8, H-12), 6.90 (d, J = 8.9 Hz, 
2H, H-15, H-17), 5.58 (d, J1,2 = 1.8 Hz, 1H, H-1), 4.04 (dd, J2,3=3.4 Hz, J1,2 = 1.9 Hz, 
1H, H-2), 3.92 (dd, J2,3 = 3.4 Hz, J3,4 = 9.5, 1H, H-3), 3.79-3.71 (m, 3H, H-4, H-6a, H-
6b), 3.60 (ddd, J4,5 = 9.8 Hz, J5,6a = 5.3 Hz, J5,6b = 2.5 Hz, 1H, H-5); 
13C NMR (125 
MHz, CD3OD): δ = 161.7 (C-16), 159.7 (C-7), 149.4 (C-10), 147.5 (C-13), 125.6 (C-15, 
C-17), 124.9 (C-8, C-12), 117.9 (C-9, C-11), 116.7 (C-14, C-18), 100.2 (C-1), 75.6 (C-
5), 72.4 (C-3), 71.9 (C-2), 68.3 (C-4), 62.7 (C-6); IR (ATR): ṽ = 3210, 1586, 1493, 
1225 cm-1; ɛ = 19804 + 750 L x mol-1 x cm-1; MALDI-TOF MS calcd for C18H20N2O7 
[M+H]+: 377.36; found: 377.17; HRMS calcd for C18H20N2O7 [M+H]
+: 377.1343; found 
377.1339. 
E-p-[p-(-D-Mannopyranosyloxy)]phenylazophenyl -D-mannopyranoside (27): 
The protected bis-glycoside 25 (100 mg, 0.114 mmol) was disssolved in dry methanol  
(2 mL) and a catalytic amount of NaOMe was added. The reaction mixture was stirred 
at RT overnight, then it was neutralized with Amberlite IR 120 ion exchange resin and 
filtered. The filtrate was evaporated to yield the bivalent title glycoside (57 mg, 0.105 
mmol, 93%) as yellow solid. M.p. 204-206 °C; Rf = O.21 (CH2Cl2/MeOH, 6:4); [α]
20
D = 
+ 1.92 (c = 0.9, DMSO); 1H NMR (600 MHz, DMSO-D6): δ = 7.84 (d, J = 8.9 Hz, 4H, 
H-9, H-11, H-14, H-18), 7.26 (d, J = 8.9 Hz, 4H, H-8, H-12, H-15, H-17), 5.51 (bs, 2H, 
2 H-1), 5.09 (d, J=4.3 Hz, 2H, 2 OH), 4.86 (d, J= 5.8 Hz, 2H, 2 OH), 4.79 (d, J=5.9 Hz, 
2H, 2 OH), 4.47 (t, J=5.9 Hz, 2H, 2 OH), 3.87 (bs, 2H, 2 H-2), 3.70 (mc, 2H, 2 H-3), 
3.60 (dd, J5,6a = 10.1, J6a,6b = 5.8 Hz, 2 H-6a), 3.54-3.46 (m, 4H, 2 H-4, 2 H-6b), 3.40-
3.36 (m, 2H, 2 H-5);  13C NMR (150 MHz, DMSO-D6): δ = 158.6 (C-7, C-16), 146.9 
(C-13, C-10), 124.51 (C-9, C-11, C-14, C-18), 117.1 (C-8, C-12, C-15, C-17), 98.7 (2 
C-1), 75.2 (2 C-5), 70.7 (2 C-3), 69.9 (2 C-2), 66.7 (2 C-4), 61.0 (2 C-6); IR (ATR): ṽ = 
3301, 2914, 1599, 1583, 1498, 1227 cm-1; ɛ = 18810 + 252 L x mol-1 x cm-1; MALDI-
TOF MS calcd for C24H30N2O12 [M+Na]
+: 561.50; found: 561.26; HRMS calcd for 
C24H30N2O12 [M+H]
+: 539.1871; found 539.1860.  
E-p-(p-Hydroxyphenylazo)phenyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside (28): 
To a solution of the glucosyl donor 11 (907 mg, 1.84 mmol) and p,p'-
dihydroxyazobenzene (23, 304 mg, 1.42 mmol) in dry DCM (5 mL) BF3-Et2O (280 μL, 
2.16 mmol) was added at 0 °C under N2 atmosphere. The reaction mixture was stirred at 
RT overnight and then aq. NaHCO3 (5 mL) was added to quench the reaction. The 
solution was extracted with dichloromethane (3 × 5 mL). The combined organic phases 
were washed with water (2 × 5 mL), dried over MgSO4 and concentrated under reduced 
pressure. Purification by flash column chromatography (cyclohexane/ethyl acetate, 1:1) 
gave the mono-glycosylated product 28 (239 mg, 0.440 mmol, 31%) as yellow solid. 
M.p. 89-91 °C; Rf;= 0.46 (cyclohexane/ethyl acetate, 1:3) []
20
D = -1.27 (c = 0.92, 
MeOH); 1H NMR (500 MHz, CDCl3): δ = 7.77 (d, J = 9.0 Hz, 2H, H-9, H-11), 7.75 (d, 
J = 8.9 Hz, 2H, H-14, H-18), 7.00 (d, J = 9.0 Hz, 2H, H-8, H-12), 6.86 (d, J = 8.9 Hz, 
2H, H-15, H-17), 6.19 (s, br, 1H, OH), 5.25 (mz, 2H, H-2, H-3), 5.12 (t, J = 9.8 Hz, 1H, 
H-4), 5.09 (d, J1,2 = 7.2 Hz, 1H, H-1), 4.30 (dd, J = 12.3, J = 5.3 Hz, 1H, 1H-6a), 4.13 
(dd, J = 2.5 Hz, J = 12.3, 1H, H-6b), 3.84 (ddd, J = 10 Hz, J = 5.4 Hz, J = 2.5 Hz, 1H, 
H-5), 2.02 (s, 3H, OAc-6), 2.01, (s, 3H, OAc-2), 1.99, (s, 3H, OAc-4), 1.98 (s, 3H, 
OAc-3); 13C NMR (150 MHz, CDCl3): δ = 170.8 (CO2CH3-6) 170.4 (CO2CH3-4), 169.5 
(CO2CH3-2), 169.5 (CO2CH3-4), 158.6 (C-16), 158.3 (C-7), 148.7 (C-10), 146.9 (C-13), 
124.8 (C-14, C-18), 124.2 (C-9, C-11), 117.1 (C-8, C-12), 115.8 (C-15, C-17), 98.8 (C-
1), 72.7 (C-2), 72.2 (C-5), 71.2 (C-3), 68.3 (C-4), 62.0 (C-6), 20.7, 20.6, 20.6, 20.5 (4 
CO2CH3); IR (ATR): ṽ = 3367, 2940, 2874, 1743, 1586, 1366, 1211 cm
-1; EI MS  calcd 
for C18H20N2O7: 376.1; found: 376.1. 
E-p-(p-Hydroxyphenylazo)phenyl β-D-glucopyranoside (29): The protected  
glycoside 28 (87 mg, 0.16 mmol) was disssolved in dry methanol (2 mL) and a catalytic 
amount of NaOMe was added. The reaction mixture was stirred at RT overnight, then it 
was neutralized with Amberlite IR 120 ion exchange resin and filtered. The filtrate was 
evaporated to yield the title glycoside 29 (53 mg, 0.14 mmol, 89%) as yellow solid. M.p. 
186-188 °C; Rf = 0.75 (ethyl acetate/methanol 3:2), [α]
20
D = -3.42 (c = 0.92, DMSO); 
1H 
NMR (500 MHz, DMSO-D6): δ = 7.79 (d, J = 8.8 Hz, 2H, H-9, H-11), 7.75 (d, J = 8.8 
Hz, 2H, H-15, H-17), 7.18 (d, J = 8.9 Hz, 2H, H-8, H-12), 6.93 (d, J = 8.8 Hz, 2H, H-14, 
H-18), 4.99 (d, J = 7.3 Hz, 1H, H-1), 3.70 (dd, J = 12.1 Hz, J = 1.9 Hz, 1H, H-6a), 3.48 
(dd. J = 5.83 Hz, J = 12.1 Hz, 1H, H-6b), 3.39 (dt, J = 2.0 Hz, J = 5.76 Hz, 1H, H-5), 
3.30 (t, J = 9.0 Hz, 1H H-3), 3.27 (t, J = 8.3 Hz, 1H, H-2), 3.18 (d, J = 7.9 Hz, 1H, H-
4); 13C NMR (150 MHz, DMSO-D6): δ = 160.7 (C-15, C-17), 159.5 (C-7), 147.4 (C-10), 
145.7 (C-13), 124.7 (C-15, C-17), 124.0 (C-9, C-11) 117.1 (C-8, C-12), 116.2 (C-14, C-
18), 100.4 (C-1), 77.5 (C-5). 76.7 (C-3), 73.5 (C-2), 69.9 (C-4), 61.0 (C-6); IR (ATR): ṽ 
= 3276, 2882, 1587, 1495, 1231; ɛ = 17871 + 788 L x mol-1 x cm-1;EI MS  calcd for 
C26H28N2O11: 544.2; found: 544.3. 
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Photoirradition of E-azobenzene glycosides: For NMR spectroscopy ~10 mg of the 
E-configured azobenzene glycoside was dissolved in DMSO-D6 (600 µL) in a NMR 
tube and irradiated for 30 min at 365 nm. Then, the sample was kept in the dark and 1H 
NMR spectroscopy was performed immediately afterwards. For UV-Vis spectroscopy 
the E-configured azobenzene glycoside was dissolved in DMSO, irradiated for 30 min 
at 365 nm in a UV cuvette and UV VIS spectra were recorded immediately afterwards, 
Extinction coefficients were deduced from UV-Vis spectra measured with 5 different 
concentrations (10 µM, 20 µM, 30 µM, 40 µM and 50 µM). 
Z-p-(Phenylazo)phenyl -D-mannopyranoside (Z-1): 1H NMR (500 MHz, DMSO-
D6): δ = 7.32 (t, J = 7.8 Hz, 2H, H-15, H-17), 7.18 (t, J = 7.4 Hz, 1H, H-16), 6.97 (d, J = 
8.9 Hz, 2H, H-9, H-11), 6.82 (dd, J = 8.2 Hz, J = 6.7 Hz, 4H, H-8, H-12, H-14, H-18), 
5.32 (d, J1,2 = 1.6 Hz, 1H, H-1), 3.77 (dd, J2,3 = 3.1 Hz, J1,2 = 1.9 Hz, 1H, H-2), 3.62 (dd, 
J3,4 = 9.3 Hz, J3,2 = 3.3 Hz, 1H, H-3), 3.52 (dd, J5,6a = 2.1 Hz, J6a,6b= 11.8 Hz, 1H, H-6a), 
3.48-3.36 (m, 2H, H-4, H-6b), 3.31 (ddd, J4,5 = 9.4 Hz, J5,6a = 5.8 Hz, J5,6b = 2.1 Hz, 1H, 
H-5); 13C NMR (125 MHz, DMSO-D6): δ = 155.4 (C-7), 153.8 (C-13), 147.3 (C-10), 
129.1 (C-15, C-17), 127.0 (C-16), 122.5 (C-8, C-12), 119.4 (C-14, C-18), 116.7 (C-9, 
C-11), 98.7 (C-1), 74.8 (C-5), 70.3 (C-3), 69.7 (C-2), 66.3 (C-4), 60.7 (C-6); ɛ = 2635 + 
76 L x mol-1 x cm-1. 
Z-p-(o-Carboxyphenylazo)phenyl -D-mannopyranoside (Z-2): 1H NMR (500 MHz, 
CD3OD): δ = 7.99 (dd, J = 7.9 Hz, J = 1.1 Hz, 1H, H-15), 7.41 (dt, J = 7.5 Hz, J = 1.4 
Hz, 1H, H-17), 7.29 (td, J = 7.8 Hz, J = 1.1 Hz, H-16), 7.06-6.99 (m, 4H, H-8, H-12, H-
9, H-11), 6.36 (dd, J = 7.9 Hz, J = 0.8 Hz, 1H, H-18), 5.45 (d, J1,2= 1.8 Hz, 1H, H-1), 
3.96 (dd, J2,3 = 3.4, J1,2 = 1.8 Hz, 1H, H-2), 3.84 (dd, J3,4 = 9.5, J2,3 = 3.4 Hz, 1H, H-3), 
3.75-3.67 (m, 3H, H-4, H-6a, H-6b), 3.50 (ddd, J4,5 = 7.5, J5,6a = 5.3 Hz, J5,6b = 2.7, 1H, 
H-5); 13C NMR (125 MHz, CD3OD): δ = 168.5 (C-19), 157.9 (C-7), 157.4 (C-13), 
149.0 (C-10), 134.5 (C-17), 132.1 (C-15), 127.6 (C-16), 126.2 (C-14), 124.5 (C-9, C-
11), 118.7 (C-18), 117.5 (C-8, C-12), 100.2 (C-1), 75.6 (C-5), 72.3 (C-3), 71.7 (C-2), 
68.2 (C-4), 62.6 (C-6); ɛ = 3106 + 144 L x mol-1 x cm-1. 
Z-p-(o-Methoxycarbonylphenylazo)phenyl -D-mannopyranoside (Z-3): 1H NMR 
(500 MHz, D2O): δ = 7.91 (dd, J = 8.0 Hz, 1.2 Hz, 1H, H-15), 7.46 (dt, J = 8.0 Hz, 7.9 
Hz, 1.3 Hz, 1H, H-17), 7.33 (dt, J = 7.9 Hz, 7.8 Hz, 1.0 Hz, 1H, H-16), 6.97 (m, 4H, H-
8, H-9, H-11, H-12), 6.61 (d, J = 8.9 Hz, 1H, H-18), 5.52 (d, J1,2 = 1.6 Hz, 1H, H-1), 
4.11 (dd, J2,3 = 3.3 Hz, J1,2 = 1.8 Hz, 1H, H-2), 3.93 (dd, J3,4 = 9.7 Hz, J3,2 = 3.4 Hz, 1H, 
H-3), 3.81 (s, 3H, OCH3), 3.66-3.60 (m, 3H, H-4, H-6a, H-6b), 3.51 (ddd, J4,5 = 9.9 Hz, 
J5,6a = 5.6 Hz, J5,6b = 2.3 Hz, 1H, H-5); 
13C NMR (125 MHz, D2O ): δ = 167.3 (C-19), 
155.2 (C-7), 153.5 (C-13), 145.9 (C-10), 134.1 (C-17), 130.8 (C-15), 127.9 (C-16), 
124.7 (C-14), 123.7 (C-9, C-11), 118.6 (C-18), 116.7 (C-8, C-12),97.5 (C-1), 73.3 (C-5), 
70.1 (C-3), 69.5 (C-2), 66.3 (C-4), 60.5 (C-6), 52.9 (C-20); ɛ = 3452 + 163 L x mol-1 x 
cm-1. 
Z-p-(Phenylazo)phenyl -D-glucopyranoside (Z-4): 1H NMR (500 MHz, DMSO-D6): 
δ = 7.33 (dd, J = 8.2, J = 7.5 Hz, 2H, H-15, H-17), 7.18 (t, J = 7.4 Hz, 1H, H-16), 6.99 
(d, J = 8.9 Hz, 2H, H-8, H-12), 6.85-6.82 (m, 4H, H-9, H-11, H-14, H-18), 5.35 (d, J1,2 
= 3.6 Hz, 1H, H-1), 3.56 (dd~t, J = 9.2 Hz, 1H, H-3), 3.51 (dd, J5,6a = 11.8, J6a,6b = 2.1, 
1H, H-6a), 3.44 (mc, 1H, H-6b), 3.38 (ddd, J5,6a = 9.9, J5,6b = 5.3, J4,5 = 2.1 Hz, 1H, H-5), 
3.33 (dd, J2,3 = 9.7, J1,2 = 3.6 Hz, 1H, H-2), 3.15 (t, J = 9.3 Hz, 1H, H-4); 
13C NMR (125 
MHz, DMSO-D6): δ = 156.4 (C-7), 154.0 (C-13), 147.4 (C-10), 129.2 (C-15, C-7), 
127.1 (C-16), 122.6 (C-9, C-11), 119.5 (C-14, C-18), 116.9 (C-8, C-12), 97.9 (C-1), 
73.8 (C-5), 72.8 (C-3), 71.3 (C-2), 69.7 (C-4), 60.5 (C-6); ɛ = 1712 + 191 L x mol-1 x 
cm-1. 
Z-p-(o-Carboxyphenylazo)phenyl -D-glucopyranoside (Z-5): 1H NMR (500 MHz, 
DMSO-D6): δ = 7.88 (dd, J = 7.8, J = 1.3 Hz, 1H, H-15 ), 7.41 (dt, J = 7.8, J =7.7, J = 
1.4, 1H, H-17), 7.25 (dt, J = 7.7, J =7.6, J = 1.1 Hz, 1H, H-16), 6.99 (d, J = 9.0 Hz, 2H, 
H-9, H-11), 6.94 (d, J = 9.0 Hz, 2H, H-8, H-12), 6.31 (dd, J = 7.9, J = 1.0 Hz, 1H, H-
18), 5.34 (d, J1,2 = 3.6 Hz, 1H, H-1), 3.56 (mc, 1H, H-3), 3.48 (mc, 1H, H-6a), 3.44 (mc, 
1H, H-6b), 3.36 (ddd, J4,5 = 10.0, J5,6a = 5.3, J5,6b = 2.1 Hz, 1H, H-5), 3.32 (dd, J2,3 = 9.7, 
J2,1 = 3.6 Hz, 1H, H-2), 3.14 (dd, J3,4 = 8.9 Hz, J4,5 = 9.8, 1H, H-4); 
13C NMR (150 
MHz, DMSO-D6): δ = 166.4 (C-19), 155.9 (C-7), 147.3 (C-10), 133.4 (C-17), 130.5 (C-
15), 126.3 (C-16), 123.3 (C-14),122.6 (C-8, C-12), 117.1 (C-18), 116.7 (C-9, C-11), 
97.8 (C-1), 73.8 (C-5), 72.8 (C-3), 71.3 (C-2), 69.7 (C-4), 60.6 (C-6); ɛ = 1407 + 67 L x 
mol-1 x cm-1. 
Z-p-(o-Methoxycarbonylphenylazo)phenyl -D-glucopyranoside (Z-6): 1H NMR 
(500 MHz, DMSO-D6): δ = 7.88 (dd, J = 7.8, J = 1.3 Hz, 1H, H-15 ), 7.45 (dt, J = 7.8, J 
=7.7, J = 1.4, 1H, H-17), 7.28 (mc, 1H, H-16), 6.99 (d, J = 8.9 Hz, 2H, H-9, H-11), 6.91 
(d, J = 8.9 Hz, 2H, H-8, H-12), 6.41 (dd, J = 7.9, J = 1.0 Hz, 1H, H-18), 5.35 (d, J1,2 = 
3.6 Hz, 1H, H-1), 3.80 (s, 3H, CO2CH3), 3.55 (dd~t, J = 9.2 Hz, 1H, H-3), 3.49 (dd, J5,6a 
= 11.8, J6a,6b = 2.1 Hz, 1H, H-6a), 3.46 (mc, 1H, H-6b), 3.34 (mc, 1H, H-5), 3.32 (dd, J2,3 
= 9.7, J2,1 = 3.6 Hz, 1H, H-2), 3.15 (mc, 1H, H-4); 
13C NMR (150 MHz, DMSO-D6): δ 
= 165.3 (C-19), 156.9 (C-7), 155.7 (C-13), 147.2 (C-10), 133.9 (C-17), 130.5 (C-15), 
126.6 (C-16), 122.4 (C-8, C-12), 117.7 (C-18), 116.9 (C-9, C-11), 97.9 (C-1), 74.0 (C-
5), 72.9 (C-3), 71.4 (C-2), 69.8 (C-4), 60.6 (C-6), 52.6 (C-20); ɛ = 1734 + 142 L x mol-1 
x cm-1. 
Z-p-(Phenylazo)phenyl β-D-glucopyranoside (Z-7): 1H NMR (500 MHz, DMSO-D6): 
δ = 7.31 (t, J = 7.81 Hz, 2H, H-15, H-17), 7.17 (t, J = 7.44 Hz, 1H, H-16), 6.9 (d, J = 
8.94 Hz, 2H, H-8, H-12), 6.83-6.79 (m, 4H, H-9, H-11, H-14, H-18), 4.80 (d, J1,2 = 7.66 
Hz, 1H, H-1), 3.43 (dd, J5,6a = 5.8 Hz, J6a,6b = 11.9, 1H, H-6a), 3.32 (mc, 1H, H-5), 3.27 
(dd~t, J = 8.9 Hz, 1H, H-3), 3.22-3.13 (m, 2H, H-2, H-4); 13C NMR (125 MHz, DMSO-
D6): δ = 157.1 (C-7), 154.4 (C-13), 147.9 (C-10), 129.9 (C-15, C-17), 128.0 (C-16), 
123.4 (C-9, C-11), 120.2 (C-14, C-18), 116.7 (C-8, C-12), 100.7 (C-1), 77.3 (C-5), 76.7 
(C-3), 73.6 (C-2), 70.2 (C-4), 61.2 (C-6); ɛ =1704 + 80 L x mol-1 x cm-1. 
Z-p-(o-Carboxyphenylazo)phenyl β-D-glucopyranoside (Z-8): 1H NMR (500 MHz, 
CD3OD): δ = 7.97 (dd, J = 7.7 Hz, J = 1.4 Hz, 1H, H-15), 7.34 (dt, J = 7.8 Hz, J = 7.7 
Hz, J = 1.4 Hz, 1H, H-17), 7.25 (dt, J = 7.6 Hz, J = 7.6 Hz, J = 1.1 Hz, 1H, H-16), 7.06-
7.00 (m, 4H, H-8, H-9, H-11, H-12), 6.31 (dd, J = 7.8 Hz, J = 0.9 Hz, 1H, H-18), 4.89-
4.86 (bs, H-1 and solvent peak), 3.89 (dd, J6a,6b = 12.1, J5,6a = 2.1 Hz, 1H, H-6a), 3.69 
(dd, J6a,6b = 12.1, J6b,5 = 5.5 Hz, 1H, H-6b), 3.46-3.42 (m, 4H, H-5, H-3, H-2, H-4); 
13C 
NMR (125 MHz, CD3OD): δ = 167.2 (C-19), 161.9 (C-7), 154.4 (C-13), 149.2 (C-10), 
133.7 (C-17), 131.9 (C-15), 131.2 (C-14), 127.5 (C-16), 124.3 (C-9/C-11), 118.5 (C-18), 
117.5 (C-8/C-12), 102.0 (C-1), 78.2 (C-5), 77.9 (C-3), 74.9 (C-2), 71.3 (C-4), 62.4 (C-
6); ɛ = 2521 + 20 L x mol-1 x cm-1. 
Z-p-(o-Methoxycarbonylphenylazo)phenyl β-D-glucopyranoside (Z-9): 1H NMR 
(500 MHz, CD3OD): δ = 7.95 (d, J = 7.7 Hz, 1H, H-15), 7.40 (dt, J = 7.9 Hz, J = 7.7 Hz, 
J = 1.4 Hz, 1H, H-17), 7.27 (dt, J = 7.8 Hz, J = 7.7 Hz, J = 1.2 Hz, 1H, H-16), 7.00-6.96 
(m, 4H, H-8, H-9, H-11, H-12), 6.39 (dd, 7.40, J = 8.1 Hz, J = 0.9 Hz, 1H, H-18), 4.86 
(d, J1,2= 7.5 Hz, 1H, H-1), 3.88 (s, 3H, OCH3), 3.85 (dd, J6a,6b = 12.1, J5,6a = 2.2 Hz, 1H, 
H-6a), 3.66 (dd, J6a,6b = 12.1, J5,6b = 5.6 Hz, 1H, H-6b), 3.43-3.38 (m, 4H, H-5, H-2, H-3, 
H-4); 13C NMR (125 MHz, CD3OD): δ = 167.5 (C-19), 159.1 (C-7), 157.3 (C-13), 
148.9 (C-10), 134.7 (C-17), 131.8 (C-15), 127.7 (C-16), 124.4 (C-9, C-11), 124.1 (C-
14), 118.9 (C-18), 117.6 (C-8, C-12), 101.9 (C-1), 78.2 (C-5), 77.9 (C-3), 74.5 (C-2), 
71.3 (C-4), 62.4 (C-6), 52.9 (C-20); ɛ = 2071 + 244 L x mol-1 x cm-1. 
Z-p-[p-(-D-Mannopyranosyloxy)]phenylazophenyl -D-mannopyranoside (Z-27): 
1H NMR (500 MHz, DMSO-D6): δ = 7.01 (d, J = 8.6 Hz, 4H, H-8, H-12, H-15, H-17), 
6.83 (d, J = 8.6 Hz, 4H, H-9, H-11, H-14, H-18), 5.34 (bs, 2H, 2 H-1), 3.78 (bs, 2H, 2 
H-), 3.63-3.53 (m, 4H, 2 H-3, 2 H-6a), 3.48-3.42 (m, 4H, 2 H-4, 2 H-6b), 3.34-3.31 (m, 
2H, 2 H-5);  13C NMR (125 MHz, DMSO-D6): δ = 155.2 (C-7, C-16), 147.6 (C-10, C-
13), 124.0 (C-9, C-11, C-14, C-18), 116.9 (C-8, C-12, C-15, C-17), 98.7 (2 C-1), 74.9 (2 
C-5), 70.3 (2 C-3), 69.7 (2 C-2), 66.4 (2 C-4), 60.8 (2 C-6); ); ɛ = 1395 + 79 L x mol-1 x 
cm-1. 
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 3.3 Sweet switches: Azobenzene glycoconjugates by click chemistry 
Vijayanand Chandrasekaran, Thisbe K. Lindhorst* 
 
Chem. Commun. 2012, 48, 7519-7521. 
 
Multiple assembly of azobenzene glyconconjugates is of special interest because it 
allows the investigation of conformational aspects of multivalency effects in 
carbohydrate recognition. However, a systematic approach how the conformation will 
control the multivalent azobenzene glycoconjugates is less explored. In this 
communication, a series of mono-, di- and trivalent azobenzene glycoconjugates were 
synthesized via click chemistry and the photochromic properties were studied in 
solution. In future perspective, multivalent azobenzene glycoarrays will be formed on 
different surface scaffolds for biological testing. (Fig 3.3) 
 
Figure 3.3: Schematic representation for the synthesis of multivalent photoswitchable glycoconjugates, 
which can be achieved by glycosylation and click chemistry reaction.  
 
In this project, I did the synthesis, substance characterization and studied the 
photochromic properties of the prepared azobenzene glycosides. T. K. Lindhorst and I 
wrote the manuscript and the supplementary material part. 
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Sweet switches: azobenzene glycoconjugates synthesized by click
chemistryw
Vijayanand Chandrasekaran and Thisbe K. Lindhorst*
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DOI: 10.1039/c2cc33542e
Azobenzene glycoconjugates can be switched between two isomeric
states, E and Z, to change the spatial orientation of the conjugated
carbohydrate ligands. Mono-, di- and trivalent azobenzene glyco-
conjugates were synthesized using click chemistry and their photo-
chromic properties determined. Multivalency eﬀects were observed
in photoisomerisation.
Molecular recognition processes in biology are governed by
the constitution and conﬁguration of the interaction partners.
Moreover, they are controlled and ﬁne-tuned by conforma-
tional changes within the supramolecular environment of the
biological system, such as a glycosylated cell surface.1 In order
to gain insight into conformational control of biological
processes, photoswitchable bioprobes have become popular.2
Typically, these are organic molecules that undergo a deﬁned
and reversible change between two sterically diﬀerent states
upon irradiation with light of an appropriate wavelength.
Some of the best investigated molecular switches are azo-
benzenes that exist in a stable planar E-form and can be
photoisomerised into a bent Z-isomer. Switching azobenzene
conjugates between these two states eﬀects a signiﬁcant steric
change within the molecule and alters the relative orientation
of the conjugated bioprobes.
Azobenzene derivatives have been shown to be well-suited
for biological applications3 and their two isomeric forms
(E and Z) can be independently addressed in biological testing.
However, to date, only few examples have been published
where carbohydrates have been combined with an azobenzene
photoswitch.4 It has been shown, though, that isomerisation of
photoswitchable glycoconjugates changes their interactions
with carbohydrate-recognizing proteins (lectins).5,6
As azobenzene glycoconjugates are important target molecules
for glycobiological research it is necessary to improve their
synthesis and facilitate their application in various contexts.
The multiple assembly (clustering) of azobenzene glyco-
conjugates is of special relevance because it allows the investi-
gation of conformational aspects of multivalency eﬀects in
carbohydrate recognition.7 In the past small glycoclusters have
proven to be very valuable tools for probing lectins.8 Here, it
has been our goal to utilize the concept of ‘‘click chemistry’’9
for the eﬀective preparation of azobenzene glycosides and
their di- and trivalent clustered analogues (cf. Fig. 1).
In order to employ click chemistry for the synthesis of
photoswitchable glycoconjugates, the best approach is to use
azobenzene propargyl ethers on the one hand and azido-
functionalised carbohydrates on the other hand.
Firstly, ether-functionalised azobenzene derivatives are
known for their favourable photochromic properties. Further-
more, the required azide-modiﬁed saccharides can be easily
obtained in great variety. Owing to our long standing interest
in mannose-speciﬁc lectins10 we have selected mannoside 4
(Scheme 1) as the prototype azide for the current study.
The synthetic routes leading tomono- as well as bis-glycosylated
azobenzene glycoconjugates were both started from 4,40-dihydroxy-
azobenzene (1, Scheme 1) which was prepared according to the
literature.11 Regioselective conversion into the mono-propargyl
ether 2 was achieved in 35% yield with recovery of B40%
starting material. The same reaction using 5 equivalents of
both propargyl bromide and potassium carbonate leads to
the bis-propargyl ether 3 as the only product in 91% yield.12
Both azobenzene propargyl ethers, 2 and 3, were subjected to
1,3-dipolar cycloaddition under ‘‘click conditions’’13 using the
2-azidoethyl mannoside 4, which was easily obtained from
D-mannose in three high-yield steps.14 The desired triazole
derivatives 5 and 7, respectively, were obtained in high yield.
Fig. 1 The combination of glycosylation and click chemistry is a powerful
method to create photoswitchable glycoconjugates of diﬀerent valencies.
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w Electronic supplementary information (ESI) available. See DOI:
10.1039/c2cc33542e
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De-O-acetylation under Zemple´n conditions15 aﬀorded the
unprotected mono- and bis-glycosylated azobenzene conjugates
6 (Man-azo) and 8 (Man-azo-Man) in nearly quantitative yields.
Alternatively, bis-glycosylated azobenzene derivatives can
be prepared by combination of a glycosylation and a cyclo-
addition step (Scheme 2). Accordingly, Lewis acid-promoted
mannosylation of 2 with the mannosyl donor 916 gave the
a-mannoside 10, which upon reaction with the azide 4 under
Cu(I) catalysis led to the triazole derivative 11 in 82% yield.
Zemple´n deprotection aﬀorded the OH-free bis-glycosylated
azobenzene glycoconjugate 12.
The two prepared conjugates of the ‘‘Man-azo-Man’’ type,
8 and 12, diﬀer in that 8 is a symmetrical compound as
reﬂected in the 1H NMR spectrum, whereas 12 consists of
two diﬀerent fragments and displays two signal sets for the
diﬀerently attached mannosidic moieties.
Next, clustering of glycoazobenzene moieties was investigated.
As scaﬀolding core molecules, the diol 13 and the branched
triol 14 were employed (Scheme 3). Our ﬁrst attempt to use
Mitsunobu conditions for the alkylation of these alcohols with
the phenol 2 failed unexpectedly. Therefore, hydroxyl groups
were activated by tosylation to subsequently undergo a classical
nucleophilic substitution reaction. Reaction of the tosylates 1417
and 1918 using the azobenzene derivative 2 led to the desired
di- and trivalent azobenzene alkynes 15 and 20, respectively.
They formed the starting materials for the subsequent click
reaction with the azide 4 using a mixture of CuSO4 and copper
powder, leading to the triazole-linked glycoconjugates 16 and 21
in good yields. Again Zemple´n deprotection occurred without any
problem, furnishing the unprotected symmetric di- and trivalent
azobenzene mannoside clusters 17 (Man-azo-azo-Man) and 22
([Man-azo]3).
The photochromic properties of mono-, di- and trivalent
azobenzene glycoconjugates were tested next. In the ground
state (GS) all azobenzene glycoconjugates, 6, 8, 12, 17, and 22,
existed in their E-conﬁguration almost exclusively (Table 1).
Irradiation in DMSO solution for 30 min at 365 nm led to
the respective photostationary states (PSS) with varying E : Z
ratios, as determined by integration of the 1H NMR signals.
The PSS E : Z ratios of the monovalent bis-glycosylated
azobenzene glycoconjugates 8 and 12 are excellent (3 : 97
and 1 : 99, respectively) with long half lives allowing indepen-
dent biological evaluation of both isomeric forms. For the
monoglycosylated azobenzene alcohol 6 on the other hand, the
PSS could not be determined by UV-VIS spectroscopy. This is
presumably due to the extremely fast kinetics of thermal relaxation
of the Z isomer, as has been described earlier for p-hydroxy-
substituted azobenzene derivatives.19 The electron-donating eﬀect
of the OH-substituent lowers the barrier for thermal back isomeri-
sation (Fig. 2) leading to relaxation times in the ms range. This
feature makes such sweet switches interesting candidates for
applications, where fast information processing is required.
Interestingly, photoisomerisation of the di- and trivalent
azobenzenes was less eﬀective than that in the case of 8 and 12,
leading to E : Z ratios in the PSS of 33 : 67 and 63 : 37,
respectively. These ratios are averaged over an equilibrium
mixture of EE, EZ and ZZ isomers for 17 having two
azobenzene branches and a mixture of EEE, EEZ, EZZ,
and ZZZ isoforms for 22 having three azobenzene branches
(cf. 1H NMR spectra in the ESIw).
The photoswitching in this case is most likely inﬂuenced by
electronic eﬀects including intramolecular quenching processes
such as excitonic coupling, which was also shown for azo-
benzene SAMs.20 The di- and trivalent azobenzene clusters
may easily adopt a conformation in which the azobenzene
branches are stacked, leading to decay of the excited state
before isomerisation takes place. In addition, nonradiative
decay could be responsible for less eﬀective photoisomerisation.
Scheme 1 Reaction conditions: (a) propargyl bromide (1.1 equiv.),
K2CO3 (0.5 equiv.), 35% 2, 7% 3, 42% recovered 1; (b) propargyl
bromide (5 equiv.), K2CO3 (5 equiv.), 91%; (c) Cu/CuSO4, t-BuOH/H2O
(1 : 1), rt, 30 h, 89% (5), 83% (7); (d) NaOMe, MeOH, rt, overnight:
92% (6), 96% (8).
Scheme 2 Reaction conditions: (a) 2, BF3–Et2O, CH2Cl2, rt, 12 h,
88%; (b) 4, Cu/CuSO4, t-BuOH/THF/H2O, 70 1C, 16 h, 82%;
(c) NaOMe, MeOH, 93%.
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The detailed kinetics of photoisomerisation of azobenzene
clusters 17 and 22 will be determined in due course.
In conclusion, mono- and oligovalent azobenzene glyco-
conjugates with exciting photochromic properties have beenmade
available employing click chemistry. Photoisomerisation of the
di- and trivalent azobenzene clusters 17 and 22 is inﬂuenced by
intramolecular eﬀects leading to a mixture of isoforms. Multi-
valent glycoazobenzenes will be further investigated in advanced
NMR studies and utilised for fabrication of photoswitchable
multivalent glycoassemblies (arrays) for biological testing.
This work was supported by the DFG (Deutsche Forschungs-
gemeinschaft, SFB 677).
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Table 1 Photochromic properties of azobenzene glycoconjugates
Azobenzene glycoconjugate E : Za GS E : Za PSS t1/2 (h)
6 Man-azo 99 : 1 — —
8 Man-azo-Man 98 : 2 3 : 97 14
12 Man-azo-Man 99 : 1 1 : 99 21.3
17 Man-(azo)2-Man 99 : 1 33 : 67
b 15.5
22 (Man-azo)3 99 : 1 63 : 37
b 16
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Fig. 2 Two resonance structures of 6 explaining fast Z- E relaxation.
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1. General methods 
Thin layer chromatography was performed on silica gel plates (GF 254, Merck). Detection was 
effected by UV and subsequent charring with 10% sulphuric acid in EtOH followed by heat 
treatment at ~180 °C. Flash chromatography was performed on silica gel 60 (Merck, 230-400 
mesh, particle size 0.040-0.063 mm) using distilled solvents. Optical rotations were measured 
with a Perkin-Elmer 241 polarimeter (sodium D-line: 589 nm, length of cell: 1 dm) in the 
solvents indicated. 1H and 13C NMR spectra were recorded on Bruker DRX-500 and AV-600 
spectrometers at 300 K. Chemical shifts are reported relative to internal tetramethylsilane (δ = 
0.00 ppm) or D2O (δ = 4.76 ppm). Full assignment of the peaks was achieved with the aid of 2D 
NMR techniques (1H-1H COSY and 1H-13C HSQC). IR spectra were measured with a Perkin 
Elmer FT-IR Paragon 1000 (ATR) spectrometer. ESI mass spectra were recorded on a Esquire-
LC instrument from Bruker Daltonics. MALDI-TOF mass spectra were recorded on a Bruker 
Biflex III instrument with 19 kV acceleration voltage. 2,5-Dihydroxybenzoic acid (DHB) was 
used as a matrix. Air/moisture sensitive reactions were carried out under nitrogen in dry 
glassware. UV-Vis absorption spectra were performed on Perkin-Elmer Lambda-241 and Varian 
Cary-5000 at a temperature of 18 + 1 °C. Photoirradiaton was carried out with a high pressure 
mercury lamp UV-P 250C from Panacol-Elosol. The bandpass filters were obtained from 
“Laser“ components. 
 
 
2. Synthetic procedures 
4-Hydroxy-4’-propargyloxy azobenzene (2): 
N NHO O
 
A mixture of p,p’-dihydroxyazobenzene (1, 1.00 g, 4.67 mmol) and propagyl bromide (611 mg, 
5.14 mmol, 1.1 equiv.) was added to acetone (50 mL) and stirred under nitrogen at room 
temperature for 30 min. K2CO3 (322 mg, 2.34 mmol, 0.5 equiv.) was added and then the reaction 
mixtue was refluxed for 12 h. TLC (cyclohexane/ethyl acetate, 4:1) showed a mixture of 3 spots 
corresponding to compounds 1, 2, and 3. After the solvent was evaporated under reduced 
pressure, the residue was dissolved in ethyl acetate (50 mL) and washed with water (50 mL), 
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dried over MgSO4, filtered and concentrated under reduced pressure. Purification by column 
chromatography on silica gel (cyclohexane/ethyl acetate, 4:1) gave the mono-substituted product 
2 as a ocher solid (410 mg, 1.63 mmol, 35%) along with the disubstituted product 3 (100 mg, 
0.34 mmol, 7%) and recovered 1 (420 mg, 1.96 mmol, 42%). Rf 0.20 (cyclohexane/ethyl acetate, 
4:1); m.p. 134 °C; 1H NMR (500 MHz, CD3OD, 300 K, TMS): δ = 7.83 (d, J = 9.1 Hz, 2 aryl-
H), 7.77 (d, J = 8.9 Hz, 2 aryl-H), 7.10 (d, J = 9.1 Hz, 2 aryl-H), 6.90 (d, J = 8.9 Hz, 2 aryl-H), 
4.81 (d, J = 2.4 Hz, 2H, H-C≡C-CH2), 2.98 (t, J = 2.4 Hz, 1H, H-C≡C-CH2) ppm; 13C NMR 
(125 MHz, CD3OD, 300 K, TMS): δ = 161.6 (Cq, aryl-C), 160.9 (Cq, aryl-C), 148.8 (aryl-C), 
147.5 (aryl-C), 125.6 (aryl-C), 124.9 (aryl-C), 116.7 (aryl-C), 116.3 (aryl-C), 79.5 (H-C≡C-
CH2), 77.1 (H-C≡C-CH2), 56.9 (H-C≡C-CH2),ppm; ESI MS calcd for C15H12N2O2: m/z 253.0898 
[M+1]+; found: m/z 253.0966 [M+1]+; IR (ATR) 3264 (C≡C), 1588, 1504, 1270, 1024, 826, 676 
cm-1. 
 
4,4’-Di-propargyloxy azobenzene (3):1 
N NO O
 
A mixture of p,p’-dihydroxyazobenzene (1, 100 mg, 0.467 mmol) and propagyl bromide 
(278 mg, 2.34 mmol, 5.0 equiv.) was added to acetone (5 mL) and the reaction mixture stirred 
under nitrogen at room temperature for 30 min. Then, K2CO3 (322 mg, 2.34 mmol, 5 equiv.) was 
added and the reaction mixture was refluxed for 16 h. TLC (cyclohexane/ethyl acetate, 4:1) 
showed a spot-to-spot conversion of product 3. After the solvent was evaporated under reduced 
pressure, the residue was dissolved in ethyl acetate (30 mL) and washed with water (10 mL), 
dried over MgSO4, filtered and concentrated under reduced pressure. Purification by column 
chromatography on silica gel (cyclohexane/ethyl acetate, 4:1) gave the disubstituted product 3 
(123 mg, 0.42 mmol, 91%) as a yellow solid. Rf 0.45 (cyclohexane/ethyl acetate, 4:1); m.p. 
191 °C; 1H NMR (500 MHz, CDCl3, 300 K, TMS): δ = 8.22 (d, J = 9.2 Hz, 4 aryl-H), 7.05 (d, 
J = 9.2 Hz, 4 aryl-H), 4.79 (d, J = 2.4 Hz, 4H, 2 H-C≡C-CH2), 2.58 (d, J = 2.4 Hz, 2H, 2 H-C≡C-
CH2) ppm; 13C NMR (125 MHz, CDCl3, 300 K, TMS): δ = 162.3 (Cq, aryl-C), 142.2 (Cq, aryl-
C), 125.8, 115.0 (aryl-C), 77.3 (H-C≡C-CH2), 76.8 (H-C≡C-CH2), 56.3 (H-C≡C-CH2) ppm; ESI 
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MS calcd for C18H14N2O2: m/z 290.1055 [M+1]+; found: m/z 291.1055 [M+1]+; IR (ATR): 3260 
(C≡CH), 1587, 1493, 1245, 1020, 844, 663 cm-1. 
 
Click reaction: Acetylated monoglycosylated azobenzene glycoconjugate 5 (Man-a z o 
[OAc]4): 
1
23
6
4 5
7
8 9
10
12
16
1311
17
14
15
18
19
22
20
21
23
OH
N
N
O
O N
OAc
AcO
AcO
OAc
N N O
 
A mixture of tert-butanol and water (1:1, 3 mL) was added to a mixture of the azobenzene 
alcohol 2 (50 mg, 0.19 mmol, 1.0 equiv.), the mannoside 42 (99.3 mg, 0.24 mmol, 1.2 equiv.). 
CuSO4 x 5H2O (3 mg) and Cu powder (30 mg). The reaction mixture was stirred at room 
temperature for 30 h. Then, TLC (cyclohexane/ethyl acetate, 1:4) showed complete consumption 
of 2. Ethyl acetate (30 mL) was added, Cu removed by filteration over celite, and the filtrate was 
dried over MgSO4. It was filtered and the filtrate concentrated under reduced pressure. 
Purification of crude product by column chromatography on silica gel (cyclohexane/ethyl 
acetate, 1:4) gave mannoside 5 as a reddish brown low melting solid (118 mg, 0.18 mmol, 89%). 
Rf 0.22 (cyclohexane/ethyl acetate, 1:4); [ ]22Dα  = + 23 (c = 0.64, CH2Cl2); m.p. 70-72 °C; 1H 
NMR (500 MHz, CDCl3, 300 K, TMS): δ = 7.83-7.81 (m, 3H, H-16, H-14, H-9), 7.78 (d, 
J = 8.7 Hz, 2H, H-19, H-23), 7.06 (d, J = 8.9 Hz, 2H, H-13, H-17), 6.94 (d, J = 8.7 Hz, 2H, H-
20, H-22), 5.27 (s, 2H, H-11), 5.25-5.23 (m, 2H, H-3, H-4), 5.21 (m, 1H, H-2), 4.80 (d, 
J = 1.4 Hz, 1H, H-1), 4.63 (t, J = 5.1 Hz, 2H, H-8a, H-8b), 4.20 (dd, J = 12.3, 5.3 Hz, 1H, H-6a), 
4.15 (mc, 1H, H-7a), 4.06 (dd, J = 12.34, 2.4 Hz, 1H, H-6b), 3.89 (mc, 1H, H-7b), 3.55 (ddd, 
J = 9.4, 5.3, 2.3 Hz, 1H, H-5), 2.14, 2.09, 2.00, 1.98 (each s, each 3H, 4 C(O)CH3) ppm; 13C 
NMR (125 MHz, CDCl3, 300 K, TMS): δ = 170.7, 170.1, 170.0, 169.7 (4 COCH3), 160.1 (C-12), 
158.4 (C-21), 147. 4 (C-15), 146.9 (C-18), 144.0 (C-10), 124.6 (C-19, C-23), 124.3 (C-10, C-14, 
C-9), 115.8 (C-20, C-22), 115.0 (C-13, C-17), 97.5 (C-1), 69.2 (C-5, C-2), 68.9 (C-3), 66.2 (C-
7), 65.7 (C-4), 62.3 (C-6), 61.9 (C-11), 49.9 (C-8), 20.8, 20.7, 20.7, 20.6 (4 COCH3) ppm; ESI 
MS calcd for C31H35N5O12: m/z 692.228 [M+Na]+; found: m/z 692.219 [M+Na]+; IR (ATR) 
3144, 1750, 1580, 1498, 1221, 1147, 850, 554 cm-1. 
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Deprotection: Monoglycosylated azobenzene glycoconjugate 6 (Man-a z o): 
1
23
6
4 5
7
8 9
10
12
16
1311
17
14
15
18
19
22
20
21
23
OH
N
N
O
O N
OH
HO
HO
OH
N N O
 
The acetyl-protected monovalent azobenzene glycoconjugate 5 (100 mg, 0.14 mmol) was 
dissolved in anhydrous methanol (5 mL) and a catalytic amount of solid NaOMe was added. The 
reaction mixture was stirred at room temperature overnight. Then, it was neutralized with 
Amberlite IR 120 ion exchange resin and filtered. The filtrate was evaporated to yield 6 as a dark 
orange syrup compound (71.8 mg, 0.143 mmol, 92% ). Rf 0.28 (CH2Cl2 / MeOH, 4:1); 
[ ]22Dα  = + 15.6 (c = 1.03, DMSO); 1H NMR (500 MHz, CD3OD, 300 K, TMS): δ = 8.13 (s, 1H, 
H-9), 7.84 (d, J = 8.9 Hz, 2H, H-14, H-16), 7.77 (d, J = 8.9 Hz, 2H, H-19, H-23), 7.16 (d, 
J = 9.0 Hz, 2H, H-13, H-17), 6.90 (d, J = 8.9 Hz, 2H, H-20, H-22), 5.26 (s, 2H, H-11a, H-11b), 
4.74 (d, J = 1.5 Hz, 1H, H-1), 4.66 (ddd, J = 10.5, 7.2, 3.9 Hz, 2H, H-8a, H-8b), 4.14 (ddd, 
J = 10.5, 6.5, 3.8 Hz, 1H, H-7a), 3.90 (ddd, J = 10.6, 6.5, 3.3 Hz, 1H, H-7b), 3.78 (dd, J = 11.8, 
2.3 Hz, 1H, H-6a), 3.75 (dd, J = 2.8, 1.8 Hz, 1H, H-2), 3.66 (dd, J = 11.8, 5.9 Hz, 1H, H-6b), 
3.61-3.56 (m, 2H, H-3, H-4), 3.23-3.24 (ddd~mc, 1H, H-5) ppm; 13C NMR (125 MHz, CDCl3, 
300 K, TMS): δ = 160.8 (C-21), 160.5 (C-12), 146.9 (C-15), 145.7 (C-18), 142.7 (C-10), 125.5 
(C-9), 124.9 (C-20, C-22), 124.4 (C-13, C-17), 116.3 (C-19, C-23), 115.7 (C-14, C-16), 100.3 
(C-1), 74.7 (C-5), 71.3 (C-3), 70.5 (C-2), 67.3 (C-4), 65.4 (C-7), 61.9 (C-11), 61.6 (C-6), 49.9 
(C-8) ppm; UV/Vis (DMSO) λmax = 364 nm; ɛ = 25804 + 1109 L x mol-1 x cm-1; MALDI-TOF 
MS calcd for C23H27N5O8: m/z 524.185 [M+Na]+; found: m/z 524.176 [M+Na]+.  
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Click reaction: Acetylated bisglycosylated azobenzene glycoconjugate 7 (Man-a z o-Man 
[OAc]8): 
1
23
6
4 5
7
8 9
10
12
16
1311
17
14
15
O
N
N
O
O N
OAc
AcO
AcO
OAc
N N O
11
7
89
10 O
N
NN
O
OAc
OAc
OAc
OAc
1
2
3
5
4
6
12
16
13
17
14
15
 
To a mixture of the azobenzene 3 (200 mg, 0.689 mmol), the mannoside 42 (633 mg, 1.52 mmol, 
2.2 equiv.), CuSO4 x 5H2O (12 mg) and Cu powder (100 mg) tert-butanol and water (1:1, 10 
mL) were added. The reaction mixture was stirred at room temperature for 48 h. Then, TLC 
(CH2Cl2/MeOH, 4:1) showed complete consumption of 3. The reaction was diluted with ethyl 
acetate (100 mL), Cu removed by filteration using celite, and the filtrate was dried over MgSO4. 
It was filtered and the filtrate concentrated under reduced pressure. Purification of the crude by 
column chromatography on silica gel (CH2Cl2/MeOH, 4:1) gave product 7 as a crystalline pale 
yellow solid (643 mg, 0.572 mmol, 83%). Rf 0.24 (cyclohexane/ethyl acetate, 1:1);[ ]22Dα  = + 29.6 
(c = 1.01, CH2Cl2); m.p. 99-103 °C; 1H NMR (500 MHz, CDCl3, 300 K, TMS): δ = 7.87 (d, 
J = 9.0 Hz, 4H, aryl-H), 7.79 (s, 2H, 2 H-9), 7.11 (d, J = 9.1 Hz, 4H, aryl-H), 5.30 (s, 4H, 2 H-
11a, 2 H-11b), 5.24- 5.22 (mc, 4H, 2 H-4, 2 H-3), 5.20-5.19 (mc, 2H, 2 H-2), 4.80 (d, J = 1.5 Hz, 
2H, 2 H-1), 4.62 (t, J = 5.2 Hz, 4H, 2 H-8a, 2 H-8b), 4.20 (dd, J = 12.3, 5.4 Hz, 2H, 2 H-6a), 
4.14 (td, J = 10.9, 5.4 Hz, 2H, 2 H-7a), 4.04 (dd, J = 12.3, 2.4 Hz, 2H, 2 H-6b), 3.91-3.87 (m, 
2H, 2 H-7b), 3.53 (ddd, J = 9.7, 5.2, 2.4 Hz, 2H, 2 H-5), 2.14, 2.09, 1.99, 1.98 (each s, each 6H, 
8 C(O)CH3) ppm; 13C NMR (125 MHz, CDCl3, 300 K, TMS): δ = 170.6, 169.9, 169.9, 169.6 (8 
COCH3), 160.3 (2 C-12), 147.4 (2 C-15), 144.0 (2 C-10), 124.4 (2 C-14, 2 C-16), 124.3 (2 C-10, 
2 C-14, 2 C-9), 115.1 (2 C-13, 2 C-17), 97.5 (2 C-1), 69.2 (2 C-5, 2 C-3), 68.8 (2 C-2), 66.2 (2 
C-7), 65.7 (2 C-4), 62.2 (2 C-6), 62.1 (2 C-11), 49.8 (2 C-8), 20.8, 20.7, 20.7, 20.6 (8 COCH3) 
ppm; ESI MS calcd for C50H60N8O22: m/z 1147.382 [M+Na]+; found: m/z 1147.373 [M+Na]+; IR 
(ATR) 2933, 1739, 1597, 1367, 1214, 1041, 841, 599 cm-1. 
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Deprotection: Bisglycoslyated azobenzene glycoconjugate 8 (Man-a z o-Man): 
1
23
6
4 5
7
8 9
10
12
16
1311
17
14
15
O
N
N
O
O N
OH
HO
HO
OH
N N O
ON
NN
O
OH
OH
OH
OH
 
The acetyl-protected azobenzene glycoconjugate 7 (100 mg, 0.09 mmol) was dissolved in 
anhydrous methanol (3 mL) and a catalytic amount of solid NaOMe was added. The reaction 
mixture was stirred at room temperature overnight. Then, it was neutralized with Amberlite IR 
120 ion exchange resin and filtered. The filtrate was evaporated to yield 8 (67 mg, 0.085 mmol, 
96%) as a reddish brown solid. Rf 0.28 (CH2Cl2/ MeOH, 3:7); [ ]22Dα  = + 22 (c = 0.96, DMSO); 
m.p. 170-171 °C; 1H NMR (600 MHz, DMSO-d6, 300 K, TMS): δ = 8.20 (s, 2H, 2 H-9), 7.82 (d, 
J = 8.9 Hz, 4H, 2 H-14, 2 H-16), 7.20 (d, J = 9.0 Hz, 4H, 2 H-13, 2 H-17), 5.22 (s, 4H, 2 H-11a, 
2 H-11b), 4.61 (d, J = 1.2 Hz, 2H, 2 H-1), 4.58 (dd, J = 4.0, 6.3 Hz, 4H, 2 H-8a, 2 H-8b), 4.53 
(dd, J = 6.6, 4.0 Hz, 2H, 2 H-7a), 3.94 (ddd, J = 10.7, 6.4, 4.0 Hz, 2H, 2 H-7b), 3.78 (dd, 
J = 11.6, 1.9 Hz, 2H, 2 H-6a), 3.56-3.53 (m, 2H, 2 H-2), 3.40 (dd, J = 11.7, 6.3 Hz, 2H, 2 H-6b), 
3.39-3.32 (m, 4H, 2 H-4, 2 H-3), 3.14-3.11 (mc, 2H, 2 H-5) ppm; 13C NMR (150 MHz, DMSO-
d6, 300 K, TMS): δ = 160.6 (2 C-12), 146.6 (2 C-15), 142.5 (2 C-10), 125.3 (2 C-9), 124.4 (2 C-
14, 2 C-16), 115.6 (2 C-13, 2 C-17), 100.0 (2 C-1), 74.2 (2 C-5), 70.9 (2 C-3), 70.2 (2 C-2), 66.8 
(2 C-4), 65.1 (2 C-7), 61.6 (2 C-11), 61.2 (2 C-6), 49.7 (2 C-8) ppm; UV/Vis (DMSO) λmax = 363 
nm; ɛ = 27858 + 902 L x mol-1 x cm-1; MALDI-TOF MS calcd for C34H44N8O14: m/z 811.297 
[M+Na]+; found: m/z 811.249 [M+Na]+; IR (ATR) 2933, 1739, 1597, 1367, 1214, 1041, 841, 
599 cm-1. 
After irradiation: Z-8: 
1H NMR (600 MHz, DMSO-d6, 300 K, TMS): δ = 8.18 (s, 2H, 2 H-9′), 7.00 (d, J = 8.9 Hz, 4H, 2 
H-13, 2 H-17), 6.87 (d, J = 8.9 Hz, 4H, 2 H-14, 2 H-16), 5.11 (s, 4H, 2 H-11a, 2 H-11b), 4.62 
(bs, 2H, 2 H-1), 4.56-4.52 (m, 4H, 2 H-8a, 2 H-8b), 3.95 (ddd, J = 10.7, 6.3, 4.1 Hz, 2H, 2 H-7a), 
3.79 (ddd, J = 10.9, 6.7, 4.0 Hz, 2H, 2 H-7b), 3.61 (dd, J = 9.9, 5.7 Hz, 2H, 2 H-6a), 3.53 (bs, 
2H, 2 H-2), 3.43-3.30 (m, 6H, 2 H-6b, 2 H-4, 2 H-3), 3.16-3.12 (m, 2H, 2 H-5) ppm; 13C NMR 
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(150 MHz, DMSO-d6, 300 K, TMS): δ = 157.1 (2 C-12), 146.9 (2 C-15), 142.3 (2 C-10), 125.0 
(2 C-9), 122.2 (2 C-14, 2 C-16), 114.8 (2 C-13, 2 C-17), 99.9 (2 C-1), 74.2 (2 C-5), 70.8 (2 C-3), 
70.1 (2 C-2), 66.8 (2 C-4), 64.9 (2 C-7), 61.3 (2 C-11), 61.2 (2 C-6), 49.4 (2 C-8) ppm; UV/Vis 
(DMSO) λmax = 448 nm; ɛ = 2466 + 782 L x mol-1 x cm-1. 
 
Glycosylation: Acetylated monoglycosylated azobenzene glycoconjugate 10 (a z o-Man 
[OAc]4): 
1
2
3
6
4
5
7
19
18
21
20 89
17 10
11 12
16
15 14
13
NO
N O
O
OAc
OAc
OAc
OAc
 
A mixture of azobenzene alcohol 2 (100 mg, 0.397 mmol, 1 equiv.) and the glycosyl donor 93,4 
(293 mg, 0.595 mmol, 1.5 equiv.) were dried under vacuum for about 15 mintues, then added of 
dry CH2Cl2 (6 mL) was added and the reaction mixture cooled to 0 °C. The Lewis acid BF3 x 
Et2O (75 µL, 0.595 mmol, 1.5 equiv.) was added and the reaction mixture stirred at room 
temperature for overnight. Then, TLC showed complete consumption of 2. Solid NaHCO3 was 
added and CH2Cl2 (30 mL). It was washed with water (10 mL) and the organic layer dried over 
MgSO4. It was filtered and the filtrate concentrated under reduced pressure. Purification of the 
crude product by column chromatography on silica gel (cyclohexane/ethyl acetate, 7:3) gave the 
title compound as a pale yellow low melting solid (203 mg, 0.348 mmol, 88%). Rf 0.29 
(cyclohexane/ethyl acetate, 7:3); [ ]22Dα  = + 72.7 (c = 0.81, CH2Cl2); m.p.: 54 °C; 1H NMR 
(500 MHz, CDCl3, 300 K, TMS): δ = 7.90 (d, J = 9.0 Hz, 2H, H-14, H-18), 7.88 (d, J = 8.9 Hz, 
2H, H-9, H-11), 7.21 (d, J = 9.0 Hz, 2H, H-8, H-12), 7.09 (d, J = 9.0 Hz, 2H, H-25, H-17), 5.61 
(d, J = 1.7 Hz, 1H, H-1), 5.58 (dd, J = 10.0, 3.5 Hz, 1H, H-3), 5.48 (dd, J = 3.5, 1.9 Hz, 1H, H-
2), 5.38 (dd~t, J = 10.1 Hz, 1H, H-4), 4.78 (d, J = 2.4 Hz, 2H, H-19a, H-19b), 4.29 (dd, J = 12.2, 
5.5 Hz, 1H, H-6a), 4.12-4.08 (m, 2H, H-5, H-6b), 2.56 (t, J = 2.38 Hz, 1H, H-21), 2.22, 2.06, 
2.05, 2.03 (each s, each 3H, 4 C(O)CH3) ppm; 13C NMR (150 MHz, CDCl3, 300 K, TMS): 
δ = 170.5, 169.9, 169.9, 169.7 (4 C(O)CH3), 159.7 (C-16), 157.2 (C-7), 148.5 (C-10), 147.5 (C-
13), 124.5 (C-14, C-18), 124.3 (C-9, C-11), 116.7 (C-8, C-12), 115.2 (C-15, C-17), 97.1 (C-1), 
78.1 (C-20), 75.9 (C-21), 69.4 (C-5), 69.3 (C-2), 68.8 (C-3), 65.8 (C-4), 62.1 (C-6), 56.0 (C-19), 
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20.8, 20.8, 20.7, 20.7 (4 C(O)CH3) ppm; ESI MS calcd for C29H30N2O11: m/z 605.184 [M+Na]+; 
found: m/z 605.173 [M+Na]+; IR (ATR) 3287, 2955, 1743, 1597, 1496, 1209, 1025, 840, 599 
cm-1. 
 
Click reaction: Acetylated bisglycosylated azobenzene glycoconjugate 11 (Man-a z o-Man 
[OAc]8): 
NO
N O
O
OAc
OAc
OAc
OAc
N
NN
O
AcO
AcO
AcO
AcO
O
1
2
3
6
4
5
718
89
17 10
11 12
16
15 14
13
1'
2'
3'
6'
4'
5'
21
19
20
22
23
 
To a mixture of the alkyne 10 (100 mg, 0.172 mmol, 1.0 equiv.), the mannoside 42 (86 mg, 
0.206 mmol, 1.2 equiv.), CuSO4 x 5H2O (6 mg) and Cu powder (60 mg) a mixture of tert-
butanol, THF and water (1:1:1, 6 mL) was added. The reaction mixture was heated at 70 °C for 
16 h. Then, TLC showed complete consumption of starting material 10. The reaction mixture 
was diluted with ethyl acetate (30 mL), Cu was removed by filteration using celite, and the 
filtrate was dried over MgSO4. It was filtered and the filtrate concentrated under reduced 
pressure. Purification of crude product by column chromatography on silica gel using 1% MeOH 
in CH2Cl2 gave the required product 11 as a pale yellow solid (122 mg, 0.122 mmol, 82%). Rf 
0.33 (cyclohexane/ethyl acetate; 2:3); [ ]22Dα  = + 66.8 (c = 1.05, CH2Cl2); m.p. 72-75 °C; 1H 
NMR (500 MHz, CDCl3, 300 K, TMS): δ = 7.89-7.86 (m, 4H, aryl-H), 7.79 (s, 1H, H-21), 7.20 
(d, J = 9.0 Hz, 2H, aryl-H), 7.12 (d, J = 9.0 Hz, 2H, aryl-H), 5.61 (d, J = 1.7 Hz, 1H, H-1), 5.58 
(dd, J = 10.0, 3.6 Hz, 1H, H-3), 5.48 (dd, J = 3.5, 1.8 Hz, 1H, H-2), 5.38 (dd~t, J = 10.2 Hz, 1H, 
H-4), 5.31 (s, 2H, H-11), 5.24-5.23 (m, 2H, H-4’, H-3’), 5.21 (mc, 1H, H-2’), 4.80 (d, J = 1.4, 
1H, H-1’), 4.63 (t, J = 5.1 Hz, 2H, H-8), 4.29 (dd, J = 12.3, 5.5 Hz, 1H, H-6’a), 4.20 (dd, J = 
12.3, 5.4 Hz, 1H, H-6’b), 4.16-4.07 (m, 3H, H-23a, H-5, H-6a), 4.04 (dd, J = 12.3, 2.4 Hz, 1H, 
H-6b), 3.89 (mc, 2H, H-7), 3.54 (ddd, J = 9.5, 5.3, 2.3 Hz, H-5’), 2.22, 2.14, 2.09, 2.06, 2.05, 
2.03, 2.00, 1.93 (each s, each 3H, 8 C(O)CH3) ppm; 13C NMR (125 MHz, CDCl3, 300 K, TMS): 
δ = 170.5, 170.5, 170.5, 169.9, 169.8 169.7, 169.7, 169.6 (8 COCH3), 160.5 (C-16), 157.2 (C-7), 
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148.5 (C-10), 147.3 (C-13), 143.9 (C-20), 124.6 (C-14, C-18), 124.3 (C-9, C-11), 124.1 (C-21), 
116.7 (C-8, C-12), 115.1 (C-15, C-17), 97.5 (C-1’), 95.7 (C-1), 69.3 (C-5, C-5′), 69.2 (C-2, C-
2′), 68.8 (C-3, C-3′), 66.2 (C-23), 65.9 (C-4’), 65.7 (C-4), 62.2 (C-6, C-6′), 62.1 (C-19), 49.8 (C-
22), 20.9, 20.8, 20.8, 20.7, 20.7, 20.6, 20.6, 20.6 (8 COCH3) ppm; ESI MS calcd for 
C43H53N5O21: m/z 1022.323 [M+Na]+; found: m/z 1022.290 [M+Na]+; IR (ATR) 2932, 1739, 
1598, 1367, 1211, 1032, 843, 599 cm-1. 
 
Deprotection: Bisglycosylated azobenzene glycoconjugate 12 (Man-a z o-Man): 
NO
N O
O
OH
OH
OH
OH
N
NN
O
HO
HO
HO
HO
O
1
2
3
6
4
5
718
89
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16
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2'
3'
6'
4'
5'
21
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20
22
23
 
The acetyl-protected biglycosylated azobenzene glycoconjugate 11 (50 mg, 0.05 mmol) was 
dissolved in anhydrous methanol (2 mL) and a catalytic amount of solid NaOMe was added. The 
reaction mixture was stirred at room temperature for 5 h. Then, TLC control indicated that the 
starting material had fully disappeared. It was neutralized with Amberlite IR 120 ion exchange 
resin and filtered. The filtrate was evaporated to yield 12 as a yellow solid (30.8 mg, 0.047 
mmol, 93%). Rf 0.31 (CH2Cl2 / MeOH, 7:3); [ ]22Dα  = + 31.2 (c = 0.91, MeOH); 1H NMR 
(600 MHz, DMSO-d6, 300 K, TMS): δ = 8.22 (s, 1H, H-21), 7.85 (d, J = 8.9 Hz, 2H, aryl-H), 
7.82 (d, J = 8.9 Hz, 2H, aryl-H), 7.24 (d, J = 9.0 Hz, 2H, aryl-H), 7.22 (d, J = 9.1 Hz, 2H, H-15, 
H-17), 5.50 (d, J = 1.6 Hz, 1H, H-1), 5.24 (s, 2H, H-19a, H-19b), 4.63 (d, J = 1.5 Hz, 1H, H-1’), 
4.59 (dd, J = 6.3, 4.2 Hz, 1H, H-22a), 4.56 (dd, J = 6.6, 4.0 Hz, 1H, H-22b), 3.96 (ddd, J = 10.7, 
6.5, 4.1 Hz, 1H, H-23a), 3.86 (dd, J = 3.3, 1.9 Hz, 1H, H-2), 3.80 (ddd, J = 10.8, 6.5, 4.0 Hz, 1H, 
H-23b), 3.70 (dd, J = 9.2, 3.5 Hz, 1H, H-3), 3.56-3.36 (m, 9H, H-6’a, H-6a, H-2’, H-4’, H-6’b, 
H-6b, H-4, H-3’, H-5’), 3.14 (dd, J = 11.1, 4.6 Hz, 1H, H-5) ppm; 13C NMR (150 MHz, DMSO-
d6, 300 K, TMS): δ = 160.8 (C-16), 158.8 (C-7), 147.4 (C-10), 146.8 (C-13), 142.7 (C-20), 125.5 
(C-21), 124.7 (C-9, C-11), 124.4 (C-14, C-18), 117.5 (C-8, C-12), 115.8 (C-15, C-17), 100.2 (C-
1’), 99.0 (C-1), 75.5 (C-5’), 74.4 (C-5), 71.03 (C-3’), 70.84 (C-3), 70.3 (C-2’), 70.2 (C-2), 67.0 
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(C-4’), 66.9 (C-4), 65.3 (C-23), 61.8 (C-19), 61.4 (C-6’), 61.2 (C-6), 49.9 (C-22) ppm; UV/Vis 
(DMSO) λmax = 360 nm; ɛ = 25562 + 865 L x mol-1 x cm-1; MALDI-TOF MS calcd for 
C29H37N5O13: m/z 686.283 [M+Na]+; found: m/z 686.131 [M+Na]+. 
After irradiation: Z-12: 
1H NMR (600 MHz, DMSO-d6, 300 K, TMS): δ = 8.16 (s, 1H, H-21), 7.02 (d, J = 8.6 Hz, 2H, 
H-8, H-12), 6.97 (d, J = 8.8 Hz, 2H, H-16, H-17), 6.85 (d, J = 8.8 Hz, 2H, H-14, H-18), 6.82 (d, 
J = 8.7 Hz, 2H, H-9, H-11), 5.35 (bs, 1H, H-1), 5.09 (2, 2H, H-19a, H-19b), 4.61 (bs, 1H, H-1’), 
4.57 (dd, J = 8.9, 4.1 Hz, 1H, H-22a), 4.53 (dd, J = 9.8, 4.2 Hz, 1H, H-22b), 3.93 (dd, J = 10.2, 
4.4 Hz, 1H, H-23a), 3.79 (m, 2H, H-2, H-23b), 3.57-3.34 (m, 10H, H-2’, H-3, H-4’, H-6’a, H-6a, 
H-4, H-3’, H-5’, H-6’b, H-6b), 3.12 (mc, 1H, H-5) ppm; 13C NMR (125 MHz, DMSO-d6, 300 K, 
TMS): δ = 157.6 (C-16), 155.6 (C-7), 148.2 (C-10), 147.2 (C-13), 142.7 (C-20), 125.5 (C-21), 
122.8 (C-9, C-11), 122.2 (C-14, C-18), 117.5 (C-8, C-12), 115.3 (C-15, C-17), 100.2 (C-1’), 99.2 
(C-1), 75.3 (C-5’), 74.4 (C-5), 71.0 (C-3’), 70.8 (C-3), 70.3 (C-2’), 70.2 (C-2), 67.0 (C-4’), 66.9 
(C-4), 65.3 (C-23), 61.6 (C-19), 61.4 (C-6’), 61.2 (C-6), 49.9 (C-22) ppm; UV/Vis (DMSO) λmax 
= 448 nm; nm ɛ = 2316 + 61 L x mol-1 x cm-1. 
 
1,3-Dihydroxy-2-methyl-1,3-di-O-tosyl-propane 145 
TsO OTs
CH3  
According to the literature, a mixture of the diol 13 (1.0 g, 0.011 mmol, 1.0 equiv.) in pyridine 
(20 mL) was treated with tosyl chloride (6.30 g, 0.033 mmol, 3 equiv.) and the reaction mixture 
was stirred at room temperature for 14 h. Then, TLC showed complete consumption of the 
starting material. Aqueous 6N HCl (100 mL) was added and the aqueous phase extracted with 
ethyl acetate (2 x 50 mL). The combined organic layers were washed with water and brine and 
dried over MgSO4. It was filtered and concentrated under reduced pressure. Purification of the 
crude product by column chromatography on silica gel (cyclohexane/ethylacetate, 4:1) gave the 
ditosylate 14 as a white solid (3.67 g, 0.01 mmol, 83%). Rf 0.27 (cyclohexane/ethyl acetate); 
m.p.: 71 °C; 1H NMR (200 MHz, CDCl3, 300 K, TMS): δ = 7.74 (d, J = 8.4 Hz, 4H, aryl-H), 
7.34 (d, J = 8.5 Hz, 4H, aryl-H), 3.90 (dd, J = 5.7 Hz, 1.5 Hz, 4H, 2 CH2-O), 2.45 (s, 6H, Ts-
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CH3), 2.14 (tt, J = 14.4 Hz, 7.1 Hz, 1H, CH(CH3)), 0.91 (d, J = 6.9 Hz, 3H, CH(CH3) ppm; 13C 
NMR (125 MHz, CDCl3, 300 K, TMS): δ = 145.1 (Cq, aryl-C), 132.6 (Cq, aryl-C), 129.9, 127.8 
(aryl-C), 70.3 (2 CH2), 33.0 (CH), 21.6 (Ts-CH3), 12.9 (CH-CH3) ppm; ESI MS calcd for 
C18H22O6S2: m/z 421.085 [M+Na]+; found: m/z 421.077 [M+Na]+; IR (ATR) 2973, 1597, 1355, 
1174, 1095, 936, 848, 667 cm-1. 
 
Bivalent azobenzene dialkyne 15: 
O
CH3
N
N O
N O
NO
 
A solution of the alcohol 2 (82.3 mg, 0.327 mmol, 2.6 equiv.) and K2CO3 (52 mg, 0.377 mmol, 3 
equiv.) in DMF (2 mL) was stirred at room temperature for ~30 min, then added the ditosylate 
14 (50 mg, 0.125 mmol, 1.0 equiv.) was added. the reaction mixture was heated at 100 ºC for 16 
h until TLC showed complete absence of 14. After the solvent was evaporated under reduced 
pressure, the residue was dissolved in ethyl acetate (30 mL) and washed with water (2 x 25 mL). 
The organic phase was dried over MgSO4, its was filtered and concentrated under reduced 
pressure. Purification by column chromatography on silica gel (cyclohexane/ethylacetate, 4:1) 
gave product 15 as a pale yellow liquid (52 mg, 0.09 mmol, 74%); m.p.: 164-166 °C; 1H NMR 
(500 MHz, CDCl3, 300 K, TMS): δ = 7.89 (d, J = 9.0 Hz, 4H), 7.88 (d, J = 8.9 Hz, 4H), 7.09 (d, 
J = 9.1 Hz, 4H), 7.03 (d, J = 9.0 Hz, 4H), 4.77 (d, J = 2.4 Hz, 4H), 4.15 (dd, J = 9.2 Hz, 6.2 Hz, 
2H), 4.09 (dd, J = 9.2 Hz, 5.8 Hz, 2H), 2.56 (t, J = 2.4 Hz, 2H), 2.54-2.53 (m, 1H), 1.25 (d, J = 
6.9 Hz, 3H) ppm; 13C NMR (125 MHz, CDCl3, 300 K, TMS): δ = 161.1 (Cq, aryl-C), 159.4 (Cq, 
aryl-C), 147.6 (Cq, aryl-C), 147.1 (Cq, aryl-C), 124.5 (aryl-C), 124.3 (aryl-C), 115.1 (aryl-C), 
114.7 (aryl-C), 78.2 (H-C≡C-CH2), 75.9, (H-C≡C-CH2) 69.9 (2 CH2), 56.0 (H-C≡C-CH2), 33.8 
(HC-CH3), 14.1 (HC-CH3) ppm; ESI MS calcd for C34H30N4O4: m/z 559.226 [M+Na]+; found: 
m/z 559.241 [M+Na]+; IR (ATR) 3275, 2916, 1596, 1579, 1495, 1232, 1146, 1013, 841, 666 cm-
1. 
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Click reaction: Acetylated bivalent azobenzene glycoconjugate 16 (Man-a z o-a z o-Man 
[OAc]8): 
123
6
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N
N N
N
NN
O
OAc
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O
O
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OAc
O
O
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N
N O
N O
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To a mixture of the dialkyne 15 (50 mg, 0.089 mmol, 1.0 equiv.), the mannoside 4 (89.7 mg, 
0.215 mmol, 2.4 equiv.). CuSO4 x 5H2O (6 mg) and Cu powder (60 mg) was added to a mixture 
of tert-butanol and water (1:1, 5 mL). The reaction mixture was stirred at 70 °C for 48 h. Then, 
TLC showed complete absence of 15. The reaction mixture was diluted with ethyl acetate (30 
mL), Cu was removed by filteration using celite, and the filtrate was dried over MgSO4. It was 
filtered and the filtrate concentrated under reduced pressure. Purification of crude product by 
column chromatography on silica gel (3% MeOH in CH2Cl2) gave the required product 16 as a 
pale yellow solid (101 mg, 0.01 mmol, 81%); Rf: 0.28 (3% MeOH in 
Dichloromethane); [ ]22Dα  = + 21.1 (c = 0.94, CH2Cl2); m.p. 85 °C (decompos.); 1H NMR 
(600 MHz, CDCl3, 300 K, TMS): δ = 7.88-7.86 (m, 8H, 2 H-14, 2 H-16, 2 H-19, 2 H-23), 7.79 
(s, 2H, 2 H-9), 7.11 (d, J = 9.0 Hz, 4H, 2 H-13, 2 H-17), 7.02 (d, J = 9.0 Hz, 4H, 2 H-20, 2 H-
22), 5.29 (bs, 4H, 2 H-11), 5.24- 5.23 (m, 4H, 2 H-4, 2 H-3), 5.20 (dd, J = 2.9, 1.6 Hz, 2H, 2 H-
2), 4.79 (d, J = 1.4 Hz, 2H, 2 H-1), 4.62 (t, J = 5.2 Hz, 4H, 2 H-8), 4.19 (dd, J = 12.3, 5.3 Hz, 
2H, 2 H-6a), 4.14 (dd, J = 9.6, 5.9 Hz, 4H, 2 H-24a, 2 H-7a), 4.07 (dd, J = 9.2, 5.6 Hz, 2H, 2 H-
24b), 4.04 (dd, J = 12.3, 2.3 Hz, 2H, 2 H-6b), 3.90-3.87 (m, 2H, 2 H-7b), 3.53 (ddd, J = 9.5, 5.2, 
2.2 Hz, 2H, 2 H-5), 2.54 (tt, J = 12.5, 6.3 Hz, 1H, H-25), 2.14, 2.09, 2.00, 1.98 (s, 3H, C(O)CH3 
x 2), 1.24 (d, J = 6.92 Hz, 3H, H-26) ppm; 13C NMR (150 MHz, CDCl3, 300 K, TMS): 
δ = 170.6, 169.9, 169.9, 169.6 (2 COCH3), 161.1 (2 C-21), 160.2 (2 C-12), 147.4 (2 C-15), 147.0 
(2 C-18), 144.0 (2 C-10), 124.4 (2 C-14, 2 C-16, 2 C-192, 2 C-23), 124.1 (2 C-9), 115.0 (2 C-13, 
2 C-17) 114.7 (2 C-20, 2 C-22), 97.4 (2 C-1), 69.8 (2 C-24), 69.4 (2 C-5), 69.2 (2 C-2), 68.8 (2 
C-3), 66.2 (2 C-7), 65.6 (2 C-4), 62.2 (2 C-6), 62.1 (2 C-11), 49.8 (2 C-8), 33.7 (C-25), 20.8, 
20.7, 20.7, 20.6 (2 COCH3), 14.1 (C-26) ppm; ESI MS calcd for C66H76N10O24: m/z 1393.503 
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[M+1]+; found: m/z 1393.550 [M+1]+; IR (ATR) 2928, 1742, 1597, 1498, 1367, 1215, 1041, 840, 
553 cm-1. 
 
Deprotection: Bivalent azobenzene glycoconjugate 17 (Man-a z o-a z o-Man): 
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The acetyl-protected divalent azobenzene glycoconjugate 16 (90 mg, 0.06 mmol, 1.0 equiv.) was 
dissolved in anhydrous methanol (3 mL) and a catalytic amount of solid NaOMe was added. The 
reaction mixture was stirred at room temperature overnight. TLC control (CH2Cl2/MeOH, 3:7) 
indicated that the starting material had fully disappeared. It was neutralized with Amberlite IR 
120 ion exchange resin and filtered. The filtrate was evaporated to yield 17 as a yellow solid (62 
mg, 0.058 mmol, 91%). Rf 0.24 (CH2Cl2 / MeOH, 3:7); [ ]22Dα  = + 17.9 (c = 0.43, DMSO); m.p. 
148-150 °C; 1H NMR (600 MHz, DMSO-d6, 300 K, TMS): δ = 8.22 (s, 2H, 2 H-9), 7.83 (m, 8H, 
2 H-14, 2 H-16, 2 H-19, 2 H-23′), 7.21 (d, J = 8.8 Hz, 4H, 2 H-13, 2 H-17), 7.14 (d, J = 8.8 Hz, 
4H, 2 H-20, 2 H-22), 5.23 (s, 4H, 2 H-11), 4.62 (bs, 2H, 2 H-1), 4.60 (dd, J = 8.9, 4.8 Hz, 2H, 2 
H-8), 4.55 (dd, J = 9.8, 3.7 Hz, 2H, 2 H-8a), 4.12 (td, J = 14.9, 9.3 Hz, 4H, 2 H-24), 3.91-3.94 
(m, 2H, 2 H-7a), 3.82-3.78 (m, 2H, 2 H-7b), 3.64-3.54 (m, 4H, 2 H-6a, 2 H-2), 3.42-3.34 (m, 6H, 
2 H-3, 2 H-6b, 2 H-4), 3.15-3.12 (m, 2H, 2 H-5), 2.47-2.44 (m, 1H, H-25), 1.15 (d, J = 6.7 Hz, 
3H, H-26) ppm; 13C NMR (150 MHz, DMSO-d6, 300 K, TMS): δ = 161.2 (2 C-21), 160.5 (2 C-
12), 146.6 (2 C-15), 146.5 (2 C-18), 142.5 (2 C-10), 125.3 (2 C-9), 124.5 (2 C-13, 2 C-17), 124.4 
(2 C-19, 2 C-23), 115.6 (2 C-14, 2 C-16), 115.4 (2 C-20, 2 C-22), 100.0 (2 C-1), 74.2 (2 C-5), 
70.1 (2 C-3), 70.2 (2 C-2), 69.9 (2 C-24), 66.8 (2 C-4), 65.2 (2 C-7), 61.7 (2 C-11), 61.2 (2 C-6), 
49.7 (2 C-8), 33.3 (C-25), 14.0 (C-26) ppm; MALDI-TOF MS calcd for C50H60N10O16: 
m/z 1079.418 [M+Na]+; found: m/z 1079.4622 [M+Na]+; UV/Vis (DMSO) λmax = 364 nm; ɛ = 
29063 + 950 L x mol-1 x cm-1. 
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After irradiation: Z-17: 
1H NMR (600 MHz, DMSO-d6, 300 K, TMS): δ = 8.16 (s, 2H, 2 H-9), 6.97 (d, J = 8.3 Hz, 4H, 2 
H-20, 2 H-22), 6.92-6.83 (m, 12H, 2 H-13, 2 H-17, 2 H-14, 2 H-16, 2 H-19, 2 H-23′), 5.09 (s, 
4H, 2 H-11), 4.61 (s, 2H, H-1), 4.58-4.51 (m, 4H, 2 H-8), 3.95-3.90 (m, 6H, 2 H-7a, 2 H-24), 
3.79-3.77 (m, 2H, 2 H-7b), 3.59-3.53 (m, 4H, 2 H-6a, 2 H-2′), 3.41-3.35 (m, 6H, 2 H-4, 2 H-6b′, 
2 H-3), 3.15-3.12 (m, 2H, 2 H-5), 2.31 (dd, J = 12.2, 5.7 Hz, 1H, H-25), 1.05 (d, J = 5.7 Hz, 3H, 
H-26) ppm; 13C NMR (150 MHz, DMSO-d6, 300 K, TMS): δ = 157.9 (2 C-21), 157.3 (2 C-12), 
147.2 (2 C-18), 146.9 (2 C-15), 142.5 (2 C-10), 124.4 (2 C-9), 122.6 (2 C-19, 2 C-23′), 122.4 (2 
C-14, 2 C-16), 115.1 (2 C-20, 2 C-22), 114.9 (2 C-13, 2 C-17), 100.0 (2 C-1), 74.2 (2 C-5), 70.9 
(2 C-3), 70.2 (2 C-2), 69.6 (2 C-24), 66.8 (2 C-4), 65.2 (2 C-7), 61.5 (2 C-11), 61.2 (2 C-6), 49.7 
(2 C-8), 33.2 (C-25), 14.1 (C-26) ppm; UV/Vis (DMSO) λmax = 449 nm; ɛ = 2544 + 77 L x mol-1 
x cm-1. 
2,2,2-Tri-[(O-tosyl)-2’-hydroxyethyl]ethane 196 
H3C OTs
3  
To a solution of the triol 18 (2.0 g, 16.66 mmol, 1.0 equiv.) in pyridine (20 mL) tosyl chloride 
(12.6 g, 66.66 mmol, 4 equiv.) was added and the reaction mixture stirred at room temperature 
for 16 h. Then, TLC showed complete absence of 18 Aqueous HCl (6N, 200 mL) was added and 
then it was extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed 
with water and brine, and dried over MgSO4. After filtration, the filtrate was concentrated under 
reduced pressure to give product 19 as a white solid (10.3 g. 17.69 mmol, quant.). Rf: 0.24 
(cyclohexane/ethyl acetate, 7:3); m.p. 132-135 °C; 1H NMR (500 MHz, CDCl3, 300 K, TMS): 
δ = 7.70 (d, J = 8.3 Hz, 6H), 7.35 (d, J = 7.9 Hz, 6H), 3.76 (s, 6H), 2.46 (s, 9H), 0.88 (s, 3H) 
ppm; 13C NMR (125 MHz, CDCl3, 300 K, TMS): δ = 145.2 (Cq, aryl-C), 131.9 (Cq, aryl-C), 
130.1, 127.9 (aryl-C), 69.8 (3 CH2), 39.4 (CH3-C), 21.7 (Ts-CH3), 14.2 (CH3-C) ppm; ESI MS 
calcd for C26H30O9S3: m/z 605.105 [M+Na]+; found: m/z 605.013 [M+Na]+; IR (ATR) 1598, 
1355, 1174, 1096, 960, 835, 666 cm-1. 
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Trivalent azobenzene trialkyne 20: 
H3C
3
NO
N O
 
A mixture of the alcohol 2 (156 mg, 0.619 mmol, 3.6 equiv.) and K2CO3 (42.6 mg, 0.309 mmol, 
1.8 equiv.) in DMF (6 mL) was stirred at room temperature for ~30 min, then the tritosylate 19 
(100 mg, 0.172 mmol, 1.0 equiv.) was added and the reaction mixture stirred at 100 ºC for 16 h. 
Then, TLC showed complete consumption of 19. After the solvent was evaporated under 
reduced pressure, the residue was dissolved in ethyl acetate (30 mL) and washed with water (2 x 
25 mL). The combined organic phases were dried over MgSO4, it was filtered and the filtrate 
concentrated under reduced pressure. Purification by column chromatography on silica gel 
(cyclohexane/ethylacetate, 3:2) gave product 20 as a pale yellow syrup (86.8 mg, 0.110 mmol, 
65%). Rf 0.26 (cyclohexane/ethyl acetate, 3:7); 1H NMR (500 MHz, CDCl3, 300 K, TMS): 
δ = 7.88 (d, J = 9.1 Hz, 6H), 7.87 (d, J = 9.1 Hz, 6H), 7.08 (d, J = 9.1 Hz, 6H), 7.05 (d, 
J = 9.0 Hz, 6H), 4.76 (s, 6H), 2.56 (t, J = 2.4 Hz, 3H), 1.48 (s, 3H) ppm; 13C NMR (125 MHz, 
CDCl3, 300 K, TMS): 159.9, 158.4, 146.6, 146.2, 123.4, 123.3, 114.1, 113.8, 77.1, 74.9, 69.3, 
55.0, 39.5, 16.3 ppm; IR (ATR) 3288, 2924, 1595, 1580, 1496, 1214, 1145, 1019, 835, 548 cm-1. 
 
Click reaction: Acetylated trivalent azobenzene glycoconjugate 21 ([Man-a z o(OAc12)]3): 
N
N N
O
O
OAc
AcO
AcO
OAc
3
CH3N O
NO
1
23
4 5
6
7
8
9
10 11
12
13 14
15
16 17
18
19 20
21
23 22
24
25
26
 
To a mixture of the trialkyne 20 (100 mg, 0.128 mmol, 1.0 equiv.), the mannoside 42 (192 mg, 
0.462 mmol, 3.6 equiv.). CuSO4. x H2O (12 mg) and Cu powder (120 mg) was added to a 
mixture of tert-butanol, THF and water (1:1:1, 6 mL). The reaction mixture was refluxed for 16 
h until TLC showed absence of starting material 20. The reaction mixture was diluted with ethyl 
acetate (30 mL), Cu was removed by filteration using celite, and the filtrate was dried over 
MgSO4. After filtration it was concentrated under reduced pressure. Purification by column 
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chromatography on silica gel (2% MeOH in CH2Cl2) gave the required product 21 as a pale 
yellow syrup (209 mg, 0.10 mmol, 79%). Rf 0.29 (3% MeOH in CH2Cl2); [ ]22Dα  = + 19.7 
(c = 1.15, CH2Cl2); m.p. 103-106 °C; 1H NMR (600 MHz, CDCl3, 300 K, TMS): δ = 7.87 (d, J = 
8.8 Hz, 12H, 3 H-14, 3 H-16, 3 H-19, 3 H-23), 7.80 (s, 3H, 3 H-9), 7.11 (d, J = 9.0 Hz, 6H, 3 H-
13, 3 H-17), 7.05 (d, J = 9.0 Hz, 6H, 3 H-20, 3 H-22), 5.30 (bs, 6H, 3 H-11a, 3H-11b), 5.25- 5.23 
(m, 6H, 3 H-4, 3 H-3), 5.21 (dd, J = 2.9, 1.6 Hz, 3H, 3 H-2), 4.80 (d, J = 1.4 Hz, 3H, 3 H-1), 
4.63 (t, J = 5.2 Hz, 6H, 3 H-8a, 3-H-8b), 4.22 (bs, 6H, 3 H-24), 4.21- 4.18 (m, 3H, 3 H-6a), 4.14 
(td, J = 10.7, 5.4 Hz, 3H, 3 H-7a), 4.04 (dd, J = 12.3, 2.3 Hz, 3H, 3 H-6b), 3.89 (td, J = 10.7, 
10.1, 3H, 3 H-7b), 3.55-3.52 (m, 3H, 3 H-5), 2.14, 2.09, 1.99, 1.98 (each s, each 9H, 12 
C(O)CH3), 1.41 (s, 3H, 3 H-26) ppm; 13C NMR (150 MHz, CDCl3, 300 K, TMS): δ = 170.6, 
169.9, 169.9, 169.6 (12 COCH3), 160.9 (3 C-21), 160.2 (3 C-12), 147.4 (3 C-15), 147.2 (3 C-18), 
144.0 (3 C-10), 124.4 (3 C-14, 3 C-16, 3 C-19, 3 C-23), 124.1 (3 C-9), 115.0 (3 C-13, 3 C-17) 
114.8 (3 C-20, 3 C-22), 97.4 (3 C-1), 70.3 (3 C-24), 69.4 (3 C-5), 68.8 (3 C-2), 68.8 (3 C-3), 66.2 
(3 C-7), 65.6 (3 C-4), 62.2 (3 C-6), 62.1 (3 C-11), 49.8 (3 C-8), 40.5 (C-25), 20.8, 20.7, 20.7, 
20.6 (12 COCH3), 17.3 (C-26) ppm; MALDI-TOF MS calcd for C98H111N15O36: m/z 2074.731 
[M+1]+; found: m/z 2074.391 [M+1]+; IR (ATR) 2926, 1742, 1596, 1498, 1367, 1215, 1042, 840, 
553 cm-1. 
 
Deprotection: Trivalent azobenzene glycoconjugate 22 ([Man-a z o]3): 
N
N N
O
O
OH
HO
HO
OH
3
CH3N O
NO
1
23
4 5
6
7
8
9
10 11
12
13 14
15
16 17
18
19 20
21
23 22
24
25
26
 
The acetyl-protected trivalent azobenzene glycoconjugate 21 (100 mg, 0.048 mmol) was 
dissolved in anhydrous methanol (3 mL) and a catalytic amount of solid NaOMe was added. The 
reaction mixture was stirred at room temperature for 16 h until TLC control (CH2Cl2 / MeOH, 
3:7) indicated that the starting material had fully disappeared. It was neutralized with Amberlite 
IR 120 ion exchange resin and filtered. The filtrate was evaporated to yield 22 as a yellow solid 
(78 mg, 0.049 mmol, quantitative). Rf 0.21 (CH2Cl2 / MeOH, 3:7); [ ]22Dα  = + 13.7 (c = 0.92, 
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DMSO); m.p. 166-167 °C; 1H NMR (600 MHz, DMSO-d6, 300 K, TMS): δ = 8.21 (s, 3H, 3 H-
9), 7.83-7.81 (m, 12H, 3 H-14, 3 H-16, 3 H-19, 3 H-23), 7.20 (d, J = 8.6 Hz, 6H, 3 H-13, 3 H-
17), 7.17 (d, J = 9.0 Hz, 6H, 3 H-20, 3 H-22), 5.22 (s, 6H, 3 H-11a, 3 H-11b), 4.63 (s, 3 H-1), 
4.59-4.53 (m, 6H, 3 H-8a, 3-H8b), 4.22 (bs, 6H, 3 H-24a, 3 H-24b), 3.97-3.94 (m, 3H, 3 H-7a), 
3.81-3.79 (m, 3H, 3 H-7b), 3.64-3.54 (m, 6H, 3 H-6a, 3 H-2), 3.42 (dd, J = 11.6, 6.2 Hz, 3H, 3 
H-6b), 3.39-3.34 (m, 6H, 3 H-3, 3 H-4), 3.14-3.13 (m, 3H, 3 H-5), 1.32 (s, 3H, 3 H-26) ppm; 13C 
NMR (150 MHz, DMSO-d6, 300 K, TMS): δ = 161.2 (3 C-21), 160.6 (3 C-12), 146.6 (3 C-15, 3 
C-18), 142.7 (3 C-10), 125.4 (3 C-9), 124.5 (3 C-14, 3 C-16, 3 C-19, 3 C-23), 115.6 (3 C-20, 3 
C-22), 115.5 (3 C-13, 3 C-17), 110.0 (3 C-1), 74.2 (3 C-5), 70.9 (3 C-3), 70.2 (3 C-2), 70.1 (3 C-
24), 66.9 (3 C-4), 65.2 (3 C-7), 61.7 (3 C-11), 61.3 (3 C-6), 49.8 (3 C-8), 40.4 (C-25), 17.2 (C-
26) ppm; MALDI-TOF MS calcd for C74H87N15O24: m/z 1592.6048 [M+Na]+; found: m/z 
1592.6006 [M+Na]+; UV/Vis (DMSO) λmax = 364 nm; ɛ = 29426 + 958 L x mol-1 x cm-1. 
After irradiation: Z-22: 
1H NMR (600 MHz, DMSO-d6, 300 K, TMS): δ = 8.15 (s, 3H, 3 H-9), 6.96 (d, J = 8.2 Hz, 6H, 3 
H-14, 3 H-16), 6.88 (d, J = 8.5 Hz, 6H, 3 H-20, 3 H-22), 6.83-6.81 (m, 12H, 3 H-13, 3 H-17, 3 
H-19, 3 H-23), 5.08 (s, 6H, 3 H-11a, 3 H11b), 4.61 (s, 3H, 3 H-1), 4.59-4.53 (m, 6H, 3 H-8a, 3 
H-8b), 4.23 (bs, 6H, 3 H-24a, 3 H-24b), 3.95 (dd, J = 10.6, 6.0 Hz, 3H, 3 H-7a), 3.80 (dd, J = 
10.8, 6.5 Hz, 3H, 3 H-7b), 3.69-3.53 (m, 6H, 3 H-6a, 3 H-2), 3.41 (dd, J = 11.8, 5.8 Hz, 3H, 3 H-
6b), 3.39-3.34 (m, 6H, 3 H-3, 3 H-4), 3.14-3.12 (m, 3H, 3 H-5), 1.16 (s, 3H, H-26) ppm; 13C 
NMR (150 MHz, DMSO-d6, 300 K, TMS): δ = 157.3 (3 C-21, 3 C-12), 147.2 (3 C-15), 147.0 (3 
C-18), 142.6 (3 C-10), 125.4 (3 C-9), 122.6 (3 C-13, 3 C-17), 122.4 (3 C-19, 3 C-23), 115.1 (3 
C-14, 3 C-16), 115.0 (3 C-20, 3 C-22), 110.0 (3 C-1), 74.2 (3 C-5), 70.9 (3 C-3), 70.2 (3 C-2), 
70.0 (3 C-24), 66.9 (3 C-4), 65.2 (3 C-7), 61.7 (3 C-11), 61.3 (3 C-6), 49.8 (3 C-8), 40.4 (C-25), 
17.2 (C-26) ppm; UV/Vis (DMSO): λmax = 449 nm; ɛ = 2749 + 101 L x mol-1 x cm-1. 
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3. Photochemistry of azobenzene glycoconjugates 
Half life determination: EZ photoisomerisation was effected using a high pressure mercury 
lamp UV-P 250C from Panacol-Elosol (50 μM solution, 30 min at 365 nm). The bandpass filters 
were obtained from Laser components. All photoisomerization and relaxation experiments were 
performed in DMSO. Upon irradiation of azobenzene glycosides in the ground state (GS) at 365 
nm, the absorption spectra showed an increase in the absorbance in the n-π* transition and 
simultaneous decrease in the π-π* transition, as expected, indicating the generation of the 
respective Z isomer. The E:Z ratios in the ground state (GS) as well as in the photostationary 
state (PSS) were determined by integration of the respective signals in the 1H NMR spectra. 
To make sure that in case of the di- and trivalent azobenzene glycoconjugates 17 and 22 PSS was 
reached after irradiation for 30 min, E:Z ratios were also determined after 60 and 90 min of 
irradiation, respectively: no significant change was observed in comparison to 30 min irradiation 
time. 
The kinetics of the Z→E relaxation process were determined by UV-Vis spectroscopy in the dark 
employing 50 μM solutions in DMSO at 18 °C. For determination of the rate constants, a graph 
of ln(A∞-At) was plotted as a function of time; where A∞ is the absorbance of ππ* transition at 
infinitive time and At is the absorbance at time t after start of the relaxation process. The negative 
slope k of the linear plot is the rate constant of the Z→E relaxation process. The half life τ1/2 was 
determined as τ1/2 = ln2/k. 
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Figure S1. Thermal relaxation of Z-8 to E-8 (Man-a z o-Man) in DMSO; τ1/2 = 14 h. 
 
Figure S2. Thermal relaxation of Z-12 to E-12 (Man-a z o-Man) in DMSO; τ1/2 = 21.3 h. 
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Figure S3. Thermal relaxation of Z-17 to E-17 (Man-a z o-a z o-Man) in DMSO; τ1/2 = 15.5 h. 
 
Figure S4. Thermal relaxation of Z-22 to E-22 ([Man-a z o]3) in DMSO; τ1/2 = 16 h. 
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4. NMR Spectra of azobenzene glycoconjugates 
 
 
 
 
 
Figure S5. 1H NMR (500 MHz, CD3OD) and 13C NMR (125 MHz, CD3OD) of E-6 (Man-a z o).  
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Figure S6. 1H NMR (600 MHz, DMSO-d6) of E-8 and Z-8 (Man-a z o-Man). 
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Figure S7. 13C NMR (150 MHz, DMSO-d6) of E-8 and Z-8 (Man-a z o-Man). 
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Figure S8. 1H NMR (600 MHz, DMSO-d6) of E-12 and Z-12 (Man-a z o-Man).  
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Figure S9. 13C NMR (150 MHz, DMSO-d6) of E-12 and Z-12 (Man-a z o-Man).  
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Figure S10. 1H NMR (600 MHz, DMSO-d6) of E-17 and Z-17 (Man-a z o-a z o-Man). 
Note, that there is an equilibrium of EE, EZ, and ZZ isoforms after irradiation (‘Z-17’)as can be 
seen from the three dubletts for the protons of the methyl group at the focal point of the molecule 
at 1.0-1.2 ppm. 
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Figure S11. 13C NMR (150 MHz, DMSO-d6) of E-17 and Z-17 (Man-a z o-a z o-Man). 
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Figure S12. 1H NMR (600 MHz, DMSO-d6) of E-22 and Z-22 ([Man-a z o]3). 
Note, that there is an equilibrium of EEE, EEZ, EZZ, and ZZZ isoforms after irradiation 
(‘Z-22’)as can be seen from the four signals for the protons of the methyl group at the focal point 
of the molecule. at 1.1-1.4 ppm. 
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Figure S13. 13C NMR (150 MHz, DMSO-d6) of E-22 and Z-22 ([Man-a z o]3). 
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3.4 UV-Vis spectroscopy of azobenzene glycosides in the   
      presence of bacteria. 
Bacterial adhesion is the first step for biofilm formation and colonization to the surface of the 
host cell, which cause serious health problems.[1, 2] For example, urinary tract infections 
(UTIs) are initiated by the adhesion of uropathogenic E. coli (UPEC) to the carbohydrate 
receptors on the surface of bladder epithelium. -D-Mannose-specific binding of UPEC is 
mediated by a lectin called FimH, which is located at the tips of type 1-fimbriae.[3] This 
carbohydrate-protein interactions are influenced by several factors like nature of the ligand, 
multivalency of carbohydrate epitopes and conformational flexibility.[4-8] In order to investigate 
the impact of conformational flexibility, photoswitchable ligand AzoMan (E-para-(ortho-
methoxycarbonyl-phenylazo)phenyl--D-mannoside) was synthesized (chapter 3.2). 
Azobenzene was chosen as a photoswitchable unit, because it adopts different structure (E 
and Z) upon irradiation at a particular wavelength of light (Scheme 3.4.1).  
 
O
OH
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HO
O
N
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N
O
OH
OH
HO
HO
O
N
NMeOOC
E-AzoMan
COOMe
Z-AzoMan  
 
Scheme 3.4.1: E:Z isomerization of AzoMan.  
 
For any kind biological testing, as a prerequisite, the respective compound should show good 
solubility in water/aqueous buffer. Indeed AzoMan showed an excellent solubility in polar 
organic solvents as well as in water. Owning to good solubility AzoMan was tested as 
inhibitor of type 1-fimbriae mediated bacterial adhesion by various biological testing systems. 
Firstly, adhesion of non-fluorescent E. coli bacteria (strain HB101 pPKL4) to both the isomers 
of AzoMan (E- and Z-) was monitored by UV-Visible spectroscopy (Fig 3.4.2 & 3.4.3). 
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secondly, enzymatic activity of bacterial lectin FimH (PKL1162) in isomerization process of Z-
AzoMan → E-AzoMan was studied by saturation transfer difference (STD) NMR experiments 
and described earlier.[9] Finally, compound E-AzoMan was tested as inhibitor to live human 
epithelial cells (see 3.4.3).[10]  
 
Before testing the isomers of azobenzene glycosides to E. coli bacteria, their photochromic 
properties were studied in solution. Due to the good solubility of AzoMan in water and 
preferred solvent for biological testing, water was used as a solvent for photoisomerization 
studies. E→Z photoisomerization and thermal reverse isomerization of Z→E was measured 
by UV-Vis spectroscopy, experiments were performed in dark conditions to prevent light 
induced switching (Fig 3.4.1). 
 
 
Figure 3.4.1: UV visible spectra showing thermal reisomerization E-1 to Z-1 in H2O (40 μM) at 18+2 
o
C in the 
dark (thermal relaxation) as a function of time. 
 
The absorption spectra of E-1 exhibits an absorption maximum at 338 nm corresponding to 
the π- π* transition of the -N=N- group. Upon irradiation at 365 nm for about 10 min by LED 
photostationary state (pss) was reached, observed by the increase in absorbance at n-π* 
transition for Z-1 at 416 nm, and simultaneous decrease in the π- π* transition, an clear 
indication of the formation of the cis-isomer. Continuous irradiation for another 5 minutes 
shows no change in the UV-Vis spectroscopy, confirming the pss was reached in 10 min. 
Thermal relaxation of Z→E showed a half-life (1/2) of 79 h which is sufficient enough to 
perform the biological testing.[7] 
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The E:Z ratios of AzoMan before irradiation and after irradiation (i.e) photostationay states 
(pss) were determined by the integration of the anomeric proton of the mannose in 1H NMR 
spectroscopy. Before irradiation ~99% of E-AzoMan and in the pss state ~88% of Z-AzoMan 
was observed by 1H NMR spectroscopy. Greater half-life and higher ratios of isomers is good 
enough to test the individual isomers for biological testing. 
3.4.1 Monitoring the complexation between bacteria-AzoMan by UV-Vis spectroscopy 
To understand the role of conformational control in adhesion of bacterial lectin FimH to carbohydrate 
recognition, two different isomers of AzoMan were tested and monitored by UV-Vis spectroscopy (Fig 
3.4.2). To avoid the turbidity problem in measuring UV-Vis spectroscopy, fixing the bacterial 
concentration was essential and thus following experiments were performed. A known 
amount of E-1 (2 mL, 30 µM) was taken in the UV cuvette and added E. coli strain HB101 
pPKL4 (250 µl, 20 mg/mL) and recorded the UV-Vis spectroscopy. Due to higher 
concentration of E. coli bacteria, turbidity in the solution was observed and UV-Vis 
spectroscopy was unable to measure. Attempts in reducing the concentration of E. coli 
bacteria from 10 mg/mL, 5 mg/mL showed poor base line in the UV-Vis spectrum. However 
addition of E. coli strain HB101 pPKL4 (250 µL, 2 mg/mL) to the E-1 (2 mL, 30 µM) gave 
good UV spectrum (Fig 3.4.3). Hence further experiments were performed by fixing the 
bacterial concentration to 2 mg/mL. 
 
Figure 3.4.2: Monitoring the bacterial adhesion by UV-Visible spectroscopy, a) E-AzoMan (2 mL, 30 µM) b) E- 
AzoMan and E. coli strain HB101 pPKL4 (250 µL, 2 mg/mL) c) Z- AzoMan (2 mL, 30 µM) b) Z- AzoMan and E. 
coli strain HB101 pPKL4 (250 µL, 2 mg/mL). 
 
Firstly, to the pure E-AzoMan in the UV cuvette, E. coli (250 µL, strain HB101 pPKL4) was 
added (Fig 3.4.2b) and UV-Vis spectroscopy was measured at 0 and 30 minutes. For control 
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experiment and for direct comparison, pure E-AzoMan in the UV cuvette (Fig 3.4.2a) was 
also measured at same interval of time. The testing results showed that, adhesion of bacteria 
to the E-AzoMan was not observed by UV-Vis spectroscopy. UV-Vis spectrums of only E- 
AzoMan and E-AzoMan in the presence of bacteria are nearly the same (Fig 3.4.3a).  
 
Figure 3.4.3: UV-Vis spectroscopy of a) only E-AzoMan at 0 and 30 min; after adding E. coli bacteria (250 µL, 
strain HB101 pPKL4) to E-AzoMan in the UV cuvette at 0 and 30 min. b) Z-AzoMan (at pss) at 0 and 30 min, 
after adding E. coli bacteria (250 µL, strain HB101 pPKL4) to Z- AzoMan in the UV cuvette at 0 and 30 min.  
 
In a similar manner, bacterial adhesion to the Z-AzoMan isomer was also performed. To get 
the Z-AzoMan, E-AzoMan was irradiated at 365 nm using light emitting diode (LED) until it 
reaches the photostationary state (pss) which was reached between 8-10 minutes. To the 
obtained Z-AzoMan (Fig 3.4.2d), E. coli (250 µL, strain HB101 pPKL4) was added and UV-Vis 
spectroscopy was measured at 0 and 30 minutes. For control experiment and for direct 
comparison Z-AzoMan (Fig 3.4.2c) was also measured at 0 and 30 minutes. No significant 
difference between the pure Z-AzoMan and Z-AzoMan in presence of bacteria was observed 
by UV-Vis spectroscopy (Fig 3.4.3b). 
In conclusion, no difference was observed, whether bacteria were added to E-AzoMan or to 
Z-AzoMan, by UV-Vis spectroscopy. May be if the molecules are immobilized on surfaces 
then there could be an effect in adhesion of bacteria to adhesive surfaces. In another 
experiment, E-AzoMan was performed as a better inhibitor for bacterial adhesion of E. coli to 
live human HT-29 cells compared to the standard MeMan and pNPMan, has been reported 
(see 3.4.3).  
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3.4.3 Inhibition of Bacterial Adhesion to Live Human Cells: Activity and                     
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The inhibitory potency of azobenzene glycoside (E-AzoMan) was tested on human colon 
carcinoma cell monolayers (Fig 3.4.3) and their toxicity on the human cells was evaluated.  E-
AzoMan showed a high inhibitory potency than the standard MeMan and showed low toxicity.  
 
 
 
Figure 3.4.3: A cartoon of -D-mannose-specific inhibition of adhesion of E. coli bacteria to a live human 
epithelial cells. 
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Carbohydrates are involved in numerous important biological
events such as in cell recognition and cell adhesion [1]. They are
found as part of cell surface glycoconjugates, making up a charac-
teristic layer that is surrounding a eukaryotic cell and called its gly-
cocalyx. There is an overwhelming molecular complexity of the
glycocalyx which is interrogated by a class of specialized proteins,
namely the lectins [2]. To learn more about carbohydrate–lectinchemical Societies. Published by E
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119interactions, synthetic glycosides and glycomimetics, respectively,
have been utilized as modulators and inhibitors of the occurring
molecular recognition processes [3–8]. As also adhesion of mi-
crobes to the surface of their target cells is frequently mediated
by carbohydrate–protein interactions, its inhibition by suitable
glycosides could provide means against, i.e., bacterial colonization
and bioﬁlm formation [9–12].
Bacteria use long hairy organelles, called ﬁmbriae or pili, to
facilitate adhesion to cell surfaces. One of the best characterized
ﬁmbriae are type 1 ﬁmbriae, that comprise an a-D-mannoside-spe-
ciﬁc lectin at their tips, named FimH [13]. Type 1 ﬁmbriae are crit-
ical virulence factors in uropathogenic Escherichia coli (UPEC) and
widely distributed among Enterobacteriaceae [14]. A large collec-
tion of different mannosides and mannose conjugates, respectively,
have been made and tested as inhibitors of type 1 ﬁmbriae-medi-
ated bacterial adhesion, primarily in vitro [15]. Only few examples
have been published, where mannoside inhibitors of type 1 ﬁmb-
riae-mediated bacterial adhesion have been tested with cells or
in animal models, respectively [16–21]. Here, it has become our
goal to examine a selection of most promising inhibitors of man-
nose-speciﬁc bacterial adhesion with live human cells (Fig. 1A)
and test their cytotoxicity, in order to assess the therapeutic poten-
tial of these compounds.lsevier B.V. All rights reserved.
Fig. 1. Five synthetic a-mannoside inhibitors of bacterial adhesion to eukaryotic cells. (A) The cartoon illustrates ﬁmbriae-mediated adhesion of bacteria to the glycocalyx of
cells and its prevention by suitable a-mannoside inhibitors and (B) structures and names (abbreviations and IUPAC nomenclature) of tested a-mannoside inhibitors.
1460 M. Hartmann et al. / FEBS Letters 586 (2012) 1459–1465In the past, we have typically tested and ranked synthetic man-
nosides as inhibitors of bacterial adhesion to the polysaccharide
mannan [15,22]. Owing to the known structure of the type 1 ﬁmb-
rial lectin FimH [17,23,24], the afﬁnity of a-D-mannoside ligands
can be greatly improved by variation of the aglycone moiety,
whereas the mannose glycone part must not be changed. Recently,
we have added a very potent low-molecular weight mannoside to
the collection (SAMan, Fig. 1B), which has the potential to serve as
a lead structure for the development of FimH antagonists [25,26].
Hence, it is important to evaluate its inhibitory potency with hu-
man cells as well as to test its cytotoxicity. In addition, a novel azo-
benzene mannoside (AzoMan, Fig. 1B) was tested as anti-adhesive
and both mannosides, SAMan and AzoMan, were compared to
known inhibitors of type 1 ﬁmbriae-mediated bacterial adhesion
[27], namely methyl a-D-mannoside (MeMan), p-nitrophenyl a-D-
mannoside (pNPMan), and heptyl mannoside (HepMan). The latter
has recently been described as high-afﬁnity ligand for FimH
[17,28,29].
Highly glycosylated HT-29 mammalian colon cells were chosen
to study bacterial adhesion, its inhibition, and cytotoxicity of the
mannosidic inhibitors. The inhibitory potencies determined using
HT-29 cells were compared to the results from a test, where the
polysaccharide mannan was used as the adhesive layer.122. Materials and methods
2.1. Synthetic mannosides (Fig. 1B)
Methyl a-D-mannoside (MeMan) and para-nitrophenyl a-D-
mannoside (pNPMan) were purchased from Sigma–Aldrich and
Senn Chemicals, respectively. For the synthesis of the squaric acid
diamide conjugate SAMan, pNPMan was reduced to the corre-
sponding amine and subsequently coupled to squaric acid diethy-
lester to obtain the respective squaric acid monoamide [25]. This
was in turn converted into the target squaric acid diamide SAMan
by reaction with ethylamine [26]. Mannosides HepMan and Azo-
Man were synthesized by standard glycosylation of heptanol and
ortho-(para-hydroxyphenylazo)benzoic acid methyl ester, respec-
tively, according to the trichloroacetimidate method [30] followed
by ﬁnal deprotection. Purity of the synthesized mannosides was
conﬁrmed by analytical HPLC and/or elemental analysis.
2.2. Cultivation of bacteria
The GFP-tagged type 1 ﬁmbriated E. coli strain PKL1162 was
grown as published [22]. Details are described in the Supplemen-
tary material.0
Fig. 2. Bacterial adhesion-inhibition assay on mannan. Type 1 ﬁmbriae-mediated
adhesion of E. coli bacteria to a mannan-coated surface is prevented by mannosides,
which inhibit the respective lectin–carbohydrate interaction. Each line represents
the sigmoidal concentration–effect curves ﬁtted by non-linear regression from 2 to
8 independent experiments. Single data points are not shown for better clarity.
Complete data are presented in the Supplementary material.
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HT-29 cells (human colon adenocarcinoma grade II cell line)
(DSMZ, Braunschweig, Germany) were kept in culture medium
consisting of DMEM/high glucose (PAA) supplemented with 10%
heat inactivated FBS (PAA), 2 mM l-glutamine (PAA), and 1 MEM
non-essential amino acids (PAA). For the experiments, HT-29 cells
were seeded into 96-well microtiter plates (0.32 cm2/well) at a
seeding density of 300000 cells/cm2 in 313 ll/cm2 medium. For
the toxicity assays (Lowry and MTT test) clear ﬂat bottom microti-
ter plates (Falcon, Becton Dickinson, Heidelberg, Germany) and
for the adhesion-inhibition assay black wall, ﬂat clear-bottom
plates (Corning Incorporated Life Sciences, MA, USA) were used.
For ﬂuorescence microscopy cells were seeded on medium cham-
ber containing glass slides (LabtecTM). Cells were kept at 37 C
and 5% CO2.
2.4. Treatment of HT-29 cells with a-mannosides
For the adhesion-inhibition assay and the cytotoxicity assays
HT-29 cells were seeded into culture plates and after 48 h treated
with different concentrations of the respective mannoside inhibi-
tors. Stock solutions and solutions of the ﬁnal concentrations were
made up in HT-29 cell culture medium. Mannoside inhibitors were
applied in the following concentration ranges: MeMan (1 lM–
1000 mM), pNPMan (0.1 lM–15 mM), HepMan (0.1 lM–10 mM),
SAMan (0.01 lM–1.5 mM), and AzoMan (0.01 lM–2 mM). The
concentration of SAMan solutions could not be increased over
10 mM due to its limited solubility in PBS. Fluorescence readout
in the adhesion-inhibition assay was performed after 45 min, cyto-
toxicity measurements were performed after 24 h.
2.5. Inhibition of adhesion of E. coli PKL1162 to mannan
Mannosides MeMan, pNPMan, HepMan, SAMan, and AzoMan
were tested as inhibitors of type 1 ﬁmbriae-mediated adhesion of
E. coli to the polysaccharide mannan as published [22]. Details are
described in the Supplementary material.
2.6. Inhibition of adhesion of E. coli PKL1162 to HT-29 cells
HT-29 cells were grown in black wall, clear ﬂat bottom plates
without change of culture medium for 72 h until a conﬂuent
monolayer was formed. Then, cells were washed with 37 C tem-
pered DMEM and their intact state was checked under the micro-
scope. Then, serial dilutions of the tested mannosides in DMEM at
37 C (50 ll/well) and bacterial suspension in DMEM at 37 C
(50 ll/well) were added to the wells. For blanks to determine max-
imal ﬂuorescence values cells were treated only with DMEM
(50 ll/well) and bacterial suspension (50 ll/well). The control
wells were ﬁlled with DMEM and the plate was incubated for
45 min at 37 C. All wells were washed 3 times with PBS (150 ll/
well) and ﬁlled with PBS (100 ll/well). Then, ﬂuorescence of the
GFP-tagged bacteria was read out (Tecan microplate reader GENios
Pro, excitation wavelength, 485 nm, emission wavelength 535 nm).
2.7. Phase contrast and ﬂuorescence microscopy showed binding of
PKL1162 to HT-29 cells
See details in the Supplementary material (Fig. S3).
2.8. Cytotoxicity assays with mannoside inhibitors on HT-29 cells
2.8.1. Cell protein (Lowry assay)
To determine total protein amounts, cells were washed 3 times
with PBS and incubated for 45 min with 0.5 N NaOH (60 ll/well).121Cell protein contents were measured by colorimetric determina-
tion at 620 nm (photometer 340 ATTC, SLT Labinstruments),
according to the method described by Lowry [31]. Bovine serum
albumin was used as standard.
2.8.2. Cell viability (MTT test)
Cells were washed once with PBS before it was replaced with
100 ll fresh growth medium per well. Cell viability was determined
bymeansof theMTTassay [32,33]. Inbrief, 25 llMTT [3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] solution (1 mg/ml
medium)was added to eachwell (37 C, 7.8% CO2) and 100 ll solubi-
lization solution (20% (w/v) SDS, 2.5% (v/v) 1 NHCl and2.5% (v/v) ace-
tic acid (80%) in 50% (v/v) DMF, pH 2) was added 15min later.
Production of formazan by viable cells was assessed after 90 min
(37 C, 7.8% CO2) by measuring the absorbance at a wavelength of
570 nm (photometer 340 ATTC, SLT Labinstruments, Germany).
2.9. Phase contrast microscopy with mannoside inhibitors on HT-29
cells
Morphological changes of HT-29 cell monolayers (in clear-bot-
tommicrotiter plates) were examined in parallel to cytotoxicity as-
says employing an inverted phase contrast microscope (IMT-2,
Olympus, Hamburg, Germany) equipped with a digital camera
(E-300, Olympus, Hamburg, Germany); cf. Supplementary material
(Fig. S4).
2.10. Statistics
Statistics were calculated as described in the Supplementary
material.
3. Results
Five a-D-mannosides were selected (Fig. 1B) and tested as
inhibitors of type 1 ﬁmbriae-mediated bacterial adhesion in two
different scenarios: (i) employing mannan-coated microtiter wells
and (ii) HT-29 cellular surfaces. All tested compounds could reduce
binding of E. coli to both surfaces.
3.1. Effect of a-mannoside inhibitors on adhesion of E. coli to the
polysaccharide mannan
Inhibitory potencies were deduced from the results of 4–5 inde-
pendent assays for each compound. Sigmoidal dose–response
curves were derived to determine IC50 values of each tested
Fig. 3. Bacterial adhesion-inhibition assay on HT-29 cells. Mannose-speciﬁc
inhibition of type 1 ﬁmbriae-mediated adhesion of E. coli bacteria to a HT-29 colon
carcinoma cell monolayer. Each line represents the sigmoidal concentration–effect
curves ﬁtted by non-linear regression from 3 to 4 independent experiments. Single
data points are not shown for better clarity. Complete data are presented in the
Supplementary material.
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calculated based on the inhibitory potency of MeMan, with
IPMeMan  1, to gain better comparability of the testing results.
Thus, increasing RIP values were identiﬁed in the order
MeMan < pNPMan < HepMan < AzoMan < SAMan (Table 1). The
two reference mannosides MeMan and pNPMan clearly had the
lowest inhibitory potency, whereas HepMan and AzoMan per-
formed in the same range. SAMan, however, showed the best value
as inhibitor of bacterial adhesion to mannan, surpassing the inhib-
itory potency of AzoMan by a factor of two.
3.2. Effect of a-mannoside inhibitors on adhesion of E. coli to HT-29
cell monolayers
To test bacterial adhesion to eukaryotic cells, type 1 ﬁmbriated
bacteria PKL1162 were allowed to adhere to a HT-29 human colon
carcinoma cell monolayer, which is highly mannosylated. After
incubation of the ﬂuorescent bacterial suspension in DMEM over
HT-29, PKL1162 E. coli were ﬁrmly adhered to the cell monolayer
and could not be removed by washing with buffer. This was con-
ﬁrmed by phase contrast and ﬂuorescence microscopy (Supple-
mentary material, Fig. S3). Incubation of human primary
ﬁbroblast cell monolayers with bacteria, on the other hand, did
not lead to reliable adhesion of bacteria.
In analogy to the results obtained on mannan, MeMan and
pNPMan were the weakest inhibitors of bacterial adhesion to HT-
29 cells, followed by HepMan. HepMan, however, performed sig-
niﬁcantly weaker in this assay than when bacterial adhesion to
mannan was inhibited. Furthermore, the performance of AzoMan
and SAMan as inhibitors of bacterial adhesion differed with HT-
29 cells compared to mannan as adhesive layer. On cells, they
showed very similar inhibitory potencies with a slight advance
for AzoMan. Thus, ranking of these two mannosides was reversed
as compared to bacterial adhesion to mannan. Also, the MeMan-
based RIP value of AzoMan is more than twofold as big when
bacterial adhesion to cells was tested than in the mannan case.
Overall, the inhibitor concentrations, which were required to effect
50% inhibition of bacterial adhesion to HT-29 cells were approxi-
mately one order of magnitude lower than in case of bacterial
adhesion to mannan (Fig. 3, Table 1).
3.3. Effect of a-mannoside inhibitors on human HT-29 cells
To determine the toxicity of mannoside inhibitors, total cell
protein, cell viability and the morphology of conﬂuent cell mono-
layers were examined. For both parameters, cell protein and viabil-
ity, a concentration-dependent toxicity could be induced for four of
the ﬁve tested substances (Fig. 4) with their toxic potencies
decreasing in the order AzoMan > HepMan > pNPMan >> MeMan
according to their half-maximal effective concentrations (EC50 val-
ues) shown in Table 2. Due to the limited solubility of SAMan,
which could not be concentrated higher than 1.5 mM in aqueous
buffer, no toxic effect could be induced by this mannoside at all.
On the other hand, SAMan is one of the most potent known inhib-Table 1
Half-maximal inhibitory concentrations (IC50) and relative inhibitory potencies of a-manno
29 human colon carcinoma cells.
a-Man inhibitor E. coli adhered to mannan
IC50 (mM) (mean ± SEM) RIP
MeMan 10.67 ± 1.26 IP 
pNPMan 0.19 ± 0.04 57
HepMan 0.025 ± 0.004 427
AzoMan 0.024 ± 0.003 445
SAMan 0.012 ± 0.001 889
12itors of type 1 ﬁmbriae-mediated bacterial adhesion. Taken that to-
gether with its obviously non-critical toxicity, SAMan appears to be
an ideal lead structure for the design of FimH antagonists.
Morphological changes of the conﬂuent HT-29 monolayer-like
formation of round shaped cells and disruption of the cell layer
were examined using light microscopy (Supplementary material,
Fig. S4). At concentrations around the EC50 values, no cytotoxic ef-
fects were observed for any of the inhibitors but MeMan. In case of
MeMan destructive changes of the cell monolayer became obvious
already at a concentration of 500 mM (EC50 = 656 mM). This ﬁnd-
ing could well correspond to the particularly steep slopes of the
viability curve of MeMan (Fig. 4B).
3.4. Correlation of the anti-adhesive effect of mannoside inhibitors on
bacteria with their toxicity on HT-29 cells
To compare the anti-adhesive effect of the tested mannoside
inhibitors on bacteria and their toxicity on HT-29 cells, their EC50
values were calculated and compared to the IC50 values (Table 2).
For all ﬁve substances the concentration range inducing 50% inhi-
bition of bacterial adhesion is clearly lower than the concentration
that induces 50% cell death. The therapeutic ratios of EC50/IC50 re-
veal a narrow range (from 507 to 1133) for all tested substances,
with that of SAMan even lying beyond 1250. For comparison rea-
sons EC50/IC50 quotients for E. coli adhered to mannan are also
listed in Table 2.
4. Discussion
The obtained results allow to compare the data about the anti-
adhesive potential of synthetic mannosides that were recorded
with a ‘simulated high-mannose type’ carbohydrate surface
(namely mannan-coated) with those resulting from tests with live
highly mannosylated cells. Type 1 ﬁmbriated E. coli bind to termi-
nal a-D-mannosyl units on many cell types, but not on all. Forsides as inhibitors of bacterial adhesion to an artiﬁcial mannan test surface and to HT-
E. coli adhered to HT-29 cells
MeMan IC50 (mM) (mean ± SEM) RIPMeMan
1 0.69 ± 0.23 IP  1
0.013 ± 0.006 74
0.0058 ± 0.0035 166
0.0009 ± 0.0005 1067
0.0012 ± 0.0003 800
2
Fig. 4. Total cell protein and cell viability curves of two toxicity assays. Effect of ﬁve different mannoside inhibitors on total cell protein (A) and the viability (B) of HT-29 colon
carcinoma cells after 24 h of incubation. Each symbol represents the mean ± SE of 3–4 independent experiments. Sigmoidal concentration–effect curves were ﬁtted by non-
linear regression.
Table 2
Effective concentrations of cytotoxicity (EC50) of a-mannoside inhibitors and their
half-maximal correlation indices deduced from correlation of their anti-adhesive and
their cytotoxic effects (EC50/IC50 ratio).
a-Man
inhibitor
HT-29 cells
(toxicity, MTT)
E. coli adhered to
HT-29 cells
E. coli adhered to
mannan
EC50 (mM)
(mean ± SEM)
EC50/IC50 EC50/IC50
MeMan 656 ± 101 951 61
pNPMan 11.49 ± 0.50 884 60
HepMan 2.94 ± 0.11 507 118
AzoMan 1.02 ± 0.03 1133 43
SAMan >1.5 >1250 >125
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ﬁbroblast cells did not occur, since these cells do not have the
appropriate glycosylation pattern. On the contrary we have suc-
cessfully utilized HT-29 human colon carcinoma cells to test inhi-
bition of bacterial adhesion. It particularly valuable to compare
these data that were obtained with colon cells with literature data
on inhibition of bacterial adhesion to human epithelial bladder
cells [17,20,21], as E. coli residing in the intestine can cause cystitis
once they reach the urogenital tract.
As it is easier and less expensive, many synthetic mannosides
have been tested as inhibitors of E. coli adhesion to mannan-coated
surfaces or to more elaborated glycoarrays [22,34]. These studies
have revealed that the molecular details of the carbohydrate deco-
ration of a test surface are critical in bacterial adhesion. Hence, it
has been asked to which extent such rather artiﬁcial glyco-surfaces
can resemble the glycocalyx of a eukaryotic cell in an adhesion as-
say. From the results depicted in Table 1 it can be seen that the rel-
ative inhibitory potencies of the tested mannosides do not differ to
a large extent when the physiological surface (HT-29 cells) is com-
pared to mannan. Thus, mannan can be considered as a reasonable
model for the glycosylated cell surface in this case. Nevertheless it
should be pointed out, that the anti-adhesive potential of a speciﬁc
mannoside that was found in a mannan-based assay does not nec-
essarily parallel with its potency in a cell-based test. For example,
the relative inhibitory potency of HepMan on mannan is 2.5
times higher than on HT-29 cells; on the other hand, in case of Azo-
Man the situation is nearly reversed. However, strikingly, all IC50
values which were determined for bacterial adhesion to HT-29
cells were lower by a factor of 10 when compared to the IC50 val-
ues deduced on mannan. An obvious interpretation of this result is
that bacterial binding to HT-29 cells is weaker than to mannan.
This could be explained by comparison of the glycosylation pattern
of HT-29 cells and yeast mannan. Whereas mannan from Saccharo-
myces cerevisiae comprises a multitude of a1,3-linked mannosyl
residues, this epitope is diluted by other mannosidic linkages in
case of the high-mannose type glycoproteins on HT-29 cells, dis-
playing lower afﬁnity to FimH. The most striking discrepancy in123the inhibition data obtained on mannan versus HT-29 cell adhesive
layer is the relative behavior of HepMan and AzoMan. While these
twomannosides showed almost the same RIP as inhibitors of adhe-
sion to mannan, AzoMan is approximately 6 times more potent as
inhibitor of bacterial adhesion to HT-29 cells than HepMan. To
facilitate the interpretation of this ﬁnding, computer-aided dock-
ing studies were performed to assess complexation of both syn-
thetic mannosides by the bacterial lectin FimH. As described
earlier [25,26], two extreme conformations of FimH were taken
as starting point for the simulation, one with the tyrosine gate at
the entrance of the carbohydrate binding site in a closed conforma-
tion [24], and the other with an open-gate conformation [35].
Docking reveals scoring values, more negative values correlating
with predicted high afﬁnities, and higher scores reﬂecting dimin-
ished binding potency. The obtained scores for HepMan are
21.5 for the closed-gate structure of FimH and 19.7 for the
open-gate structure; AzoMan on the other hand scores much bet-
ter with the respective values being 35.6 and 33.5, respectively.
The docked mannoside conformations suggest that pp-stacking of
the azobenzene aglycon with the tyrosine gate at the entrance of
the FimH carbohydrate binding site is more favorable to enhance
afﬁnity than the interactions that can be established by HepMan
(details see Supplementary material, Figs. S5 and S6).
This computer-aided assessment of the afﬁnities of FimH for
HepMan and AzoMan parallels nicely with the experimental ﬁnd-
ings obtained in the HT-29 cell assay, but not with the results ob-
tained on mannan. A possible interpretation could be found in
multivalency effects that might dominate inhibition of bacterial
adhesion in case of the less sensitive scenario on mannan, whereas
in case of the cell-based adhesion assay the individual complexa-
tion event between a mannosidic inhibitor and type 1 ﬁmbrial
FimH might gain more importance. This hypothesis receives some
support by the clear multivalency effects that have been found
with multivalent HepMan conjugates [36,37].
HepMan is known as a promising high-afﬁnity FimH antagonist
[17,20,24] and has been tested earlier with humen epithelial blad-
der 5637 cells in a ﬂow cytometry-based assay [21]. In this assay,
HepMan performed 64 times better than MeMan (based on IC50
determination). In another report a 100-fold lower concentration
of HepMan (1 mM), in comparison to MeMan, was enough to com-
pletely inhibit bacterial binding to bladder cells [17]. In our study
with HT-29 human carcinoma cells, the relative performance of
HepMan and MeMan was similar: here the inhibitory potency of
HepMan surpassed that of MeMan by even 166-fold, suggesting
an even better effect of HepMan in the intestine. A 5.8 lM concen-
tration of HepMan led to 50% inhibition of bacterial adhesion to
HT-29 cells and 1 mM HepMan led to 90% reduction of bacterial
adhesion (Table 3).
To relate the anti-adhesive potential of the tested manno-
side inhibitors to their cytotoxicity, the respective half-maximal
Table 3
Biocompatibility index: EC10/IC90 quotients of a-mannoside inhibitors of bacterial adhesion based on their cytotoxicity determined with HT-29 cells and their inhibitory potencies
in adhesion of bacteria to mannan and human cells, respectively.
a-Man inhibitor HT-29 cells (toxicity, MTT) E. coli adhered to HT-29 cells E. coli adhered to mannan
EC10 (mm) (mean ± SE) IC90 (mM) (mean ± SE) RIPMeMan EC10/IC90 IC90 (mM) (mean ± SE) RIPMeMan EC10/IC90
MeMan 501 ± 59 61.0 ± 46.9 IP  1 8.2 495 ± 131 IP  1 1.01
pNPMan 4.26 ± 0.53 1.11 ± 1.07 55 3.8 11.2 ± 5.1 44 0.38
HepMan 1.17 ± 0.09 0.96 ± 1.34 64 1.2 1.37 ± 0.52 361 0.85
AzoMan 0.52 ± 0.04 0.15 ± 0.17 407 3.5 0.63 ± 0.20 786 0.83
SAMan >1.5 0.022 ± 0.015 2773 >68.2 0.34 ± 0.08 1447 >4.41
1464 M. Hartmann et al. / FEBS Letters 586 (2012) 1459–1465correlation indices were calculated (EC50/IC50, Table 2). According
to these therapeutic ratios, AzoMan and SAMan are leading com-
pounds in the tested library. We have considered that for a reason-
able medical application 50% cell death is too high and otherwise
50% inhibition of adhesion not sufﬁcient for an anti-adhesion treat-
ment. Thus, EC10/IC90 ratios were calculated for a more ambitious
estimate of a possible therapeutic window (Table 3). As the EC10
reﬂects those concentrations leading to only 10% cell death and
the IC90 value corresponds to 90% inhibition of bacterial adhesion
the ratio EC10/IC90 can be taken as a robust biocompatibility index
and considered as measure for the therapeutic window of an anti-
adhesive compound. The EC10/IC90 ratios follow a different course
than EC50/IC50 ratios, resulting from the speciﬁc slopes of the ﬁtted
dose–response curves at different concentrations. The determined
EC10/IC90 ratios indicate increasing cell biocompatibility in the or-
der of HepMan < AzoMan/pNPMan < MeMan << SAMan. According
to this analysis SAMan shows by far the best biocompatibility leav-
ing even MeMan far behind.
Surprisingly, HepMan appears less biocompatible according to
the herein reported toxicity studies. The EC50 value determined
for HepMan is 3 mM, however it has been reported that no acute
toxicity of HepMan was assessed when HepMan was administered
to mice even at 50 mM concentrations [16,17,24,29]. Possibly, the
animal organism can cope with harmful effects, which cannot be
compensated by a conﬂuent cell layer applied in vitro.
Interestingly the rather unusual azobenzene mannoside Azo-
Man shows no extreme toxicity when compared to the less foreign
glycoside MeMan, for example. This is in accordance with reports
on biocompatibility of azobenzene dyes [38]. Thus this compound
becomes a promising candidate for the development of photo-
switchable anti-adhesive surfaces [39]. Isomerization of the azo-
benzene N@N double bond allows to manipulate the orientation
of the attached mannose portion for binding, an approach which
is currently under investigating in our laboratory.
In conclusion, in this study inhibition of bacterial adhesion to
HT-29 human carcinoma cells by ﬁve different mannosides was
compared to data obtained in a mannan-based assay and to litera-
ture-known results obtained with human epithelial bladder cells.
In addition, cytotoxicity studies were performed to assess the bio-
compatibility of the anti-adhesive mannosides. The mannosidic
squaric acid derivative SAMan [26] turned out to be a particularly
potent inhibitor of type 1 ﬁmbriae-mediated bacterial adhesion
with the potential to be developed and employed in in vivo-stud-
ies, owing to its advantageous biocompatibility index. This manno-
side comes close to a 3000-fold higher potency when compared to
MeMan to effect 90% inhibition of bacterial adhesion to human co-
lon cells. Moreover, SAMan did not cause any cytotoxicity effects
even when a saturated solution was applied to the cells.
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4. Preparation and applications of azobenzene glycosides on surfaces 
 
Investigation of carbohydrate-protein interactions using glycoarrays is of growing interest and 
has received much attention in the glycosciences.[45, 104-106] Glycoarrays are carbohydrates-
functionalized surfaces, in which carbohydrates are immobilized on different surfaces like 
gold, glass or polystyrene. Each surface requires a specific type of functional group for 
immobilization of the respective molecule.  
For example, one of the most reliable and flexible constructions of well-ordered glycoarrays 
are self-assembled monolayers (SAMs) on gold.[107, 108] For the formation of SAMs, mercapto-
functionalized alkanes are used to form ordered layers on the gold surface via the formation 
of Au-S bonds. SAMs that are functionalized with carbohydrate head groups, are called 
glyco-SAMs.[109-110] Glyco-SAMs offer an extensive control over the density and orientation of 
the carbohydrate ligands on the surface. In addition, glyco-SAMs can be used to study 
carbohydrate-protein interactions on surfaces.[111] When SAMs are used that expose 
photoswitchable glycoazobenzene moieties, even conformational effects of carbohydrate 
recognition can be studied. Thus, we have designed photoswitchable glyco-SAMs to form 
carbohydrate-functionalized monolayers on gold-surfaces (chapter 4.1). In addition, 
glycoazobenzene decorated gold nanoparticles (GNPs) were formed and their 
photoisomerization and interaction with lectin ConA was studied (chapter 4.2). 
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4.1 Monitoring of trans→cis isomerization of azobenzene glyco-SAMs on gold 
surfaces using IRRAS 
 
The molecules that were required for the formation of such SAMs are prepared by a 
combination of glycosylation and Mitsunobu reaction (Fig 4.1). To study the success of E→Z 
isomerization of azobenzene glyco-SAMs on the gold wafers, this process was monitored by 
infrared reflection absorption spectroscopy (IRRAS) in collaboration with the group of Prof. F. 
Tuczek (CAU Kiel). The respective work is presented here in the form of a first manuscript. 
 
 
Figure 4.1: Schematic depiction for the construction of photoswitchable azobenzene glyco-SAMs on gold.  
 
 
In this collaborative work, K. Kathirvel and H. Jacob (Prof. Tuczek research group) did the 
IRRAS measurements. I did the synthesis and characterization of the substances, studied the 
photochromic properties in solution, prepared the SAMs and mSAMs. I and T. K. Lindhorst 
wrote the manuscript. 
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4.1.1  Introduction 
Besides proteins and nucleic acids, the third class of essential biomolecules, the 
carbohydrates, serve as molecular key players in cell recognition and cell communication. 
They are displayed on cell surfaces largely in the form of glycoconjugates, that are partly 
embedded in the plasma membrane or are attached to the cell surface molecules by 
adhesive forces forming a sticky, nanodimensioned layer termed “glycocalyx”. Glycocalyx 
carbohydrates like mannosides and other glycosides are implicated in essential biological 
events such as cell development and health, cell adhesion, cell signaling and immune 
response.[1-3] However, the  glycome of a cell comprises an overwhelming molecular 
complexity and it has been difficult to connect carbohydrate-dependent biological phenomena 
to distinct carbohydrate structures. To deepen our understanding of the various molecular 
interactions that occur on glycosylated cell surfaces, carbohydrate-protein and recently also 
carbohydrate-carbohydrate interactions have been extensively studied.[4-8] In addition, it has 
been attempted to vary the presentation of carbohydrate ligands on surfaces and their 
conformational availability. A well-defined and reliable system for studies of this kind is 
offered by self-assembled monolayers on gold, in short SAMs[9-11] which can be 
functionalized with carbohydrate head groups to obtain “glyco-SAMs”.[12-17] 
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In order to obtain switchable monolayers, SAMs have also been fabricated employing 
photoresponsive functionalized azobenzene derivatives.[18] In azobenzene SAMs the E→Z 
isomerization of an immobilized azobenzene derivative allows to manipulate the spatial 
arrangement of functional groups connected to the azobenzene moiety. It has become our 
goal to utilize a new class of glycosidic azobenzenes to switch the status of a glycosylated 
monolayer to eventually study the effect of conformational changes within a glycosylated 
surface on carbohydrate-specific cellular adhesion. This will allow to learn more about the 
importance of conformational control in carbohydrate recognition, a well-known biological 
principle, that has not received considerable attention in the glycosciences so far. 
For any biological study with switchable surfaces, it is of primary importance to characterize if 
irradiation of the surface has the desired effect on the immobilized molecular monolayer. 
Consequently, we have synthesized glycosidic azobenzene derivatives suited for SAM 
formation on gold (Fig. 4.1.1) and investigated infrared reflection absorption spectroscopy 
(IRRAS) to monitor isomerization of the monolayer upon irradiation at the appropriate 
wavelength of 365 nm. 
 
 
 
Figure 4.1.1: Schematic representation of switchable glyco-SAMs on a Au(111) surface. 
Photoinduced trans→cis isomerization of azobenzene glycoside head groups is thought to change the 
presentation of carbohydrate ligands on a surface.  
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Results and discussion 
4.1.2 Synthesis of azobenzene derivatives for SAM formation  
To achieve our target molecules for glyco-SAM formation, azobenezene glycoside 3 was 
prepared first (Scheme 4.1.1). Thus, p,p′-dihydroxyazobenzene 1 was synthesised according 
toa literature procedure.[19] Glycosylation of 1 with mannosyl donor 2 gave the glycosylated 
product 3 in 37% yield.[20] Reaction of 3 with 6-bromohexan-1-ol and 10-bromodecan-1-ol 
under Mitsunobu conditions gave the required product 4 in 82% and 5 in 79% yield 
respectively.[21, 22] At room temperature potassium thioacetate converted the bromo alkanes 4 
and 5 into the desired thioacetates 6 and 7 in 88 and 91% yields.[23] The obtained 
glycothioacetates were used for the formation of self-assembled monolayers (SAMs) on gold 
wafers. 
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Scheme 4.1.1: a) BF3·Et2O, dry CH2Cl2, 0 °C→rt, overnight, 37%; b) PPh3, DEAD, rt, 5 h, 82% (4), 79% (5); c) 
KSAc, rt, overnight, 88% (6), 91% (7). 
 
147
4.1.3 Fabrication of SAMs and their characterization by IRRAS 
First, optimal conditions for SAM formation were investigated. SAM formation on Au(111) 
depends on the formation of Au-S bonds between the gold surface and an applied thiols. 
Thioacetates are advantageous over free thiols as they are stable against oxidation to the 
respective disulfides, which readily occurs at air.[24, 25] In order to obtain SAMs, thioacetates 
can be easily deprotected by deacetylation with a base to form the respective thiols.[26, 27] 
Some investigations, however, have shown that no cleavage agent is required to form SAMs 
with thioacetates and direct deprotection to deliver the thiol can occur at the gold surface.[28] 
Thus, the formation of SAMs using thioester 6 has been tested by both methods, direct 
adsorption and base-promoted adsorption. In direct adsorption higher concentrations of the 
thioester substrate are required to achieve monolayer coverage in a given interval. In 
addition, slow deprotection of the acetyl group of thioester 6 required longer reaction times to 
form a well-ordered SAM. When SAM formation was performed base-promoted, using 
ammonium hydroxide in a solution of 6, SAMs of higher quality were obtained (Fig 4.1.2). In 
case of base-promoted adsorption, the vibrational band exhibits stronger intensity when 
compared to that of the direct adsorption, whereas in direct adsorption some of the bands 
were broadened. 
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Figure 4.1.2: Mid- to low-frequency regions of IR spectroscopic data of bulk 6 in KBr and SAM of 6 
prepared by direct and base-promoted method.  
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In the bulk spectrum of compound 6, C=O stretching vibration of the acetyl group originating 
from the mannoside moiety is observed at 1753 cm-1. The carbonyl band from thioester is 
observed at a lower frequency at 1689 cm-1. In both, direct and base-promoted adsorption of 
6, the absence of the C=O stretching vibration related to thioester indicates the complete 
conversion of thioacetate to thiolate, chemisorbed to the gold surface. The intensity of the 
carbonyl band related to ester groups from the sugar unit remains almost the same in both 
direct and base-promoted adsorption. The employed weak base (which) selectively 
deprotects the thioacetate bond without affecting the O-acetyl protecting groups of the 
mannose moiety. In addition, the employed basic conditions did not affect or even destroy the 
monolayer. On the contrary, base results in SAMs of better quality. Consequently, base-
promoted adsorption was used to prepare all other monolayers investigated in this study.  
It has been shown earlier that thiols and thioacetates, respectively, of longer chain length 
result in better SAMs than shorter chain molecules.[29] In order to study the effect of chain 
lengths on the SAM formation glycosylated azobenzene alkanethioacetates with two different 
alkane spacer lengths were used (Fig 4.1.3) compound 6 with a hexyl spacer and compound 
7 with a decyl spacer. 
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Figure 4.1.3: Glycoazobenzenes with different alkane spacer lengths used for SAM formation.  
 
Indeed, SAM formation with mannoside 7 resulted in a well-ordered monolayer with a higher 
degree of surface coverage and less defects than those SAMs formed from mannoside 6. In 
the mid- to low-frequency regions (1800-800 cm-1) the IRRAS spectra of compounds 6 and 7 
look similar. The CH2 symmetric and asymmetric stretching vibrations are more pronounced 
in the case of compound 7 and relatively weak in the case of compound 6. These results 
encouraged us to use the longer chain length compound 7 for further experiments and 
explore the E→Z isomerization on the gold surface. 
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As per the surface selection rule (SSR), only the vibrations with a component of the transition 
dipole moment (TDM) aligned perpendicular to surface plane can interact with the incident 
light and can be observed in the infrared spectrum. The presence of less number of bands in 
the IRRAS when compared to that of the bulk spectrum is a result of the surface selection 
rule. Vibrational bands with TDMs that are exactly perpendicular to the gold surface are most 
intense. On the other hand the TDMs which are parallel to the metal surface are absent. 
Some TDMs are neither parallel nor perpendicular are seen in IRRAS. In compound 7 the 
highly intense peak originates from the carbonyl group of the mannose sugar. This indicates 
that the molecules are oriented perpendicular to the surface. The bulk KBr pellet IR 
measurements and calculated vibrational frequencies were assigned for compound 7 to 
compare with the IRRAS measurements (Table S1: see supporting information).  
4.1.4 E→Z isomerization of compound 7 in solution  
As the mannosyloxy-azobenzene alkane thioester 7 formed glyco-SAMs which could be 
characterized by IRRAS, their photoisomerization was studied next. Before exploring the 
E→Z isomerization of compound 7 on the gold surface, its photochromic properties were 
determined in solution. Photoirradiation of trans-7 in CDCl3 was carried out in the dark at 
room temperature using high pressure Hg lamp. Photostationary states (pss) were reached 
after 30 min and formation of cis-7 was monitored by UV-Vis and 1H NMR spectroscopy. 
Based on the integration of anomeric H-1 protons, the cis:trans ratio was determined by 
proton NMR spectroscopy. In the ground state more than >99% of the trans-isomer was 
observed and after irradiation > 99% of the cis isomer was observed, in PSS (Fig 4.1.4). 
5.56.06.57.07.58.0 ppm 
Figure 4.1.4: Partial 1H NMR spectra (500 MHz, CDCl3) spectra (a) cis-7; (b) trans-7. 
(a) 
(b) 
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In addition, E→Z isomerization of compound 7 can be nicely distinguished by UV-VIS 
spectroscopy, showing the typical absorption maxima of 353 nm for the trans-isomer and 
after reaching PSS an increase in absorption maxima of 444 nm and decrease in absorption 
at 353 nm for cis-isomer was observed (Fig 4.1.5). By using UV-Vis spectroscopy, the rate 
constant and half life of both cis-configured azobenzene mannosides 6 and 7 were obtained 
(see supporting information).  
 
 
Figure 4.1.5: UV-Visible spectra of cis-7 and trans-7 in ethanol at ± 18 oC  
 
4.1.5 IRRAS study of E→Z isomerization of photoswitchable glyco-SAMs 
Next, it has to be tested by IRRAS whether E→Z isomerization of azobenzenes glyco-SAMs 
occurs. This was tested applying two different approaches. In the first approach a solution of 
the trans-isomer was irradiated to reach the PSS to obtain the cis-isomer and then gold 
wafers were immersed into the irradiated solution to form a SAM with cis- isomer of 7 on the 
gold surface. By this approach, no difference in the vibrational structures was observed 
between the cis- and trans-isomers of compound 7 on the gold surface by IRRAS.  
In the second approach, the SAMs were first formed from trans-7 on the gold surface. Then 
the trans-7-functionalized gold substrates were irradiated with UV light at 365 nm for about 
30-45 min to form the cis-7. It is noted after irradiation, a peak at 1253 cm-1 assigned for C-O 
stretching, carbon from the aromatic ring attached to the oxygen of anomeric carbon of 
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mannose, showed a slight decrease in intensity.  Mid to low frequency region of compound 7 
with cis- and trans-isomers are shown (Fig 4.1.6a), a decrease in the intensity at 1253 cm-1 
for the cis-isomer with respect to the trans-isomer are observed (Fig 4.1.6b).  
 
Figure 4.1.6: cis-trans isomerization of compound 7 on the gold surface by IRRAS spectra a) Mid to 
low frequency region of trans- and cis-isomer; b) Caromatic-Omannose stretching frequency of trans and 
cis-isomer. 
  
In solution E→Z isomerization of compound 7 was clearly differentiated by UV-Vis and 1H 
NMR spectroscopy. But, this was not observed on the gold surface. It might be reasoned 
that, in solution azobenzene molecules are free in motion but on the surface these molecules 
are closely packed where steric hindrance comes into play. The closely packed 
arrangements of molecules on SAM can alter the behavior and in addition, the molecules are 
tilted on the surface which may also cause less degree of freedom required for the E→Z 
isomerization process. 
4.1.6 Preparation of mixed monolayers and IRRAS study of E→Z 
isomerization 
From the previous experiment it was observed that the trans-7 forms a well-ordered SAM 
which is stable at room temperature. But apparently the E→Z isomerisation of this SAM did 
not work, most likely due to steric hinderance. To address these concerns, mixed SAMs 
(mSAMs) were prepared, which increase the space between trans-7 molecules and the E→Z 
isomerization on the surface should be facilitated. mSAMs formation was effected by two 
different approaches: a co-adsorption method and a two- step deposition method.  In the co-
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adsorption method, the SAM is formed from a mixture of different substances. Firstly, a 
solution mixture of diluting molecule 8 or 9, respectively (Fig 4.1.7) along with the required 
azobenzene derivative 7 was used for mSAMs formation. The second method is a two-step 
deposition process: first a SAM was formed using either 8 or 9 and later it was allowed to 
undergo an exchange reaction by addition of trans-7 to form mSAMs. As ‘diluter’ molecules, 
in this study the phenoxy-headed hexylthioacetate 8 and 1-undecanethioacetate 9 were used 
and prepared according to the literature.[23, 30, 31]  
O
8 9
SAc SAc
 
Figure 4.1.7: ‘Diluter’ molecules for formation mixed SAMs.  
Compound 8 was chosen as the bulky phenyl head group might push the azobenzene 
moieties apart and to facilitate E→Z isomerization on the mSAMs (Fig 4.1.8). 
 
Figure 4.1.8: Schematic representation of E→Z isomerization of mSAMs formed from 7 and 8. 
 
In the two-step deposition approach, the SAM was formed using 8 in 1 mM ethanol and 
immersion for 24 h. In the second step, the SAM obtained from diluter molecule 8 was then 
immersed into a 1 mM solution of trans-7. The carbonyl band related to the mannosyl moiety 
was expected in the respective IRRAS spectrum. This particular vibrational band is used as a 
marker to follow the exchange reaction. Unfortunately even after 2 days no vibrational band 
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related to C-O was observed, this supports the assumption that exchange reaction was not 
successful. In the co-adsorption method, mSAMs was performed by using different ratios of 
diluter and azobenzene glycosides (a solution of 7and 8 at ratios of (a) 3:7, (b) 1:1, (c) 1:10) 
were tried. In the respective IRRAS spectrum, the vibrational bands related to trans-7 are 
dominating and no bands related to 8 are pronounced, confirming the formation of mSAMs by 
this approach was also unsuccessful. 
 
 
Figure 4.1.9: E→Z isomerization of mSAMs formed from 7 and 9. 
 
Our next attempt was to prepare the mixed monolayer using 9 as the diluting molecule (Fig 
4.1.9). The, formation of mixed SAMs was attempted by using different ratios of trans-7 and 
9. The best result was obtained with a ratio of 7:9 of 1:4. Typically, an ethanolic mixture of 
trans-7 and 9 was co-adsorbed with a total thiol concentration of 1 mM for 24 hours. Finally, 
with this mSAMs photoirradiation at 365 nm for about 30 min was successful, leading to cis-
isomer of 7 on the gold surface (Fig 4.1.10).  
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 Figure 4.1.10: E→Z isomerization of mSAMs formed from trans-7 and 9 (1:4). (a) Mid to low 
frequency regions; (b) C-O stretching frequency (1253 cm-1) of trans- and cis-mSAMs. 
After photoirradiation, a change in the vibrational frequeny at ~1253 cm-1 was observed and 
rest of the vibrational frequencies did not alter much (Fig 4.1.10a). After irradiation, 
pronounced difference in the intensity of the C-O stretching band was observed (Fig 4.1.10b). 
Thus, this mSAM was suited to effect E→Z photoisomerization on SAM. 
 
4.1.7 Conclusion 
In conclusion, photoswitchable azobenzene glycosides were synthesised in high yields and 
used for the formation of self-assembled monolayers (SAMs). SAM formation of acetyl 
protected azobenzene mannosides was monitered by IRRAS. The E→Z isomerization 
process was successfull in mSAMs using 7 and 9 with the ratio of 1:4. Our next goal is to 
reproduce the mSAMs with OH-free mannoside as a photoswitchable adhesive surface and 
test bacterial adhesion to the different isomers on the surface. 
 
Experimental  
 Materials and Methods 
Thin-layer chromatography was performed on silica gel plates (GF 254, Merck). Detection 
was effected by UV and subsequent charring with 10% sulphuric acid in EtOH followed by 
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heat treatment ~ 180 oC. Flash chromatography was performed on silica gel 60 (230-400 
mesh, particle size 0.040-0.063 mm, Merck) using distilled solvents. Optical rotations were 
measured with a Perkin-Elmer 241 polarimeter (sodium D-line: 589 nm, length of cell: 1 dm) 
in the noted solvent. 1H and 13C NMR spectra were recorded with Bruker DRX-500 and AV-
600 spectrometers. Chemical shifts are reported relative to internal tetramethylsilane (δ = 
0.00 ppm) or D2O (δ = 4.76 ppm). Data are reported as follows: chemical shift, multiplicity (s 
= singlet, d = doublet, t = triplet, q = quadruplet and m = multiplet), coupling constant in Hz, 
integration and assignment. IR spectra were measured with a Perkin Elmer FT-IR Paragon 
1000 (ATR) spectrometer. ESI-MS measurements were recorded at the Esquire-LC from 
Bruker Daltonics. MALDI-TOF mass spectra were recorded on a Bruker Biflex III instrument 
with 19 kV acceleration voltage. 2,5-dihydroxybenzoic acid (DHB) was used as a matrices. 
Air/moisture sensitive reactions were carried out under nitrogen. UV-Vis absorption spectra 
were performed on Perkin-Elmer Lambda-14 and Varian Cary-5000 with temperature (18 + 1 
oC). Photoirradiaton was carried out with a high pressure mercury lamp UV-P 250C from 
Panacol-Elosol. The bandpass filters were purchased from Laser components. Melting points 
were determined on Büchi 510 apparatus. Glass substrates with a 50 Å titanium base layer 
and a 1000 Å evaporated gold film were purchased from EMF Corporation (Ithaca, NY) for 
IRRAS measurements.  
Synthesis of phtoswitchable azobenzene glycosides 
4-(4′-Hydroxyphenylazo)phenyl -D-mannopyranoside (3): The azobenzene derivative 1 
(200 mg, 0.934 mmol) and the mannosyl donor 2 (1.0 g, 2.03 mmol) were dissolved in dry 
CH3CN (15 mL) , BF3-Et2O (260 μL, 2.01 mmol) was added at 0 
oC, under nitrogen 
atmosphere and maintained at this temperature for about 15 min. The reaction mixture was 
stirred at room temperature overnight, then added NaHCO3 (5 mL) and further diluted with 
ethyl acetate (100 mL) and washed with water (2×20 mL), phase separated, organic layer 
dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to get 
the crude product which after purification by column chromatography (cyclohexane/ethyl 
acetate, 6:4) gave the desired mannoside 3 as an yellow crystalline solid (190 mg, 0.349 
mmol, 37%). Mp 109-110 o C; Rf = 0.26 (cyclohexane/ethyl acetate, 1:1); [α]
20
D = + 0.75 (c = 
1.0, CH2Cl2); 
1H NMR (600 MHz, CDCl3, 300.1 K): δ = 7.85 (d, J = 8.9 Hz, 2H,14,18), 7.83 (d, 
J = 8.9 Hz, 2H, 9,11), 7.19 (d, J = 8.9 Hz, 2H, 15,17), 6.94 (d, J = 8.8 Hz, 2H, 8,12), 5.61 (d, 
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J1,2 = 1.6 Hz, 1H, H-1), 5.59 (dd, J3,4 = 10.0, J3,2 = 3.4 Hz, 1H, H-3), 5.48 (dd, J2,3=3.5 Hz, J2,1 
= 1.8 Hz, 1H, H-2), 5.39 (t, J4,3 = J4,5 = 10.1 Hz, 1H, H-4), 4.30 (dd, J6a,5 = 12.1, J6a,6b = 5.3 
Hz, 1H, H-6a), 4.12-4.08 (m, 2H, H-5, H6b), 2.22, 2.07, 2.06, 2.04 (s, 12H, 4 OAc); 13C-NMR 
(150 MHz, CD3OD, 299.9 K): δ = 170.7, 170.3, 170.1, 169.8 (C=O, OAc), 158.3 (C-7), 157.2 
(C-16), 148.5 (C-13), 147.1 (C-10), 124.8 (14/18), 124.3 (9/11), 116.8 (15/17), 115.8 (8/12), 
95.7 (C-1), 69.4 (C-5), 69.3 (C-2), 68.9 (C-3), 65.9 (C-4), 62.1 (C-6), 20.9, 20.7, 20.7, 20.7 
(CH3COO); IR (ATR): 3407, 1744, 1587, 1498, 1368, 1211 cm
-1; ESI-MS: Calcd for 
C26H28N2O11 [M+Na]
+: Mcalcd = 567.51, Mfound = 567.16. 
trans-4-(4′-Bromohexylphenylazo)phenyl 2,3,4,6-tetra-O-acetyl--D-mannopyranoside (4): 
To a mixture of mannoside 3 (300 mg, 0.551 mmol), 1-bromohexanol (150 mg, 0.827 mmol), 
triphenylphosphine (217 mg, 0.827 mmol) in dry THF (6 mL) at 0 oC DEAD (143.9 mg, 0.827 
mmol) was added and the reaction mixture stirred for 5 h. Then it was evaporated to dryness 
and the crude product purified by column chromatography (cyclohexane/ethyl acetate, 3:2) 
gave the title compound 4 as a light yellow solid (320 mg, 0.453 mmol, 82%).  Mp 99-100 ºC; 
Rf = 0.41 (cyclohexane/ethyl acetate, 3:2); [α]
20
D = + 0.588 (c = 1.0, CH2Cl2); 
1H NMR (500 
MHz, CDCl3, 300.0 K): δ = 7.81 (d, J = 8.9 Hz, 2H, 14, 18), 7.80 (d, J = 8.9 Hz, 2H, 9, 11), 
7.14 (d, J = 8.9 Hz, 2H, 8, 12), 6.92 (d, J = 8.9 Hz, 2H, 15, 17), 5.54 (d, J1,2 = 1.4 Hz, 1H, H-
1), 5.51 (dd, J3,4 = 10.0, J3,2 = 3.5 Hz, 1H, H-3), 5.41 (dd, J2,3 = 3.4 Hz, J2,1 = 1.8 Hz, 1H, H-2), 
5.31 (t, J4,3 = J4,5 = 10.2 Hz, 1H, H-4), 4.22 (dd, J6a,6b = 12.3, J6a,5 = 5.5 Hz, 1H, H-6a), 4.03 
(J6b,6a = 12.4, J5, 6a = 8.3, J5, 6b = 2.1Hz, 2H, H-5, H6b), 3.98 (t, J = 6.4 Hz, 2H, H-19), 3.37 (t, 
J = 6.8 Hz, 2H, H-24), 2.14, 1.99, 1.98, 1.96 (s, 12H, 4 OAc), 1.87-1.80 (m, 2H, H-23), 1.79-
1.73 ( m, 2H, H-20), 1.48-1.46 (m, 4H, H-22, H-21); 13C NMR (125 MHz, CDCl3, 300.0 K): δ = 
170.5, 169.9, 169.9, 169.7 (C=O, OAc), 161.5 (16), 157.1 (7), 148.6 (10), 146.9 (13), 124.6 
(14/18), 124.2 (9/11), 116.7 (8/12), 114.7 (15/17), 95.8 (C-1), 69.4 (C-5), 69.3 (C-2), 68.8 (C-
3), 68.1 (C-19), 65.9 (C-4), 62.1 (C-6), 33.8 (C-24), 32.7 (C-23), 29.0 (C-20), 27.9 (C-21), 
25.3 (C-22), 20.9, 20.9, 20.7, 20.7 (CH3COO) ppm. ESI-MS: Calcd for C32H39BrN2O11 [M+1]
+ 
Mcalcd = 708.56, Mfound = 708.19. 
trans-4-(4′-Bromodecylphenylazo)phenyl 2,3,4,6-tetra-O-acetyl--D-mannopyranoside (5): 
To a mixture of mannoside 3 (250 mg, 0.459 mmol), 1-bromodecanol (163 mg, 0.689 mmol), 
triphenylphosphine (180.6 mg, 0.689 mmol) in dry THF (5 mL) at 0 oC DEAD ( 120 mg, 0.689 
mmol) was added and the reaction mixture stirred for 5 h. Then, it was evaporated to 
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dryness, and the crude product was purified by column chromatography (cyclohexane/ethyl 
acetate, 3:2) gave the title compound 5 as yellow solid (277 mg, 0.363 mmol, 79%). Mp 107-
109 ºC; Rf = 0.19 (cyclohexane/ethyl acetate, 3:7); [α]
20
D = + 0.562 (c= 1.0, CH2Cl2); 
1H NMR 
(500 MHz, CDCl3, 300.0 K): δ = 7.87 (d, J = 9.0 Hz, 2H, 14, 18), 7.86 (d, J = 9.0 Hz, 2H, 9, 
11), 7.20 (d, J = 9.0 Hz, 2H, 8, 12), 6.99 (d, J = 9.0 Hz, 2H, 15, 17), 5.61 (d, J1,2 = 1.8 Hz, 1H, 
H-1), 5.58 (dd, J3,4 = 10.0, J3,2 = 3.6 Hz, 1H, H-3), 5.48 (dd, J2,3=3.5 Hz, J2,1 = 1.8 Hz, 1H, H-
2), 5.38 (t, J4,3 = J4,5 = 10.1 Hz, 1H, H-4), 4.29 (dd, J6a,6b = 12.2, J6a,5 = 5.5 Hz, 1H, H-6a), 
4.12-4.09 (m, 1H, H-5, H6b), 4.04 (t, J = 6.6 Hz, 2H, H-19), 3.41 (t, J = 6.9 Hz, 2H, H-28), 
2.21, 2.06, 2.05, 2.03 (s, 12H, 4 OAc), 1.89-1.79 (m, 4H, H-20, H-27), 1.51-1.45 ( m, 2H, H-
21), 1.38-1.27 (m, 10H, H-22, H-23, H-24, H-25, H-26); 13C NMR (125 MHz, CDCl3, 300.0 K): 
δ = 170.5, 169.9, 169.9, 169.7 (C=O, OAc), 161.6 (16), 157.1 (7), 148.6 (10), 146.9 (13), 
124.6 (14/18), 124.2 (9/11), 116.7 (8/12), 114.7 (15/17), 95.8 (C-1), 69.4 (C-5), 69.3 (C-2), 
68.8 (C-3), 68.3 (C-19), 65.9 (C-4), 62.1 (C-6), 34.0 (C-28), 32.8 (C-20), 29.4 (C-27), 29.4 (C-
22), 29.3 (C-23), 29.2 (C-24), 28.7 (C-25), 28.2 (C-26), 20.9, 20.9, 20.7, 20.7 (CH3COO) 
ppm; ESI-MS: Calcd for C36H47BrN2O11 [M+1]
+ Mcalcd = 764.67, Mfound = 764.09. 
4-(4′-Acetylthiohexylphenylazo)phenyl 2,3,4,6-tetra-O-acetyl--D-mannopyranoside 
(trans-6): To a stirred solution of KSAc (53.0 mg, 0.467 mmol) in DMF (5 mL) the bromide 4 
(300 mg, 0.424) was added and the reaction mixture stirred at room temperature overnight. 
Then, it was diluted with diethylether (100 mL) and the combined organic layer washed with 
water (25 mL x 2), dried over Na2SO4, filtered and the filtrate was evaporated to dryness, and 
the crude product was purified by column chromatography (cyclohexane/ethyl acetate, 3:2) 
gave compound 6 as a yellow solid (262 mg, 0.373 mmol, 88%). Mp 102-103 oC; [α]20D = + 
0.39 (c=0.81, CH2Cl2); Rf = 0.38 (cyclohexane/ethyl acetate, 3:2); ɛ = 48842 + 1000 L.mol
-
1.cm-1; 1H NMR (500 MHz, CDCl3, 300.1 K): δ = 7.88 (d, J = 9.0 Hz, 2H, 14, 18), 7.87 (d, J = 
9.0 Hz, 2H, 9, 11), 7.20 (d, J = 9.1 Hz, 2H, 8, 12), 6.99 (d, J = 9.1 Hz, 2H, 15, 17), 5.61 (d, 
J1,2 = 1.8 Hz, 1H, H-1), 5.58 (dd, J3,4 = 10.0, J3,2 = 3.6 Hz, 1H, H-3), 5.48 (dd, J2,3=3.5 Hz, J2,1 
= 1.8 Hz, 1H, H-2), 5.38 (t, J4,3 = J4,5 = 10.1 Hz, 1H, H-4), 4.30 (dd, J6a,6b = 12.5, J6a,5 = 5.7 
Hz, 1H, H-6a), 4.12-4.07 (m, 2H, H-5, H6b), 4.03 (t, J = 6.5 Hz, 2H, H-19), 2.89 (t, J =7.0 Hz, 
2H, H-24), 2.33 (s, 3H, SAc), 2.22, 2.06, 2.05, 2.03 (s, 12H, 4 OAc), 1.85-1.79 (m, 2H, H-23), 
1.65-1.59 ( m, 2H, H-20), 1.52-1.43 (m, 4H, H-22, H-21); 13C NMR (125 MHz, CDCl3, 300.0 
K): δ = 195.9 (C-25, C=O, SAc), 170.5, 169.9, 169.9, 169.7 (C=O, OAc), 161.5 (16), 157.1 
(7), 148.6 (10), 146.8 (13), 124.6 (14/18), 124.2 (9/11), 116.7 (8/12), 114.7 (15/17), 95.7 (C-
158
1), 69.4 (C-5), 69.3 (C-2), 68.8 (C-3), 68.1 (C-19), 65.9 (C-4), 62.1 (C-6), 30.7 (C-26), 29.5 
(C-20), 29.1 (C-23), 29.0 (C-24), 28.5 (C-21), 25.6 (C-22), 20.9, 20.9, 20.7, 20.7 (CH3COO) 
ppm; ESI-MS: Calcd for C34H42N2O12S [M+Na]
+ Mcalcd = 725.25, Mfound = 725.24. 
4-(4′-Acetylthiodecylphenylazo)phenyl 2,3,4,6-tetra-O-acetyl--D-mannopyranoside (trans-
7): To a stirred solution of KSAc (41 mg, 0.360 mmol) in DMF (5 mL) the bromide 5 (250 mg, 
0.328) was added and the reaction mixture stirred at room temperature overnight. Then, it 
was diluted with diethylether ( 100 mL), the combined organic layers were washed with water 
(25 ml x 2), dried over Na2SO4, filtered and the filtrate was evaporated to dryness, and the 
crude product was purified by column chromatography (cyclohexane/ethyl acetate, 3:2) gave 
the title compound 7 as a yellow solid (226 mg, 0.298 mmol, 91%). Mp 113-114 oC; Rf = 0.17 
(cyclohexane/ethyl acetate, 7:3); [α]20D = + 0.32 (c= 0.67, CH2Cl2); ɛ = 18715 + 498 L.mol
-1. 
cm-1; 1H NMR (500 MHz, CDCl3, 300.1 K): δ = 7.87 (d, J = 9.0 Hz, 2H, 14, 18), 7.86 (d, J = 
9.0 Hz, 2H, 9, 11), 7.20 (d, J = 9.0 Hz, 2H, 8, 12), 6.99 (d, J = 9.0 Hz, 2H, 15, 17), 5.61 (d, 
J1,2 = 1.7 Hz, 1H, H-1), 5.58 (dd, J3,4 = 10.0, J3,2 = 3.6 Hz, 1H, H-3), 5.48 (dd, J2,3=3.5 Hz, J2,1 
= 1.8 Hz, 1H, H-2), 5.38 (t, J4,3 = J4,5 = 10.2 Hz, 1H, H-4), 4.30 (dd, J6a,6b = 12.6, J6a,5 = 5.9 
Hz, 1H, H-6a), 4.13-4.07 (m, 2H, H-5, H6b), 4.03 (t, J = 6.4 Hz, 2H, H-19), 2.87 (t, J =6.9 Hz, 
2H, H-28), 2.32 (s, 3H, SAc), 2.22, 2.06, 2.05, 2.03 (s, 12H, 4 OAc), 1.84-1.79 (m, 2H, H-20), 
1.59-1.54 ( m, 2H, H-27), 1.50-1.44 (m, 2H, H-21), 1.37-1.26 (m, 10H); 13C NMR (125 MHz, 
CDCl3, 300.0 K): δ = 196.1 (C-30, C=O, SAc), 170.5, 169.9, 169.9, 169.7 (C=O, OAc), 161.6 
(16), 157.1 (7), 148.6 (10), 146.8 (13), 124.6 (14/18), 124.2 (9/11), 116.7 (8/12), 114.7 
(15/17), 95.7 (C-1), 69.4 (C-5), 69.3 (C-2), 68.8 (C-3), 68.4 (C-19), 65.9 (C-4), 62.1 (C-6), 
30.6 (C-30), 29.5 (C-27), 29.4-26.9 (C-20, C22-C28), 26.0 (C-21), 20.9, 20.9, 20.7, 20.7 
(CH3COO); ESI-MS: Calcd for C38H50N2O12S [M+Na]
+ Mcalcd = 781.308, Mfound = 781.292. 
 
4-(4′-Acetylthiohexylphenylazo)phenyl 2,3,4,6-tetra-O-acetyl--D-mannopyranoside (cis-6):  
ɛ = 4579 + 192 L x mol-1 x cm-1 
1H NMR (500 MHz, CDCl3, 300.1 K): δ = 7.00 (d, J = 8.9 Hz, 2H, 8, 12), 6.88 (d, J = 8.9 Hz, 
2H, 14, 18), 6.87 (d, J = 8.9 Hz, 2H, 9, 11), 6.76 (d, J = 8.9 Hz, 2H, 15, 17), 5.52 (dd, J3,4 = 
10.0, J3,2 = 3.5 Hz, 1H, H-3), 5.48 (d, J1,2 = 1.8 Hz, 1H, H-1), 5.41 (dd, J2,3=3.5 Hz, J2,1 = 1.8 
Hz, 1H, H-2), 5.35 (t, J4,3 = J4,5 = 10.1 Hz, 1H, H-4), 4.27 (dd, J6a,6b = 12.6, J6a,5 = 5.9 Hz, 1H, 
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H-6a), 4.09-4.06 (m, 2H, H-5, H6b), 3.92 (t, J = 6.5 Hz, 2H, H-19), 2.87 (t, J =7.0 Hz, 2H, H-
24), 2.32 (s, 3H, SAc), 2.19, 2.05, 2.03, 2.01 (s, 12H, 4 OAc), 1.79-1.73 (m, 2H, H-23), 1.63-
1.57 ( m, 2H, H-20), 1.48-1.42 (m, 4H, H-22, H-21); 13CNMR (125 MHz, CDCl3, 300.0 K): δ = 
195.9 (C-25, C=O, SAc), 170.5, 170.0, 169.9, 169.7 (C=O, OAc), 158.6 (16), 154.4 (7), 148.9 
(10), 146.1 (13), 123.2 (14/18), 122.1 (9/11), 116.7 (8/12), 114.3 (15/17), 95.9 (C-1), 69.3 (C-
5), 68.7 (C-2), 68.0 (C-3), 68.0 (C-19), 65.9 (C-4), 62.1 (C-6), 30.6 (C-26), 29.4 (C-20), 29.0 
(C-23), 28.9 (C-24), 28.5 (C-21), 25.6 (C-22), 20.9, 20.9, 20.7, 20.7 (CH3COO) ppm. 
 
4-(4′-Acetylthiodecylphenylazo)phenyl 2,3,4,6-tetra-O-acetyl--D-mannopyranoside (cis-7):  
ɛ = 1780 + 69 L x mol-1 x cm-1 
1H NMR (500 MHz, CDCl3, 300.1 K): δ = 7.00 (d, J = 8.9 Hz, 2H, 8, 12), 6.88 (d, J = 8.9 Hz, 
2H, 14, 18), 6.87 (d, J = 8.9 Hz, 2H, 9, 11), 6.76 (d, J = 8.9 Hz, 2H, 15, 17), 5.52 (dd, J3,4 = 
10.0, J3,2 = 3.5 Hz, 1H, H-3), 5.48 (d, J1,2 = 1.7 Hz, 1H, H-1), 5.41 (dd, J2,3=3.5 Hz, J2,1 = 1.8 
Hz, 1H, H-2), 5.35 (t, J4,3 = J4,5 = 9.9 Hz, 1H, H-4), 4.27 (dd, J6a,6b = 12.6, J6a,5 = 6.0 Hz, 1H, 
H-6a), 4.09-4.06 (m, 2H, H-5, H6b), 3.92 (t, J = 6.6 Hz, 2H, H-19), 2.86 (t, J =7.4 Hz, 2H, H-
28), 2.32 (s, 3H, SAc), 2.19, 2.05, 2.03, 2.01 (s, 12H, 4 OAc), 1.78-1.72 (m, 2H, H-20), 1.58-
1.53 ( m, 2H, H-27), 1.44-1.39 (m, 2H, H-21), 1.34-1.26 (m, 10H); 13CNMR (125 MHz, CDCl3, 
300.0 K): δ = 196.0 (C-30, C=O, SAc), 170.5, 170.0, 169.9, 169.7 (C=O, OAc), 158.7 (16), 
154.4 (7), 148.9 (10), 146.1 (13), 123.2 (14/18), 122.1 (9/11), 116.7 (8/12), 114.3 (15/17), 
95.9 (C-1), 69.3 (C-5), 69.3 (C-2), 68.7 (C-3), 68.3 (C-19), 65.9 (C-4), 62.1 (C-6), 30.6 (C-30), 
29.5 (C-27), 29.4-26.9 (C-20, C22-C28), 26.0 (C-21), 20.9, 20.9, 20.7, 20.7 (CH3COO) ppm. 
 
Preparation of SAMs 
Self-assembled monolayers (SAMs) were prepared on Au(111) by two different methods. 
Thioacetates were prepared as 1 mM ethanolic solutions in which the gold wafers were 
immersed for direct adsorption. According a second method, SAM was formed by the in situ 
ammonium hydroxide (~63 mM) promoted deprotection of acetyl protected thiols in ethanol 
solution. In both cases, the sample was removed from the solution after 24 hours of 
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immersion at room temperature, thoroughly rinsed with ethanol and finally dried in a stream 
of nitrogen gas. 
Instrumentation 
Bulk IR: IR for all the compounds was recorded on Bruker VERTEX 70 FT-IR spectrometer 
in transmission mode using a DTGS detector. 
IRRAS: IRRAS was performed using a Bruker VERTEX 70 FT-IR spectrometer equipped 
with a liquid nitrogen cooled MCT detector and a horizontal reflection unit for grazing 
incidence (Bruker A518). A p-polarized beam at an incident angle of 80° to the surface 
normal was used for measurements. The resolution was set to 4 cm-1. The sample chamber 
was purged with dry nitrogen before and during measurements. A deuterated hexadecane-
thiol SAM on Au(111) was used as a reference for the background spectrum. The IRRAS 
data were processed using the OPUS program (Bruker, Germany). 
 
Calculation details: The vibrational frequencies were calculated using a commercial 
program package, Gaussian 03, B3LYP (Becke-3-Parameter-Lee-Yang-Parr) functional 
together with a 6-31++G(d,p) basis set. After geometry optimizations, theoretical frequencies 
were calculated. No negative frequencies were observed. The vibrational modes were 
assigned by using the GaussView program. 
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Supporting Information 
Monitoring of trans→cis isomerization of azobenzene glyco-SAMs on gold 
surfaces using IRRAS 
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Figure S1: UV visible spectra showing thermal reisomerization of cis-6 to trans-6 in ethanol (50 μM) 
at 18 oC in the dark as a function of time.  
 
 
 
Figure S2: First order kinetics plot for the thermal cis-6 to trans-6 in ethanol. 
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Figure S3: UV visible spectra showing thermal reisomerization of cis-7 to trans-7 in ethanol (50 μM) 
at 18 oC in the dark as a function of time. 
 
 
 
Figure S4: First order kinetics plot for the thermal cis-7 to trans-7 in ethanol. 
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Table S1: The vibrational frequencies (wavenumber, cm-1) for compound 7 obtained from the 
calculation, transition dipole moment (TDM) with respect to the surface (perpendiclar: : , 
parallel: ǀǀ, and neither parallel nor perpendicular: //) and assignment of the bands are given.  
 
Peak 
Number 
Calculated 
wavenumber (cm-1) 
Transition  
Dipole Moment 
(TDM) 
Assignment 
1 210,83 // CH3 (C-3mann) 
2 212,15 // Molecule deformation 
3 221.43 // CH3 (C-3 mann) 
4 226,79 // CH3 (C-3 mann) 
5 236,11 // Molecule deformation 
6 240.48 // Molecule deformation 
7 241,77 // Molecule deformation 
8 248,41 ǀǀ CH2 (CH2SAC) 
9 251,35 // C-6 (mann) 
10 259,16 // Mann deformation 
11 278,14  & // Molecule deformation 
12 284,35 // Mann deformation  
13 310,67 // Mann deformation  
14 318,59 // Mann deformation  
15 322,63 // Mann deformation  
16 339,82 // & ǀǀ Mann deformation  
17 356,25 // Aromatic & aliphatic deformation 
167
18 380,06 // Molecule deformation 
19 392,31 // Molecule deformation 
20 398,22 // Molecule deformation 
21 415,09 // &  Mann deformation 
22 421,80 // Aromatic deformation 
23 434,60 // Mann deformation 
24 438,51 ǀǀ Aromatic ring deformation 
25 444,39 // & ǀǀ Molecule deformation  
26 448,22 // Molecule deformation  
27 458,71 // & ǀǀ Molecule deformation  
28 459,70 // Molecule deformation  
29 488,01 // Molecule deformation,. 
30 491,37  // CH3 (OAc Mann) 
31 505,57  // CH3 (OAc Mann) 
32 514,99 // &  Molecule deformation
33 518,33 // &  Mann deformation 
34 528,44 // &  Mannose deformation  
35 540,64 // -N=N- & Aromatic ring deformation  
36 542,02 // Mannose ring rocking,  
37 556,95 // CH3 (SAc), rocking,  
38 558,91 // Molecule deformation 
39 574,56 // Molecule deformation  
40 595,43 // Molecule deformation 
41 597,07 // CH2 (C-3 Mannose) rocking  
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42 598,01 // CH2 (C-6 Mannose), rocking 
43 599,10 // CH2 (C-4 Mannose), rocking 
44 601,45 // C-O (SC=OCH3) deformation 
45 615,45 // C-O & Molecule deformation,  
46 621,90 // C-O & Molecule deformation 
47 624,54 // C-O & Molecule deformation 
48 633,89 // 
Aromatic and Mannose 
deformation   
49 640,50 // Aromatic ring deformation  
50 646,47 // CH2 (CH2-SAc) deformation 
51 649,79 // Ring 2 deformation 
52 666,54 ǀǀ & // 
C-C (C-2 mannose) and ring 
deformation  
53 690,21 // 
Mannose and Aromatic 
deformation 
54 718,85 // & . 
Mannose and Aromatic 
deformation  
55 728,88 ǀǀ & // 
Mannose and Aromatic 
deformation  
56 739,48 // CH2 aliphatic, rocking  
57 744,65 ǀǀ & // Aromatic ring deformation  
58 756,09 // CH2 aliphatic, rocking  
59 782,25 // & . 
Mannose and Aromatic 
deformation 
60 787,79 // & . 
Mannose and Aromatic 
deformation  
61 799,05 ǀǀ & // Aromatic ring deformation 
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62 802,30 // 
Mannose and Aromatic 
deformation 
63 813,55 // 
Mannose and Aromatic 
deformation 
64 825 // C-H aromatic wagging 
65 831,82 // CH2 (mannose) rocking 
66 840,12 ǀǀ 
Aromatic Ring with liner (R1), C-H 
twisting 
67 848,32  C-H aromatic(R1)  
68 852,36 // C=C, symmetric stretching 
69 864,92 // C-H asymmetric. Stretching 
70 872,97  ǀǀ Aromatic Ring 1, C-H wagging 
71 882,61 // Aromatic Ring 1, C-H twisting 
72 883,64 // Aliphatic CH2 rocking 
73 926,13 // O-C asymmetric stretching 
74 940,96 ǀǀ N=N asymmetric stretching 
75 951,15 ǀǀ C-C asymmetric stretching 
76 965,25 ǀǀ C-O wagging 
77 967,53 ǀǀ 
C-H aliphatic, symmetric stretching, 
(SAcCH3) 
78 968,84 ǀǀ C-H aromatic, rocking, II 
79 971,25 // 
O-C aromatic (R1), symmetric 
stretching,   
80 979,86 // C-H aromatic (R2), rocking  
81 982,24 // C-H(CH3 of acetyl mann), scissoring  
82 986,64   C-H(CH3 of acetyl mann), scissoring 
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83 993,29   C-H (CH3 of acetyl mann) scissoring  
84 995,00  ǀǀ C-H aliphatic, rocking, II 
85 1003,98  // 
C-C aliphatic, asymmetric 
stretching 
86 1011,81  ǀǀ C-H (CH3 of acetyl mann),rocking, II 
87 1012,48   // 
C-C aliphatic, asymmetric 
stretching 
88 1015,96   
C-O (man-O-COCH3), asymmetric 
stretching  
89 1023,09  // 
C=C (aromatic ring 1), symm 
stretching 
90 1030,21 ǀǀ C-O (C-3 man C-O-OAc), symm 
91 1045,97   // CH2 (C-6 mann) rocking 
92 1049.52    C-C aliphatic, rocking 
93 1058,08   C-C aliphatic symm 
94 1064,66  // CH3 (mann) rocking  
95 1069, 84  // CH3 (mann) rocking  
96 1070,77  // CH3 (mann) rocking  
97 1073,28  // CH3 (mann) rocking  
98 1077,22  // Mannose deformation  
99 1100.98  // CH2 aliphatic, rocking  
100 1104,31 //  CH2 (mannose) rocking 
101 1106,38   // C-C aliphatic (mannose) symm 
102 1117,40     C-H aromatic  (R1), scissoring 
103 1123.08    C-H aromatic (R2), scissoring 
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103 1125,66    C4-C5 (mannose), symm 
104 1129,99  // CH3 (SCOCH3), scissoring 
105 1140,66  // C-H (mannose), rocking 
106 1151    C-H aromatic (R2), scissoring 
107 1160,25  // C-H, scissoring  
108 1165,02  // C-H (mannose), deformation 
109 1183,01   O-C & C-H, scissoring  
110 1187,43  // C-H aliphatic, rocking 
111 1190.07   CH3 (Acetyl mannose), rocking 
112 1200,51  // Mannose deformation  
113 1204,78  // C-H (Aromatic Ring 1), scissoring  
114 1215.19   C-H (CH3 mannose) rocking 
115 1225,78  // Mannose deformation 
116 1226,74   ǀǀ C-H aliphatic, scissoring 
117 1229,48   C-O aromatic (R2), stretching  
118 1233,33   // C-H (mannose), rocking 
119 1252,74   
Aromatic-C-N=N- and C-H (ring) 
rocking  
120 1256,76  // C-H aliphatic, scissoring  
121 1257,16  // CH2 of mannose, rocking,  
122 1272,89   CH2 aliphatic, scissoring,  
123 1285,96  // C-H aliphatic, scissoring  
124 1300,49   CH2 aliphatic, rocking  
125 1318,78  // C-H, Aromatic R-2, rocking  
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126 1321,71   CH2 aliphatic, rocking  
127 1323,21  // C-H (mannose), scissoring  
128 1330,96   CH2 aliphatic, scissoring 
129 1339,02   CH2 aliphatic, scissoring  
130 1341,64   C-H aliphatic, rocking  
131 1343,73  // C-H (mannose), scissoring  
132 1346,82  // C-H (mannose), scissoring  
133 1350,23  // Aromatic ring deformation  
134 1359,34   // Aromatic ring deformation 
135 1375,16   // CH2 (mannose), wagging 
136 1383,26   C-H aliphatic, wagging  
137 1384,61   // C-H (mannose), scissoring 
138 1386,56  // C-H (mannose), scissoring  
139 1400,56   // C-H (mannose), scissoring 
140 1402,22   ǀǀ CH3 (SOAc), scissoring 
141 1408,17   // CH3 (mannose), scissoring 
142 1409,29   CH2 aliphatic, scissoring  
143 1409,46  // CH3 (mannose), wagging  
144 1410,97  // CH3 (mannose), wagging  
145 1415,39 //  CH3 (mannose), wagging  
146 1417,07    Aromatic ring deformation 
147 1424,65   CH2 aliphatic, wagging 
148 1435,73  // CH2 (mannose), scissoring  
149 1453,55  // C=C aromatic, asymmetric  
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150 1468,51  // CH2 of (CH2SAC), scissoring 
151 1475,48  // Aromatic ring deformation 
152 1475,51 ǀǀ CH3 (SOAc), scissoring  
153 1477,87 //  CH3 (mannose), scissoring 
154 1480,27  // CH3 (mannose), scissoring 
155 1488,43 ǀǀ CH3 (SOAc), scissoring  
156 1488,87  // CH3 (mannose), scissoring  
157 1489,27  // &  CH3 (mannose), scissoring  
158 1491,25  // &  CH3 (mannose), scissoring  
159 1498,57 ǀǀ CH3 (mannose), scissoring  
160 1501,46   CH3 (mannose), scissoring 
161 1501,51   CH3 (mannose), scissoring  
162 1502,74   ǀǀ CH2 aliphatic, scissoring  
163 1503,65   CH2  (mannose), scissoring  
164 1503,91 ǀǀ CH2  (mannose), scissoring  
165 1511,88 //  C-H aliphatic, scissoring  
165 1518,93   C-H aliphatic, scissoring  
166 1521,33  //  Aromatic deformation 
167 1525,95   CH2 aliphatic, scissoring  
168 1535,35   C-H aliphatic, scissoring 
169 1615,45 //  Ring deformation (R2) 
170 1620,87 //  Ring deformation (R1)  
171 1639,69  // Ring deformation (R2)  
172 1640,67  // Aromatic ring deformation  
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173 1676,49  // C=O (SAc), symmetric  
174 1710,27  // C=O (mann-C2), symmetric  
175 1736,37   C=O (mann-C6),  symmetric  
176 1739,49    C=O (mann-C3), symmetric   
177 3002,50   ǀǀ CH2 aliphatic, wagging  
178 3009,61   ǀǀ CH2 aliphatic, wagging  
179 3014,11 ǀǀ  CH2 aliphatic, wagging  
180 3048,16   CH3 (mannose), wagging  
181 3051.87   ǀǀ C-H asymmetric stretching  
182 3054,24  // CH2 mannose, wagging  
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4.2 Photosensitive glyconanoparticles: A new tool to switch carbohydrate-
protein interactions 
In another approach, carbohydrate-protein interactions were studied using gold 
glyconanoparticles (GNPs). In GNPs, multiple copies of carbohydrates are covalently linked 
to the surface of gold nanoparticles. GNPs holds some advantages over other multivalent 
systems like control over the size of the nanoparticle metal core, quantification of the bound 
ligands on the surface, detection of binding events by surface plasmon resonance and high 
solubility in aqueous media which is ideal for all the biological testing under physiological 
conditions.[112-115] 
 
 
Figure 4.2: Strategy for the synthesis of GNPs functionalized with photoswitchable azobenzene glycosides. 
In view of this we have recently developed methods for preparation of photosensitive gold 
glyconanoparticles (GNPs) (Fig 4.2). Upon irradiation with UV light of appropriate 
wavelength, photosensitive GNPs undergo E→Z isomerzation of the multivalently 
presentated azobenzene glycosides moieties, resulting in an altered ligand orientation to its 
binding partners. Multivalent interactions with the two different isomers of GNPs with the 
lectin Concanavalin A were studied by UV-Vis spectroscopy. The study was performed in 
collaboration with the group of Prof. Knud J. Jensen (University of Copenhagen, Denmark). A 
first manuscript is presented in the following. 
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 This collaborative work was financed by a short term scientific mission (STSM) within 
european cooperation in science and technology (COST). I did the synthesis of all the 
photoswitchable glycosides at CAU Kiel. Under the supervision of Mikkel B. Thygesen, I 
prepared the photosensitive gold glyconanoparticles (GNPs) and studied their interactions 
with Concanavalin A (ConA) in Prof. Knud J. Jensen’s research group at University of 
Copenhagen, Denmark.  
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4.2.1 Introduction 
 
Carbohydrates are functionalized with gold nanoparticles of sizes between 1 to 100 
nanometer, are called Glyconanoparticles (GNPs). Normally, GNPs consists of three 
important building blocks namely, a gold metal core, carbohydrate ligand and a linker 
connecting the gold core and the ligand. GNPs are emerging tools in the field of glycobiology 
due to their enormous potential in biology with applications such as biomedical imaging, in 
vitro and in vivo imaging, investigation of carbohydrate-protein interactions,  
glyconanotechnology, etc. [1-6] GNPs are highly soluble in water and in aqueous buffer, a 
prerequisite for  biological experiments.[7] In addition, GNPs can be prepared in various 
particle size, quantification of the bound ligand on each nanoparticles and furthermore their 
interactions with proteins can be determined  using spectroscopic techniques like UV-Vis 
spectroscopy, electron microscopy or Dynamic light scattering (DLS). 
 
In GNPs, multiple carbohydrate ligands are attached to the gold core through thiol group. 
Multivalent presentation of these ligands on the gold nanoparticle increases binding affinity to 
lectins in many cases. In addition to multivalency effects, carbohydrate-protein interactions 
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are also influenced by the spatial distribution and orientation of carbohydrate ligands. In order 
to understand this principle,  we are interested in making GNP which can change the 
orientation or presentation of the ligands, triggered by external stimuli such as light. 
Incorporation of azobenzene moieties into the GNPs will eventually allow us to follow the 
effect of conformational change in carbohydrate-protein interactions. Azobenzenes are well 
established photoswitchable molecules which undergoe E→Z isomerization at appropriate 
wavelength. Moreover, azobenzenes are well studied photoswitchable molecule with various 
biological applications.[8-13] 
 
 
Figure 4.2.1: schematic representation of photosensitive glyconanoparticles and its interaction with ConA. 
Here the synthesis of photoswitchable ligands, photoswitchable GNPs and their 
photochromic properites in solution and on nanoparticle surface were studied and explained. 
Unlike GNPs, photoswitchable GNPs have an additional photoswitchable unit, namely 
azobenzene. Photosensitive GNPs and their interaction with the lectin Concanavalin (ConA) 
from Concanavalia ensiformis were studied and reported here (Figure 4.2.1).  
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Results and Discussion 
 
4.2.2 Synthesis of photoswitchable ligands: The aim was to synthesis three different types 
of photoswitchable ligands, each are different in their spacer units. Each ligand has three 
important functional moieties (Figure 4.2.2), mannose as a terminal group and as the specific 
ligand for the lectin ConA, an azobenzene portion as a switchable unit for the E→Z 
photoisomerization and a spacer unit between the anchoring thiol group and the azobenzene 
chromophore. The structures of mannosides 1, 2 and 3 differ only in their spacer units. 
Ligand 1 contains only alkyl spacers for dense packing on the Au nanoparticle core shell, 
ligand 2 contains oligo ethylene glycol (OEG) spacer increases the hydrophilicity of the 
molecule to dissolve in water and buffer medium and in top of that it avoids unspecific binding 
of proteins. Finally, a combination of OEG- and alkyl-spacered ligand 3 was prepared. Here, 
the spacer plays a dual role of providing a dense packing and biocompatibility. 
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Figure 4.2.2:  Structure of compounds used for the synthesis of photosensitive gold glyconanoparticles. 
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The photoswitchable ligands 1, 2 and 3 were synthesized from the common intermediate 4. 
Compound 4 was prepared by standard glycosylation of p,p′-dihydroxy azobenzene as 
previously described from our lab.[14, 15] To achieve our first target molecule 1, Mitsunobu 
reaction was employed (scheme 4.2.1). Thus, reaction of 4 with 10-bromodecan-1-ol in the 
presence of triphenylphosphine and diethyl azodicarboxylate (DEAD) gave the required 
product 5 in 79% yield.[16] At room temperature potassium thioacetate converted the 
alkylbromide 5 into the desired thioacetate 6 in 91% yield.[17] Deprotection of acetyl groups in 
6 under Zemplén conditions gave the target compound 1 in 98% yield.[17] 
 
O
AcO
AcO
OAc
O
OAc
N
N OH
4
O
AcO
AcO
OAc
O
OAc
N
N O R
5 R = Br
6 R = SAc
b)
1
c)
8
a)
 
Scheme 4.2.1: Reaction conditions: (a) Bromodecanol (1.5 equiv.), PPh3 (1.5 equiv.), DEAD (1.5 equiv.), dry 
THF, rt, 79%; (b) KSAc (1.1 equiv.), DMF, rt, 91%; (c) NaOMe, MeOH, rt, 98%.
 
For the synthesis of 2 commercially available hexaethylene glycol was used and converted 
into the respective dibromide 9 according to the literature.[18]  Reaction of mannoside 4 with 9 
under base treatment with K2CO3 in DMF gave the bromo- substituted compound 10 in 74% 
yield. Then, the bromo group was substituted by thioacetate to get required product 11 in 
good yield. Treatment of 11 under Zemplén conditions gave the target molecule 2 in good 
yield (Scheme 4.2.2).  
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Scheme 4.2.2: Reaction conditions: (a) dibromohexaethyleneglycol 9 (2.0 equiv.), K2CO3 (2.0 equiv.), DMF, 40 
°C, 74%; (b) KSAc (1.1 equiv.), DMF, rt, 86%; (c) NaOMe, MeOH, rt, 97% (2), 93% (3); (d) PS-PPh3 (1.5 equiv.), 
DEAD (1.5 equiv.), acetylthioundecyl-tetraethylene glycol 7 (2.0 equiv.), dry. THF, rt, 71%. 
Finally, synthesis of the advanced ligand 3 was carried out in two synthetic steps using 
Mitsunobu reaction and Zemplén reaction conditions (scheme 4.2.2). Our initial attempt to 
prepare 3 under Mitsunobu conditions using triphenylphophine, lead to difficulties in removing 
the by-product PPh3O, even after several purification steps. However, this problem was 
overcome by using the polymer-supported triphenylphosphine (PS-PPh3). Thus, reaction of 4 
with commercially available 7, in the presence of PS- triphenylphosphine and 
diethylazodicarboxylate (DEAD) yielded 8 in 71%. Deprotection of O- and S- acetyl protecting 
groups was achieved in a single step under Zemplén conditions, which gave the final 
compound 3 in 93% yield.[17] 
4.2.3 Synthesis and characterization of photoswitchable glyco-AuNPs: Citrate-stabilized 
gold nanoparticles (AuNPs) were prepared according to a modified method of Turkevich et al. 
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to provide AuNPs with an average diameter of 13.2 nm.[19, 20] The size of the prepared AuNPs 
was determined by UV-Vis spectroscopy using equation (1), in which Aspr is the absorbance 
at the surface plasma resonance band and A450 is the absorbance at 450 nm.
[7, 21, 22] These 
particles were washed with 1 mM NaOH as described by Whitesides et al. in order to 
facilitate self-assembly with alkanethiols.[23 
 
dAuNPs = 0.112 · e
3A
spr
/A
450  eq (1) 
 
To the synthesized 13.2 nm AuNPs, photoswitchable ligands 1-3 were attached by stirring in 
aqueous solution for 14 h at room temperature to get E-AuNP1, E-AuNP2 and E-AuNP3. To 
our surprise ligand-1 showed poor solubity in organic solvents, water and aqueous buffer. It 
might be due to the hydrophoic interaction of the alkyl spacers. Due to its poor solubility, 
preparation of E-AuNP1 was unsuccessful. Our next attempt was to prepare E-AuNP2 using 
ligand 2. However, during the functionalization of  AuNP with ligand 2, immediate aggregation 
of the nanoparticles was observed within 5 min. After addition of ligand 2 to the nanoparticle 
solution, colour of the reaction mixture turned from light red wine to dark brown (see 
Supporting Information). However, anchoring of ligand 3 onto AuNP was successful and 
procceded nicely to afford the photoswitchable glyconanoparticle E-AuNP3. By retaining the 
red wine colour in the reaction mixture solution, an indication for proper functionalization of 
AuNP. Thus, E-AuNP3 was chosen as the best candidate for further experiments (see 
Supporting Information). 
The photoswitchable glyconanoparticle 3 (E-AuNP3) were prepared as follows. A 5 mM 
solution of ligand 3 in methanol (1 mL) was added to a stirring solution of AuNP (in 10 
mLwater) and this mixture was stirred for about 18 h at room temperature. Functionalized E-
AuNP3 were washed with phosphate buffer (0.1 mM) at pH 7.0 (10 mL x 5) by washing in a 
centrifugal filtration using 50 kDa cut-off. UV-Vis spectroscopy of E-AuNP3 showed a 
characteristic peak at 339 nm due to the azobenzene chromophore and at 530 nm arising 
from surface plasmon resonance band (SPR band). After irradiation at 365 nm for 8-10 min, 
the Z-AuNP3 isomer was observed by a decrease in the π-π* transition of azobenzene 
chromophore at 339 nm. But, the formation of band at 419 nm region due to the n-π* 
transition was weak due to the overlap of SPR absorption band, which was also slightly blue-
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shifted from 530 nm to 528 nm due to the influence of switching and isomerization (Figure 
4.2.3). 
 
Figure 4.2.3: Monitoring E→Z isomerization in solution and on the surface by UV-Vis spectroscopy in 0.1 mM 
phosphate buffer (pH 7). Isomerization of free ligands, E-3 (6 M) and Z-3 (5 M). Isomerization of ligand 
functionalized gold nanoparticles, E-AuNP-3 (6 nM) and, Z -AuNP-3 (6 nM). 
Formation of two different isomers, E-AuNP3 and Z-AuNP3, was also observed by dynamic 
light scattering (DLS) measurements, which gave the hydrodynamic diameter d(H) from the 
core of Au to the head group mannose. The results showed that E-AuNP3 gave a diameter of 
29.5 nm whereas Z-AuNP3 gave only 16.4 nm. As expected, the difference between these 
two E-AuNP3 and Z-AuNP3 is another clear evidence for the formation of the two different 
isomers on the AuNP surface. 
4.2.4 Photochromic properties of free ligand and photoswitchable glyconanoparticles: 
E →Z isomerization ratios of the free ligands 1- 3 were determined by 1H NMR spectroscopy 
by integrating the H-1 proton of mannose (Table 4.2.1). In the ground state (G.S) all the 
compounds exhibited >98% of E-isomer, after irradiation at 365 nm using light emitting diode 
(LED) for 8-10 min photostationary state (PSS) was reached. This was clearly observed by 
the drastic chemical shift in the aromatic protons and H-1 proton of the mannose. But, E:Z 
ratio of E-AuNP3 was not determined as 1H NMR spectra of functionalized 
glyconanoparticles often gives broad signals and obtaining the E:Z ratio exactly is difficult.  
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Kinetics and half-life of azobenzene glycosides were studied in the dark at room temperature. 
Due to the poor solubility of 1 in organic solvent like methanol and ethanol, kinetic 
measurement of 1 was performed in DMSO, but 2 and 3 were measured in methanol. Before 
irradiation, the E-isomer of all the compounds exhibited an absorption  band (λmax) at 362 nm 
for 1 and ~353 nm for 2 and 3 due to the π-π* transition of the azobenzene moiety. 
Photoirradiation of the E-isomer at 365 nm for about 8-10 min leads to photostationary state 
(PSS)  which was observed by a decrease in π-π* and increase in λmax of n-π* region at 449 
nm for 1 and ~445 nm for 2 and 3, a clear indication for the formation of Z isomer. Kinetics of 
back isomerization from Z→E and corresponding half-life (1/2) are given in Table 5.2.1. 
Azobenzene glycoside 2 showed a greater 1/2 of 7 h 45 min compared to 1 and 3.  
Table 4.2.1: Photochromic properties of 1, 2, 3 and E-AuNP3   
Compounds Solvent Rate Constant (k) 
min
-1 [a] 
 
E- isomer 
[b]
 Z- isomer 
[c]
 
Ligand 1 DMSO 2.01 x 10
-3
 > 98 > 98 
Ligand 2 MeOH 1.55 x 10
-3
 > 97 > 98 
Ligand 3 MeOH 2.32 x 10
-3
 > 99 > 97 
Ligand 3 Phosphate buffer 2.27 x 10
-2
 -- -- 
AuNP-3 Phosphate buffer 1.90 x 10
-2
 -- -- 
 
Percentage of E and Z isomers were determined by 
1
H NMR spectroscopy based on the integrals of the 
respective anomeric protons (H-1) [a] rate contsant were determined by UV-Vis spectroscopy, [b] before 
irradiation, [c] after irradiation, photostationary state (pss) 
Rate constant (k) and half-life (1/2) determination of E-AuNP3 → Z-AuNP3 was performed in 
phosphate buffer. Before irradiation, E-AuNP3 showed a characteristic peak at 339 nm due 
to the azobenzene chromophore and a peak at 530 nm arising due surface plasmon 
resonance (SPR) band of AuNPs. After irradiation with LED at 365 nm for 8-10 min 
photostationary state (PSS) was reached, indicating the formation of Z-AuNP3 with a 
decrease in the π-π* at 339 nm. However, observation of the n-π* transition at the 419 nm 
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region was weak due to the overlap with the broad SPR absorption band. Notably, a slight 
shift in the SPR band from 530 nm to 528 nm was observed which might be due to the 
influence of E→Z isomerization (Figure 3). It was observed that the rate of back 
isomerization, Z→E on the AuNP surface has a greater half-life compare to the free ligand 3 
in phosphate buffer solution.[24]  
4.2.5 Recognition by the lectin ConA: ConA exists as a tetramer at pH 7.0 and each 
monomeric unit binds to α-D-mannoside. Individual isomers of photoswitchable 
glyconanoparticles, E-AuNP3 and Z-AuNP3 were taken and their interactions with the lectin 
ConA were tested. Lectin-mediated aggregation was monitored by UV-Vis spectroscopy by 
the shift in the SPR band. Though the interaction of ConA with glyconanoparticles is known in 
the literature, the impact of how the conformational control of the photoswitchable AuNP 
would influence the binding to proteins and lectins has not been explored.[1, 6, 25, 26]  
In light of this, binding affinity of two individual isomers E-AuNP3 and Z-AuNP3 with different 
orientation of ligand to the lectin ConA were tested and the effect of conformational change to 
binding event was evaluated. Firstly, to a 900 µL of E-AuNP3 (5.6 nM in phosphate buffer), 
100 µL of 5 M ConA in 0.1 mM phosphate buffer pH 7 was added. To get the Z-AuNP3, 900 
µL of E-AuNP3 (5.6 nM in phosphate buffer) was irradiated for  ~8-10 min at 365 nm to reach 
the photo-stationary state (pss), which was confirmed by UV-Vis spectroscopy. To the 
obtained Z-AuNP3 was added 100 µL of 5 M of ConA in 0.1 mM of phosphate buffer pH 7. 
ConA-mediated aggregation of E-AuNP3 and Z-AuNP3 was monitored by the shift in the 
SPR band by UV-Vis  spectroscopy. As a control experiment only ConA was also measured 
by UV-Vis  spectroscopy which showed no absorption band. As a negative control bovine 
serum albumin (BSA), 100 µL of 5 M, was added to E-AuNP3 (900 µL in 0.1 mM phosphate 
buffer) which showed no shift in the UV-Vis spectrum, (i.e). no SPR band shift was observed 
which indicated that the ligand is specific to ConA only.  
We found that the λmax of the SPR band of E-AuNP3 after adding ConA moved from 529 nm 
to 544 nm which clearly showed the selective aggregation between ConA and E-AuNP3.  In 
the case of Z-AuNP-3, the λmax of the SPR band before ConA additon was 528 nm; after the 
addition of ConA the λmax of the SPR band moved to 540 nm over the period of time. Overall 
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a red-shift of 14.5 nm was observed for E-AuNP3 and 12 nm for Z-AuNP3. To deduce the 
kinetics of the binding of lectin ConA with the individual isomers E-AuNP-3 and Z-AuNP-3  
was obtained by plotting a graph of SPR band shift (nm) as a function of time (Figure 4.2.4). 
This allowed us to determine the rate of individual isomer binding with ConA, both followed 
first order kinetics according to using equation (2).[23]   
 
Figure 4.2.4: A plot of λmax of SPR band shifts due to the ConA-mediated aggregation with E-AuNP3 and    Z-
AuNP3 as a function of time. 
 
ΔλSP = ΔλSP,max [1 − e
−k
obs
.t]       eq (2) 
where ΔλSP  is the SP band shift over the period of time, ΔλSP,max is the maximal SP band shift 
and kobs is the rate constant for the binding event. This preliminary analysis showed that E-
AuNP3 had a greater shift in the SPR band and faster kinetics of aggregation than its Z-
AuNP3 (Figure 4). We speculate that these results indicate that the mannosyl ligands in E-
AuNP3 are more easily available to the lectin relative compare to Z-AuNP3. Also, during the 
interaction between the Z-AuNP3 and the lectin ConA, there could be a substantial back 
isomerization of Z-AuNP3 → E-AuNP3 takes place. This results in a possible mixture of both 
E-AuNP3 and Z-AuNP3 in the system which makes it more complex for the binding event 
with the lectin ConA, hence slower binding constant for Z-AuNP3 was observed. 
187
4.2.6 Conclusion 
 
In conclusion, synthetic route to different azobenzene glycosides with varied spacer units has 
been accomplished.  Photochromic properties of free ligands 1- 3 in solution and 
functionalized ligand 3 on the AuNP surface (E-AuNP3→Z-AuNP3) were studied. Back 
isomerization of Z→E is faster in solution than on the AuNP surface. Investigation of the 
individual isomers, E-AuNP3 and Z-AuNP3, and its interaction with the lectin ConA was 
performed.  E-AuNP3 had greater binding with the lectin ConA than the Z-AuNP3. The faster 
binding kinetics of E-AuNP3 might be due to the spatial orientation and easy availability of 
the ligand to interact with the lectin compared to the Z-AuNP3. 
 
 Experimental Section 
HAuCl4 and Concanavalia ensiformis (ConA) were purchased from Sigma Aldrich. 
Air/moisture sensitive reactions were carried out under nitrogen in dry glassware. Thin layer 
chromatography was performed on silica gel plates (GF 254, Merck). Detection was effected 
by UV and subsequent charring with 10% sulphuric acid in EtOH followed by heat treatment 
at ~180 °C. Flash chromatography was performed on silica gel 60 (Merck, 230-400 mesh, 
particle size 0.040-0.063 mm) using distilled solvents. Optical rotations were measured with a 
Perkin-Elmer 241 polarimeter (sodium D-line: 589 nm, length of cell: 1 dm) in the solvents 
indicated. 1H and 13C NMR spectra were recorded on Bruker DRX-500 and AV-600 
spectrometers at 300 K. Chemical shifts are reported relative to internal tetramethylsilane (δ 
= 0.00 ppm) or D2O (δ = 4.76 ppm). Full assignment of the peaks was achieved with the aid 
of 2D NMR techniques (1H-1H COSY and 1H-13C HSQC). IR spectra were measured with a 
Perkin Elmer FT-IR Paragon 1000 (ATR) spectrometer. ESI mass spectra were recorded on 
an Esquire-LC instrument from Bruker Daltonics. MALDI-TOF mass spectra were recorded 
on a Bruker Biflex III instrument with 19 kV acceleration voltage. 2,5-Dihydroxybenzoic acid 
(DHB) was used as a matrix. For glyconanoparticle analysis and Lectin mediated aggregation 
UV-Vis spectroscopy Jasco V-650 spectrometer was used, and for other measurements 
Perkin-Elmer Lambda-241 was used at a temperature of 18 + 1 °C. Dynamic light scattering 
measurements were performed on a BI-200SM instrument from Brookhaven Instruments 
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Corporation. Photoirradiaton was carried out with LED lights from Nichia Corporation 
(NJSE107) power dissipation: 1.4 W, luminous flux: 44 [lm] 
E-p-(p′-Bromodecylphenylazo)phenyl 2,3,4,6-tetra-O-acetyl--D-mannopyranoside (5): 
To a mixture of 4 (250 mg, 0.459 mmol), 1-Bromodecanol (163 mg, 0.689 mmol), 
Triphenylphosphine (181 mg, 0.689 mmol) in dry THF (5 mL) at 0 oC was added 
Diethylazodicarboxylate (120 mg, 0.689 mmol). The reaction mixture was stirred at room 
temperature for 5 h, then, it was evaporated to dryness to get the crude product. The crude 
product was purified by column chromatography (cyclohexane: ethyl acetate 3:1) which 
provided 5 (277 mg, 0.364 mmol, 79%) as yellow crystalline solid. Rf = 0.19 (cyclohexane: 
ethyl acetate 7:3); [α]20D =  + 0.562 (c= 1.0, CH2Cl2); 
1H-NMR (500 MHz, CDCl3, 300.0 K): δ = 
7.87 (d, J = 9.0 Hz, 2H; H-14, H-18), 7.86 (d, J = 9.0 Hz, 2H; H-9, H-11), 7.20 (d, J = 9.0 Hz, 
2H; H-8, H-12), 6.99 (d, J = 9.0 Hz, 2H; H-15, H-17), 5.61 (d, J1,2 = 1.8 Hz, 1H; H-1), 5.58 (dd, 
J2,3 = 3.6, J3,4 = 10.0 Hz, 1H; H-3), 5.48 (dd, J1,2= 1.8 Hz, J2,3 = 3.8 Hz, 1H; H-2), 5.38 (t, J3,4 = 
J4,5 = 10.1 Hz, 1H; H-4), 4.29 (dd, J5,6a = 5.5 Hz, J6a,6b = 12.2, 1H; H-6a), 4.12-4.09 (m, 2H; H-
5, H6b), 4.04 (t, J = 6.6 Hz, 2H; H-19), 3.41 (t, J = 6.9 Hz, 2H; H-28), 2.21, 2.06, 2.05, 2.03 
(s, 12H, 4 OAc), 1.89-1.79 (m, 4H, H-20, H-27), 1.51-1.45 (m, 2H, H-21), 1.38-1.27 ppm (m, 
10H, H-22, H-23, H-24, H-25, H-26); 13C-NMR (125 MHz, CDCl3, 300.0 K): δ = 170.5, 169.9, 
169.9, 169.7 (C=O, OAc), 161.6 (C-16), 157.1 (C-7), 148.6 (C-10), 146.9 (C-13), 124.6 (C-
14/C-18), 124.2 (C-9/C-11), 116.7 (C-8/C-12), 114.7 (C-15/C-17), 95.8 (C-1), 69.4 (C-5), 69.3 
(C-2), 68.8 (C-3), 68.3 (C-19), 65.9 (C-4), 62.1 (C-6), 34.0 (C-28), 32.8 (C-20), 29.4 (C-27), 
29.4 (C-22), 29.3 (C-23), 29.2 (C-24), 28.7 (C-25), 28.2 (C-26), 20.9, 20.9, 20.7, 20.7 ppm 
(CH3COO); ESI-MS calcd for C36H47BrN2O11 [M+Na]
+: 785.24; Mfound = 785.09 . 
E-p-(p′-Acetylthio-decyl-phenylazo)phenyl 2,3,4,6-tetra-O-acetyl--D-mannopyranoside  (6): 
A solution of potassium thioacetate (41 mg, 0.361 mmol) and bromo derivative 5 (250 mg, 
0.328 mmol) in DMF (5 mL) was stirred at room temperature overnight (15 hr), then it was 
concentration under reduced pressure. Purification of the crude product by column 
chromatography (cyclohexane:ethyl acetate, 3:1) gave the title compound 6 as a pale yellow 
solid (226 mg, 0.298 mmol, 91%). Mp 113-114 oC; Rf = 0.17 (cyclohexane:ethyl acetate, 7:3); 
[α]20D = + 0.317 (c= 0.67, CH2Cl2); 
1H-NMR (500 MHz, CDCl3, 300.1 K): δ = 7.87 (d, J = 9.0 
Hz, 2H; H-14, H-18), 7.86 (d, J = 9.0 Hz, 2H; H-9, H-11), 7.20 (d, J = 9.0 Hz, 2H; H-8, H-12), 
6.99 (d, J = 9.0 Hz, 2H; H-15, H-17), 5.61 (d, J1,2 = 1.7 Hz, 1H; H-1), 5.58 (dd, J2,3 = 3.6 Hz, 
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J3,4 = 10.0, 1H; H-3), 5.48 (dd, J1,2 = 1.8 Hz, J2,3 = 3.5 Hz, 1H; H-2), 5.38 (t, J3,4 = J4,5 = 10.2 
Hz, 1H; H-4), 4.30 (dd, J5,6a = 5.9 Hz, J6a,,6b = 12.6, 1H; H-6a), 4.13-4.07 (m, 2H; H-5, H6b), 
4.03 (t, J = 6.4 Hz, 2H; H-19), 2.87 (t, J =6.9 Hz, 2H; H-28), 2.32 (s, 3H; H-30, SCOCH3),  
2.22, 2.06, 2.05, 2.03 (s, 12H; 4 OCOCH3), 1.84-1.79 (m, 2H; H-20), 1.59-1.54 (m, 2H; H-27), 
1.50-1.44 (m, 2H; H-21), 1.37-1.26 ppm (m, 10H; H-22, H-23, H-24, H-25, H-26); 13C-NMR 
(125 MHz, CDCl3, 300.0 K): δ = 196.1 (C-29, SCOCH3), 170.5, 169.9, 169.9, 169.7 (4 
OCOCH3), 161.6 (C-16), 157.1 (C-7), 148.6 (C-10), 146.8 (C-13), 124.6 (C-14/C-18), 124.2 
(C-9/C-11), 116.7 (C-8/C-12), 114.7 (C-15/C-17), 95.7 (C-1), 69.4 (C-5), 69.3 (C-2), 68.8 (C-
3), 68.4 (C-19), 65.9 (C-4), 62.1 (C-6), 30.6 (C-30), 29.5 (C-28), 29.4-26.9 (C-20, C-22, C-23, 
C-24, C-25, C-26, C-27), 26.0 (C-21), 20.9, 20.9, 20.7, 20.7 ppm (CH3COO); ESI-MS calcd 
for C38H50N2O12S [M+Na]
+: 781.30; Mfound = 781.09 . 
E-p-(p′-Mercaptodecyl-phenylazo)phenyl -D-mannopyranoside (E-1): To a solution of 
the acetyl-protected glycoside 6 (100 mg, 0.132 mmol) in dry MeOH (6 mL), a catalytic 
amount of solid NaOMe was added under N2 atmosphere. The reaction mixture was stirred 
for 5 h at room temperature, then it was neutralization with Amberlite IR 120 ion-exchange 
resin and filtered. The filtrate was evaporated under reduced pressure to yield the 
deprotected mannoside 1 as a yellow solid (71 mg, 1.09 mmol, 98%). Mp 240°C 
(decomposition); 1H-NMR (600 MHz, DMSO-d6, 300.1 K): δ = 7.82-7.79 (m, 4H; H-9, H-11, H-
15, H-17), 7.23 (dd, J = 8.9 Hz, J = 8.9 Hz, 2H; H-8, H-12), 7.08 (dd, J = 8.9 Hz, J = 8.9 Hz, 
2H; H-15, H-17), 5.49 (s, 1H; H-1), 4.05-4.01 (m, 2H; H-19), 3.85 (dd, J1,2 = 1.9 Hz, J2,3 = 3.1 
Hz, 1H; H-2), 3.69 (dd, J2,3 = 3.6 Hz, J3,4 = 9.2, 1H; H-3), 3.52-3.45 (m, 3H; H-4, H-6a, H-5), 
3.37 (dd, J5,6a = 5.6 Hz, J6a,6b = 10.0, 1H; H-6b), 2.65 (t, J = 7.2 Hz, 2H; H-28), 1.73-1.69 (m, 
2H; H-20), 1.42-1.21 ppm (m, 14H; H-21, H-22, H-23, H-24, H-25, H-26, H-27); 13C-NMR 
(150 MHz, DMSO-d6, 300.0 K): δ = 161.6 (C-16), 159.1 (C-7), 148.6 (C-10), 146.1 (C-13), 
124.6 (C-14/C-18), 124.1 (C-9/C-11), 117.3 (C-8/C-12), 115.2 (C-15/C-17), 98.9 (C-1), 75.1 
(C-5), 69.2 (C-2), 68.6 (C-3), 68.2 (C-19), 66.6 (C-4), 61.2 (C-6), 38.2 (C-28), 29.1-26.5 ppm 
(C-20, C-21, C-22, C-23, C-24, C-25, C-26, C-27).  
Z-p-(p′-Mercaptodecyl-phenylazo)phenyl -D-mannopyranoside (Z-1): 1H-NMR (600 
MHz,DMSO-d6, 300.1 K): δ = 7.07 (dd, J = 8.8 Hz, J = 8.9 Hz, 2H; H-8, H-12), 6.90-6.87 (m, 
6H; H-9, H-11, H-14, H-15, H-17, H-18), 5.41 (s, 1H; H-1), 3.99-3.95 (m, 2H; H-19), 3.85 (mc, 
1H; H-2), 3.71-3.59 (m, 2 H; H-3, H-6a), 3.55-3.49 (m, 2H; H-4, H-6b), 3.39 (ddd, J4,5  = 3.3 
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Hz, J5,6a  = 5.9 Hz, J6a,6b = 11.4, 1H; H-5), 2.72 (t, J = 7.2 Hz, 2H; H-28), 1.71 (dd, J = 7.2 Hz, 
J = 14.0 Hz, 2H; H-20), 1.39-1.28 ppm (m, 14H; H-21, H-22, H-23, H-24, H-25, H-26, H-27); 
13C-NMR (150 MHz, DMSO-d6, 300.0 K): δ = 161.6 (C-16), 155.5 (C-7), 148.6 (C-10), 146.6 
(C-13), 122.8 (C-14/C-18), 122.3 (C-9/C-11), 117.5 (C-8/C-12), 114.8 (C-15/C-17), 99.1 (C-
1), 75.4 (C-5), 70.8 (C-3), 70.2 (C-2), 68.2 (C-19), 66.9 (C-4), 61.3 (C-6), 38.2 (C-28), 29.3-
25.8 ppm (C-20, C-21, C-22, C-23, C-24, C-25, C-26, C-27). 
1,17-Dibromohexaethylene glycol (9): To a solution of hexaethylene glycol (200 mg, 0.709 
mmol) in THF (2 mL) was added triphenyl phosphine (372 mg, 1.42 mmol) and CBr4 (469 mg, 
1.42 mmol) at 0° C. The reaction mixture was stirred for 16 h at room temperature. The white 
residue was filtered and the filtrate was evaporated, the resulting pasty colourless residue 
was extracted several times with hexane (20 ml x 5). The combined extract was evaportaed 
to get the dibromohexaethylene 9 as colourless oil (237 mg, 0.581 mmol, 82%). Rf = 0.23 
(ethyl acetate:cyclohexane 4:1); 1H-NMR (200 MHz, CDCl3, 300.0 K): 3.81 (t, J = 6.3 Hz, 
4H;O-CH2-CH2-Br), 3.67-3.65 (m, 16H, 4 x O-CH2-CH2-O), 3.47 ppm (t, J = 6.3 Hz, 4H; O-
CH2-CH2-Br),
 13C-NMR (75 MHz, CDCl3, 300.0 K): δ = 71.2 (O-CH2-CH2-Br), 70.6-70.4 (O-
CH2-CH2-O), 30.3 ppm (O-CH2-CH2-Br); ESI-MS Calcd for C12H24Br2O5 [M+Na]
+:430.99; 
Mfound = 430.92. 
E-p-(p′-Bromohexaethyleneglycol-phenylazo)phenyl 2,3,4,6-tetra-O-acetyl-          
-D-mannopyranoside (10): A mixture of 4 (100 mg, 0.184 mmol), di-bromohexaethylene 
glycol 9 (149 mg, 0.367 mmol), potassium carbonate (50.7 mg, 0.367 mmol) in dry DMF (3 
mL) was stirred at 40 °C for overnight, 16 h. The reaction mixture was diluted with ethyl 
acetate (20 mL), washed with water (10 mL) and dried over Na2SO4. This was filtered and the 
filtrate was concentrated under reduced pressure. Purification of the crude product by column 
chromatography (ethyl acetate:cyclohexane 7:3) gave the title compound 10 as reddish 
brown syrup (118 mg, 0.136 mmol, 74%). Rf = 0.23 (ethyl acetate:cyclohexane 7:3); 
1H-NMR 
(500 MHz, CDCl3, 300.0 K): δ = 7.88 (d, J = 9.0 Hz, 2H; H-14, H-18), 7.87 (d, J = 9.0 Hz, 2H; 
H-9, H-11), 7.20 (d, J = 9.0 Hz, 2H; H-8, H-12), 7.02 (d, J = 9.0 Hz, 2H; H-15, H-17), 5.60 (d, 
J1,2 = 1.8 Hz, 1H; H-1), 5.57 (dd, J2,3 = 3.6 Hz, J3,4 = 10.0, 1H; H-3), 5.47 (dd, J1,2 = 1.8 Hz, 
J2,3= 3.5 Hz, 1H; H-2), 5.38 (t, J3,4 = J4,5 = 10.0 Hz, 1H; H-4), 4.29 (dd, J5,6a = 5.6 Hz, J6a,6b = 
12.4, 1H; H-6a), 4.22-4.20 (m, 2H; H-19), 4.12-4.07 (m, 2H; H-5, H-6b), 3.90-3.88 (m, 2H; H-
20), 3.71 (t, J = 6.3 Hz, 2H; H-30), 3.75-3.64 (m, 16H; H-21, H-22, H-23, H-24, H-25, H-26, H-
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27, H-28), 3.46 (t, J = 6.3 Hz, 2H; H-30), 2.21, 2.06, 2.04, 2.03 ppm (each s, each 3 H, 4 
COCH3);
13C-NMR (125 MHz, CDCl3, 299.9 K): δ = 170.5, 169.9, 169.9, 169.7 (4 COCH3), 
161.2 (C-16), 157.2 (C-7), 148.5 (C-10), 146.9 (C-13), 124.6 (C-14/C-18), 124.2 (C-9/C-11), 
116.7 (C-8/C-12), 114.9 (C-15/C-17), 95.7 (C-1), 70.9-70.5 (C-21, C-22, C-23, C-24, C-25, C-
26, C-27, C-28) 69.6 (C-29), 69.4 (C-20), 69.3 (C-5), 69.1 (C-2), 68.8 (C-3), 67.6 (C-19), 65.9 
(C-4), 62.1 (C-6), 30.3 (C-30), 20.9, 20.7, 20.7, 20.7 ppm (COCH3); MALDI-TOF Calcd for 
C38H51BrN2O16 [M+Na]
+: 893.24; Mfound = 893.54. 
 
E-p-(p′-Acetylthio-hexaethyleneglycol-phenylazo)phenyl 2,3,4,6-tetra-O-acetyl--D-
mannopyranoside (11): A mixture of bromo derivative 10 (100 mg, 0.115 mmol), and 
potassium thioacetate (14.4 mg, 0.127 mmol) in DMF (3 mL) was stirred at room temperature  
overnight (15 hr). The reaction mixture was concentrated under reduced pressure, 
purification of the crude product by column chromatography (ethyl acetate:cyclohexane 7:3) 
gave the title compound 11 as brown syrup.(86 mg, 99.3 µmol, 86%) Rf = 0.23 (ethyl 
acetate:cyclohexane 4:1); [α]20D = + 92.4 (c= 0.8, CH2Cl2);
1H-NMR (500 MHz, CDCl3, 300.2 
K): δ = 7.81 (d, J = 8.9 Hz, 2H; H-14, H-18), 7.80 (d, J = 8.9 Hz, 2H; H-9, H-11), 7.14 (d, J = 
8.9 Hz, 2H; H-8, H-12), 6.95 (d, J = 8.9 Hz, 2H; H-15, H-17), 5.54 (d, J1,2 = 1.7 Hz; 1H, H-1), 
5.51 (dd, J2,3 = 3.5 Hz, J3,4 = 10.0 Hz, 1H; H-3), 5.41 (dd, J1,2 = 1.8 Hz, J2,3= 3.5 Hz, 1H; H-2), 
5.31 (t, J3,4 = J4,5 = 10.2 Hz, 1H; H-4), 4.22 (dd, J5,6a = 5.6 Hz, J6a,6b = 12.3 Hz, 1H; H-6a), 
4.16-4.14 (m, 2H; H-19), 4.03 (mc, 2H; H-5, h-6b), 3.84-3.82 (m, 2H; H-20), 3.68-3.66 (m, 
16H, H-21, H-22, H-23, H-24, H-25, H-26, H-27, H-28), 3.01 (t, J = 6.5 Hz, 2H, H-30), 2.26 (s, 
3H; H-32), 2.14, 1.99, 1.98, 1.96 ppm (each s, each 3 H, 4 COCH3); 
13C-NMR (125 MHz, 
CDCl3, 300.1 K): δ = 195.5 (C-31), 170.5, 169.9, 169.9, 169.7 (4 COCH3), 161.2 (C-16), 
157.2 (C-7), 148.5 (C-10), 146.9 (C-13), 124.6 (C-14/C-18), 124.2 (C-9/C-11), 116.7 (C-8/C-
12), 114.9 (C-15/C-17), 95.7 (C-1), 70.9-69.7 (C-21, C-22, C-23, C-24, C-25, C-26, C-27, C-
28), 69.6 (C-29), 69.4 (C-20), 69.3 (C-5), 69.1 (C-2), 68.8 (C-3), 67.8 (C-19), 65.9 (C-4), 62.1 
(C-6), 30.5 (C-32), 28.8 (C-30), 20.9, 20.7, 20.7, 20.7 ppm (COCH3); MALDI-TOF Calcd for 
C40H54N2O17S [M+Na]
+: 889.31 (M+Na)+; Mfound = 889.39. 
E-p-(p′-Mercaptohexaethyleneglycol-phenylazo)phenyl -D-mannopyranoside (E-2): 
Acetyl-protected glycoside 11 (80 mg, 92.4 µmol) was dissolved in dry MeOH (2 mL) and a 
catalytic amount of solid NaOMe was added under N2 atmosphere. The reaction mixture was 
stirred for 4 h at room temperature, then it was neutralization with Amberlite IR 120 ion- 
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exchange resin and filtered. The filtrate was evaporated under reduced pressure to yield the 
title mannoside 2 as a organe syrup (59 mg, 88.4 µmol, 97%). [α]20D = + 82.3 (c= 0.8, 
DMSO); 1H-NMR (500 MHz, CD3OD, 299.9 K): δ = 7.75 (d, J = 9.1 Hz, 2H; H-14, H18), 7.74 
(d, J = 9.0 Hz, 2H; H-9, H-11), 7.16 (d, J = 9.1 Hz, 2H; H-8, H-12), 6.97 (d, J = 9.1 Hz, 2H; H-
15, H-17), 5.49 (d, J1,2 = 1.6 Hz, 1H; H-1), 4.12-4.10 (m, 2H; H-19), 3.94 (dd, J1,2 = 1.8 Hz, 
J2,3= 3.4 Hz, 1H; H-2), 3.82 (dd, J2,3 = 3.5 Hz, J3,4= 9.5 Hz, 1H; H-3), 3.78-3.76 (m, 2H; H-20), 
3.69-3.47 (m, 22H; H-4, H-5, H-6a, H-6b, H-21, H-22, H-23, H-24, H-25, H-26, H-27, H-28, H-
29 ), 2.75 (t, J = 6.4 Hz, 2H, H-30; 13C-NMR (125 MHz, CD3OD, 299.9 K): δ = 162.6 (C-16), 
160.1 (C-7), 148.7 (C-10), 148.3 (C-13), 125.5 (C-14/C-18), 125.2 (C-9/C-11), 118.0 (C-8/C-
12), 116.0 (C-15/C-17), 100.1 (C-1), 75.7 (C-5), 72.4 (C-3), 71.9 (C-2), 71.6-71.5 (C-21, C-
22, C-23, C-24, C-25, C-26, C-27, C-28), 71.4 (C-29), 70.8 (C-20), 69.0 (C-19), 68.2 (C-4), 
62.7 (C-6), 39.6 ppm (C-30). ESI-MS calcd for C30H44N2O12S [M+Na]
+: 679.26; Mfound = 
679.25. 
Z-p-(p′-Mercaptohexaethyleneglycol-phenylazo)phenyl -D-mannopyranoside (Z-2): 1H-
NMR (500 MHz, CD3OD, 300.4 K): δ = 7.07 (d, J = 9.0 Hz, 2H; H-8, H12), 6.89-6.87 (m, 6H; 
H-9, H-11, H-12, H-14, H-15, H-17, H-18), 5.47 (d, J1,2 = 1.7 Hz, 1H; H-1), 4.12-4.10 (m, 2H; 
H-19), 3.98 (dd, J1,2 = 1.8 Hz, J2,3= 3.4 Hz, 1H; H-2), 3.86 (dd, J2,3 = 3.5 Hz, J3,4= 9.4 Hz, 1H; 
H-3), 3.82-3.81 (m, 2H; H-20), 3.74-3.67 (m, 4H; H-4, H-5, H-6a, H-6b), 3.65-3.61 (m, 18H; 
H-21, H-22, H-23, H-24, H-25, H-26, H-27, H-28, H-29 ), 2.88 ppm (t, J = 6.4 Hz, 2H, H-30; 
13C-NMR (125 MHz, CD3OD, 300.1 K): δ = 160.0 (C-16), 157.1 (C-7), 148.7 (C-10), 148.3 (C-
13), 124.1 (C-14/C-18), 123.4 (C-9/C-11), 118.0 (C-8/C-12), 115.8 (C-15/C-17), 100.2 (C-1), 
75.6 (C-5), 72.4 (C-3), 71.9 (C-2), 71.7-71.4 (C-4, C-21, C-22, C-23, C-24, C-25, C-26, C-27, 
C-28), 70.7 (C-20), 70.5 (C-29), 68.9 (C-19), 68.3 (C-4), 62.7 (C-6), 39.6 ppm (C-30). 
E-p-(p′-Acetylthioundecyl-tetraethyleneglycol-phenylazo)phenyl 2,3,4,6-tetra-O-acetyl-
-D-mannopyranoside (8): To a suspension of 4 (150 mg, 0.275 mmol) and polymer 
supported Triphenylphosphine (180 mg, 0.275 mmol, 1.6 mmol g-1) in dry THF (3 mL) 
diethylazodicarboxylate (86 µL, 0.551 mmol) was added at 0 oC.  To this cooled solution a 
predissolved solution of 7 (250 mg, 0.592 mmol) in dry THF (1 mL) was added. The reaction 
mixture was stirred at room temperature over night (14 h), the resin containing reaction 
mixture was filtered, thoroughly washed with THF (20 mL), filtrate concentrated under 
reduced pressure. Purification of the crude product by column chromatography (ethyl 
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acetate:cyclohexane 4:1) gave compound 8 as yellowish syrup (185 mg, 0.196 mmol, 71%). 
Rf = 0.29 (ethyl acetate:cyclohexane 4:1); 
1H-NMR (500 MHz, CDCl3, 300.0 K): δ = 7.88 (d, J 
= 9.0 Hz, 2H; H-14, H-18), 7.87 (d, J = 9.0 Hz, 2H; H-9, H-11), 7.21 (d, J = 9.1 Hz, 2H; H-8, 
H-12), 7.02 (d, J = 9.1 Hz, 2H; H-15, H-17), 5.61 (s, J1,2 = 1.8 Hz, 1H; H-1), 5.58 (dd, J2,3 = 
3.6 Hz, J3,4 = 10.0, 1H; H-3), 5.48 (dd, J1,2 = 1.8 Hz, J2,3= 3.5 Hz; 1H, H-2), 5.38 (t, J = 10.1 
Hz; H-4), 4.30 (dd, J5,6a = 5.5 Hz, J6a,6b = 12.3 Hz, 1H, H-6a), 4.22-4.20 (m, 2H; H-19), 4.12-
4.07 (m, 2H, H-5, H-6b), 3.90 (dd, J = 5.3 Hz, J = 4.4 Hz, 2H, H-20), 3.75-3.63 (m, 10 H; H-21, 
H-22, H-23, H-24, H-25), 3.57 (dd, J = 3.4 Hz, J = 6.1 Hz, 2H; H-26), 3.44 (t = 6.8 Hz, 2H; H-
27), 2.85 (mc, 2H; H-37), 2.32 (s, 3H; H-39, SCOCH3), 2.22, 2.06, 2.05, 2.03 (each s, each 3 
H, 4 COCH3), 1.55 (m, 4H, H-28, H-36), 1.37-1.21 ppm (m, 14 H; H- 29, H-30, H-31, H-32, H-
33, H-34, H-35); 13C-NMR (125 MHz, CDCl3, 299.9 K): δ =  196.0 (C-38), 170.5, 169.9, 169.8, 
169.7 (4 COCH3), 161.1 (C-16), 157.1 (C-7), 148.5 (C-10), 147.0 (C-13), 124.5 (C-14/C-18), 
124.2 (C-9/C-11), 116.7 (C-8/C-12), 114.9 (C-15/C-17), 95.7 (C-1), 70.9-70.5 (C-21, C-22, C-
23, C-24, C-25, C-26), 69.6 (C-27), 69.4 (C-5), 69.3 (C-2), 68.8 (C-3), 67.7 (C-20), 65.6 (C-
19), 65.9 (C-4), 62.1 (C-6), 30.6 (C-39), 29.6-29.4 (C-28, C- 29, C-30, C-31, C-32, C-33, C-
34, C-35, C-36), 29.1 (C-37), 20.8, 20.7, 20.7 20.6 ppm (4 x COCH3); MALDI-TOF Calcd for 
C47H68N2O16S [M+Na]
+; 971.42; Mfound = 971.72. 
E-p-(p′-Mercaptoundecyl-tetraethyleneglycol-phenylazo)phenyl--D-mannopyranoside 
(E-3): Acetyl-protected glycoside 8 (100 mg, 0.105 mmol) was dissolved in dry MeOH (2 mL) 
and a catalytic amount of solid NaOMe was added under N2 atmosphere. The reaction 
mixture was stirred for 6 h at room temperature, then it was neutralization with Amberlite IR 
120 ion-exchange resin and filtered. The filtrate was concentrated under reduced pressure to 
yield the title mannoside 3 as a pale yellow syrup (72 mg, 97.6 µmol, 93%) 1H-NMR (600 
MHz, CD3OD, 298.0 K): δ = 7.86 (d, J = 8.9 Hz, 2H; H-14, H-18), 7.85 (d, J = 8.9 Hz, 2H; H-9, 
H-11), 7.26 (d, J = 8.9 Hz, 2H; H-8, H-12), 7.08 (d, J = 9.0 Hz, 2H; H-15, H-17), 5.59 (s, J1,2 = 
1.2 Hz, 1H; H-1), 4.23-4.22 (m, 2H; H-19), 4.04 (dd, J1,2 = 1.8 Hz, J2,3= 3.4 Hz; 1H, H-2), 3.93 
(dd, J2,3 = 3.5 Hz, J3,4 = 9.5, 1H; H-3), 3.89-3.87 (m, 2H; H-20), 3.75-3.72 (m, 4H; H-4, H-5, 
H-6a, H-6b), 3.68-3.54 (m, 12H; H-21, H-22, H-23, H-24, H-25, H-26), 3.54 -27), 3.43 (t, J = 
6.6 Hz, 2H; H-27), 2.46 (t = 7.2 Hz, 2H; H-37), 1.58 -1.51 (m, 4H; H-28, H-36); 1.37-1.23 (m, 
14 H, H- 29, H-30, H-31, H-32, H-33, H-34, H-35); 13C-NMR (150 MHz, CD3OD, 298.0 K): δ = 
162.7 (C-16), 159.9 (C-7), 149.3 (C-10), 148.4 (C-13), 125.5 (C-14/C-18), 125.2 (C-9/C-11), 
117.9 (C-8/C-12), 115.9 (C-15/C-17), 100.1 (C-1), 75.7 (C-5), 72.4 (C-27), 71.9 (C-3), 71.8 
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(C-2), 71.6-71.2 (H-21, H-22, H-23, H-24, H-25, H-26), 70.8 (C-20), 69.0 (C-19), 68.3 (C-4), 
62.7 (C-6), 30.7-27.2 (C-28, H- 29, H-30, H-31, H-32, H-33, H-34, H-35, H-36), 24.9 (C-37). 
MALDI-TOF: Calcd for C37H58N2O11S [M+Na]
+; 761.38, Mfound = 761.72 
Z-p-(p′-(4′-Mercaptoundecyl-tetraethyleneglycol-phenylazo)phenyl--D-mannopyranoside 
(Z-3): 1H-NMR (600 MHz, CD3OD, 298.0 K): δ = 7.07 (d, J = 8.7 Hz, 2H; H-8, H-12), 6.91-
6.87 (m, 6H; H-9, H-11, H-12, H-14, H-15, H-17, H-18), 5.47 (s, 1H; H-1), 4.12-4.10 (m, 2H; 
H-19), 3.97 (mc, 1H, H-2), 3.86 (dd, J2,3 = 3.3 Hz, J3,4 = 9.4, 1H; H-3), 3.83-3.81 (m, 2H; H-
20), 3.76-3.52 (m, 16H; H-4, H-5, H-6a, H-6b, H-21, H-22, H-23, H-24, H-25, H-26), 3.45 (t, J 
= 6.6 Hz, 2H; H-27), 2.67 (t = 7.3 Hz, 2H; H-37), 1.56 -1.53 (m, 4H; H-28, H-36); 1.36-1.24 
(m, 14 H; H- 29, H-30, H-31, H-32, H-33, H-34, H-35); 13C-NMR (150 MHz, CD3OD, 298.0 K): 
δ = 160.1 (C-16), 157.2 (C-7), 149.3 (C-10), 147.8 (C-13), 124.1 (C-14/C-18), 123.4 (C-9/C-
11), 118.0 (C-8/C-12), 115.8 (C-15/C-17), 100.2 (C-1), 75.6 (C-5), 72.4 (C-27), 71.8 (C-3), 
71.6 (C-2), 71.5-71.2 (C-4, H-21, H-22, H-23, H-24, H-25, H-26), 70.7 (C-20), 68.9 (C-19), 
68.3 (C-4), 62.6 (C-6), 30.7-27.2 (C-28, H- 29, H-30, H-31, H-32, H-33, H-34, H-35, H-36), 
24.9 ppm (C-37). 
Preparation of citrate stabilized gold nanoparticles. HAuCl4 (80 mg) was added to 
degassed MilliQ water (100 mL), stirred vigorously and heated to 60 °C for 10 min.  To this 
hot yellow mixture, a solution of sodium citrate (228 mg) in degassed MilliQ water was added 
quickly between 50-60 °C. The reaction mixture turned to colourless and then became red 
wine colour. Reflux was continued for another 30 min, then the mixture was brought to room 
temperature and then it was filtered using suction funnel and the filtrate was stored at 
refrigerator. 
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5 Azobenzene glycoconjugates for conjugation with antifreeze       
proteins 
5.1 Introduction 
 
Some species like plants, fish, insects, fungi, etc. possess the ability to survive in cold 
regions (polar and alpine) at really low temperature (subzero). One of the mechanisms 
underlying their survival at subzero temperature is based on the expression of a very special 
kind of proteins called “antifreeze proteins (AFPs)”. These AFPs have the tendency to bind to 
ice crystals and prevent them from growing, thus protecting the organism from freezing.[1, 2]  
Antifreeze protein (AFP) activity is called "thermal hysteresis". There are two different types 
of proteins of the same family, one is called antifreeze glycoproteins (AFGPs) and the other is 
antifreeze protein (AFPs).[3, 4] In principle, both AFGPs and AFPs exhibit nearly the same 
functions and properties, in particular to prevent ice growth and prevent organisms from 
freezing to survive at subzero temperatures.[2]  
 
AFPs were first discovered in fish, later studies showed the presence of AFPs in other 
organism like spiders, fungi, bacteria and in plants.[5] These AFPs are classified into four 
types, namely type I, type II, type III and type IV. Although all the AFPs, type I to IV, have 
similar function in preventing death by freezing, their structures differ from organism to 
organism.[6-9] For example, cystein-rich AFPs are found in insects and glycine-rich AFPs are 
found in plants. Among all the different AFPs, type I are of particular interest because of its 
simple structure.[10] Type I AFPs are found in winter flounder. These type I AFPs have 
applications in the preservation of frozen food, storing cells and for other biomedical 
purposes.[5, 11, 12] 
 
We became curious about the applications of AFPs and interested to turn type I APFs into 
derivatives with a photoswitchable activity. For this purpose, azobenzene crosslinkers were 
required and thus, bifunctionalized azobenzene glycosides were targeted. E→Z isomerization 
of azobenzene glycosides will alter the protein structure (active in helical conformation, 
inactive in random coil peptide) and allows us to study the protein activity in a photocontrolled 
manner. In the depicted example, the E-configured crosslinker retains protein structure and 
219
active in biological function, namely, preventing ice growth. E→Z photoisomerization of the 
crosslinker distorts the protein structure resulting in activity loss (Fig 5.1). This leads to 
deactivation of its biological function.  
 
 
 
 
Figure 5.1: Proposed mode of action for the investigation of type I AFPs activity in a photocontrolled manner. 
The E-configured crosslinker retains the protein in its active helical form. After photoirradiation, the Z-form of the 
crosslinker leads to a distorted protein structure and deactivation of its function. 
 
For this project, I synthesized the first prototype crosslinker molecule and rest of the work is 
currently advanced in collaboration with Prof. Sönnichsen’s research group. Synthesis of first 
crosslinker is described in the following. 
 
5.2 Synthesis of photoswitchable crosslinkers 
For the synthesis of our first target compound 9, two building blocks were needed (Fig 6.2). 
Glycosylation of diol 7 using 6 should give the symmetrical azobenzene derivative which has 
to be further reacted with chloroacetic acid under modified Staudinger reaction conditions to 
yield the target compound 9. Later, the chloride group in compound 9 will be crosslinked with 
two cysteine side chains of type I AFPs. 
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Figure 5.2: Retrosynthesis of photoswitchable crosslinker 9. 
Synthesis of building block 9 was started with glucose 1. First, the primary hydroxyl group of 
free sugar 1 was tosylated using p-toluene sulphonic acid to provide 2 in moderate yield, after 
column chromatography (scheme 5.1).[13] Compound 2 was then protected with acetyl groups 
using acetic anhydride and pyridine to give 3 in good yield. Later, compound 3 underwent a 
nucleophilic substitution reaction at C-6 employing NaN3 providing the glycosyl azide 4 in 
moderate yield.[14, 15] Treatment of compound 4 with ethylenediamine and acetic acid at room 
temperature resulted in the reducing sugar 5, with the anomeric hydroxyl group unprotected. 
Reaction of 5 with trichloroacetonitrile and DBU as a base yielded the glucosyl 
trichloroacetimidate 6 in good yield.[16] 
 
The next building block 7 was synthesized from p-nitrophenol in a single step according to 
the literature procedure.[17,18] Glycosylation of 6 with p,p′-di-hydroxy azobenzene employing 
BF3-etherate as a promoter provided the symmetrical azobenzene glycoconjugate 8 in low 
yield. The reaction needs to be optimized to increase the yield substantially. Finally, the 
desired target compound 9 was prepared by Staudinger ligation of compound 8.[19] Thus 
coupling of 8 and chloroacetic acid in the presence of HATU and tributyl phosphine gave the 
required symmetrical disaccharide 9 in moderate yield. 
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Scheme 5.1: a) tosyl chloride, p-TsOH, pyridine, rt, overnight, 41%; b) acetic anhydride, pyridine, rt, overnight, 
85%; c) NaN3, TBAB, DMF, 80 °C, 4.5 h and rt overnight,  56%; d) ethylenediamine, acetic anhydride, THF, rt, 
overnight, 70%; e) trichloroacetonitrile, DBU, CH2Cl2, rt, 30 min, 82; f) BF3·Et2O, CH2Cl2, rt, overnight, 31%; g) 
chloroacetic acid, DIC, HATU, Bu3P, THF, rt, overnight,  69%. 
 
 
The chloroacetamide groups in compound 9 will eventually serve as short linkers between 
the carbohydrate and the cysteine side chains of the peptide. [20, 21] Later, effective switching 
of the symmetrically crosslinked glycopeptide has to be investigated. 
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In conclusion, to allow photoswitching of type I AFP activity, a photoswitchable crosslinker 9 
was synthesized. Covalent attachment of the crosslinker to the side chain of the protein and 
investigation of AFPs activity in a photocontrol manner will be studied in collaboration with 
Prof. Sönnichsen’s research group. As the project is currently in progress, the so-far 
elaborated experimental details are collected in the following. 
 
 
6-O-Toluolsulfonyl-α,β-D-glucopyranose (2):[13]  D-glucose (10.0 g, 55.5 mmol) was 
dissolved in pyridine (250 mL) and the mixture was cooled to - 20 °C. To this cooled solution, 
TsCl (10.6 g, 55.6 mmol) in pyridine (100 mL) was added dropwise and then the reaction 
mixture was stirred at room temperature overnight. The reaction mixture was evaporated and 
co-distilled with toluene to get the crude product, which was purified by flash chromatography 
(ethyl acetate/methanol, 6:1) to give compound 2 as a colorless solid. (7.52 g, 22.5 mmol, 
41%).  Rf = 0.5 (ethyl acetate/methanol, 6:1); 
1H NMR (500 MHz, CD3OD, 300 K): δ = 7.78 
(m, 2H, Harom), 7.45 (m, 2H, Harom), 5.04 (d, J = 3.7 Hz, 1H, H-1α), 4.46 (d, J = 7.8 Hz, 1H, H-
1β), 4.35 (dd, J = 1.9 Hz, J = 10.6 Hz, 1H, H-6β), 4.29 (dd, J = 1.9 Hz, J = 10.6 Hz, 1H, H-
6α), 4.20 (dd, J = 5.5 Hz, J = 10.6 Hz, 1H, H-6´α), 4.15 (dd, J = 6.1, J = 10.6 Hz, 1H, H-6´β), 
3.94 (ddd, J = 10.0, J = 1.9, 5.5 Hz, 1H, H- 5α), 3.65 (t, J = 9.5 Hz, J = 9.2 Hz, 1H, H-3α), 
3.47 (ddd, J = 1.9 Hz, J = 6.1 Hz, J = 12.0 Hz, 1H, H-5β), 3.35 (dd, J = 9.0 Hz, J = 9.4 Hz, 
1H, H-3β), 3.31 (dd, J = 3.7 Hz, J = 9.5 Hz, 1H, H-2α), 3.25 (dd, J = 9.4 Hz, J = 12.0 Hz, 1H, 
H-4β), 3.23 (dd, J = 9.2 Hz, J = 10.0 Hz, 1H, H-4α), 3.13 (dd, J = 7.8 Hz, J = 9.0 Hz, 1H, H-
2β), 2.5 (s, 3H, Ph-CH3) ppm; 
13C NMR (150 MHz, CD3OD, 300 K): δ = 134.3, 134.2 (Carom), 
131.0, 130.9, 130.8, 129.1 (Carom), 98.1 (C-1β), 93.9 (C-1α), 77.8 (C-3β), 75.9 (C-2β), 75.1 
(C-5β), 74.7 (C-3α), 73.5 (C-2α), 71.4 (C-4α), 71.2 (C-4β), 71.1 (C-6α), 70.8 (C-6β), 70.5 (C-
5α), 21.6 ppm (CH3).  
 
1,2,3,4-Tetra-O-acetyl-6-O-toluolsulfonyl-α,β-D-glucopyranose (3):[14] To a solution of 2 
(7.50 g, 22.4 mmol) in pyridine (100 mL) was added acetic anhydride (16.9 mL, 165.7 mmol) 
and the reaction mixture stirred at room temperature for overnight. The reaction mixture was 
distilled to half the volume, after that dichloromethane (100 mL) was added foll0wed by water 
(50 mL). Phase seperated, compound in aq. phase was extracted twice with dichloromethane 
(100 mL x 2). The combined organic phase was washed with sat. NaHCO3 solution (50 mL) 
and water (50 mL). Organic layer dried over Na2SO4, filtered, filtrate evaporated to dryness to 
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get the crude product, which was purified by flash column chromatography (ethyl 
acetate/cyclohexane, 3:1) provided compound 3 as colorless solid (9.54 g, 19.0 mmol, 85%). 
Rf = 0.58 (ethyl acetate/cyclohexane, 3:1); 
1H-NMR (500 MHz, CDCl3, 300 K, TMS): δ = 7.77 
(d, 2H, Harom), 7.35 (d, 2H, Harom), 6.21 (d, J = 3.6 Hz, 1H, H-1α), 5.65 (d, J = 8.2 Hz, 1H, H-
1β), 5.42 (t, J = 9.8 Hz, 1H, H-3α), 5.20 (t, J = 9.4, 1H, H-3β), 5.05 (dd, J  = 8.2, J = 9.4 Hz, 
1H, H-2β), 5.04 (dd, J = 9.4, J = 10.0 Hz, 1H, H-4β), 5.02-4.92 (m, 2H, H-2α, H-4α), 4.16 (dd, 
J = 2.8, J = 14.4 Hz, 1H, H-6α), 4.15-4.11(dd, H-6β, H-6′β, H-5α, H-6′α), 3.85 (ddd, J = 10.1, 
J = 2.7, J = 4.6 Hz, 1H, H-5β), 2.45 (s, 3H, CH3), 2.15, 2.09, 2.01, 1.99 (s, 12H, 4 OCOCH3) 
ppm; 13C-NMR (150 MHz, CDCl3, 300 K): δ = 170.1, 170.0, 169.5 ,169.2, 169.1, 169.2, 168.2, 
168.6 (OCOCH3), 145.2 (SO3-Carom), 145.1 (SO3-Carom), 132.4 (Carom-CH3), 129.8 (Carom), 
128.1 (Carom), 128.1 (Carom), 91.2 (C-1β), 88.7 (C-1α), 72.4 (C-3β), 72.4 (C-5β), 70.0 (C-2β), 
69.6 (C-3α), 69.7 (C-5α), 68.8 (C-2α), 68.9 (C-4α), 67.2 (C-4β), 67.2 (C-6α), 66.8 (C-6β), 21.6 
(Carom-CH3), 20.8, 20.7, 20.8, 20.5, 20.5, 20.4, 20.4, 20.3 (OCOCH3) ppm; ESI-MS: m/z calcd 
for C21H26O12S: 525.103 (M + Na)
+; Mfound = 525.104 
 
1,2,3,4-Tetra-O-acetyl-6-azido-6-deoxy-α,β-D-glucopyranose (4):[22] A mixture of 3 (13.1 g, 
26.1 mmol) and sodium azide (3.60 g, 55.4 mmol) in DMSO (110 mL) was heated to 80 °C 
for 4.5 h followed by stirring at room temperature for overnight. To the reaction mixture ice 
water (10 mL) was added followed by ethyl acetate (100 mL). Phase were seperated, organic 
layer washed with water (20 mL), dried over Na2SO4, filtered, filtrate evaportated to dryness. 
The obtained crude showed a  mixture of α : β = 3:1 by 1H-NMR, which  was purified by flash 
chromatography (ethyl acetate/cyclohexane, 1:1) gave the title compound 4 as colorless solid 
(7.12 g, 19.1 mmol, 73%). Rf = 0.27; 
1H-NMR of α anomer  (500 MHz, CDCl3, 300 K, TMS): 
δ = 6.36 (d, J = 3.7 Hz, 1H, H-1α), 5.47 (t, J = 10.0 Hz, 1H, H-3α), 5.15-5.05 (m, 2H, H-2, H-
4), 4.08 (ddd, J = 3.0 Hz, J = 5.3 Hz, J = 10.2 Hz, 1H, H-5), 3.34-3.14 (m, 2H, H-6a, H-6b), 
2.19, 2.06, 2.03, 2.02 (each s, each 3 H, 4 COCH3) ppm; δ = 170.1, 169.4, 169.2, 168.9 
(OCOCH3), 88.7 (C-1), 70.9 (C-5), 70.1 (C-4), 69.2 (C-3), 69.0 (C-2), 50.7 (C-6), 20.7, 20.6, 
20.6, 20.6 (OCOCH3) ppm. 
 
O-(2,3,4-Tri-O-acetyl-6-azido-6-deoxy-α-D-glucopyranosyl)-trichloroacetimidate(6):[16] 
Under N2 atmosphere, to a solution of 5 (250 mg, 0.755 mmol) in dry CH2Cl2 (5 mL) were 
added trichloroacetonitrile (908 µL, 9.06 mmol) and DBU (33 µL, 0.23 mmol) at 0 °C. The 
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reaction mixture was stirred at room temperature for about 30 min and  the reaction mixture 
was immediately subjected to flash column chromatography (cyclohexane/ethyl acetate, 7:3) 
gave the mannosyl donor 6 as a colourless solid (293 mg, 0.618 mmol, 82%). Rf = 0.31 
(cyclohexane/ethyl acetate, 4:1); 1H- NMR (500 MHz, CDCl3, 300 K): δ = 8.70 (s, 1H, 
C(NH)CCl3), 6.59 (d, J = 3.7 Hz, 1H, H-1), 5.56 (mc, H-3), 5.14-5.11 (m, 2H, H-2, H-4),  4.19 
(ddd, J = 10.2 Hz, J = 5.5 Hz, J = 2.7 Hz, 1H, H-5), 3.39 (dd, J = 13.5 Hz, J = 2.7 Hz, 1H, H-
6a), 3.34 (dd, J = 13.6 Hz, J = 5.6 Hz, 1H, H-6b), 2.06, 2.04, 2.02 ppm (each s, each 3 H, 3 
COCH3); 
13C NMR (125 MHz, CDCl3) δ = 170.0, 169.8, 169.5 (3 COCH3), 160.7 (s, C=NH-
CCl3), 92.7 (C-1), 71.2 (C-5), 70.6 (C-3), 69.7 (C-2), 68.9 (C-4), 50.6 (C-6), 20.7, 20.6 20.4 
ppm (3 COCH3); ESI-MS m/z Calcd for C14H17Cl3N4O8: 497.02 (M+Na)
+; Mfound = 497.00. 
 
E-p-[p′-(2,3,4-Tri-O-acetyl-6-azido-6-deoxy-β-D-glucopyranosyl)]phenylazophenyl   
2,3,4-tri-O-acetyl-6-azido-6-deoxy-β-D-glucopyranoside (8): To a solution of the mannosyl 
donor 6 (244 mg, 514 µmol) and p,p'-dihydroxyazobenzene 7[18] (50.0 mg, 234 µmol) in dry 
CH2Cl2 (5 mL), BF3·Et2O (44 μL, 350 µmol) was added at 0 °C under N2 atmosphere. The 
reaction mixture was stirred at room temperatuer overnight and then aq. NaHCO3 (5 mL) was 
added to quench the reaction. It was diluted with ethyl acetate (100 mL), the phases were 
separated and the organic phase was washed with water (2 × 15 mL). It was dried over 
Na2SO4, filtered and the filtrate was concentrated under reduced pressure. Purification by 
flash column chromatography (cyclohexane/ethyl acetate, 8:2) gave the divalent glycoside 8 
as pale yellow solids (62.1 mg, 73.8 µmol, 32%). Rf = 0.18 (cyclohexane/ethyl acetate, 4:2); 
1H NMR (500 MHz, CDCl3): δ = 7.89 (dd, J = 8.9 Hz, 4H, H-9, H-11, H-14, H-18), 7.12 (d, J = 
8.9 Hz, 4H, H-8, H-12, H-15, H-17), 5.32-5.30 (m, 4H, 2 H-2, 2 H-3), 5.20 (mc, 2H, 2 H-1), 
5.01 (mc, 2H, 2 H-4), 3.83 (ddd, J = 9.9 Hz, J = 7.3 Hz, J = 2.7 Hz, 2H, 2 H-5), 3.45 (dd, J = 
13.4 Hz, J = 7.3 Hz, 2H, 2 H-6a), 3.35 (dd, J = 13.4 Hz, J = 2.7 Hz, 2H, 2 H-6b), 2.08, 2.07, 
2.05 ppm (each s, each 6 H, COCH3); 
13C NMR (125 MHz, CDCl3) δ = 170.0, 169.5, 169.3 (3 
COCH3), 158.5, 148.7, 124.5, 117.3, 98.8 (C-1), 73.7 (C-5), 72.5 (C-3), 71.2 (C-2), 69.4 (C-
4), 51.3 (C-6), 20.6, 20.6, 20.6 (OCOCH3); ESI-MS m/z Calcd for C36H40N8O16: 863.26 
(M+Na)+; Mfound = 863.25. 
E-p-[p′-(2,3,4-Tri-O-acetyl-6-[2-chloroacetyl)amido-6-deoxy-β-D-glucopyranosyl)] 
phenylazophenyl-2,3,4-tri-O-acetyl-6-[2-chloroacetyl)amino-6-deoxy-β-D-
glucopyranoside (9): A mixture of 8 (50.0 mg, 59.5 µmol) and HATU (67.9 mg, 179 µmol) 
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was taken and dried under vacuum for about 30 min. Then to the above mixture, chloroacetic 
acid (16.9 mg, 179 µmol) in dry THF (7 mL) was added under inert atmosphere. The reaction 
mixture was cooled to 0 °C and added DIC (27.9 µL, 179 µmol) followed by Bu3P (36 mg, 179 
µmol). The reaction mixture was stirred at room temperature for overnight (~16 h) and then 
added water (10 mL). Product extracted with ethyl acetate (10 mL x 3), combined organic 
layer dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to 
get the crude, which was purified by flash column chromatography (dichloromethane/ethyl 
acetate, 6:4) provided 9 as pale yellow solid (38.6 mg, 41.1 µmol, 69%). Rf = 0.18 
(cyclohexane/ethyl acetate, 4:2); 1H NMR (500 MHz, CDCl3): δ = 7.88 (dd, J = 8.9 Hz, 4H, H-
9, H-11, H-14, H-18), 7.08 (d, J = 8.9 Hz, 4H, H-8, H-12, H-15, H-17), 6.97 (t, J = 6.1 Hz, 2H, 
-NH), 5.34-5.27 (m, 4H, 2 H-2, 2 H-3), 5.20 (mc, 2H, 2 H-1), 5.04 (mc, 2H, 2 H-4), 4.06 (d, J = 
1.8 Hz, 4H, -CH2Cl), 3.85-3.75 (m, 4H, 2 H-5, 2 H-6a), 3.42 (dd, J = 12.6 Hz, J = 6.0 Hz, 2H, 
2 H-6b), 2.09, 2.08, 2.05 ppm (each s, each 6 H, COCH3); 
13C NMR (125 MHz, CDCl3) δ = 
170.2, 169.8, 169.3 (3 COCH3), 166.2 (COCH2Cl) 158.4, 148.6, 124.6, 116.9, 98.6 (C-1), 
72.8 (C-5), 72.4 (C-3), 71.2 (C-2), 69.0 (C-4), 42.6 (COCH2Cl),39.7 (C-6), 20.6, 20.6, 20.6 
(OCOCH3); ESI-MS m/z Calcd for C36H40N8O16: 863.26 (M+Na)
+; Mfound = 863.25. 
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6. Resume 
To investigate the importance of conformational control in carbohydrate-protein interactions 
such as in the context of glycocalyx biology, we got interested in photoswitchable 
glycomimetics. Thus, azobenzene glycosides became principal target molecules for our 
research and a series of different azobenzene glycoconjugates were synthesized, their 
photochromic properties were studied and their biological properties investigated. The 
photoswitchable (E)-p-(Phenylazo)phenyl 3-O-(α-D-mannopyranosyl)-α-D-mannopyranoside 
mannobioside was synthesized as ligand for the bacterial lectin FimH and tested as inhibitor 
for type 1 fimbriae-mediated adhesion of E. coli bacteria in solution (Fig 6.1). Both isomers (Z 
and E) showed the same, but a high inhibitory potency than the standard methyl -D-
mannoside in solution (chapter 3.1). This result can be rationalized by computer docking 
studies which showed that the terminal mannoside is complexed in the carbohydrate binding 
site for bacterial adhesion, the first mannoside moiety acts as a bulky space, doesnot 
involved in the binding event and the azobenzene part is involved in favourable π-π* 
interactions with the tyrosine gate at the entrance of the CRD. As the azobenzene is little 
faraway from the binding pocket E→Z isomerization doesnot have influence in binding with 
the bacterial lectin FimH. 
 
 
Figure 6.1: Inhibition of type 1 fimbriated E. coli bacteria by E- and Z-configured, respectively, photoswitchable 
azobenzene mannobioside.  
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 For any advanced biological application of azobenzene glycosides, detailed knowledge about 
their photochromic properties is essential. Thus, a series of different azobenzene glycosides 
with varying anomeric configuration and different substituents on the azobenzene moiety 
were synthesized and their photochromic properties determined (chapter 3.2). Unsubstituted 
azobenzene glycosides varied with regard to the glycosidic linkage ( or , mannose or 
glucose respectively) photoisomerized from E→Z completely and showed half lifes upto 89 h. 
However, carboxy- and methoxycarbonyl-substituted azobenzene glycosides showed poor 
photoisomerization with the half lifes < 5 h. This might be due to substitution effects as well 
as the structure of the carbohydrate glycone. Theoretical studies might help to eventually 
understand how the photochromic properties of azobenzene glycosides and their kinetics are 
tuned. 
Next, mono-, di- and trivalent azobenzene glycoconjugates were synthesized to investigate 
multivalent photoswitchable glycomimetics (chapter 3.3). Interestingly, the divalent compound 
with two azobenzene branches showed a mixture of EE, EZ and ZZ isomers in the PSS. The 
trivalent analogue having three azobenzene branches showed a mixture of EEE, EEZ, EZZ 
and ZZZ isomers in the PSS, according to 1H NMR spectroscopy. The kinetic details of the 
isomerization process will be further investigated by advanced NMR techniques. 
Another interesting photoswitchable ligand of FimH, E-p-(o-Methoxycarbonyl-
phenylazo)phenyl -D-mannoside (AzoMan in Figure 6.2) was synthesized and investigated 
(chapter 3.4). Type 1 fimbriae-mediated adhesion of E. coli bacteria to the isomers of 
photoswitchable ligand was studied in solution medium and monitored by UV-Vis 
spectroscopy (Fig 6.2). No significant difference was observed in the adhesion process by 
UV-Vis spectroscopy. In another experiment, the inhibitory potency of AzoMan was tested 
with live human cells. AzoMan showed a high inhibitory potency and low toxicity at the same 
time. Thus, this compound is a prime candidate for potent FimH antagonists. 
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Figure 6.2: Addition of E. coli (strain HB101 pPKL4) bacteria to the E- and Z- isomers of azobenzene 
mannoside (Azo Man) in the UV-Cuvette. Bacterial adhesion was monitored by UV-Vis spectroscopy. 
 
In all the above methods, molecules were made and tested in solution and this might be one 
of the reasons why conformation-induced changes of their activity were not observed. We 
speculated that the scenario will be different once photoswitchable molecules are 
immobilized on surfaces to form “glycoarrays”. Thus, photoswitchable azobenzene glycosides 
were immobilized on gold surface to form photoswitchable glyco-SAMs (chapter 4). Switching 
experiments were performed on the planar gold surface/wafers and E→Z isomerization was 
successfully monitored (Fig 6.3) by infrared reflection absorptions Spectroscopy (IRRAS) 
(chapter 4.1). 
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Figure 6.3:  mixed SAM formation of azobenzene glycosides with undecane thioacetates (ratio 1:4). E→Z 
isomerisation of mixed SAM on the gold surface was observed by IRRAS. 
 
To understand the conformational control in carbohydrate-protein interactions in multivalent 
context, photosensitive gold glyconanoparticles (GNPs) were prepared (chapters 4.2). E→Z 
isomerization on the GNPs surface was successfully observed by UV-Vis spectroscopy and 
dynamic light scattering (DLS) measurements. DLS gave the hydrodynamic diameter d(H) of 
29.5 nm for the E-configured GNPs and 16.8 nm for Z-isomer. Interactions of E- and Z-GNPs, 
respectively, were tested with the lectin ConA and monitored by UV-Vis spectroscopy (Fig 
6.4). The results showed that the E-isomer binds ConA more strongly than the Z-isomer. This 
may be due to the spatial freedom, the E-form of the azobenzene mannoside interacts with 
the carbohydrate binding sites of ConA effectively. In case of the Z-isomer the terminal 
mannose is bend downwards, which is critical for lectin binding. 
231
 Figure 6.4:  Interaction of Con A with E and Z isomers of photosensitive glyco goldnanoparticles (GNPs). In E-
isomer ligands are freely available for lectin interactions, whereas in Z-isomer ligands are bend downwards 
making them difficult to interact with lectins.  
 
The above results showed that the conformational changes within azobenzene 
glycoconjugates lead to clearly pronounced differences in lectin binding once the molecules 
are immobilized on a surface than when tested in solution. This finding supports that 
conformational changes of carbohydrate ligands have an effect on cellular adhesion. We 
strongly believe that the results reported here will shed some light on the importance of 
conformational control in carbohydrate-receptor functions and will lead to a considerable 
attention and deeper interest in glycobiology.     
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